# Parkinson disease

Nature Reviews Disease Primers
3, 17013
DOI: 10.1038/nrdp.2017.13

Citation Report

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | The implication of neuronimmunoendocrine (NIE) modulatory network in the pathophysiologic process of Parkinsonâ€™s disease. Cellular and Molecular Life Sciences, 2017, 74, 3741-3768. | 2.4 | 9 |
| 2 | Magnetic resonance imaging for the diagnosis of Parkinsonâ€™s disease. Journal of Neural Transmission, 2017, 124, 915-964. | 1.4 | 178 |
| 3 | Therapeutic approaches to target alpha-synuclein pathology. Experimental Neurology, 2017, 298, 225-235. | 2.0 | 197 |
| 4 | Clinical profiles associated with LRRK2 and GBA mutations in Brazilians with Parkinson's disease. Journal of the Neurological Sciences, 2017, 381, 160-164. | 0.3 | 27 |
| 5 | Ginsenosides Rd and Re co-treatments improve rotenone-induced oxidative stress and mitochondrial impairment in SH-SY5Y neuroblastoma cells. Food and Chemical Toxicology, 2017, 109, 38-47. | 1.8 | 35 |
| 6 | The Oligomer Hypothesis in Î±-Synucleinopathy. Neurochemical Research, 2017, 42, 3362-3371. | 1.6 | 53 |
| 7 | <sup>18</sup>F-FDG PET in Parkinsonism: Differential Diagnosis and Evaluation of Cognitive Impairment. Journal of Nuclear Medicine, 2017, 58, 1888-1898. | 2.8 | 139 |
| 8 | Quantitative susceptibility mapping differentiates between parkinsonian disorders. Parkinsonism and Related Disorders, 2017, 44, 51-57. | 1.1 | 77 |
| 9 | ASK1 in neurodegeneration. Advances in Biological Regulation, 2017, 66, 63-71. | 1.4 | 40 |
| 10 | On the integrity of functional brain networks in schizophrenia, Parkinson's disease, and advanced age: Evidence from connectivityâ€based singleâ€subject classification. Human Brain Mapping, 2017, 38, 5845-5858. | 1.9 | 35 |
| 11 | Insulin signalling: new target for Parkinson's treatments?. Lancet, The, 2017, 390, 1628-1630. | 6.3 | 4 |
| 12 | Merging Clinical and Imaging Biomarkers to Tackle Parkinson's Disease. Movement Disorders Clinical Practice, 2017, 4, 652-662. | 0.8 | 6 |
| 13 | Expression patterns of key Sonic Hedgehog signaling pathway components in the developing and adult mouse midbrain and in the MN9D cell line. Cell and Tissue Research, 2017, 370, 211-225. | 1.5 | 7 |
| 14 | Drug Safety Analysis in a Real-Life Cohort of Parkinsonâ€™s Disease Patients with Polypharmacy. CNS Drugs, 2017, 31, 1093-1102. | 2.7 | 15 |
| 15 | Current Status, Gaps, and Weaknesses of the Mechanism of Selective Dopaminergic Toxicity of MPTP/MPP +. Advances in Molecular Toxicology, 2017, 11, 81-122. | 0.4 | 6 |
| 16 | Mild Inflammatory Profile without Gliosis in the c-Rel Deficient Mouse Modeling a Late-Onset Parkinsonism. Frontiers in Aging Neuroscience, 2017, 9, 229. | 1.7 | 12 |
| 17 | Biological and Clinical Implications of Comorbidities in Parkinsonâ€™s Disease. Frontiers in Aging Neuroscience, 2017, 9, 394. | 1.7 | 67 |
| 18 | Differential Effects of Parkinsonâ€™s Disease on Interneuron Subtypes within the Human Anterior Olfactory Nucleus. Frontiers in Neuroanatomy, 2017, 11, 113. | 0.9 | 19 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Running wheel exercise reduces Î±-synuclein aggregation and improves motor and cognitive function in a transgenic mouse model of Parkinson's disease. PLoS ONE, 2017, 12, e0190160. | 1.1 | 65 |
| 20 | The ER retention protein RER1 promotes alpha-synuclein degradation via the proteasome. PLoS ONE, 2017, 12, e0184262. | 1.1 | 15 |
| 21 | Ultra high-field SWI of the substantia nigra at 7T: reliability and consistency of the swallow-tail sign. BMC Neurology, 2017, 17, 194. | 0.8 | 35 |
| 22 | Machine Learning Based Approaches for SWEDD diagnosis in DaTSCAN SPECT imaging. , 2017, , . | | 2 |
| 23 | Progress toward an integrated understanding of Parkinsonâ€™s disease. F1000Research, 2017, 6, 1121. | 0.8 | 23 |
| 24 | ERâ€“mitochondria signaling in Parkinsonâ€™s disease. Cell Death and Disease, 2018, 9, 337. | 2.7 | 118 |
| 25 | Parkinson's disease genetic risk in a midbrain neuronal cell line. Neurobiology of Disease, 2018, 114, 53-64. | 2.1 | 29 |
| 26 | Prevalence of restless legs syndrome in Parkinson's disease: a systematic review and meta-analysis of observational studies. Sleep Medicine, 2018, 43, 40-46. | 0.8 | 48 |
| 27 | The level of 24-hydroxycholesteryl esters decreases in plasma of patients with Parkinsonâ€™s disease. Neuroscience Letters, 2018, 672, 108-112. | 1.0 | 22 |
| 28 | A review of physiological and behavioral monitoring with digital sensors for neuropsychiatric illnesses. Physiological Measurement, 2018, 39, 05TR01. | 1.2 | 86 |
| 29 | Inhibition of Î±â€synuclein Amyloid Fibril Elongation by Blocking Fibril Ends. Angewandte Chemie - International Edition, 2018, 57, 5690-5694. | 7.2 | 27 |
| 30 | International Parkinson and movement disorder society evidenceâ€based medicine review: Update on treatments for the motor symptoms of Parkinson's disease. Movement Disorders, 2018, 33, 1248-1266. | 2.2 | 601 |
| 31 | Multitarget effects of Korean Red Ginseng in animal model of Parkinson's disease: antiapoptosis, antioxidant, antiinflammation, and maintenance of bloodâ€“brain barrier integrity. Journal of Ginseng Research, 2018, 42, 379-388. | 3.0 | 47 |
| 32 | Designer exosomes produced by implanted cells intracerebrally deliver therapeutic cargo for Parkinsonâ€™s disease treatment. Nature Communications, 2018, 9, 1305. | 5.8 | 451 |
| 33 | Neurons Generated by Mouse ESCs with Hippocampal or Cortical Identity Display Distinct Projection Patterns When Co-transplanted in the Adult Brain. Stem Cell Reports, 2018, 10, 1016-1029. | 2.3 | 19 |
| 34 | Targeting AMPK Signaling as a Neuroprotective Strategy in Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2018, 8, 161-181. | 1.5 | 89 |
| 35 | Inhibition of Î±â€synuclein Amyloid Fibril Elongation by Blocking Fibril Ends. Angewandte Chemie, 2018, 130, 5792-5796. | 1.6 | 4 |
| 36 | Refolding of helical soluble Î±â€synuclein through transient interaction with lipid interfaces. FEBS Letters, 2018, 592, 1464-1472. | 1.3 | 38 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Parkinson's disease, epileptic seizures, and sudden death: Three faces of the same coin. Epilepsy and Behavior, 2018, 83, 239-241. | 0.9 | 3 |
| 39 | Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations. Movement Disorders, 2018, 33, 660-677. | 2.2 | 275 |
| 40 | Methamphetamine use and future risk for Parkinsonâ€™s disease: Evidence and clinical implications. Drug and Alcohol Dependence, 2018, 187, 134-140. | 1.6 | 51 |
| 41 | Excitotoxicity in the pathogenesis of neurological and psychiatric disorders: Therapeutic implications. Journal of Psychopharmacology, 2018, 32, 265-275. | 2.0 | 136 |
| 42 | Optical Structural Analysis of Individual Î±â€Synuclein Oligomers. Angewandte Chemie - International Edition, 2018, 57, 4886-4890. | 7.2 | 40 |
| 43 | Basal Mitophagy Occurs Independently of PINK1 in Mouse Tissues of High Metabolic Demand. Cell Metabolism, 2018, 27, 439-449.e5. | 7.2 | 439 |
| 44 | Optical Structural Analysis of Individual Î±â€Synuclein Oligomers. Angewandte Chemie, 2018, 130, 4980-4984. | 1.6 | 0 |
| 45 | Mesencephalic Astrocyte-Derived Neurotrophic Factor (MANF) Elevates Stimulus-Evoked Release of Dopamine in Freely-Moving Rats. Molecular Neurobiology, 2018, 55, 6755-6768. | 1.9 | 11 |
| 46 | From Genomics to Omics Landscapes of Parkinson's Disease: Revealing the Molecular Mechanisms. OMICS A Journal of Integrative Biology, 2018, 22, 1-16. | 1.0 | 38 |
| 47 | Nigrosome Imaging and Neuromelanin Sensitive MRI in Diagnostic Evaluation of Parkinsonism. Movement Disorders Clinical Practice, 2018, 5, 131-140. | 0.8 | 46 |
| 48 | Advances in prodrug design for Parkinsonâ€™s disease. Expert Opinion on Drug Discovery, 2018, 13, 295-305. | 2.5 | 13 |
| 49 | The genetics of Parkinson disease. Ageing Research Reviews, 2018, 42, 72-85. | 5.0 | 398 |
| 50 | Pupillometry as an indicator of l-DOPA dosages in Parkinsonâ€™s disease patients. Journal of Neural Transmission, 2018, 125, 699-703. | 1.4 | 12 |
| 51 | Wnt Signaling in the Central Nervous System: New Insights in Health and Disease. Progress in Molecular Biology and Translational Science, 2018, 153, 81-130. | 0.9 | 68 |
| 52 | Back to the future: new target-validated Rab antibodies for evaluating LRRK2 signalling in cell biology and Parkinson's disease. Biochemical Journal, 2018, 475, 185-189. | 1.7 | 4 |
| 53 | Intermittent metabolic switching, neuroplasticity and brain health. Nature Reviews Neuroscience, 2018, 19, 81-94. | 4.9 | 380 |
| 54 | D409H GBA1 mutation accelerates the progression of pathology in A53T Î±-synuclein transgenic mouse model. Acta Neuropathologica Communications, 2018, 6, 32. | 2.4 | 26 |
| 55 | Cardiac abnormalities in Parkinsonâ€™s disease and Parkinsonism. Journal of Clinical Neuroscience, 2018, 53, 1-5. | 0.8 | 100 |

| # | Article | IF | Citations |
|---|---|---|---|
| 56 | Targeted Therapies for Parkinson's Disease: From Genetics to the Clinic. Movement Disorders, 2018, 33, 684-696. | 2.2 | 140 |
| 57 | Alpha-synuclein mitochondrial interaction leads to irreversible translocation and complex I impairment. Archives of Biochemistry and Biophysics, 2018, 651, 1-12. | 1.4 | 45 |
| 58 | Educational Needs and Considerations for a Visual Educational Tool to Discuss Parkinson's Disease. Movement Disorders Clinical Practice, 2018, 5, 66-74. | 0.8 | 7 |
| 59 | Old wines in new bottles: Repurposing opportunities for Parkinson's disease. European Journal of Pharmacology, 2018, 830, 115-127. | 1.7 | 15 |
| 60 | Phosphorylated Î±-Synuclein Accumulations and Lewy Body-like Pathology Distributed in Parkinsonâ€™s Disease-Related Brain Areas of Aged Rhesus Monkeys Treated with MPTP. Neuroscience, 2018, 379, 302-315. | 1.1 | 24 |
| 61 | Medial septum differentially regulates dopamine neuron activity in the rat ventral tegmental area and substantia nigra via distinct pathways. Neuropsychopharmacology, 2018, 43, 2093-2100. | 2.8 | 24 |
| 62 | When natureâ€™s robots go rogue: exploring protein homeostasis dysfunction and the implications for understanding human aging disease pathologies. Expert Review of Proteomics, 2018, 15, 293-309. | 1.3 | 4 |
| 63 | Parkinsonâ€™s Disease: Contemporary Concepts and Clinical Management. , 2018, , 349-378. | | 0 |
| 64 | Interaction of amyloidogenic proteins in pancreatic Î² cells from subjects with synucleinopathies. Acta Neuropathologica, 2018, 135, 877-886. | 3.9 | 59 |
| 65 | Comprehensive grading of Parkinsonâ€™s disease using motor and non-motor assessments: addressing a key unmet need. Expert Review of Neurotherapeutics, 2018, 18, 41-50. | 1.4 | 30 |
| 66 | Are rodent models of Parkinsonâ€™s disease behaving as they should?. Behavioural Brain Research, 2018, 352, 133-141. | 1.2 | 46 |
| 67 | Immunization with Î±â€synuclein/Grp94 reshapes peripheral immunity and suppresses microgliosis in a chronic Parkinsonism model. Glia, 2018, 66, 191-205. | 2.5 | 24 |
| 68 | Cognitive and behavioral disorders in Parkinsonâ€™s disease: an update. I: cognitive impairments. Neurological Sciences, 2018, 39, 215-223. | 0.9 | 81 |
| 69 | Nano-carrier enabled drug delivery systems for nose to brain targeting for the treatment of neurodegenerative disorders. Journal of Drug Delivery Science and Technology, 2018, 43, 295-310. | 1.4 | 86 |
| 70 | Nutritional habits, risk, and progression of Parkinson disease. Journal of Neurology, 2018, 265, 12-23. | 1.8 | 45 |
| 71 | Alterations in the reduced pteridine contents in the cerebrospinal fluids of LRRK2 mutation carriers and patients with Parkinsonâ€™s disease. Journal of Neural Transmission, 2018, 125, 45-52. | 1.4 | 11 |
| 72 | Neuromelanin in Parkinsonâ€™s Disease: from Fenton Reaction to Calcium Signaling. Neurotoxicity Research, 2018, 33, 515-522. | 1.3 | 32 |
| 73 | In vivo models of alpha-synuclein transmission and propagation. Cell and Tissue Research, 2018, 373, 183-193. | 1.5 | 51 |

| # | Article | IF | Citations |
|---|---|---|---|
| 74 | Synaptic Regulator Î±-Synuclein in Dopaminergic Fibers Is Essentially Required for the Maintenance of Subependymal Neural Stem Cells. Journal of Neuroscience, 2018, 38, 814-825. | 1.7 | 16 |
| 75 | Neurodegenerative Disease Proteinopathies Are Connected to Distinct Histone Post-translational Modification Landscapes. ACS Chemical Neuroscience, 2018, 9, 838-848. | 1.7 | 25 |
| 76 | Caenorhabditis elegans as a model system for target identification and drug screening against neurodegenerative diseases. European Journal of Pharmacology, 2018, 819, 169-180. | 1.7 | 63 |
| 77 | MR planimetry in neurodegenerative parkinsonism yields high diagnostic accuracy for PSP. Parkinsonism and Related Disorders, 2018, 46, 47-55. | 1.1 | 45 |
| 78 | Historical perspective: The pros and cons of conventional outcome measures in Parkinson's disease. Parkinsonism and Related Disorders, 2018, 46, S47-S52. | 1.1 | 9 |
| 79 | Therapeutic nanoplatforms and delivery strategies for neurological disorders. Nano Convergence, 2018, 5, 35. | 6.3 | 65 |
| 80 | Efficacy of Yokukansankachimpihange on sleep disturbance in Parkinson's disease. Medicine (United) Tj ETQq0 0 0 rgBT /Overlock 10 Tf | 0.4 | 4 |
| 81 | miRNA-based signatures in cerebrospinal fluid as potential diagnostic tools for early stage Parkinsonâ€™s disease. Oncotarget, 2018, 9, 17455-17465. | 0.8 | 94 |
| 82 | Goal management training Â® home-based approach for mild cognitive impairment in Parkinsonâ€™s disease: a multiple baseline case report. Neurocase, 2018, 24, 276-286. | 0.2 | 3 |
| 83 | Resveratrol provides neuroprotective effects through modulation of mitochondrial dynamics and ERK1/2 regulated autophagy. Free Radical Research, 2018, 52, 1371-1386. | 1.5 | 53 |
| 84 | Detailed Analysis of the Luria's Alternating SeriesTests for Parkinson's Disease Diagnostics. , 2018, , . | | 10 |
| 85 | NOP Receptor Ligands and Parkinsonâ€™s Disease. Handbook of Experimental Pharmacology, 2018, 254, 213-232. | 0.9 | 9 |
| 86 | Potential Application of Yokukansan as a Remedy for Parkinsonâ€™s Disease. Evidence-based Complementary and Alternative Medicine, 2018, 2018, 1-19. | 0.5 | 9 |
| 87 | Gene therapy reduces Parkinsonâ€™s disease symptoms by reorganizing functional brain connectivity. Science Translational Medicine, 2018, 10, . | 5.8 | 58 |
| 88 | CXCL12 and CXCR4 in the Peripheral Blood of Patients with Parkinsonâ€™s Disease. NeuroImmunoModulation, 2018, 25, 201-205. | 0.9 | 27 |
| 89 | EEG Microstates Change in Response to Increase in Dopaminergic Stimulation in Typical Parkinsonâ€™s Disease Patients. Frontiers in Neuroscience, 2018, 12, 714. | 1.4 | 29 |
| 90 | Parkinsonism in Inherited Metabolic Disorders: Key Considerations and Major Features. Frontiers in Neurology, 2018, 9, 857. | 1.1 | 15 |
| 91 | Serum Inflammatory Profile for the Discrimination of Clinical Subtypes in Parkinson's Disease. Frontiers in Neurology, 2018, 9, 1123. | 1.1 | 19 |

| # | Article | IF | Citations |
|---|---|---|---|
| 92 | Quantifying Dynamic Balance in Young, Elderly and Parkinson's Individuals: A Systematic Review. Frontiers in Aging Neuroscience, 2018, 10, 387. | 1.7 | 46 |
| 93 | TRH Analog, Taltirelin Improves Motor Function of Hemi-PD Rats Without Inducing Dyskinesia via Sustained Dopamine Stimulating Effect. Frontiers in Cellular Neuroscience, 2018, 12, 417. | 1.8 | 10 |
| 94 | TRH Analog, Taltirelin Protects Dopaminergic Neurons From Neurotoxicity of MPTP and Rotenone. Frontiers in Cellular Neuroscience, 2018, 12, 485. | 1.8 | 21 |
| 95 | Neuroprotective Effects of a Traditional Multi-Herbal Medicine Kyung-Ok-Ko in an Animal Model of Parkinson's Disease: Inhibition of MAPKs and NF-Î¹B Pathways and Activation of Keap1-Nrf2 Pathway. Frontiers in Pharmacology, 2018, 9, 1444. | 1.6 | 15 |
| 96 | Histaminergic Modulation of Recognition Memory. Handbook of Behavioral Neuroscience, 2018, 27, 415-445. | 0.7 | 0 |
| 97 | Direct CNS delivery of proteins using thermosensitive liposome-in-gel carrier by heterotopic mucosal engrafting. PLoS ONE, 2018, 13, e0208122. | 1.1 | 17 |
| 98 | The Synergy of Aging and LPS Exposure in a Mouse Model of Parkinsonâ€™s Disease. , 2018, 9, 785. | | 24 |
| 99 | microRNAs in Neurodegeneration: Current Findings and Potential Impacts. , 2018, 08, . | | 37 |
| 100 | When Neuroscience Meets Pharmacology: A Neuropharmacology Literature Analysis. Frontiers in Neuroscience, 2018, 12, 852. | 1.4 | 17 |
| 101 | Ketamine Does Not Exert Protective Properties on Dopaminergic Neurons in the Lactacystin Mouse Model of Parkinsonâ€™s Disease. Frontiers in Behavioral Neuroscience, 2018, 12, 219. | 1.0 | 1 |
| 102 | Neuroimaging of Sleep Disturbances in Movement Disorders. Frontiers in Neurology, 2018, 9, 767. | 1.1 | 15 |
| 103 | Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs. Nature Reviews Drug Discovery, 2018, 17, 804-822. | 21.5 | 178 |
| 104 | Signature of Aberrantly Expressed microRNAs in the Striatum of Rotenone-Induced Parkinsonian Rats. Neurochemical Research, 2018, 43, 2132-2140. | 1.6 | 30 |
| 105 | What have we learned recently from transgenic mouse models about neurodegeneration? The most promising discoveries of this millennium. Pharmacological Reports, 2018, 70, 1105-1115. | 1.5 | 7 |
| 106 | Structural Imaging in Atypical Parkinsonism. International Review of Neurobiology, 2018, 142, 67-148. | 0.9 | 27 |
| 107 | Hypericum polyanthemum cyclohexane extract potentiates behavioral effects and neurodegeneration induced by nigral infusions of 6-hydroxydopamine in rats. Neuroscience Letters, 2018, 687, 177-182. | 1.0 | 5 |
| 108 | Technology-based assessment of motor and nonmotor phenomena in Parkinson disease. Expert Review of Neurotherapeutics, 2018, 18, 825-845. | 1.4 | 31 |
| 109 | Speech disorders in Parkinson's disease: pathophysiology, medical management and surgical approaches. Neurodegenerative Disease Management, 2018, 8, 337-348. | 1.2 | 66 |

| # | Article | IF | Citations |
|---|---|---|---|
| 110 | Cognitive and Affective Theory of Mind in Mild Cognitive Impairment and Parkinsonâ€™s Disease: Preliminary Evidence from the Italian Version of the Yoni Task. Developmental Neuropsychology, 2018, 43, 764-780. | 1.0 | 27 |
| 111 | Evaluation of cerebrospinal fluid proteins as potential biomarkers for early stage Parkinsonâ€™s disease diagnosis. PLoS ONE, 2018, 13, e0206536. | 1.1 | 29 |
| 112 | Design of a Wearable Mechatronic Device to Measure the Wrist Rigidity in Parkinson's Disease Patients. , 2018, , . | | 3 |
| 113 | Inflammasome inhibition prevents Î±-synuclein pathology and dopaminergic neurodegeneration in mice. Science Translational Medicine, 2018, 10, . | 5.8 | 493 |
| 114 | Cancer enzyme affects Parkinson's disease. Science, 2018, 362, 521-522. | 6.0 | 14 |
| 115 | Oxidative stress and mitochondrial dysfunction in parafacial respiratory group induced by maternal cigarette smoke exposure in rat offspring. Free Radical Biology and Medicine, 2018, 129, 169-176. | 1.3 | 17 |
| 116 | A Cortical Pathogenic Theory of Parkinsonâ€™s Disease. Neuron, 2018, 99, 1116-1128. | 3.8 | 108 |
| 117 | Genome Editing and the Problem of Tetraploidy in Cell Modeling of the Genetic Form of Parkinsonism. Biochemistry (Moscow), 2018, 83, 1040-1045. | 0.7 | 0 |
| 118 | Diagnosis of PSP-P: Can a newly developed MRPI make the difference?. Parkinsonism and Related Disorders, 2018, 54, 1-2. | 1.1 | 1 |
| 119 | Chaperone-mediated autophagy as a therapeutic target for Parkinson disease. Expert Opinion on Therapeutic Targets, 2018, 22, 823-832. | 1.5 | 31 |
| 120 | G2019S LRRK2 mutation facilitates Î±-synuclein neuropathology in aged mice. Neurobiology of Disease, 2018, 120, 21-33. | 2.1 | 56 |
| 121 | Parkinson Disease. Annals of Internal Medicine, 2018, 169, ITC33-ITC48. | 2.0 | 62 |
| 122 | Mitochondria at the Base of Neuronal Innate Immunity in Alzheimerâ€™s and Parkinsonâ€™s Diseases. , 2018, , . | | 1 |
| 123 | Fatty acid chemical mediator provides insights into the pathology and treatment of Parkinsonâ€™s disease. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 6322-6324. | 3.3 | 10 |
| 124 | Gangliosides, Î±-Synuclein, and Parkinson's Disease. Progress in Molecular Biology and Translational Science, 2018, 156, 435-454. | 0.9 | 56 |
| 125 | Full sequencing and haplotype analysis of MAPT in Parkinson's disease and rapid eye movement sleep behavior disorder. Movement Disorders, 2018, 33, 1016-1020. | 2.2 | 31 |
| 126 | Is Targeting the Inflammasome a Way Forward for Neuroscience Drug Discovery?. SLAS Discovery, 2018, 23, 991-1017. | 1.4 | 17 |
| 127 | Protective effects of hydroxytyrosol against Î±-synuclein toxicity on PC12â€¯cells and fibril formation. Food and Chemical Toxicology, 2018, 120, 41-49. | 1.8 | 26 |

| # | Article | IF | Citations |
|---|---|---|---|
| 128 | Longâ€term immunosuppression for <scp>CNS</scp> mouse xenotransplantation: Effects on nigrostriatal neurodegeneration and neuroprotective carotid body cell therapy. Xenotransplantation, 2018, 25, e12410. | 1.6 | 10 |
| 129 | Progression Rate Associated Peripheral Blood Biomarkers of Parkinsonâ€™s Disease. Journal of Molecular Neuroscience, 2018, 65, 312-318. | 1.1 | 12 |
| 130 | Relationships between gait and emotion in Parkinsonâ€™s disease: A narrative review. Gait and Posture, 2018, 65, 57-64. | 0.6 | 54 |
| 131 | Smartphone Allows Capture of Speech Abnormalities Associated With High Risk of Developing Parkinsonâ€™s Disease. IEEE Transactions on Neural Systems and Rehabilitation Engineering, 2018, 26, 1495-1507. | 2.7 | 77 |
| 132 | Evidence for dopaminergic axonal degeneration as an early pathological process in Parkinson's disease. Parkinsonism and Related Disorders, 2018, 56, 9-15. | 1.1 | 58 |
| 133 | Accumulation of Cholesterol and Homocysteine in the Nigrostriatal Pathway of Brain Contributes to the Dopaminergic Neurodegeneration in Mice. Neuroscience, 2018, 388, 347-356. | 1.1 | 16 |
| 134 | On-Chip Studies of Magnetic Stimulation Effect on Single Neural Cell Viability and Proliferation on Glass and Nanoporous Surfaces. ACS Applied Materials & Interfaces, 2018, 10, 28269-28278. | 4.0 | 11 |
| 135 | Anti-Parkinson Potential of Silymarin: Mechanistic Insight and Therapeutic Standing. Frontiers in Pharmacology, 2018, 9, 422. | 1.6 | 63 |
| 136 | Multi-Target Protective Effects of Gintonin in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Mediated Model of Parkinsonâ€™s Disease via Lysophosphatidic Acid Receptors. Frontiers in Pharmacology, 2018, 9, 515. | 1.6 | 44 |
| 137 | Long-Term Intravitreal Ranibizumab as a Potential Additional Risk Factor for Neurodegeneration in Parkinsonâ€™s Disease: A Case Report. Frontiers in Pharmacology, 2018, 9, 608. | 1.6 | 8 |
| 138 | Development of Microplatforms to Mimic the In Vivo Architecture of CNS and PNS Physiology and Their Diseases. Genes, 2018, 9, 285. | 1.0 | 22 |
| 139 | GPCRs in NLRP3 Inflammasome Activation, Regulation, and Therapeutics. Trends in Pharmacological Sciences, 2018, 39, 798-811. | 4.0 | 47 |
| 140 | Secondary carbamate linker can facilitate the sustained release of dopamine from brain-targeted prodrug. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 2856-2860. | 1.0 | 21 |
| 141 | Diseaseâ€modifying approaches for Parkinson disease. Medical Journal of Australia, 2018, 208, 377-378. | 0.8 | 3 |
| 142 | Of Microbes and Minds: A Narrative Review on the Second Brain Aging. Frontiers in Medicine, 2018, 5, 53. | 1.2 | 71 |
| 143 | Promising Metabolite Profiles in the Plasma and CSF of Early Clinical Parkinson's Disease. Frontiers in Aging Neuroscience, 2018, 10, 51. | 1.7 | 74 |
| 144 | Alpha-Synuclein: From Early Synaptic Dysfunction to Neurodegeneration. Frontiers in Neurology, 2018, 9, 295. | 1.1 | 138 |
| 145 | Are We Ready for Detecting Î±-Synuclein Prone to Aggregation in Patients? The Case of â€œProtein-Misfolding Cyclic Amplificationâ€•and â€œReal-Time Quaking-Induced Conversionâ€•as Diagnostic Tools. Frontiers in Neurology, 2018, 9, 415. | 1.1 | 66 |

| # | Article | IF | Citations |
|---|---|---|---|
| 146 | Do We Need to Rethink the Epidemiology and Healthcare Utilization of Parkinson's Disease in Germany?. Frontiers in Neurology, 2018, 9, 500. | 1.1 | 45 |
| 147 | Parkinson's Disease Skin Fibroblasts Display Signature Alterations in Growth, Redox Homeostasis, Mitochondrial Function, and Autophagy. Frontiers in Neuroscience, 2017, 11, 737. | 1.4 | 52 |
| 148 | Linking Glycation and Glycosylation With Inflammation and Mitochondrial Dysfunction in Parkinsonâ€™s Disease. Frontiers in Neuroscience, 2018, 12, 381. | 1.4 | 51 |
| 149 | Microglia Gone Rogue: Impacts on Psychiatric Disorders across the Lifespan. Frontiers in Molecular Neuroscience, 2017, 10, 421. | 1.4 | 151 |
| 150 | The LRRK2 Variant E193K Prevents Mitochondrial Fission Upon MPP+ Treatment by Altering LRRK2 Binding to DRP1. Frontiers in Molecular Neuroscience, 2018, 11, 64. | 1.4 | 32 |
| 151 | Emerging Biosensing Technologies for Neuroinflammatory and Neurodegenerative Disease Diagnostics. Frontiers in Molecular Neuroscience, 2018, 11, 164. | 1.4 | 25 |
| 152 | Fire prevention in the Parkinsonâ€™s disease brain. Nature Medicine, 2018, 24, 900-902. | 15.2 | 3 |
| 153 | Old Drugs as New Treatments for Neurodegenerative Diseases. Pharmaceuticals, 2018, 11, 44. | 1.7 | 213 |
| 154 | Acupuncture for improving gait disturbance in Parkinsonâ€™s disease: A study protocol for a pilot randomized controlled trial. European Journal of Integrative Medicine, 2018, 20, 16-21. | 0.8 | 8 |
| 155 | Long-term neurotoxic effects of domoic acid on primary dopaminergic neurons. Toxicology in Vitro, 2018, 52, 279-285. | 1.1 | 4 |
| 156 | Activity of translation regulator eukaryotic elongation factor-2 kinase is increased in Parkinson disease brain and its inhibition reduces alpha synuclein toxicity. Acta Neuropathologica Communications, 2018, 6, 54. | 2.4 | 48 |
| 157 | LRRK2 G2019S Parkinson's disease with more benign phenotype than idiopathic. Acta Neurologica Scandinavica, 2018, 138, 425-431. | 1.0 | 22 |
| 158 | Prevention of progression in Parkinsonâ€™s disease. BioMetals, 2018, 31, 737-747. | 1.8 | 58 |
| 159 | Parkinson Disease. , 2018, , 83-91. | | 0 |
| 160 | Determinants of dopaminergic neuron loss in Parkinson's disease. FEBS Journal, 2018, 285, 3657-3668. | 2.2 | 251 |
| 161 | Plin4-Dependent Lipid Droplets Hamper Neuronal Mitophagy in the MPTP/p-Induced Mouse Model of Parkinsonâ€™s Disease. Frontiers in Neuroscience, 2018, 12, 397. | 1.4 | 63 |
| 162 | Mitochondrial dysfunction in protein conformational disorders. Journal of Genetics, 2018, 97, 703-713. | 0.4 | 1 |
| 163 | MicroRNA-7 facilitates the degradation of alpha-synuclein and its aggregates by promoting autophagy. Neuroscience Letters, 2018, 678, 118-123. | 1.0 | 47 |

| # | Article | IF | Citations |
|---|---|---|---|
| 164 | Typical features of Parkinson disease and diagnostic challenges with microdeletion 22q11.2. Neurology, 2018, 90, e2059-e2067. | 1.5 | 35 |
| 165 | Acid ceramidase inhibition ameliorates Î±-synuclein accumulation upon loss of GBA1 function. Human Molecular Genetics, 2018, 27, 1972-1988. | 1.4 | 53 |
| 166 | Ceruloplasmin in Parkinson's disease and the nonmotor symptoms. Brain and Behavior, 2018, 8, e00995. | 1.0 | 14 |
| 167 | Cell-penetrating artificial mitochondria-targeting peptide-conjugated metallothionein 1A alleviates mitochondrial damage in Parkinsonâ€™s disease models. Experimental and Molecular Medicine, 2018, 50, 1-13. | 3.2 | 41 |
| 168 | Modeling Parkinsonâ€™s Disease in C. elegans. Journal of Parkinson's Disease, 2018, 8, 17-32. | 1.5 | 114 |
| 169 | Effects of Genetic Variability in Dopaminergic Pathway on Treatment Response in Parkinsonâ€™s Disease. , 0, , . | | 0 |
| 170 | Interactions between the Intrinsically Disordered Proteins Î²â€Synuclein and Î±â€Synuclein. Proteomics, 2018, 18, e1800109. | 1.3 | 16 |
| 171 | Macro roles for microRNAs in neurodegenerative diseases. Non-coding RNA Research, 2018, 3, 154-159. | 2.4 | 40 |
| 172 | Connexin 30 deficiency attenuates A2 astrocyte responses and induces severe neurodegeneration in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride Parkinsonâ€™s disease animal model. Journal of Neuroinflammation, 2018, 15, 227. | 3.1 | 71 |
| 173 | Go with the Flowâ€”Microfluidics Approaches for Amyloid Research. Chemistry - an Asian Journal, 2018, 13, 3437-3447. | 1.7 | 12 |
| 174 | Effect of Chlorogenic Acid Supplementation in MPTP-Intoxicated Mouse. Frontiers in Pharmacology, 2018, 9, 757. | 1.6 | 93 |
| 175 | p11 Gene Therapy as a Novel Target for Treatment of Symptoms and Medication Complications in Parkinsonâ€™s Disease. , 2018, , 195-205. | | 0 |
| 176 | Challenges and strategies among women and men with Parkinsonâ€™s disease: Striving toward joie de vivre in daily life. British Journal of Occupational Therapy, 2018, 81, 700-708. | 0.5 | 6 |
| 177 | Neuroimaging advances in Parkinson's disease. Current Opinion in Neurology, 2018, 31, 415-424. | 1.8 | 25 |
| 178 | Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Antiâ€Î±-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease. JAMA Neurology, 2018, 75, 1206. | 4.5 | 217 |
| 179 | Revisiting the Paraquat-Induced Sporadic Parkinsonâ€™s Disease-Like Model. Molecular Neurobiology, 2019, 56, 1044-1055. | 1.9 | 65 |
| 180 | Loss of Microglial Parkin Inhibits Necroptosis and Contributes to Neuroinflammation. Molecular Neurobiology, 2019, 56, 2990-3004. | 1.9 | 44 |
| 181 | MPTP-driven NLRP3 inflammasome activation in microglia plays a central role in dopaminergic neurodegeneration. Cell Death and Differentiation, 2019, 26, 213-228. | 5.0 | 260 |

| # | Article | IF | Citations |
|---|---|---|---|
| 182 | The Pattern of Hospital Admissions Prior to Care Home Placement in People With Parkinsonâ€™s Disease: Evidence of a Period of Crisis for Patients and Carers. Journal of Aging and Health, 2019, 31, 1616-1630. | 0.9 | 6 |
| 183 | Dementia associated with disorders of the basal ganglia. Journal of Neuroscience Research, 2019, 97, 1728-1741. | 1.3 | 10 |
| 184 | Profiles of brain oxidative damage, ventricular alterations, and neurochemical metabolites in the striatum of PINK1 knockout rats as functions of age and gender: Relevance to Parkinson disease. Free Radical Biology and Medicine, 2019, 143, 146-152. | 1.3 | 16 |
| 185 | Selective catecholamine detection in living cells by a copper-mediated oxidative bond cleavage. Chemical Science, 2019, 10, 8519-8526. | 3.7 | 12 |
| 186 | Chemogenetic Modulation of Orexin Neurons Reverses Changes in Anxiety and Locomotor Activity in the A53T Mouse Model of Parkinsonâ€™s Disease. Frontiers in Neuroscience, 2019, 13, 702. | 1.4 | 17 |
| 187 | Roles for the adaptive immune system in Parkinsonâ€™s and Alzheimerâ€™s diseases. Current Opinion in Immunology, 2019, 59, 115-120. | 2.4 | 38 |
| 188 | Fully automated leg tracking of Drosophila neurodegeneration models reveals distinct conserved movement signatures. PLoS Biology, 2019, 17, e3000346. | 2.6 | 16 |
| 189 | Design and Validation of a Tremor Stabilizing Handle for Patients with Parkinson Disease and Essential Tremor. Lecture Notes in Computer Science, 2019, , 274-283. | 1.0 | 2 |
| 190 | A Gutsy Move for Cell-Based Regenerative Medicine in Parkinsonâ€™s Disease: Targeting the Gut Microbiome to Sequester Inflammation and Neurotoxicity. Stem Cell Reviews and Reports, 2019, 15, 690-702. | 1.7 | 14 |
| 191 | Acupuncture protects from 6-OHDA-induced neuronal damage by balancing the ratio of DMT1/Fpn1. Saudi Journal of Biological Sciences, 2019, 26, 1948-1955. | 1.8 | 7 |
| 192 | Psychostimulant use and the brain. Addiction, 2019, 114, 2065-2077. | 1.7 | 59 |
| 193 | Risk for neurodegenerative disorders in Korean patients with vitiligo: A nationwide retrospective cohort study. Journal of the American Academy of Dermatology, 2019, 81, 621-623. | 0.6 | 3 |
| 194 | Role of Dietary Supplements in the Management of Parkinsonâ€™s Disease. Biomolecules, 2019, 9, 271. | 1.8 | 51 |
| 195 | Neuroprotective Effects of Methanolic Extract of Avocado Persea americana (var. Colinred) Peel on Paraquat-Induced Locomotor Impairment, Lipid Peroxidation and Shortage of Life Span in Transgenic knockdown Parkin Drosophila melanogaster. Neurochemical Research, 2019, 44, 1986-1998. | 1.6 | 41 |
| 196 | Abnormal Mitochondria in a Non-human Primate Model of MPTP-induced Parkinson's Disease: Drp1 and CDK5/p25 Signaling. Experimental Neurobiology, 2019, 28, 414-424. | 0.7 | 29 |
| 197 | Role of the endolysosomal system in Parkinsonâ€™s disease. Journal of Neurochemistry, 2019, 150, 487-506. | 2.1 | 98 |
| 198 | Resting State Dynamic Functional Connectivity in Neurodegenerative Conditions: A Review of Magnetic Resonance Imaging Findings. Frontiers in Neuroscience, 2019, 13, 657. | 1.4 | 80 |
| 199 | DNA repair and neurological disease: From molecular understanding to the development of diagnostics and model organisms. DNA Repair, 2019, 81, 102669. | 1.3 | 27 |

| # | Article | IF | Citations |
|---|---|---|---|
| 200 | New therapeutic approaches to target alpha-synuclein in Parkinson's disease: The role of immunotherapy. International Review of Neurobiology, 2019, 146, 281-295. | 0.9 | 13 |
| 201 | Label-free detection of Î³-aminobutyric acid based on silicon nanowire biosensor. Nano Convergence, 2019, 6, 13. | 6.3 | 39 |
| 202 | Early Sociability and Social Memory Impairment in the A53T Mouse Model of Parkinsonâ€™s Disease Are Ameliorated by Chemogenetic Modulation of Orexin Neuron Activity. Molecular Neurobiology, 2019, 56, 8435-8450. | 1.9 | 18 |
| 203 | Versatile guideline-based physiotherapy intervention in groups to improve gait speed in Parkinsonâ€™s disease patients. NeuroRehabilitation, 2019, 44, 579-586. | 0.5 | 9 |
| 204 | Neurodegenerative disorders and sterile inflammation: lessons from a Drosophila model. Journal of Biochemistry, 2019, 166, 213-221. | 0.9 | 13 |
| 207 | A modulator of wild-type glucocerebrosidase improves pathogenic phenotypes in dopaminergic neuronal models of Parkinsonâ€™s disease. Science Translational Medicine, 2019, 11, . | 5.8 | 77 |
| 208 | Neuronal exosomes in saliva of Parkinson's disease patients: A pilot study. Parkinsonism and Related Disorders, 2019, 67, 21-23. | 1.1 | 57 |
| 209 | Recent Advances in Fluorescence Imaging of Bioactive Molecules in Neurons and in Vivo. Chinese Journal of Analytical Chemistry, 2019, 47, 1537-1548. | 0.9 | 7 |
| 210 | Crosstalk between Nrf2 signaling and mitochondrial function in Parkinson's disease. Molecular and Cellular Neurosciences, 2019, 101, 103413. | 1.0 | 46 |
| 211 | Study on Effect of Striatal mGluR2/3 in Alleviating Motor Dysfunction in Rat PD Model Treated by Exercise Therapy. Frontiers in Aging Neuroscience, 2019, 11, 255. | 1.7 | 9 |
| 212 | Reduced sphingolipid hydrolase activities, substrate accumulation and ganglioside decline in Parkinsonâ€™s disease. Molecular Neurodegeneration, 2019, 14, 40. | 4.4 | 100 |
| 213 | Ablation of RIP3 protects from dopaminergic neurodegeneration in experimental Parkinsonâ€™s disease. Cell Death and Disease, 2019, 10, 840. | 2.7 | 32 |
| 214 | Hsp60 in Modifications of Nervous System Homeostasis and Neurodegeneration. Heat Shock Proteins, 2019, , 241-266. | 0.2 | 2 |
| 215 | Generation of 5 hiPSC lines derived from three unrelated idiopathic Parkinson disease patients and two unrelated healthy control individuals. Stem Cell Research, 2019, 41, 101640. | 0.3 | 5 |
| 216 | Pharmacological and chemogenetic orexin/hypocretin intervention ameliorates Hipp-dependent memory impairment in the A53T mice model of Parkinsonâ€™s disease. Molecular Brain, 2019, 12, 87. | 1.3 | 25 |
| 217 | Amelioration of Mitochondrial Quality Control and Proteostasis by Natural Compounds in Parkinsonâ€™s Disease Models. International Journal of Molecular Sciences, 2019, 20, 5208. | 1.8 | 21 |
| 218 | Targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of Parkinson's disease. Future Medicinal Chemistry, 2019, 11, 1953-1977. | 1.1 | 16 |
| 219 | Antiviral Therapy in Patients With Chronic Hepatitis C Is Associated With a Reduced Risk of Parkinsonism. Movement Disorders, 2019, 34, 1882-1890. | 2.2 | 14 |

| # | Article | IF | Citations |
|---|---|---|---|
| 220 | REM sleep without atonia as prodromal marker of Lewy body disease: Fake news or the real deal?. Parkinsonism and Related Disorders, 2019, 67, 34-35. | 1.1 | 2 |
| 221 | Adrenergic Receptors as Pharmacological Targets for Neuroinflammation and Neurodegeneration in Parkinsonâ€™s Disease. , 2019, , . | | 2 |
| 222 | Acoustic Tracking of Pitch, Modal, and Subharmonic Vibrations of Vocal Folds in Parkinsonâ€™s Disease and Parkinsonism. IEEE Access, 2019, 7, 150339-150354. | 2.6 | 23 |
| 223 | Talipexole variations as novel bitopic dopamine D2 and D3 receptor ligands. MedChemComm, 2019, 10, 1926-1929. | 3.5 | 5 |
| 224 | Probiotics for Parkinsonâ€™s Disease. International Journal of Molecular Sciences, 2019, 20, 4121. | 1.8 | 97 |
| 225 | Impaired D2 receptor-dependent dopaminergic transmission in prefrontal cortex of awake mouse model of Parkinsonâ€™s disease. Brain, 2019, 142, 3099-3115. | 3.7 | 17 |
| 226 | Sudden unexpected death in Parkinsonâ€™s disease: why is drinking water important?. Neurodegenerative Disease Management, 2019, 9, 241-246. | 1.2 | 7 |
| 227 | Early-Onset Parkinson's Disease Caused by PLA2G6 Compound Heterozygous Mutation, a Case Report and Literature Review. Frontiers in Neurology, 2019, 10, 915. | 1.1 | 22 |
| 228 | Innate immune responses to paraquat exposure in a Drosophila model of Parkinsonâ€™s disease. Scientific Reports, 2019, 9, 12714. | 1.6 | 42 |
| 229 | Increased functional connectivity of thalamic subdivisions in patients with Parkinsonâ€™s disease. PLoS ONE, 2019, 14, e0222002. | 1.1 | 20 |
| 230 | Postural Control in Individuals with Parkinsonâ€™s Disease. , 0, , . | | 3 |
| 231 | The Association Between Vitamin D Status, Vitamin D Supplementation, Sunlight Exposure, and Parkinsonâ€™s Disease: A Systematic Review and Meta-Analysis. Medical Science Monitor, 2019, 25, 666-674. | 0.5 | 61 |
| 232 | Apomorphine for Parkinsonâ€™s Disease: Efficacy and Safety of Current and New Formulations. CNS Drugs, 2019, 33, 905-918. | 2.7 | 92 |
| 233 | Ageing as a risk factor for neurodegenerative disease. Nature Reviews Neurology, 2019, 15, 565-581. | 4.9 | 1,578 |
| 234 | Bioenergetics and Autophagic Imbalance in Patients-Derived Cell Models of Parkinson Disease Supports Systemic Dysfunction in Neurodegeneration. Frontiers in Neuroscience, 2019, 13, 894. | 1.4 | 29 |
| 235 | Antioxidant and anti-inflammatory effects of dexrazoxane on dopaminergic neuron degeneration in rodent models of Parkinson's disease. Neuropharmacology, 2019, 160, 107758. | 2.0 | 14 |
| 236 | Altered Gut Microbiome and Intestinal Pathology in Parkinsonâ€™s Disease. Journal of Movement Disorders, 2019, 12, 67-83. | 0.7 | 65 |
| 237 | Comparison Between Levodopa-Carbidopa Intestinal Gel Infusion and Subthalamic Nucleus Deep-Brain Stimulation for Advanced Parkinson's Disease: A Systematic Review and Meta-Analysis. Frontiers in Neurology, 2019, 10, 934. | 1.1 | 16 |

| # | Article | IF | Citations |
|---|---|---|---|
| 238 | â€œBucketsâ€• Early Observations on the Use of Red and Infrared Light Helmets in Parkinson's Disease Patients. Photobiomodulation, Photomedicine, and Laser Surgery, 2019, 37, 615-622. | 0.7 | 30 |
| 239 | Long noncoding RNA NORAD regulates MPP+-induced Parkinsonâ€™s disease model cells. Journal of Chemical Neuroanatomy, 2019, 101, 101668. | 1.0 | 27 |
| 241 | Association of daily physical activity with cognition and mood disorders in treatment-naive patients with early-stage Parkinsonâ€™s disease. Journal of Neural Transmission, 2019, 126, 1617-1624. | 1.4 | 7 |
| 242 | Expression Profiling of Blood microRNAs 885, 361, and 17 in the Patients with the Parkinsonâ€™s disease: Integrating Interaction Data to Uncover the Possible Triggering Age-Related Mechanisms. Scientific Reports, 2019, 9, 13759. | 1.6 | 21 |
| 243 | Increased Serum Levels of Mesencephalic Astrocyte-Derived Neurotrophic Factor in Subjects With Parkinsonâ€™s Disease. Frontiers in Neuroscience, 2019, 13, 929. | 1.4 | 26 |
| 244 | NAD+ in Brain Aging and Neurodegenerative Disorders. Cell Metabolism, 2019, 30, 630-655. | 7.2 | 412 |
| 245 | Vision Optical-Based Evaluation of Senshand Accuracy for Parkinsonâ€™s Disease Motor Assessment. , 2019, , . | | 3 |
| 246 | Viability of Neural Cells on 3D Printed Graphene Bioelectronics. Biosensors, 2019, 9, 112. | 2.3 | 23 |
| 247 | Gene-environment interaction and Mendelian randomisation. Revue Neurologique, 2019, 175, 597-603. | 0.6 | 9 |
| 248 | The prion-like spreading of Î±-synuclein: From in vitro to in vivo models of Parkinsonâ€™s disease. Ageing Research Reviews, 2019, 50, 89-101. | 5.0 | 59 |
| 249 | Impairment of Motor Function Correlates with Neurometabolite and Brain Iron Alterations in Parkinsonâ€™s Disease. Cells, 2019, 8, 96. | 1.8 | 28 |
| 250 | Synthesis and evaluation of chromone derivatives as inhibitors of monoamine oxidase. Molecular Diversity, 2019, 23, 897-913. | 2.1 | 21 |
| 251 | Environmental neurotoxicant-induced dopaminergic neurodegeneration: a potential link to impaired neuroinflammatory mechanisms. , 2019, 197, 61-82. | | 28 |
| 252 | Distinct differences in rates of oxygen consumption and ATP synthesis of regionally isolated nonâ€synaptic mouse brain mitochondria. Journal of Neuroscience Research, 2019, 97, 961-974. | 1.3 | 22 |
| 253 | Novel Immunotherapeutic Approaches to Target Alpha-Synuclein and Related Neuroinflammation in Parkinsonâ€™s Disease. Cells, 2019, 8, 105. | 1.8 | 30 |
| 254 | Chronotherapies for Parkinsonâ€™s disease. Progress in Neurobiology, 2019, 174, 16-27. | 2.8 | 37 |
| 255 | Cerebrospinal fluid levels of alpha-synuclein measured using a poly-glutamic acid-modified gold nanoparticle-doped disposable neuro-biosensor system. Analyst, The, 2019, 144, 611-621. | 1.7 | 58 |
| 256 | Influence of DRD1 and DRD3 Polymorphisms in the Occurrence of Motor Effects in Patients with Sporadic Parkinsonâ€™s Disease. NeuroMolecular Medicine, 2019, 21, 295-302. | 1.8 | 6 |

| # | Article | IF | Citations |
|---|---|---|---|
| 257 | Neuroprotective attributes of L-theanine, a bioactive amino acid of tea, and its potential role in Parkinson's disease therapeutics. Neurochemistry International, 2019, 129, 104478. | 1.9 | 47 |
| 258 | Combined transcriptomic and proteomic analysis reveals a diversity of venom-related and toxin-like peptides expressed in the mat anemone Zoanthus natalensis (Cnidaria, Hexacorallia). Archives of Toxicology, 2019, 93, 1745-1767. | 1.9 | 14 |
| 259 | Tear Off the Disease. , 2019, , 51-84. | | 0 |
| 260 | Guanosine prevents depressive-like behaviors in rats following bilateral dorsolateral striatum lesion induced by 6-hydroxydopamine. Behavioural Brain Research, 2019, 372, 112014. | 1.2 | 12 |
| 261 | Shared Molecular Signatures Across Neurodegenerative Diseases and Herpes Virus Infections Highlights Potential Mechanisms for Maladaptive Innate Immune Responses. Scientific Reports, 2019, 9, 8795. | 1.6 | 29 |
| 262 | Cerebrovascular plasticity: Processes that lead to changes in the architecture of brain microvessels. Journal of Cerebral Blood Flow and Metabolism, 2019, 39, 1413-1432. | 2.4 | 42 |
| 263 | Reactive oxygen species-responsive drug delivery systems for the treatment of neurodegenerative diseases. Biomaterials, 2019, 217, 119292. | 5.7 | 97 |
| 264 | The levels of the NMDA receptor co-agonist D-serine are reduced in the substantia nigra of MPTP-lesioned macaques and in the cerebrospinal fluid of Parkinsonâ€™s disease patients. Scientific Reports, 2019, 9, 8898. | 1.6 | 31 |
| 265 | Synthesis and Biological Evaluation of Novel Selenyl and Sulfur-l-Dopa Derivatives as Potential Anti-Parkinsonâ€™s Disease Agents. Biomolecules, 2019, 9, 239. | 1.8 | 8 |
| 266 | Mitochondrial DNA Variants and Common Diseases: A Mathematical Model for the Diversity of Age-Related mtDNA Mutations. Cells, 2019, 8, 608. | 1.8 | 66 |
| 267 | Carboxamides vs. methanimines: Crystal structures, binding interactions, photophysical studies, and biological evaluation of (indazole-5-yl)methanimines as monoamine oxidase B and acetylcholinesterase inhibitors. European Journal of Medicinal Chemistry, 2019, 179, 404-422. | 2.6 | 15 |
| 268 | Cardiovascular alterations in rats with Parkinsonism induced by 6-OHDA and treated with Domperidone. Scientific Reports, 2019, 9, 8965. | 1.6 | 16 |
| 269 | Antiparkinsonism anticholinergics increase dementia risk in patients with Parkinson's disease. Parkinsonism and Related Disorders, 2019, 65, 224-229. | 1.1 | 22 |
| 270 | Î±-Synuclein pathology in Parkinsonâ€™s disease and related Î±-synucleinopathies. Neuroscience Letters, 2019, 709, 134316. | 1.0 | 177 |
| 271 | Tau is required for progressive synaptic and memory deficits in a transgenic mouse model of Î±-synucleinopathy. Acta Neuropathologica, 2019, 138, 551-574. | 3.9 | 58 |
| 272 | Human myeloperoxidase (hMPO) is expressed in neurons in the substantia nigra in Parkinson's disease and in the hMPO-Î±-synuclein-A53T mouse model, correlating with increased nitration and aggregation of Î±-synuclein and exacerbation of motor impairment. Free Radical Biology and Medicine, 2019, 141, 115-140. | 1.3 | 34 |
| 273 | The A1 astrocyte paradigm: New avenues for pharmacological intervention in neurodegeneration. Movement Disorders, 2019, 34, 959-969. | 2.2 | 68 |
| 274 | Metabolomics Analyses from Tissues in Parkinsonâ€™s Disease. Methods in Molecular Biology, 2019, 1996, 217-257. | 0.4 | 14 |

| # | Article | IF | Citations |
|---|---|---|---|
| 275 | Nabilone for non-motor symptoms of Parkinsonâ€™s disease: a randomized placebo-controlled, double-blind, parallel-group, enriched enrolment randomized withdrawal study (The NMS-Nab Study). Journal of Neural Transmission, 2019, 126, 1061-1072. | 1.4 | 16 |
| 276 | Temporal changes in neuroinflammation and brain glucose metabolism in a rat model of viral vector-induced Î±-synucleinopathy. Experimental Neurology, 2019, 320, 112964. | 2.0 | 12 |
| 277 | N-acetyl-cysteine blunts 6-hydroxydopamine- and l-buthionine-sulfoximine-induced apoptosis in human mesenchymal stromal cells. Molecular Biology Reports, 2019, 46, 4423-4435. | 1.0 | 10 |
| 278 | Gutting the brain of inflammation: A key role of gut microbiome in human umbilical cord blood plasma therapy in Parkinson's disease model. Journal of Cellular and Molecular Medicine, 2019, 23, 5466-5474. | 1.6 | 23 |
| 279 | Parkinson's disease in the Western Pacific Region. Lancet Neurology, The, 2019, 18, 865-879. | 4.9 | 116 |
| 280 | Clinical-Pharmacogenetic Predictive Models for Time to Occurrence of Levodopa Related Motor Complications in Parkinsonâ€™s Disease. Frontiers in Genetics, 2019, 10, 461. | 1.1 | 13 |
| 281 | Alphaâ€synuclein at the nexus of genes and environment: the impact of environmental enrichment and stress on brain health and disease. Journal of Neurochemistry, 2019, 150, 591-604. | 2.1 | 22 |
| 282 | Use of human pluripotent stem cell-derived cells for neurodegenerative disease modeling and drug screening platform. Future Medicinal Chemistry, 2019, 11, 1305-1322. | 1.1 | 23 |
| 283 | The Roles of Intracellular Chaperone Proteins, Sigma Receptors, in Parkinsonâ€™s Disease (PD) and Major Depressive Disorder (MDD). Frontiers in Pharmacology, 2019, 10, 528. | 1.6 | 34 |
| 284 | Anti-oligomerization sheet molecules: Design, synthesis and evaluation of inhibitory activities against Î±-synuclein aggregation. Bioorganic and Medicinal Chemistry, 2019, 27, 3089-3096. | 1.4 | 10 |
| 285 | MicroRNAs: Game Changers in the Regulation ofÎ±-Synuclein in Parkinsonâ€™s Disease. Parkinson's Disease, 2019, 2019, 1-10. | 0.6 | 27 |
| 286 | CD157 and CD200 at the crossroads of endothelial remodeling and immune regulation. Stem Cell Investigation, 2019, 6, 10-10. | 1.3 | 5 |
| 287 | The Mechanisms by Which the Ketone Body D-Î²-Hydroxybutyrate May Improve the Multiple Cellular Pathologies of Parkinson's Disease. Frontiers in Nutrition, 2019, 6, 63. | 1.6 | 73 |
| 288 | Afobazole Restores the Dopamine Level in a 6-Hydroxydopamine Model of Parkinsonâ€™s Disease. Neurochemical Journal, 2019, 13, 49-56. | 0.2 | 5 |
| 289 | Heterogeneity in progression of prodromal features in Parkinson's disease. Parkinsonism and Related Disorders, 2019, 64, 275-279. | 1.1 | 15 |
| 290 | Shame in Parkinsonâ€™S Disease: A Review. Journal of Parkinson's Disease, 2019, 9, 489-499. | 1.5 | 20 |
| 291 | Lipopolysaccharide-Induced Neuroinflammation as a Bridge to Understand Neurodegeneration. International Journal of Molecular Sciences, 2019, 20, 2293. | 1.8 | 287 |
| 292 | Effects of inspiratory muscle training on respiratory muscle strength, lung function, functional capacity and cardiac autonomic function in Parkinson's disease: Randomized controlled clinical trial protocol. Physiotherapy Research International, 2019, 24, e1777. | 0.7 | 7 |

| # | Article | IF | Citations |
|---|---|---|---|
| 293 | Alternative cleavage and polyadenylation of genes associated with protein turnover and mitochondrial function are deregulated in Parkinsonâ€™s, Alzheimerâ€™s and ALS disease. BMC Medical Genomics, 2019, 12, 60. | 0.7 | 26 |
| 294 | Neuroprotective Effect of Î²-Lapachone in MPTP-Induced Parkinsonâ€™s Disease Mouse Model: Involvement of Astroglial p-AMPK/Nrf2/HO-1 Signaling Pathways. Biomolecules and Therapeutics, 2019, 27, 178-184. | 1.1 | 33 |
| 295 | GBA, Gaucher Disease, and Parkinsonâ€™s Disease: From Genetic to Clinic to New Therapeutic Approaches. Cells, 2019, 8, 364. | 1.8 | 187 |
| 296 | E46K-like Î±-synuclein mutants increase lipid interactions and disrupt membrane selectivity. Journal of Biological Chemistry, 2019, 294, 9799-9812. | 1.6 | 32 |
| 297 | Melting Down Protein Stability: PAPS Synthase 2 in Patients and in a Cellular Environment. Frontiers in Molecular Biosciences, 2019, 6, 31. | 1.6 | 10 |
| 298 | UsingDrosophilaas a platform for drug discovery from natural products in Parkinson's disease. MedChemComm, 2019, 10, 867-879. | 3.5 | 24 |
| 299 | Autonomic Dysfunction in Î±-Synucleinopathies. Frontiers in Neurology, 2019, 10, 363. | 1.1 | 87 |
| 300 | The landscape of Parkin variants reveals pathogenic mechanisms and therapeutic targets in Parkinsonâ€™s disease. Human Molecular Genetics, 2019, 28, 2811-2825. | 1.4 | 61 |
| 301 | Neurodegeneration and contralateral Î±-synuclein induction after intracerebral Î±-synuclein injections in the anterior olfactory nucleus of a Parkinsonâ€™s disease A53T mouse model. Acta Neuropathologica Communications, 2019, 7, 56. | 2.4 | 13 |
| 302 | Moving beyond neurons: the role of cell type-specific gene regulation in Parkinsonâ€™s disease heritability. Npj Parkinson's Disease, 2019, 5, 6. | 2.5 | 83 |
| 303 | Mitochondrial transport serves as a mitochondrial quality control strategy in axons: Implications for central nervous system disorders. CNS Neuroscience and Therapeutics, 2019, 25, 876-886. | 1.9 | 51 |
| 304 | The Effects of Hydrotherapy on Balance, Functional Mobility, Motor Status, and Quality of Life in Patients with Parkinson Disease: A Systematic Review and Metaâ€analysis. PM and R, 2019, 11, 278-291. | 0.9 | 31 |
| 306 | Oral administration of carvacrol/Î²-cyclodextrin complex protects against 6-hydroxydopamine-induced dopaminergic denervation. Neurochemistry International, 2019, 126, 27-35. | 1.9 | 13 |
| 307 | Systematic Literature Review of Quetiapine for the Treatment of Psychosis in Patients With Parkinsonism. Journal of Neuropsychiatry and Clinical Neurosciences, 2019, 31, 188-195. | 0.9 | 13 |
| 308 | Genetic variability of inflammation and oxidative stress genes does not play a major role in the occurrence of adverse events of dopaminergic treatment in Parkinsonâ€™s disease. Journal of Neuroinflammation, 2019, 16, 50. | 3.1 | 22 |
| 309 | Activation of Î±7â€nAChRs protects SHâ€SY5Y cells from 1â€methylâ€4â€phenylpyridiniumâ€induced apoptotic cell death via ERK/p53 signaling pathway. Journal of Cellular Physiology, 2019, 234, 18480-18491. | 2.0 | 18 |
| 310 | The flavor test is a sensitive tool in identifying the flavor sensorineural dysfunction in Parkinsonâ€™s disease. Neurological Sciences, 2019, 40, 1351-1356. | 0.9 | 11 |
| 311 | Autoimmunity in Parkinson's Disease: The Role of Î±-Synuclein-Specific T Cells. Frontiers in Immunology, 2019, 10, 303. | 2.2 | 120 |

| # | Article | IF | Citations |
|---|---|---|---|
| 312 | Analysis of repetitive element expression in the blood and skin of patients with Parkinsonâ€™s disease identifies differential expression of satellite elements. Scientific Reports, 2019, 9, 4369. | 1.6 | 12 |
| 313 | Pathogenic alpha-synuclein aggregates preferentially bind to mitochondria and affect cellular respiration. Acta Neuropathologica Communications, 2019, 7, 41. | 2.4 | 133 |
| 314 | Mitophagy could fight Parkinsonâ€™s disease through antioxidant action. Reviews in the Neurosciences, 2019, 30, 729-742. | 1.4 | 6 |
| 315 | Entanglement of Genetics and Epigenetics in Parkinsonâ€™s Disease. Frontiers in Neuroscience, 2019, 13, 277. | 1.4 | 51 |
| 316 | Quality of life in Parkinson's disease: A genderâ€specific perspective. Acta Neurologica Scandinavica, 2019, 140, 17-22. | 1.0 | 36 |
| 317 | Minocycline Protects against Rotenone-Induced Neurotoxicity Correlating with Upregulation of Nurr1 in a Parkinsonâ€™s Disease Rat Model. BioMed Research International, 2019, 2019, 1-7. | 0.9 | 22 |
| 318 | Handwritten pattern recognition for early Parkinsonâ€™s disease diagnosis. Pattern Recognition Letters, 2019, 125, 78-84. | 2.6 | 35 |
| 319 | Characterizing Histone Post-translational Modification Alterations in Yeast Neurodegenerative Proteinopathy Models. Journal of Visualized Experiments, 2019, , . | 0.2 | 2 |
| 320 | Indirect Comparison of Ropinirole and Pramipexole as Levodopa Adjunctive Therapy in Advanced Parkinsonâ€™s Disease: A Systematic Review and Network Meta-Analysis. Advances in Therapy, 2019, 36, 1252-1265. | 1.3 | 15 |
| 321 | Small molecule-driven NLRP3 inflammation inhibition via interplay between ubiquitination and autophagy: implications for Parkinson disease. Autophagy, 2019, 15, 1860-1881. | 4.3 | 250 |
| 322 | Brain Redox Imaging Using In Vivo Electron Paramagnetic Resonance Imaging and Nitroxide Imaging Probes. Magnetochemistry, 2019, 5, 11. | 1.0 | 11 |
| 323 | Discovery of coumarin Mannich base derivatives as multifunctional agents against monoamine oxidase B and neuroinflammation for the treatment of Parkinson's disease. European Journal of Medicinal Chemistry, 2019, 173, 203-212. | 2.6 | 31 |
| 324 | CSF and blood biomarkers for Parkinson's disease. Lancet Neurology, The, 2019, 18, 573-586. | 4.9 | 393 |
| 325 | Astrocyte Heterogeneity: Impact to Brain Aging and Disease. Frontiers in Aging Neuroscience, 2019, 11, 59. | 1.7 | 256 |
| 326 | N-Methyl-4-phenylpyridinium Scaffold-Containing Lipophilic Compounds Are Potent Complex I Inhibitors and Selective Dopaminergic Toxins. ACS Chemical Neuroscience, 2019, 10, 2977-2988. | 1.7 | 4 |
| 327 | Influencing factors when living with Parkinsonâ€™s disease: A crossâ€sectional study. Journal of Clinical Nursing, 2019, 28, 3168-3176. | 1.4 | 25 |
| 328 | Recapitulating Parkinson's disease pathology in a three-dimensional human neural cell culture model. DMM Disease Models and Mechanisms, 2019, 12, . | 1.2 | 31 |
| 329 | Stimulation of noradrenergic transmission by reboxetine is beneficial for a mouse model of progressive parkinsonism. Scientific Reports, 2019, 9, 5262. | 1.6 | 19 |

| # | Article | IF | Citations |
|---|---|---|---|
| 330 | Î±-Synuclein and astrocytes: tracing the pathways from homeostasis to neurodegeneration in Lewy body disease. Acta Neuropathologica, 2019, 138, 1-21. | 3.9 | 109 |
| 331 | Diagnostic utility of gut Î±-synuclein in Parkinsonâ€™s disease: A systematic review and meta-analysis. Behavioural Brain Research, 2019, 364, 340-347. | 1.2 | 26 |
| 332 | Parkinsonisms and Glucocerebrosidase Deficiency: A Comprehensive Review for Molecular and Cellular Mechanism of Glucocerebrosidase Deficiency. Brain Sciences, 2019, 9, 30. | 1.1 | 17 |
| 333 | HSP90 and Its Novel Co-Chaperones, SGT1 and CHP-1, in Brain of Patients with Parkinsonâ€™s Disease and Dementia with Lewy Bodies. Journal of Parkinson's Disease, 2019, 9, 97-107. | 1.5 | 17 |
| 334 | Dopaminergic Pathway Genes Influence Adverse Events Related to Dopaminergic Treatment in Parkinson's Disease. Frontiers in Pharmacology, 2019, 10, 8. | 1.6 | 39 |
| 335 | Dynamics of Parkinsonâ€™s Disease Multimodal Complex Treatment in Germany from 2010â€“2016: Patient Characteristics, Access to Treatment, and Formation of Regional Centers. Cells, 2019, 8, 151. | 1.8 | 26 |
| 336 | Neurotoxic effects of MPTP on mouse cerebral cortex: Modulation of neuroinflammation as a neuroprotective strategy. Molecular and Cellular Neurosciences, 2019, 96, 1-9. | 1.0 | 22 |
| 337 | Ordered mesoporous carbon-covered carbonized silk fabrics for flexible electrochemical dopamine detection. Journal of Materials Chemistry B, 2019, 7, 2145-2150. | 2.9 | 15 |
| 338 | Serum Amyloid Alpha Is Downregulated in Peripheral Tissues of Parkinsonâ€™s Disease Patients. Frontiers in Neuroscience, 2019, 13, 13. | 1.4 | 19 |
| 339 | Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. Neurology, 2019, 92, 329-337. | 1.5 | 194 |
| 340 | Neuroprotection of Fasting Mimicking Diet on MPTP-Induced Parkinson's Disease Mice via Gut Microbiota and Metabolites. Neurotherapeutics, 2019, 16, 741-760. | 2.1 | 121 |
| 341 | Mechanistic Understanding of the Interactions between Nano-Objects with Different Surface Properties and Î±-Synuclein. ACS Nano, 2019, 13, 3243-3256. | 7.3 | 51 |
| 342 | Glial Contribution to Excitatory and Inhibitory Synapse Loss in Neurodegeneration. Frontiers in Cellular Neuroscience, 2019, 13, 63. | 1.8 | 99 |
| 343 | Peripheral Nervous System Toxicity Biomarkers. , 2019, , 187-207. | | 0 |
| 344 | Refining initial diagnosis of Parkinson's disease after followâ€up: A 4â€year prospective clinical and magnetic resonance imaging study. Movement Disorders, 2019, 34, 487-495. | 2.2 | 22 |
| 345 | Effects of Î±-Synuclein Monomers Administration in the Gigantocellular Reticular Nucleus on Neurotransmission in Mouse Model. Neurochemical Research, 2019, 44, 968-977. | 1.6 | 1 |
| 346 | rAAV-based brain slice culture models of Alzheimerâ€™s and Parkinsonâ€™s disease inclusion pathologies. Journal of Experimental Medicine, 2019, 216, 539-555. | 4.2 | 48 |
| 347 | Classification of Parkinson disease data with artificial neural networks. IOP Conference Series: Materials Science and Engineering, 2019, 675, 012031. | 0.3 | 12 |

| # | Article | IF | Citations |
|---|---|---|---|
| 348 | Analysis of hand movements in patients with Parkinsonâ€™s Disease using Kinect. , 2019, , . | | 3 |
| 349 | STARDUST: Optogenetics, Electrophysiology and Pharmacology with an Ultrasonically Powered DUST for Parkinson's Disease. , 2019, , . | | 9 |
| 350 | A Portable and Wireless System for Monitoring Hand Tremors in Parkinson's Disease Patients. , 2019, , . | | 1 |
| 351 | A Cloud-based Framework for Implementing Portable Machine Learning Pipelines for Neural Data Analysis. , 2019, 2019, 4466-4469. | | 0 |
| 352 | Fenotipos de linfocitos perifÃ©ricos en las enfermedades de Alzheimer y Parkinson. NeurologÃa, 2022, 37, 110-121. | 0.3 | 8 |
| 353 | Neurotransplantation: the Time Has Come?. Human Physiology, 2019, 45, 834-841. | 0.1 | 0 |
| 354 | Circuit Mechanisms of Neurodegenerative Diseases: A New Frontier With Miniature Fluorescence Microscopy. Frontiers in Neuroscience, 2019, 13, 1174. | 1.4 | 22 |
| 355 | Generation of two iPSC lines, (ICGi015-A and ICGi015-B), by reprogramming peripheral blood mononuclear cells from a patient with Parkinson's disease. Stem Cell Research, 2019, 41, 101652. | 0.3 | 4 |
| 356 | The Landscape of Gene Expression and Molecular Regulation Following Spinal Cord Hemisection in Rats. Frontiers in Molecular Neuroscience, 2019, 12, 287. | 1.4 | 17 |
| 357 | Psychosocial stress enhances susceptibility to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity in C57BL/6N mice. Biomedical Research, 2019, 40, 251-255. | 0.3 | 1 |
| 358 | Cicadidae Periostracum, the Cast-Off Skin of Cicada, Protects Dopaminergic Neurons in a Model of Parkinsonâ€™s Disease. Oxidative Medicine and Cellular Longevity, 2019, 2019, 1-17. | 1.9 | 17 |
| 359 | Multiple system atrophy. International Review of Neurobiology, 2019, 149, 137-192. | 0.9 | 74 |
| 360 | Chaperone Sigma1R mediates the neuroprotective action of afobazole in the 6-OHDA model of Parkinsonâ€™s disease. Scientific Reports, 2019, 9, 17020. | 1.6 | 23 |
| 361 | Mechanical somatosensory stimulation decreases blood pressure in patients with Parkinson's disease. Journal of Hypertension, 2019, 37, 1714-1721. | 0.3 | 9 |
| 362 | Correlations of Neuropsychological and Metabolic Brain Changes in Parkinson's Disease and Other Î±-Synucleinopathies. Frontiers in Neurology, 2019, 10, 1204. | 1.1 | 13 |
| 363 | Autophagic Degradation of Misfolded Nuclear Receptor Co-repressor (NCoR) Is Linked to the Growth of Tumor Cells in HBX Positive Hepatocellular Carcinoma (HCC). Frontiers in Oncology, 2019, 9, 1335. | 1.3 | 1 |
| 364 | Association of periodic limb movements during sleep and Parkinson disease. Medicine (United States), 2019, 98, e18444. | 0.4 | 4 |
| 365 | The NLRP3 inflammasome: a new player in neurological diseases. Turkish Journal of Biology, 2019, 43, 349-359. | 2.1 | 31 |

| # | Article | IF | Citations |
|---|---|---|---|
| 366 | Alpha-Synuclein Nitration and Its Implications in Parkinsonâ€™s Disease. ACS Chemical Neuroscience, 2019, 10, 777-782. | 1.7 | 37 |
| 367 | Sudden death in Parkinsonâ€™s disease: Unjustifiably forgotten. Parkinsonism and Related Disorders, 2019, 58, 88-89. | 1.1 | 7 |
| 368 | Prevalence and Associated Factors of Sarcopenia and Frailty in Parkinsonâ€™s Disease: A Cross-Sectional Study. Gerontology, 2019, 65, 216-228. | 1.4 | 63 |
| 369 | Initial diagnostic workup of parkinsonism: Dopamine transporter positron emission tomography versus susceptibility map-weighted imaging at 3T. Parkinsonism and Related Disorders, 2019, 62, 171-178. | 1.1 | 12 |
| 370 | Genetic effects of welding fumes on the progression of neurodegenerative diseases. NeuroToxicology, 2019, 71, 93-101. | 1.4 | 37 |
| 371 | The longâ€term direct and indirect economic burden among Parkinson's disease caregivers in the United States. Movement Disorders, 2019, 34, 236-245. | 2.2 | 56 |
| 372 | Reproducible detection of nigral iron deposition in 2 Parkinson's disease cohorts. Movement Disorders, 2019, 34, 416-419. | 2.2 | 40 |
| 373 | c-Jun/Bim Upregulation in Dopaminergic Neurons Promotes Neurodegeneration in the MPTP Mouse Model of Parkinsonâ€™s Disease. Neuroscience, 2019, 399, 117-124. | 1.1 | 9 |
| 374 | Doping effect and fluorescence quenching mechanism of N-doped graphene quantum dots in the detection of dopamine. Talanta, 2019, 196, 563-571. | 2.9 | 93 |
| 375 | Zonisamide Administration Improves Fatty Acid Î²-Oxidation in Parkinsonâ€™s Disease. Cells, 2019, 8, 14. | 1.8 | 5 |
| 376 | Peptide-Based Polyelectrolyte Promotes Directional and Long Neurite Outgrowth. ACS Applied Bio Materials, 2019, 2, 518-526. | 2.3 | 14 |
| 377 | Mass spectrometry: A platform for biomarker discovery and validation for Alzheimer's and Parkinson's diseases. Journal of Neurochemistry, 2019, 151, 397-416. | 2.1 | 34 |
| 378 | Pathogenesisâ€targeted therapeutic strategies in Parkinson's disease. Movement Disorders, 2019, 34, 41-44. | 2.2 | 44 |
| 379 | 5-Substituted-N-pyridazinylbenzamides as potent and selective LRRK2 inhibitors: Improved brain unbound fraction enables efficacy. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 212-215. | 1.0 | 11 |
| 380 | Guanosine Protects Striatal Slices Against 6-OHDA-Induced Oxidative Damage, Mitochondrial Dysfunction, and ATP Depletion. Neurotoxicity Research, 2019, 35, 475-483. | 1.3 | 18 |
| 381 | Low Molecular Weight Sulfated Chitosan: Neuroprotective Effect on Rotenone-Induced In Vitro Parkinsonâ€™s Disease. Neurotoxicity Research, 2019, 35, 505-515. | 1.3 | 19 |
| 382 | (Pyrrolo-pyridin-5-yl)benzamides: BBB permeable monoamine oxidase B inhibitors with neuroprotective effect on cortical neurons. European Journal of Medicinal Chemistry, 2019, 162, 793-809. | 2.6 | 19 |
| 383 | 3D Cultures of Parkinson's Diseaseâ€Specific Dopaminergic Neurons for High Content Phenotyping and Drug Testing. Advanced Science, 2019, 6, 1800927. | 5.6 | 92 |

| # | Article | IF | Citations |
|---|---|---|---|
| 384 | The Potential of L-Type Calcium Channels as a Drug Target for Neuroprotective Therapy in Parkinson's Disease. Annual Review of Pharmacology and Toxicology, 2019, 59, 263-289. | 4.2 | 80 |
| 385 | A Randomized Crossover Pilot Study of Telemedicine Delivered via iPads in Parkinsonâ€™s Disease. Parkinson's Disease, 2019, 2019, 1-7. | 0.6 | 26 |
| 386 | Update on treatments for nonmotor symptoms of Parkinson's diseaseâ€”an evidenceâ€based medicine review. Movement Disorders, 2019, 34, 180-198. | 2.2 | 619 |
| 387 | Integrated use of LC/MS/MS and LC/Q-TOF/MS targeted metabolomics with automated label-free microscopy for quantification of purine metabolites in cultured mammalian cells. Purinergic Signalling, 2019, 15, 17-25. | 1.1 | 9 |
| 388 | A Review of Biomarkers Use in Parkinson with Deep Brain Stimulation: A Successful Past Promising a Bright Future. World Neurosurgery, 2019, 123, 197-207. | 0.7 | 10 |
| 389 | The impact of histone post-translational modifications in neurodegenerative diseases. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 1982-1991. | 1.8 | 33 |
| 390 | The influence of SLC6A3 and DRD2 polymorphisms on levodopa-therapy in patients with sporadic Parkinson's disease. Journal of Pharmacy and Pharmacology, 2019, 71, 206-212. | 1.2 | 20 |
| 391 | Machine Learning Based Classification Using Clinical and DaTSCAN SPECT Imaging Features: A Study on Parkinsonâ€™s Disease and SWEDD. IEEE Transactions on Radiation and Plasma Medical Sciences, 2019, 3, 170-177. | 2.7 | 21 |
| 392 | Neurotheranostics as personalized medicines. Advanced Drug Delivery Reviews, 2019, 148, 252-289. | 6.6 | 63 |
| 393 | Cellular and Molecular Aspects of Parkinson Treatment: Future Therapeutic Perspectives. Molecular Neurobiology, 2019, 56, 4799-4811. | 1.9 | 28 |
| 394 | A non-human primate model for stable chronic Parkinsonâ€™s disease induced by MPTP administration based on individual behavioral quantification. Journal of Neuroscience Methods, 2019, 311, 277-287. | 1.3 | 30 |
| 395 | Extensive exploration of a novel rat model of Parkinson's disease using partial 6â€hydroxydopamine lesion of dopaminergic neurons suggests newÂtherapeutic approaches. Synapse, 2019, 73, e22077. | 0.6 | 11 |
| 396 | Abnormal phasic activity in saliency network, motor areas, and basal ganglia in Parkinson's disease during rhythm perception. Human Brain Mapping, 2019, 40, 916-927. | 1.9 | 12 |
| 397 | 22q11.2 Deletion Syndromeâ€“Associated Parkinson's Disease. Movement Disorders Clinical Practice, 2019, 6, 11-16. | 0.8 | 22 |
| 398 | Design, Synthesis, and Pharmacological Characterization of Carbazole Based Dopamine Agonists as Potential Symptomatic and Neuroprotective Therapeutic Agents for Parkinsonâ€™s Disease. ACS Chemical Neuroscience, 2019, 10, 396-411. | 1.7 | 23 |
| 399 | Emerging Immunotherapies for Parkinson Disease. Neurology and Therapy, 2019, 8, 29-44. | 1.4 | 49 |
| 400 | Ethical issues in susceptibility genetic testing for lateâ€onset neurodegenerative diseases. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2019, 180, 609-621. | 1.1 | 11 |
| 401 | Efficient Cholera Toxin B Subunitâ€Based Nanoparticles with MRI Capability for Drug Delivery to the Brain Following Intranasal Administration. Macromolecular Bioscience, 2019, 19, e1800340. | 2.1 | 13 |

| # | Article | IF | Citations |
|---|---|---|---|
| 402 | FDG-PET hypometabolism is more sensitive than MRI atrophy in Parkinson's disease: A whole-brain multimodal imaging meta-analysis. NeuroImage: Clinical, 2019, 21, 101594. | 1.4 | 53 |
| 403 | Synaptic, Mitochondrial, and Lysosomal Dysfunction in Parkinsonâ€™s Disease. Trends in Neurosciences, 2019, 42, 140-149. | 4.2 | 206 |
| 404 | Proteomics of neurodegenerative diseases: analysis of human postâ€mortem brain. Journal of Neurochemistry, 2019, 151, 435-445. | 2.1 | 48 |
| 405 | JM-20, a novel hybrid molecule, protects against rotenone-induced neurotoxicity in experimental model of Parkinsonâ€™s disease. Neuroscience Letters, 2019, 690, 29-35. | 1.0 | 13 |
| 406 | Alpha Synuclein and Parkinsonâ€™s Disease. , 2019, , 1-14. | | 3 |
| 407 | Sudden unexpected death in Parkinsonâ€™s disease: why do neuroscientists still ignore this condition?. Neurological Sciences, 2019, 40, 413-414. | 0.9 | 2 |
| 408 | The heart in Parkinson's disease: Opening Pandora's box. Autonomic Neuroscience: Basic and Clinical, 2019, 216, 91-92. | 1.4 | 1 |
| 409 | Redox Mechanisms in Neurodegeneration: From Disease Outcomes to Therapeutic Opportunities. Antioxidants and Redox Signaling, 2019, 30, 1450-1499. | 2.5 | 90 |
| 410 | A clinical-anatomical signature of Parkinson's disease identified with partial least squares and magnetic resonance imaging. NeuroImage, 2019, 190, 69-78. | 2.1 | 66 |
| 411 | Active information storage in Parkinsonâ€™s disease: a resting state fMRI study over the sensorimotor cortex. Brain Imaging and Behavior, 2020, 14, 1143-1153. | 1.1 | 4 |
| 412 | LRRK2 mutations impair depolarization-induced mitophagy through inhibition of mitochondrial accumulation of RAB10. Autophagy, 2020, 16, 203-222. | 4.3 | 124 |
| 413 | Rapid eye movement sleep deprivation enhances vulnerability of striatal dopaminergic neurons to 1â€methylâ€4â€phenylâ€1,2,3,6â€tetrahydropyridine neurotoxicity in mice. Psychogeriatrics, 2020, 20, 129-130. | 0.6 | 2 |
| 414 | Deep learning based diagnosis of Parkinsonâ€™s disease using convolutional neural network. Multimedia Tools and Applications, 2020, 79, 15467-15479. | 2.6 | 137 |
| 415 | Efficacy of oral administration of licorice as an adjunct therapy on improving the symptoms of patients with Parkinson's disease, A randomized double blinded clinical trial. Journal of Ethnopharmacology, 2020, 247, 112226. | 2.0 | 40 |
| 416 | Apelin-36 mediates neuroprotective effects by regulating oxidative stress, autophagy and apoptosis in MPTP-induced Parkinsonâ€™s disease model mice. Brain Research, 2020, 1726, 146493. | 1.1 | 42 |
| 417 | Recuperative effect of metformin loaded polydopamine nanoformulation promoting EZH2 mediated proteasomal degradation of phospho-Î±-synuclein in Parkinsonâ€™s disease model. Nanomedicine: Nanotechnology, Biology, and Medicine, 2020, 24, 102088. | 1.7 | 29 |
| 418 | An in silico analysis of deleterious single nucleotide polymorphisms and molecular dynamics simulation of disease linked mutations in genes responsible for neurodegenerative disorder. Journal of Biomolecular Structure and Dynamics, 2020, 38, 4259-4272. | 2.0 | 11 |
| 419 | Genetic analysis of NUS1 in Chinese patients with Parkinson's disease. Neurobiology of Aging, 2020, 86, 202.e5-202.e6. | 1.5 | 11 |

| # | Article | IF | Citations |
|---|---|---|---|
| 420 | A single intranigral administration of Î²-sitosterol Î²-d-glucoside elicits bilateral sensorimotor and non-motor alterations in the rat. Behavioural Brain Research, 2020, 378, 112279. | 1.2 | 12 |
| 421 | Conditional, inducible gene silencing in dopamine neurons reveals a sex-specific role for Rit2 GTPase in acute cocaine response and striatal function. Neuropsychopharmacology, 2020, 45, 384-393. | 2.8 | 26 |
| 422 | Biological bases for a possible effect of cannabidiol in Parkinsonâ€™s disease. Revista Brasileira De Psiquiatria, 2020, 42, 218-224. | 0.9 | 18 |
| 423 | Identification of Biomolecular Information in Rotenone-Induced Cellular Model of Parkinson's Disease by Public Microarray Data Analysis. Journal of Computational Biology, 2020, 27, 888-903. | 0.8 | 4 |
| 424 | The imbalance between dynamic and stable microtubules underlies neurodegeneration induced by 2,5-hexanedione. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2020, 1866, 165581. | 1.8 | 8 |
| 425 | Role of endolysosomes and inter-organellar signaling in brain disease. Neurobiology of Disease, 2020, 134, 104670. | 2.1 | 18 |
| 426 | Modifiable risk and protective factors in disease development, progression and clinical subtypes of Parkinson's disease: What do prospective studies suggest?. Neurobiology of Disease, 2020, 134, 104671. | 2.1 | 48 |
| 427 | Genetic deletion of GPR88 enhances the locomotor response to L-DOPA in experimental parkinsonism while counteracting the induction of dyskinesia. Neuropharmacology, 2020, 162, 107829. | 2.0 | 8 |
| 428 | Knowledge and attitudes of Parkinsonâ€™s disease risk in the Gaucher population. Journal of Genetic Counseling, 2020, 29, 105-111. | 0.9 | 7 |
| 429 | Motor Neurons Pathology After Chronic Exposure to MPTP in Mice. Neurotoxicity Research, 2020, 37, 298-313. | 1.3 | 13 |
| 430 | Mitochondrial dysfunction plays a key role in the development of neurodegenerative diseases in diabetes. American Journal of Physiology - Endocrinology and Metabolism, 2020, 318, E750-E764. | 1.8 | 36 |
| 431 | Managing Parkinson's disease: moving ON with NOP. British Journal of Pharmacology, 2020, 177, 28-47. | 2.7 | 11 |
| 432 | Effects of glucocerebrosidase gene polymorphisms and mutations on the risk of Parkinsonâ€™s disease dementia: A meta-analysis. Neuroscience Letters, 2020, 714, 134544. | 1.0 | 5 |
| 433 | Flexible platinum electrodes as electrochemical sensor and immunosensor for Parkinson's disease biomarkers. Biosensors and Bioelectronics, 2020, 152, 112016. | 5.3 | 56 |
| 434 | Systemic activation of NLRP3 inflammasome and plasma Î±-synuclein levels are correlated with motor severity and progression in Parkinsonâ€™s disease. Journal of Neuroinflammation, 2020, 17, 11. | 3.1 | 127 |
| 435 | Î´-secretase in neurodegenerative diseases: mechanisms, regulators and therapeutic opportunities. Translational Neurodegeneration, 2020, 9, 1. | 3.6 | 60 |
| 436 | SNHG1 promotes MPP+-induced cytotoxicity by regulating PTEN/AKT/mTOR signaling pathway in SH-SY5Y cells via sponging miR-153-3p. Biological Research, 2020, 53, 1. | 1.5 | 58 |
| 437 | The â€œLong and Winding Roadâ€•of the Diseaseâ€Modifying Effects of Levodopa Has Not Ended Yet. Movement Disorders, 2020, 35, 397-399. | 2.2 | 6 |

| # | Article | IF | Citations |
|---|---|---|---|
| 438 | â€œEffect of valerenic acid on neuroinflammation in a MPTP-induced mouse model of Parkinsonâ€™s diseaseâ€• IBRO Reports, 2020, 8, 28-35. | 0.3 | 9 |
| 439 | Nigrosome 1 imaging in REM sleep behavior disorder and its association with dopaminergic decline. Annals of Clinical and Translational Neurology, 2020, 7, 26-35. | 1.7 | 32 |
| 440 | Mitochondrial DNA heteroplasmy rises in substantial nigra of aged PINK1 KO mice. Biochemical and Biophysical Research Communications, 2020, 521, 1024-1029. | 1.0 | 3 |
| 441 | Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology. Clinics in Geriatric Medicine, 2020, 36, 1-12. | 1.0 | 487 |
| 442 | Characterization of novel conformation-selective Î±-synuclein antibodies as potential immunotherapeutic agents for Parkinson's disease. Neurobiology of Disease, 2020, 136, 104712. | 2.1 | 31 |
| 443 | Analysis of Cerebrospinal Fluid Soluble TREM2 and Polymorphisms in Sporadic Parkinsonâ€™s Disease in a Chinese Population. Journal of Molecular Neuroscience, 2020, 70, 294-301. | 1.1 | 14 |
| 444 | Quantification and discriminative power of 18F-FE-PE2I PET in patients with Parkinsonâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1913-1926. | 3.3 | 24 |
| 445 | Pramipexole Inhibits MPP+-Induced Neurotoxicity by miR-494-3p/BDNF. Neurochemical Research, 2020, 45, 268-277. | 1.6 | 19 |
| 446 | Role of a novel (â˜)-epigallocatechin-3-gallate delivery system on the prevention against oxidative stress damage in vitro and in vivo model of Parkinson's disease. Journal of Drug Delivery Science and Technology, 2020, 55, 101466. | 1.4 | 13 |
| 447 | The â€˜mitochondrial contact site and cristae organising systemâ€™ (MICOS) in health and human disease. Journal of Biochemistry, 2020, 167, 243-255. | 0.9 | 62 |
| 448 | Muscle-derived Dpp regulates feeding initiation via endocrine modulation of brain dopamine biosynthesis. Genes and Development, 2020, 34, 37-52. | 2.7 | 15 |
| 449 | Psychological Stress Phenocopies Brain Mitochondrial Dysfunction and Motor Deficits as Observed in a Parkinsonian Rat Model. Molecular Neurobiology, 2020, 57, 1781-1798. | 1.9 | 22 |
| 450 | Glottal Source Analysis of Voice Deficits in Newly Diagnosed Drug-naÃ¯ve Patients with Parkinsonâ€™s Disease: Correlation Between Acoustic Speech Characteristics and Non-Speech Motor Performance. Biomedical Signal Processing and Control, 2020, 57, 101818. | 3.5 | 25 |
| 451 | New awakenings: current understanding of sleep dysfunction and its treatment in Parkinsonâ€™s disease. Journal of Neurology, 2020, 267, 288-294. | 1.8 | 25 |
| 452 | Î±-Synuclein BAC transgenic mice exhibit RBD-like behaviour and hyposmia: a prodromal Parkinsonâ€™s disease model. Brain, 2020, 143, 249-265. | 3.7 | 66 |
| 453 | Impacts of exercise intervention on various diseases in rats. Journal of Sport and Health Science, 2020, 9, 211-227. | 3.3 | 61 |
| 454 | SHâ€SY5Y and LUHMES cells display differential sensitivity to MPP+, tunicamycin, and epoxomicin in 2D and 3D cell culture. Biotechnology Progress, 2020, 36, e2942. | 1.3 | 7 |
| 455 | The Role of Xenobiotics and Trace Metals in Parkinsonâ€™s Disease. Molecular Neurobiology, 2020, 57, 1405-1417. | 1.9 | 10 |

| # | Article | IF | Citations |
|---|---|---|---|
| 456 | Unique white matter structural connectivity in early-stage drug-naive Parkinson disease. Neurology, 2020, 94, e774-e784. | 1.5 | 24 |
| 457 | Integrated Plasma and Neuroimaging Biomarkers Associated with Motor and Cognition Severity in Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2020, 10, 77-88. | 1.5 | 20 |
| 458 | Glycosylation changes in inflammatory diseases. Advances in Protein Chemistry and Structural Biology, 2020, 119, 111-156. | 1.0 | 31 |
| 459 | Imbalance of Lysine Acetylation Contributes to the Pathogenesis of Parkinsonâ€™s Disease. International Journal of Molecular Sciences, 2020, 21, 7182. | 1.8 | 21 |
| 460 | Developmental deficits and early signs of neurodegeneration revealed by PD patient derived dopamine neurons. Stem Cell Research, 2020, 49, 102027. | 0.3 | 3 |
| 461 | Toxic Metamorphosisâ€"How Changes from Lysosomal to Cytosolic pH Modify the Alpha-Synuclein Aggregation Pattern. Biomacromolecules, 2020, 21, 4673-4684. | 2.6 | 14 |
| 462 | Theta and gamma connectivity is linked with affective and cognitive symptoms in Parkinson's disease. Journal of Affective Disorders, 2020, 277, 875-884. | 2.0 | 11 |
| 463 | Cell type-specific lipid storage changes in Parkinsonâ€™s disease patient brains are recapitulated by experimental glycolipid disturbance. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 27646-27654. | 3.3 | 59 |
| 464 | Parkinsonâ€™s Disease-Related Risk of Suicide and Effect of Deep Brain Stimulation: Meta-Analysis. Parkinson's Disease, 2020, 2020, 1-10. | 0.6 | 9 |
| 465 | Self-Replication of Prion Protein Fragment 89-230 Amyloid Fibrils Accelerated by Prion Protein Fragment 107-143 Aggregates. International Journal of Molecular Sciences, 2020, 21, 7410. | 1.8 | 3 |
| 466 | Enhancing mitophagy as a therapeutic approach for neurodegenerative diseases. International Review of Neurobiology, 2020, 155, 169-202. | 0.9 | 20 |
| 467 | Overdosing on iron: Elevated iron and degenerative brain disorders. Experimental Biology and Medicine, 2020, 245, 1444-1473. | 1.1 | 26 |
| 468 | Restricted Arm Swing in People With Parkinson's Disease Decreases Step Length and Time on Destabilizing Surfaces. Frontiers in Neurology, 2020, 11, 873. | 1.1 | 9 |
| 469 | A Standardized <scp>MR</scp> Imaging Protocol for Parkinsonism. Movement Disorders, 2020, 35, 1745-1750. | 2.2 | 7 |
| 470 | Loss of MINAR2 impairs motor function and causes Parkinsonâ€™s disease-like symptoms in mice. Brain Communications, 2020, 2, fcaa047. | 1.5 | 6 |
| 471 | Environment and Gene Association With Obesity and Their Impact on Neurodegenerative and Neurodevelopmental Diseases. Frontiers in Neuroscience, 2020, 14, 863. | 1.4 | 61 |
| 472 | Is COVID-19 a Perfect Storm for Parkinsonâ€™s Disease?. Trends in Neurosciences, 2020, 43, 931-933. | 4.2 | 99 |
| 473 | Parthanatos in the pathogenesis of nervous system diseases. Neuroscience, 2020, 449, 241-250. | 1.1 | 44 |

| # | Article | IF | Citations |
|---|---|---|---|
| 474 | Identification of Activities of Daily Living through Artificial Intelligence: an accelerometry-based approach. Procedia Computer Science, 2020, 175, 308-314. | 1.2 | 2 |
| 475 | Contribution of functional dopamine D2 and D3 receptor variants to motor and non-motor symptoms of early onset Parkinsonâ€™s disease. Clinical Neurology and Neurosurgery, 2020, 199, 106257. | 0.6 | 4 |
| 476 | Sub-second Dopamine and Serotonin Signaling in Human Striatum during Perceptual Decision-Making. Neuron, 2020, 108, 999-1010.e6. | 3.8 | 59 |
| 477 | Gangliosides in the Brain: Physiology, Pathophysiology and Therapeutic Applications. Frontiers in Neuroscience, 2020, 14, 572965. | 1.4 | 150 |
| 478 | Histone Deacetylase 6 and the Disease Mechanisms of Î±-Synucleinopathies. Frontiers in Synaptic Neuroscience, 2020, 12, 586453. | 1.3 | 17 |
| 479 | Characterization of a Cul9â€“Parkin double knockout mouse model for Parkinsonâ€™s disease. Scientific Reports, 2020, 10, 16886. | 1.6 | 5 |
| 480 | Mean Apparent Propagator MRI Is Better Than Conventional Diffusion Tensor Imaging for the Evaluation of Parkinsonâ€™s Disease: A Prospective Pilot Study. Frontiers in Aging Neuroscience, 2020, 12, 563595. | 1.7 | 26 |
| 481 | Balancing neurotrophin pathway and sortilin function: Its role in human disease. Biochimica Et Biophysica Acta: Reviews on Cancer, 2020, 1874, 188429. | 3.3 | 19 |
| 482 | Immunoproteasome is up-regulated in rotenone-induced Parkinsonâ€™s disease rat model. Neuroscience Letters, 2020, 738, 135360. | 1.0 | 10 |
| 483 | Defects in mRNA Translation in LRRK2-Mutant hiPSC-Derived Dopaminergic Neurons Lead to Dysregulated Calcium Homeostasis. Cell Stem Cell, 2020, 27, 633-645.e7. | 5.2 | 38 |
| 484 | The Role of Oxidative Stress in Parkinsonâ€™s Disease. Antioxidants, 2020, 9, 597. | 2.2 | 130 |
| 485 | Nonsteroidal <scp>Antiâ€inflammatory</scp> Use and <scp>LRRK2</scp> Parkinson's Disease Penetrance. Movement Disorders, 2020, 35, 1755-1764. | 2.2 | 57 |
| 486 | The lack of association between ubiquinolâ€cytochrome c reductase core protein I (UQCRC1) variants and Parkinson's disease in an eastern Chinese population. CNS Neuroscience and Therapeutics, 2020, 26, 990-992. | 1.9 | 6 |
| 487 | Phosphodiesterase-4 enzyme as a therapeutic target in neurological disorders. Pharmacological Research, 2020, 160, 105078. | 3.1 | 54 |
| 488 | An Integrated System for Parkinsonâ€™s Disease Patients Diagnosis, Using Affordable Technology. , 2020, , . | | 0 |
| 489 | Long nonâ€coding <scp>RNA</scp> NORAD functions as a <scp>microRNAâ€204â€5p</scp> sponge to repress the progression of Parkinson's disease in vitro by increasing the solute carrier family 5 member 3 expression. IUBMB Life, 2020, 72, 2045-2055. | 1.5 | 23 |
| 490 | Current Evidence for a Bidirectional Loop Between the Lysosome and Alpha-Synuclein Proteoforms. Frontiers in Cell and Developmental Biology, 2020, 8, 598446. | 1.8 | 18 |
| 491 | Connectome-Based Model Predicts Deep Brain Stimulation Outcome in Parkinson's Disease. Frontiers in Computational Neuroscience, 2020, 14, 571527. | 1.2 | 10 |

| # | Article | IF | Citations |
|---|---|---|---|
| 492 | Genome Editing for CNS Disorders. Frontiers in Neuroscience, 2020, 14, 579062. | 1.4 | 18 |
| 493 | Extracellular Vesicles in Alzheimerâ€™s and Parkinsonâ€™s Disease: Small Entities with Large Consequences. Cells, 2020, 9, 2485. | 1.8 | 36 |
| 494 | Gait Disturbance Improvement and Cerebral Cortex Rearrangement by Acupuncture in Parkinsonâ€™s Disease: A Pilot Assessor-Blinded, Randomized, Controlled, Parallel-Group Trial. Neurorehabilitation and Neural Repair, 2020, 34, 1111-1123. | 1.4 | 21 |
| 495 | Disease Ionomics: Understanding the Role of Ions in Complex Disease. International Journal of Molecular Sciences, 2020, 21, 8646. | 1.8 | 11 |
| 496 | Alpha-Synuclein in the Gastrointestinal Tract as a Potential Biomarker for Early Detection of Parkinsonâ€™s Disease. International Journal of Molecular Sciences, 2020, 21, 8666. | 1.8 | 13 |
| 497 | Cytochrome P450 Metabolism of Polyunsaturated Fatty Acids and Neurodegeneration. Nutrients, 2020, 12, 3523. | 1.7 | 26 |
| 498 | ATP13A2-mediated endo-lysosomal polyamine export counters mitochondrial oxidative stress. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 31198-31207. | 3.3 | 57 |
| 499 | Wearable Health Technology to Quantify the Functional Impact of Peripheral Neuropathy on Mobility in Parkinsonâ€™s Disease: A Systematic Review. Sensors, 2020, 20, 6627. | 2.1 | 9 |
| 500 | Association of the Plasma Long Non-coding RNA MEG3 With Parkinson's Disease. Frontiers in Neurology, 2020, 11, 532891. | 1.1 | 25 |
| 501 | Molecular Mechanisms of Glutamate Toxicity in Parkinsonâ€™s Disease. Frontiers in Neuroscience, 2020, 14, 585584. | 1.4 | 106 |
| 502 | When Friendship Turns Sour: Effective Communication Between Mitochondria and Intracellular Organelles in Parkinson's Disease. Frontiers in Cell and Developmental Biology, 2020, 8, 607392. | 1.8 | 12 |
| 503 | The Dichotomous Role of Extracellular Vesicles in the Central Nervous System. IScience, 2020, 23, 101456. | 1.9 | 22 |
| 504 | Self-Medication with Ganoderma lucidum (â€œReishiâ€) to Combat Parkinson's Disease Symptoms: A Single Case Study. Journal of Medicinal Food, 2021, 24, 766-773. | 0.8 | 3 |
| 505 | Brain White-Matter Degeneration Due to Aging and Parkinson Disease as Revealed by Double Diffusion Encoding. Frontiers in Neuroscience, 2020, 14, 584510. | 1.4 | 18 |
| 506 | Teaghrelin Protects SH-SY5Y Cells against MPP+-Induced Neurotoxicity through Activation of AMPK/SIRT1/PGC-1Î± and ERK1/2 Pathways. Nutrients, 2020, 12, 3665. | 1.7 | 14 |
| 507 | TRIM11 Prevents and Reverses Protein Aggregation and Rescues a Mouse Model of Parkinsonâ€™s Disease. Cell Reports, 2020, 33, 108418. | 2.9 | 39 |
| 508 | Propagated Î±-synucleinopathy recapitulates REM sleep behaviour disorder followed by parkinsonian phenotypes in mice. Brain, 2020, 143, 3374-3392. | 3.7 | 42 |
| 509 | Mitochondrial Miro GTPases coordinate mitochondrial and peroxisomal dynamics. Small GTPases, 2021, 12, 372-398. | 0.7 | 12 |

| # | Article | IF | Citations |
|---|---|---|---|
| 510 | Complex Interaction between Resident Microbiota and Misfolded Proteins: Role in Neuroinflammation and Neurodegeneration. Cells, 2020, 9, 2476. | 1.8 | 31 |
| 511 | Data-driven evolution of neurosurgical gene therapy delivery in Parkinsonâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1210-1218. | 0.9 | 16 |
| 512 | Loss of Presynaptic Terminal Integrity in the Substantia Nigra in Early Parkinson's Disease. Movement Disorders, 2020, 35, 1977-1986. | 2.2 | 52 |
| 513 | Progress in the molecular pathogenesis and nucleic acid therapeutics for Parkinson's disease in the precision medicine era. Medicinal Research Reviews, 2020, 40, 2650-2681. | 5.0 | 32 |
| 514 | Experimental studies of mitochondrial and lysosomal function in in vitro and in vivo models relevant to Parkinson's disease genetic risk. International Review of Neurobiology, 2020, 154, 279-302. | 0.9 | 5 |
| 515 | Papaverine inhibits Î±-synuclein aggregation by modulating neuroinflammation and matrix metalloproteinase-3 expression in the subacute MPTP/P mouse model of Parkinsonâ€™s disease. Biomedicine and Pharmacotherapy, 2020, 130, 110576. | 2.5 | 16 |
| 516 | Baicalein Attenuates Neuroinflammation by Inhibiting NLRP3/Caspase-1/GSDMD Pathway in MPTP-Induced Mice Model of Parkinsonâ€™s Disease. International Journal of Neuropsychopharmacology, 2020, 23, 762-773. | 1.0 | 94 |
| 517 | Upregulating Î²-hexosaminidase activity in rodents prevents Î±-synuclein lipid associations and protects dopaminergic neurons from Î±-synuclein-mediated neurotoxicity. Acta Neuropathologica Communications, 2020, 8, 127. | 2.4 | 17 |
| 518 | Induced Pluripotent Stem Cells: Hope in the Treatment of Diseases, including Muscular Dystrophies. International Journal of Molecular Sciences, 2020, 21, 5467. | 1.8 | 9 |
| 519 | Efficacy and safety of atypical antipsychotics for psychosis in Parkinson's disease: A systematic review and Bayesian network meta-analysis. Parkinsonism and Related Disorders, 2020, 78, 82-90. | 1.1 | 19 |
| 520 | Quickcard-Based Approach to Guiding Specific Nonpharmacological Treatments in a German Parkinsonâ€™s Network. Journal of Clinical Medicine, 2020, 9, 2272. | 1.0 | 6 |
| 521 | The hot sites of Î±-synuclein in amyloid fibril formation. Scientific Reports, 2020, 10, 12175. | 1.6 | 10 |
| 522 | Hand Resting Tremor Assessment of Healthy and Patients With Parkinsonâ€™s Disease: An Exploratory Machine Learning Study. Frontiers in Bioengineering and Biotechnology, 2020, 8, 778. | 2.0 | 19 |
| 523 | Modeling Î±-Synucleinopathy in Organotypic Brain Slice Culture with Preformed Î±-Synuclein Amyloid Fibrils. Journal of Parkinson's Disease, 2020, 10, 1397-1410. | 1.5 | 6 |
| 524 | LRRK2 and Protein Aggregation in Parkinsonâ€™s Disease: Insights From Animal Models. Frontiers in Neuroscience, 2020, 14, 719. | 1.4 | 13 |
| 525 | The Functional Roles and Applications of Immunoglobulins in Neurodegenerative Disease. International Journal of Molecular Sciences, 2020, 21, 5295. | 1.8 | 18 |
| 526 | From Synaptic Dysfunction to Neuroprotective Strategies in Genetic Parkinsonâ€™s Disease: Lessons From LRRK2. Frontiers in Cellular Neuroscience, 2020, 14, 158. | 1.8 | 15 |
| 527 | Relationship between Blood and Standard Biochemistry Levels with Periodontitis in Parkinsonâ€™s Disease Patients: Data from the NHANES 2011â€“2012. Journal of Personalized Medicine, 2020, 10, 69. | 1.1 | 21 |

| # | Article | IF | Citations |
|---|---|---|---|
| 528 | Enhanced activity of glycolytic enzymes in Drosophila and human cell models of Parkinson's disease based on DJ-1 deficiency. Free Radical Biology and Medicine, 2020, 158, 137-148. | 1.3 | 25 |
| 529 | Embarrassment and Shame in People With Parkinson's Disease: A New Tool for Self-Assessment. Frontiers in Neurology, 2020, 11, 779. | 1.1 | 1 |
| 530 | Neuroimmunogastroenterology: At the Interface of Neuroimmunology and Gastroenterology. Frontiers in Neurology, 2020, 11, 787. | 1.1 | 7 |
| 531 | Antiâ€Parkinson's Disease Function of Dioscinâ€Zeinâ€Carboxymethyl Cellulose Nanocomplex in Caenorhabditis elegans. Biotechnology Journal, 2020, 15, 2000080. | 1.8 | 6 |
| 532 | Intraocular pressure and circumpapillary retinal nerve fibre layer thickness in the Northern Ireland Cohort for the Longitudinal Study of Ageing (NICOLA): distributions and associations. British Journal of Ophthalmology, 2021, 105, 948-956. | 2.1 | 8 |
| 533 | The insect molting hormone 20-hydroxyecdysone protects dopaminergic neurons against MPTP-induced neurotoxicity in a mouse model of Parkinson's disease. Free Radical Biology and Medicine, 2020, 159, 23-36. | 1.3 | 19 |
| 534 | Parkinson's: A Disease of Aberrant Vesicle Trafficking. Annual Review of Cell and Developmental Biology, 2020, 36, 237-264. | 4.0 | 54 |
| 535 | Role of Prefrontal Cortex on Recognition Memory Deficits in Rats following 6-OHDA-InducedLocus CoeruleusLesion. Oxidative Medicine and Cellular Longevity, 2020, 2020, 1-10. | 1.9 | 6 |
| 536 | GCH1 variants contribute to the risk and earlier age-at-onset of Parkinsonâ€™s disease: a two-cohort case-control study. Translational Neurodegeneration, 2020, 9, 31. | 3.6 | 30 |
| 537 | Caenorhabditis elegans as a model system for studying aging-associated neurodegenerative diseases. Translational Medicine of Aging, 2020, 4, 60-72. | 0.6 | 27 |
| 538 | Antioxidant and Anti-inflammatory Effect of Nrf2 Inducer Dimethyl Fumarate in Neurodegenerative Diseases. Antioxidants, 2020, 9, 630. | 2.2 | 62 |
| 539 | Subthalamic nucleus deep brain stimulation suppresses neuroinflammation by Fractalkine pathway in Parkinsonâ€™s disease rat model. Brain, Behavior, and Immunity, 2020, 90, 16-25. | 2.0 | 26 |
| 540 | Endocannabinoid levels in patients with Parkinsonâ€™s disease with and without levodopa-induced dyskinesias. Journal of Neural Transmission, 2020, 127, 1359-1367. | 1.4 | 13 |
| 541 | Clinical Characteristics and Electrophysiological Biomarkers of Parkinson's Disease Developed From Essential Tremor. Frontiers in Neurology, 2020, 11, 582471. | 1.1 | 3 |
| 542 | Pharmacological management of Parkinsonâ€™s disease in older people. Journal of Pharmacy Practice and Research, 2020, 50, 445-454. | 0.5 | 6 |
| 543 | Efficient Pre-diagnosis Approach for Rarkinsonâ€™s Disease with Machine Learning. , 2020, , . | | 0 |
| 544 | Î±-Bisabolol, a Dietary Bioactive Phytochemical Attenuates Dopaminergic Neurodegeneration through Modulation of Oxidative Stress, Neuroinflammation and Apoptosis in Rotenone-Induced Rat Model of Parkinsonâ€™s Disease. Biomolecules, 2020, 10, 1421. | 1.8 | 37 |
| 545 | Parkinson's disease is an autoimmune disease: A reappraisal. Autoimmunity Reviews, 2020, 19, 102684. | 2.5 | 27 |

| # | Article | IF | Citations |
|---|---|---|---|
| 546 | Synchronization to auditory and visual beats in Parkinson's disease. Parkinsonism and Related Disorders, 2020, 79, 47-54. | 1.1 | 2 |
| 547 | Identification of Molecular Network Associated with Neuroprotective Effects of Yashtimadhu (Glycyrrhiza glabra L.) by Quantitative Proteomics of Rotenone-Induced Parkinsonâ€™s Disease Model. ACS Omega, 2020, 5, 26611-26625. | 1.6 | 22 |
| 548 | Unraveling Pathophysiological Mechanisms of Parkinsonâ€™s Disease: Contribution of CSF Biomarkers. Biomarker Insights, 2020, 15, 117727192096407. | 1.0 | 7 |
| 549 | Dietary Antioxidants and the Mitochondrial Quality Control: Their Potential Roles in Parkinsonâ€™s Disease Treatment. Antioxidants, 2020, 9, 1056. | 2.2 | 11 |
| 550 | Functional Recovery in Parkinsonâ€™s Disease: Current State and Future Perspective. Journal of Clinical Medicine, 2020, 9, 3413. | 1.0 | 3 |
| 551 | Sigma-1 receptor regulates mitophagy in dopaminergic neurons and contributes to dopaminergic protection. Neuropharmacology, 2021, 196, 108360. | 2.0 | 12 |
| 552 | A new neuroprotective strategy for the drug therapy of Parkinson's disease: Ca2+/cAMP signaling as therapeutic targets. , 2020, , 427-443. | | 0 |
| 553 | Novel Drosophila model for parkinsonism by targeting phosphoglycerate kinase. Neurochemistry International, 2020, 139, 104816. | 1.9 | 7 |
| 554 | Can Growth Factors Cure Parkinsonâ€™s Disease?. Trends in Pharmacological Sciences, 2020, 41, 909-922. | 4.0 | 29 |
| 555 | Dual-Ionomer-Based Device: Acetylcholine Transport and Nonenzymatic Sensing. ACS Applied Materials & Interfaces, 2020, 12, 50039-50051. | 4.0 | 3 |
| 556 | Multimodal Evaluation of Neurovascular Functionality in Early Parkinson's Disease. Frontiers in Neurology, 2020, 11, 831. | 1.1 | 13 |
| 557 | Early Biomarkers of Neurodegenerative and Neurovascular Disorders in Diabetes. Journal of Clinical Medicine, 2020, 9, 2807. | 1.0 | 45 |
| 558 | Fraternine, a Novel Wasp Peptide, Protects against Motor Impairments in 6-OHDA Model of Parkinsonism. Toxins, 2020, 12, 550. | 1.5 | 8 |
| 559 | Parkinsonâ€™s Disease-Induced Zebrafish Models: Focussing on Oxidative Stress Implications and Sleep Processes. Oxidative Medicine and Cellular Longevity, 2020, 2020, 1-15. | 1.9 | 24 |
| 560 | Blood pressure lability is associated with subcortical atrophy in early Parkinson's disease. Journal of Hypertension, 2020, 38, 2043-2049. | 0.3 | 7 |
| 561 | Miniaturized Intracerebral Potential Recorder for Long-Term Local Field Potential of Deep Brain Signals. , 2020, 2020, 5188-5191. | | 0 |
| 562 | Differential effects of deep brain stimulation and levodopa on brain activity in Parkinsonâ€™s disease. Brain Communications, 2020, 2, fcaa005. | 1.5 | 18 |
| 563 | The role of natural killer cells in Parkinsonâ€™s disease. Experimental and Molecular Medicine, 2020, 52, 1517-1525. | 3.2 | 42 |

| # | Article | IF | Citations |
|---|---|---|---|
| 564 | Effects of an Innovative Telerehabilitation Intervention for People With Parkinson's Disease on Quality of Life, Motor, and Non-motor Abilities. Frontiers in Neurology, 2020, 11, 846. | 1.1 | 58 |
| 565 | Has Deep Brain Stimulation Changed the Very Longâ€Term Outcome of Parkinson's Disease? A Controlled Longitudinal Study. Movement Disorders Clinical Practice, 2020, 7, 782-787. | 0.8 | 11 |
| 566 | Discovery of Novel Procaineâ€Imidazole Derivative as Inhibitor of Monoamine Oxidaseâ€B for Potential Benefit in Parkinson's Disease. ChemistrySelect, 2020, 5, 10928-10932. | 0.7 | 1 |
| 567 | Post-GWAS knowledge gap: the how, where, and when. Npj Parkinson's Disease, 2020, 6, 23. | 2.5 | 19 |
| 568 | Risk factors of Parkinson disease. Neurology, 2020, 95, e2500-e2508. | 1.5 | 41 |
| 569 | Genetic variants of vitamin D metabolism-related DHCR7/NADSYN1 locus and CYP2R1 gene are associated with clinical features of Parkinsonâ€™s disease. International Journal of Neuroscience, 2022, 132, 439-449. | 0.8 | 5 |
| 570 | Pluripotent Stem Cell Therapies for Parkinson Disease: Present Challenges and Future Opportunities. Frontiers in Cell and Developmental Biology, 2020, 8, 729. | 1.8 | 65 |
| 571 | Monoamine Oxidase Inhibitors: From Classic to New Clinical Approaches. Handbook of Experimental Pharmacology, 2020, 264, 229-259. | 0.9 | 20 |
| 572 | Investigation of anti-Parkinson activity of dicyclomineÂ. International Journal of Neuroscience, 2022, 132, 338-351. | 0.8 | 8 |
| 573 | The Mitochondrial Unfolded Protein Response: A Hinge Between Healthy and Pathological Aging. Frontiers in Aging Neuroscience, 2020, 12, 581849. | 1.7 | 36 |
| 574 | Therapeutic strategies for Parkinsonâ€™s disease: promising agents in early clinical development. Expert Opinion on Investigational Drugs, 2020, 29, 1249-1267. | 1.9 | 6 |
| 575 | Pro-inflammatory Cytokines and Sudden Death in Parkinsonâ€™s Disease: a Missing Piece of the Jigsaw Puzzle. Journal of NeuroImmune Pharmacology, 2020, 15, 570-571. | 2.1 | 1 |
| 576 | Protein synthesis is suppressed in sporadic and familial Parkinsonâ€™s disease by LRRK2. FASEB Journal, 2020, 34, 14217-14233. | 0.2 | 17 |
| 577 | Calcium, Bioenergetics, and Parkinsonâ€™s Disease. Cells, 2020, 9, 2045. | 1.8 | 46 |
| 578 | Integrative Medicine and Health Therapy for Parkinson Disease. Topics in Geriatric Rehabilitation, 2020, 36, 176-186. | 0.2 | 11 |
| 579 | PET Imaging for Oxidative Stress in Neurodegenerative Disorders Associated with Mitochondrial Dysfunction. Antioxidants, 2020, 9, 861. | 2.2 | 25 |
| 580 | Correlates of polyneuropathy in Parkinsonâ€™s disease. Annals of Clinical and Translational Neurology, 2020, 7, 1898-1907. | 1.7 | 5 |
| 581 | Exercise for Older Adults Improves the Quality of Life in Parkinsonâ€™s Disease and Potentially Enhances the Immune Response to COVID-19. Brain Sciences, 2020, 10, 612. | 1.1 | 15 |

| # | Article | IF | Citations |
|---|---|---|---|
| 582 | Enhanced accumulation of reduced glutathione by Scopoletin improves survivability of dopaminergic neurons in Parkinsonâ€™s model. Cell Death and Disease, 2020, 11, 739. | 2.7 | 26 |
| 583 | <p><em>PINK1</em> Overexpression Promotes Cell Migration and Proliferation via Regulation of Autophagy and Predicts a Poor Prognosis in Lung Cancer Cases</p>. Cancer Management and Research, 2020, Volume 12, 7703-7714. | 0.9 | 19 |
| 584 | Gene-Editing Technologies Paired With Viral Vectors for Translational Research Into Neurodegenerative Diseases. Frontiers in Molecular Neuroscience, 2020, 13, 148. | 1.4 | 20 |
| 585 | Dopamine D1 receptor signalling in dyskinetic Parkinsonian rats revealed by fiber photometry using FRET-based biosensors. Scientific Reports, 2020, 10, 14426. | 1.6 | 21 |
| 586 | Treatment with the flavonoid 7,8-Dihydroxyflavone: a promising strategy for a constellation of body and brain disorders. Critical Reviews in Food Science and Nutrition, 2022, 62, 13-50. | 5.4 | 30 |
| 587 | NIR-II-Activated Yolkâ€“Shell Nanostructures as an Intelligent Platform for Parkinsonian Therapy. ACS Applied Bio Materials, 2020, 3, 6876-6887. | 2.3 | 17 |
| 588 | Ferroptosis: Biological Rust of Lipid Membranes. Antioxidants and Redox Signaling, 2021, 35, 487-509. | 2.5 | 42 |
| 589 | A single-cell atlas of the human substantia nigra reveals cell-specific pathways associated with neurological disorders. Nature Communications, 2020, 11, 4183. | 5.8 | 178 |
| 590 | Possible Neuroprotective Mechanisms of Physical Exercise in Neurodegeneration. International Journal of Molecular Sciences, 2020, 21, 5895. | 1.8 | 127 |
| 591 | Emergence of Beta Oscillations of a Resonance Model for Parkinsonâ€™s Disease. Neural Plasticity, 2020, 2020, 1-15. | 1.0 | 9 |
| 592 | LncRNA-T199678 Mitigates Î±-Synuclein-Induced Dopaminergic Neuron Injury via miR-101-3p. Frontiers in Aging Neuroscience, 2020, 12, 599246. | 1.7 | 20 |
| 593 | Insights Into the Proteomic Profiling of Extracellular Vesicles for the Identification of Early Biomarkers of Neurodegeneration. Frontiers in Neurology, 2020, 11, 580030. | 1.1 | 29 |
| 594 | Mitophagy and the Brain. International Journal of Molecular Sciences, 2020, 21, 9661. | 1.8 | 32 |
| 595 | The Roles of Matrix Metalloproteinases and Their Inhibitors in Human Diseases. International Journal of Molecular Sciences, 2020, 21, 9739. | 1.8 | 585 |
| 596 | Targeting Vesicular Glutamate Transporter Machinery: Implications on Metabotropic Glutamate Receptor 5 Signaling and Behavior. Molecular Pharmacology, 2020, 98, 314-327. | 1.0 | 2 |
| 597 | Targeting Microglia for Therapy of Parkinsonâ€™s Disease by Using Biomimetic Ultrasmall Nanoparticles. Journal of the American Chemical Society, 2020, 142, 21730-21742. | 6.6 | 97 |
| 598 | The Convergence of Alpha-Synuclein, Mitochondrial, and Lysosomal Pathways in Vulnerability of Midbrain Dopaminergic Neurons in Parkinsonâ€™s Disease. Frontiers in Cell and Developmental Biology, 2020, 8, 580634. | 1.8 | 40 |
| 599 | Insights Into Translatomics in the Nervous System. Frontiers in Genetics, 2020, 11, 599548. | 1.1 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 600 | Multi-parameter Behavioral Phenotyping of the MPP+ Model of Parkinsonâ€™s Disease in Zebrafish. Frontiers in Behavioral Neuroscience, 2020, 14, 623924. | 1.0 | 10 |
| 601 | Unmet needs in Parkinson disease: Motor and non-motor. Parkinsonism and Related Disorders, 2020, 80, S7-S12. | 1.1 | 56 |
| 602 | Regulatory Roles of Bone in Neurodegenerative Diseases. Frontiers in Aging Neuroscience, 2020, 12, 610581. | 1.7 | 10 |
| 603 | Acylated Ghrelin as a Multi-Targeted Therapy for Alzheimer's and Parkinson's Disease. Frontiers in Neuroscience, 2020, 14, 614828. | 1.4 | 30 |
| 604 | Panax notoginseng saponins and their applications in nervous system disorders: a narrative review. Annals of Translational Medicine, 2020, 8, 1525-1525. | 0.7 | 20 |
| 605 | Protective Role of Heat Shock Proteins During Neurodegeneration in Parkinsonâ€™s Disease. Heat Shock Proteins, 2020, , 33-51. | 0.2 | 2 |
| 607 | Cytokine-, Neurotrophin-, and Motor Rehabilitation-Induced Plasticity in Parkinsonâ€™s Disease. Neural Plasticity, 2020, 2020, 1-15. | 1.0 | 5 |
| 608 | PasoDoble, a Proposed Dance/Music for People With Parkinson's Disease and Their Caregivers. Frontiers in Neurology, 2020, 11, 567891. | 1.1 | 2 |
| 609 | Quantitative Proteomic Analysis of Primitive Neural Stem Cells from LRRK2 G2019S-Associated Parkinsonâ€™s Disease Patient-Derived iPSCs. Life, 2020, 10, 331. | 1.1 | 7 |
| 610 | In Vitro and In Silico ADME-Tox Profiling and Safety Significance of Multifunctional Monoamine Oxidase Inhibitors Targeting Neurodegenerative Diseases. ACS Chemical Neuroscience, 2020, 11, 3793-3801. | 1.7 | 7 |
| 611 | Genetic Risk Profiling in Parkinsonâ€™s Disease and Utilizing Genetics to Gain Insight into Disease-Related Biological Pathways. International Journal of Molecular Sciences, 2020, 21, 7332. | 1.8 | 16 |
| 612 | Multiple neuroprotective features of Scutellaria pinnatifidaâ€“derived small molecule. Heliyon, 2020, 6, e04737. | 1.4 | 7 |
| 613 | Stem Cell-Based Therapies for Parkinson Disease. International Journal of Molecular Sciences, 2020, 21, 8060. | 1.8 | 41 |
| 614 | Blood neurofilament light: a critical review of its application to neurologic disease. Annals of Clinical and Translational Neurology, 2020, 7, 2508-2523. | 1.7 | 132 |
| 615 | Pharmacogenetic profile and the development of the dyskinesia induced by levodopa-therapy in Parkinsonâ€™s disease patients: a population-based cohort study. Molecular Biology Reports, 2020, 47, 8997-9004. | 1.0 | 6 |
| 616 | Improving the Delivery of Levodopa in Parkinsonâ€™s Disease: A Review of Approved and Emerging Therapies. CNS Drugs, 2020, 34, 1149-1163. | 2.7 | 25 |
| 617 | Dopaminergic modulation of novelty repetition in Parkinsonâ€™s disease: A study of P3 event-related brain potentials. Clinical Neurophysiology, 2020, 131, 2841-2850. | 0.7 | 6 |
| 618 | Constipation and sleep behaviour disorder associate with processing speed and attention in males with Parkinsonâ€™s disease over five years follow-up. Scientific Reports, 2020, 10, 19014. | 1.6 | 15 |

| # | Article | IF | Citations |
|---|---|---|---|
| 619 | TRPM2 channel-mediated cell death: An important mechanism linking oxidative stress-inducing pathological factors to associated pathological conditions. Redox Biology, 2020, 37, 101755. | 3.9 | 71 |
| 620 | Deferred Administration of Afobazole Induces Sigma1R-Dependent Restoration of Striatal Dopamine Content in a Mouse Model of Parkinsonâ€™s Disease. International Journal of Molecular Sciences, 2020, 21, 7620. | 1.8 | 6 |
| 621 | Friend or Foe: Lipid Droplets as Organelles for Protein and Lipid Storage in Cellular Stress Response, Aging and Disease. Molecules, 2020, 25, 5053. | 1.7 | 39 |
| 622 | An Optimized Brain-Based Algorithm for Classifying Parkinsonâ€™s Disease. Applied Sciences (Switzerland), 2020, 10, 1827. | 1.3 | 32 |
| 623 | Modeling Neurodegenerative Disorders in Drosophila melanogaster. International Journal of Molecular Sciences, 2020, 21, 3055. | 1.8 | 67 |
| 624 | Fibroblast growth factor 21 and autophagy: A complex interplay in Parkinson disease. Biomedicine and Pharmacotherapy, 2020, 127, 110145. | 2.5 | 18 |
| 625 | Cardiovascular autonomic function testing in multiple system atrophy and Parkinsonâ€™s disease: an expert-based blinded evaluation. Clinical Autonomic Research, 2020, 30, 255-263. | 1.4 | 10 |
| 626 | Metformin as a Potential Neuroprotective Agent in Prodromal Parkinson's Diseaseâ€”Viewpoint. Frontiers in Neurology, 2020, 11, 556. | 1.1 | 28 |
| 627 | Iroquois Homeobox Protein 2 Identified as a Potential Biomarker for Parkinsonâ€™s Disease. International Journal of Molecular Sciences, 2020, 21, 3455. | 1.8 | 7 |
| 628 | Impact of Aging on the 6-OHDA-Induced Rat Model of Parkinsonâ€™s Disease. International Journal of Molecular Sciences, 2020, 21, 3459. | 1.8 | 24 |
| 629 | Air pollution and sudden death risk in patients with Parkinsonâ€™s disease: Assessing the evidence to date. Public Health in Practice, 2020, 1, 100008. | 0.7 | 0 |
| 630 | Independence of Coping Styles With the Patientâ€“Doctor Relationship and Shared Decision-Making in People With Parkinsonâ€™s Disease. Journal of Patient Experience, 2020, 7, 1271-1277. | 0.4 | 2 |
| 631 | Therapeutic Strategies to Treat or Prevent Off Episodes in Adults with Parkinsonâ€™s Disease. Drugs, 2020, 80, 775-796. | 4.9 | 23 |
| 632 | Progression of grey and white matter brain damage in Parkinson's disease: a critical review of structural MRI literature. Journal of Neurology, 2021, 268, 3144-3179. | 1.8 | 63 |
| 633 | Decreased Vacuolar Ca2+ Storage and Disrupted Vesicle Trafficking Underlie Alpha-Synuclein-Induced Ca2+ Dysregulation in S. cerevisiae. Frontiers in Genetics, 2020, 11, 266. | 1.1 | 6 |
| 634 | Aerobic Exercise and Healthy Nutrition as Neuroprotective Agents for Brain Health in Patients with Parkinsonâ€™s Disease: A Critical Review of the Literature. Antioxidants, 2020, 9, 380. | 2.2 | 9 |
| 635 | Roles of Autophagy in Oxidative Stress. International Journal of Molecular Sciences, 2020, 21, 3289. | 1.8 | 189 |
| 636 | A-Type Cinnamon Procyanidin Oligomers Protect Against 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Neurotoxicity in Mice Through Inhibiting the P38 Mitogen-Activated Protein Kinase/P53/BCL-2 Associated X Protein Signaling Pathway. Journal of Nutrition, 2020, 150, 1731-1737. | 1.3 | 12 |

| # | Article | IF | Citations |
|---|---|---|---|
| 637 | Absent Arm Swing and Dual Tasking Decreases Trunk Postural Control and Dynamic Balance in People With Parkinson's Disease. Frontiers in Neurology, 2020, 11, 213. | 1.1 | 16 |
| 638 | Domperidone in Parkinsonâ€™s disease: a valuable controversy, but unnecessary panic. Family Practice, 2020, 37, 723-724. | 0.8 | 0 |
| 639 | Functionalized Mesoporous Silicas Direct Structural Polymorphism of Amyloid-Î² Fibrils. Langmuir, 2020, 36, 7345-7355. | 1.6 | 3 |
| 640 | The evidence for multidisciplinary care in Parkinsonâ€™s disease. Expert Review of Neurotherapeutics, 2020, 20, 539-549. | 1.4 | 14 |
| 641 | Potential Role of Vitamin D in the Elderly to Resist COVID-19 and to Slow Progression of Parkinsonâ€™s Disease. Brain Sciences, 2020, 10, 284. | 1.1 | 69 |
| 642 | Polymicrobial Infections and Neurodegenerative Diseases. Current Clinical Microbiology Reports, 2020, 7, 20-30. | 1.8 | 5 |
| 643 | Longitudinal brain connectivity changes and clinical evolution in Parkinsonâ€™s disease. Molecular Psychiatry, 2021, 26, 5429-5440. | 4.1 | 39 |
| 644 | Identifying drugs with diseaseâ€modifying potential in Parkinson's disease using artificial intelligence and pharmacoepidemiology. Pharmacoepidemiology and Drug Safety, 2020, 29, 864-872. | 0.9 | 22 |
| 645 | Alpha-Synuclein and LRRK2 in Synaptic Autophagy: Linking Early Dysfunction to Late-Stage Pathology in Parkinsonâ€™s Disease. Cells, 2020, 9, 1115. | 1.8 | 18 |
| 646 | The role of mitochondrial-related nuclear genes in age-related common disease. Mitochondrion, 2020, 53, 38-47. | 1.6 | 25 |
| 647 | Access and Use of Deviceâ€Aided Therapies for Parkinsonâ€™s Disease in Denmark. Movement Disorders Clinical Practice, 2020, 7, 656-663. | 0.8 | 12 |
| 648 | Genetic analysis of arylsulfatase A (ARSA) in Chinese patients with Parkinsonâ€™s disease. Neuroscience Letters, 2020, 734, 135094. | 1.0 | 3 |
| 649 | Microglia depletion prior to lipopolysaccharide and paraquat treatment differentially modulates behavioral and neuronal outcomes in wild type and G2019S LRRK2 knock-in mice. Brain, Behavior, & Immunity - Health, 2020, 5, 100079. | 1.3 | 9 |
| 650 | Small Molecule Chaperones for the Treatment of Gaucher Disease and GBA1-Associated Parkinson Disease. Frontiers in Cell and Developmental Biology, 2020, 8, 271. | 1.8 | 40 |
| 651 | A novel multi-marker discovery approach identifies new serum biomarkers for Parkinsonâ€™s disease in older people: an EXosomes in PArkiNson Disease (EXPAND) ancillary study. GeroScience, 2020, 42, 1323-1334. | 2.1 | 32 |
| 652 | Nanomedicine-based immunotherapy for central nervous system disorders. Acta Pharmacologica Sinica, 2020, 41, 936-953. | 2.8 | 38 |
| 653 | The preclinical discovery and development of opicapone for the treatment of Parkinsonâ€™s disease. Expert Opinion on Drug Discovery, 2020, 15, 993-1003. | 2.5 | 5 |
| 654 | Role of Long Noncoding RNAs in Parkinsonâ€™s Disease: Putative Biomarkers and Therapeutic Targets. Parkinson's Disease, 2020, 2020, 1-12. | 0.6 | 20 |

| # | Article | IF | Citations |
|---|---|---|---|
| 655 | Amide derivatives of Gallic acid: Design, synthesis and evaluation of inhibitory activities against in vitro Î±-synuclein aggregation. Bioorganic and Medicinal Chemistry, 2020, 28, 115596. | 1.4 | 14 |
| 656 | Neuroprotective Effect of Chlorogenic Acid on Mitochondrial Dysfunction-Mediated Apoptotic Death of DA Neurons in a Parkinsonian Mouse Model. Oxidative Medicine and Cellular Longevity, 2020, 2020, 1-14. | 1.9 | 101 |
| 657 | Reversing a model of Parkinsonâ€™s disease with in situ converted nigral neurons. Nature, 2020, 582, 550-556. | 13.7 | 316 |
| 658 | On â€œComparative Effectiveness of mHealth-Supported Exercise Compared With Exercise Alone for People With Parkinson Disease: Randomized Controlled Pilot Study.â€•Ellis TD, Cavanaugh JT, DeAngelis T, Hendron K, Thomas CA, Saint-Hilaire M, Pencina K, Latham NK. Phys Ther. 2019; 99:203â€“216. Physical Therapy, 2020, 100, 1229-1229. | 1.1 | 3 |
| 659 | The human olfactory system in two proteinopathies: Alzheimerâ€™s and Parkinsonâ€™s diseases. Translational Neurodegeneration, 2020, 9, 22. | 3.6 | 62 |
| 660 | Discovery and optimization of 3-thiophenylcoumarins as novel agents against Parkinsonâ€™s disease: Synthesis, in vitro and in vivo studies. Bioorganic Chemistry, 2020, 101, 103986. | 2.0 | 14 |
| 661 | Novel drug delivery systems of Î²2 adrenoreceptor agonists to suppress SNCA gene expression and mitochondrial oxidative stress in Parkinsonâ€™s disease management. Expert Opinion on Drug Delivery, 2020, 17, 1119-1132. | 2.4 | 10 |
| 662 | Application of a Simple Parkinson's Disease Risk Score in a Longitudinal <scp>Populationâ€Based</scp> Cohort. Movement Disorders, 2020, 35, 1658-1662. | 2.2 | 11 |
| 663 | Mechanisms of neurodegeneration in Parkinsonâ€™s disease: keep neurons in the PINK1. Mechanisms of Ageing and Development, 2020, 189, 111277. | 2.2 | 11 |
| 664 | Analysis of Quinone Reductase 2 Implication in Mechanism of Antiparkinsonian Action of Afobazole. Neurochemical Journal, 2020, 14, 227-234. | 0.2 | 3 |
| 665 | Editorial: The Role of Stem Cells, Epigenetics and MicroRNAs in Parkinson's Disease. Frontiers in Neuroscience, 2020, 14, 515. | 1.4 | 3 |
| 666 | Recent Advancements of Nanomedicine in Neurodegenerative Disorders Theranostics. Advanced Functional Materials, 2020, 30, 2003054. | 7.8 | 83 |
| 667 | Design of amino acid-based self-assembled nano-drugs for therapeutic applications. Journal of Controlled Release, 2020, 326, 140-149. | 4.8 | 18 |
| 668 | Safety and immunogenicity of the Î±-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial. Lancet Neurology, The, 2020, 19, 591-600. | 4.9 | 83 |
| 669 | Mutation screening and burden analysis of VPS13C in Chinese patients with early-onset Parkinson's disease. Neurobiology of Aging, 2020, 94, 311.e1-311.e4. | 1.5 | 16 |
| 670 | PDMeter: A Wrist Wearable Device for an at-Home Assessment of the Parkinsonâ€™s Disease Rigidity. IEEE Transactions on Neural Systems and Rehabilitation Engineering, 2020, 28, 1325-1333. | 2.7 | 24 |
| 671 | In vitro Models of Neurodegenerative Diseases. Frontiers in Cell and Developmental Biology, 2020, 8, 328. | 1.8 | 149 |
| 672 | Translation Imaging in Parkinsonâ€™s Disease: Focus on Neuroinflammation. Frontiers in Aging Neuroscience, 2020, 12, 152. | 1.7 | 28 |

| # | Article | IF | Citations |
|---|---|---|---|
| 673 | Identification of Diseases Based on the Use of Inertial Sensors: A Systematic Review. Electronics (Switzerland), 2020, 9, 778. | 1.8 | 10 |
| 674 | Glial cell line-derived neurotrophic factors (GFLs) and small molecules targeting RET receptor for the treatment of pain and Parkinsonâ€™s disease. Cell and Tissue Research, 2020, 382, 147-160. | 1.5 | 22 |
| 675 | Brain insulin resistance: role in neurodegenerative disease and potential for targeting. Expert Opinion on Investigational Drugs, 2020, 29, 333-348. | 1.9 | 94 |
| 676 | Long-Term Alleviation of Parkinsonian Resting Tremor Using Wireless Optogenetic Nanonetworks. IEEE Transactions on Nanobioscience, 2020, 19, 403-409. | 2.2 | 0 |
| 677 | Parkinson's Disease: A Comprehensive Analysis of Fungi and Bacteria in Brain Tissue. International Journal of Biological Sciences, 2020, 16, 1135-1152. | 2.6 | 37 |
| 678 | Dysarthria enhancement mechanism under external clear speech instruction in Parkinson's disease, progressive supranuclear palsy and multiple system atrophy. Journal of Neural Transmission, 2020, 127, 905-914. | 1.4 | 7 |
| 679 | Hemispheric asymmetry in the human brain and in Parkinsonâ€™s disease is linked to divergent epigenetic patterns in neurons. Genome Biology, 2020, 21, 61. | 3.8 | 40 |
| 680 | Targeting Î±-Synuclein for PD Therapeutics: A Pursuit on All Fronts. Biomolecules, 2020, 10, 391. | 1.8 | 43 |
| 681 | PF-06649751 efficacy and safety in early Parkinsonâ€™s disease: a randomized, placebo-controlled trial. Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642091129. | 1.5 | 22 |
| 682 | The PERK-Dependent Molecular Mechanisms as a Novel Therapeutic Target for Neurodegenerative Diseases. International Journal of Molecular Sciences, 2020, 21, 2108. | 1.8 | 45 |
| 683 | Proteostasis of Î±-Synuclein and Its Role in the Pathogenesis of Parkinsonâ€™s Disease. Frontiers in Cellular Neuroscience, 2020, 14, 45. | 1.8 | 21 |
| 684 | Distribution of Parkinsonâ€™s disease associated RAB39B in mouse brain tissue. Molecular Brain, 2020, 13, 52. | 1.3 | 19 |
| 685 | Salient Features of Monomeric Alpha-Synuclein Revealed by NMR Spectroscopy. Biomolecules, 2020, 10, 428. | 1.8 | 14 |
| 686 | Sexual dysfunction in male patients with Parkinsonâ€™s disease: related factors and impact on quality of life. Neurological Sciences, 2020, 41, 2201-2206. | 0.9 | 13 |
| 687 | Accelerated Discovery of Novel Ponatinib Analogs with Improved Properties for the Treatment of Parkinsonâ€™s Disease. ACS Medicinal Chemistry Letters, 2020, 11, 491-496. | 1.3 | 8 |
| 688 | Exercising for People with Parkinsonâ€™s Disease and Their Support Group. ACSM's Health and Fitness Journal, 2020, 24, 5-7. | 0.3 | 2 |
| 689 | Cynomolgus Monkeys With Spontaneous Type-2-Diabetes-Mellitus-Like Pathology Develop Alpha-Synuclein Alterations Reminiscent of Prodromal Parkinsonâ€™s Disease and Related Diseases. Frontiers in Neuroscience, 2020, 14, 63. | 1.4 | 17 |
| 690 | Glia-Derived Extracellular Vesicles in Parkinsonâ€™s Disease. Journal of Clinical Medicine, 2020, 9, 1941. | 1.0 | 18 |

| # | Article | IF | Citations |
|---|---|---|---|
| 691 | Biomarker Organization in Circulating Extracellular Vesicles: New Applications in Detecting Neurodegenerative Diseases. Advanced Biology, 2020, 4, e1900309. | 3.0 | 10 |
| 692 | Overexpression of PGC-1Î± influences the mitochondrial unfolded protein response (mtUPR) induced by MPP+ in human SH-SY5Y neuroblastoma cells. Scientific Reports, 2020, 10, 10444. | 1.6 | 13 |
| 693 | Circulating Inflammatory miRNAs Associated with Parkinsonâ€™s Disease Pathophysiology. Biomolecules, 2020, 10, 945. | 1.8 | 29 |
| 694 | Association Between Glycemic Status and the Risk of Parkinson Disease: A Nationwide Population-Based Study. Diabetes Care, 2020, 43, 2169-2175. | 4.3 | 54 |
| 695 | Midbrain Dopaminergic Neuron Development at the Single Cell Level: In vivo and in Stem Cells. Frontiers in Cell and Developmental Biology, 2020, 8, 463. | 1.8 | 34 |
| 696 | Hand Fine Motor Skill Disability Correlates with Cognition in Patients with Moderate-to-Advanced Parkinsonâ€™s Disease. Brain Sciences, 2020, 10, 337. | 1.1 | 10 |
| 697 | Molecular Regulation in Dopaminergic Neuron Development. Cues to Unveil Molecular Pathogenesis and Pharmacological Targets of Neurodegeneration. International Journal of Molecular Sciences, 2020, 21, 3995. | 1.8 | 16 |
| 698 | Liposomal maneuvers against Parkinson's disease. , 2020, , 75-88. | | 0 |
| 699 | Measures of Retinal Structure and Function as Biomarkers in Neurology and Psychiatry. Biomarkers in Neuropsychiatry, 2020, 2, 100018. | 0.7 | 32 |
| 700 | Parkinson's disease a futile entangle of Mankind's credence on an herbal remedy: A review. Life Sciences, 2020, 257, 118019. | 2.0 | 0 |
| 701 | Novel decision algorithm to discriminate parkinsonism with combined blood and imaging biomarkers. Parkinsonism and Related Disorders, 2020, 77, 57-63. | 1.1 | 18 |
| 702 | Post-Developmental Roles of Notch Signaling in the Nervous System. Biomolecules, 2020, 10, 985. | 1.8 | 16 |
| 703 | Diagnostic accuracy of the appearance of Nigrosome-1 on magnetic resonance imaging in Parkinson's disease: A systematic review and meta-analysis. Parkinsonism and Related Disorders, 2020, 78, 12-20. | 1.1 | 30 |
| 704 | Potential use of corneal confocal microscopy in the diagnosis of Parkinsonâ€™s disease associated neuropathy. Translational Neurodegeneration, 2020, 9, 28. | 3.6 | 20 |
| 705 | Purine molecules in Parkinson's disease: Analytical techniques and clinical implications. Neurochemistry International, 2020, 139, 104793. | 1.9 | 7 |
| 706 | Parkinsonâ€™s disease: etiopathogenesis and treatment. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 795-808. | 0.9 | 459 |
| 707 | Diffusion-weighted MRI in neurodegenerative and psychiatric animal models: Experimental strategies and main outcomes. Journal of Neuroscience Methods, 2020, 343, 108814. | 1.3 | 3 |
| 708 | Chaperones and Proteostasis: Role in Parkinsonâ€™s Disease. Diseases (Basel, Switzerland), 2020, 8, 24. | 1.0 | 12 |

| # | Article | IF | Citations |
|---|---|---|---|
| 709 | Parkinsonâ€™s Disease Multimodal Complex Treatment (PD-MCT): Analysis of Therapeutic Effects and Predictors for Improvement. Journal of Clinical Medicine, 2020, 9, 1874. | 1.0 | 8 |
| 710 | Dynamical system based compact deep hybrid network for classification of Parkinson disease related EEG signals. Neural Networks, 2020, 130, 75-84. | 3.3 | 51 |
| 711 | Deep Learning Identifies Digital Biomarkers for Self-Reported Parkinson's Disease. Patterns, 2020, 1, 100042. | 3.1 | 40 |
| 712 | Glial cells in ParkinsonÂ´s disease: protective or deleterious?. Cellular and Molecular Life Sciences, 2020, 77, 5171-5188. | 2.4 | 22 |
| 713 | PDGNet: Predicting Disease Genes Using a Deep Neural Network With Multi-View Features. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 2022, 19, 575-584. | 1.9 | 16 |
| 714 | Lrrk2 modulation of Wnt signaling during zebrafish development. Journal of Neuroscience Research, 2020, 98, 1831-1842. | 1.3 | 4 |
| 715 | High fluorescence quenching probe-based reverse fluorescence enhancement LFTS coupling with IS-primer amplification reaction for the rapid and sensitive Parkinson Disease-associated MicroRNA detection. Biosensors and Bioelectronics, 2020, 165, 112278. | 5.3 | 22 |
| 716 | Nanocarrier-mediated brain delivery of bioactives for treatment/prevention of neurodegenerative diseases. Journal of Controlled Release, 2020, 321, 211-221. | 4.8 | 50 |
| 717 | Paroxetine suppresses reactive microglia-mediated but not lipopolysaccharide-induced inflammatory responses in primary astrocytes. Journal of Neuroinflammation, 2020, 17, 50. | 3.1 | 18 |
| 718 | Synergy between plasminogen activator inhibitor-1, Î±-synuclein, and neuroinflammation in Parkinsonâ€™s disease. Medical Hypotheses, 2020, 138, 109602. | 0.8 | 21 |
| 719 | A Self-Assembled Î±-Synuclein Nanoscavenger for Parkinsonâ€™s Disease. ACS Nano, 2020, 14, 1533-1549. | 7.3 | 71 |
| 720 | Interrelation between Sarcopenia and the Number of Motor Neurons in Patients with Parkinsonian Syndromes. Gerontology, 2020, 66, 409-415. | 1.4 | 19 |
| 721 | A Curcumin Derivative Activates TFEB and Protects Against Parkinsonian Neurotoxicity in Vitro. International Journal of Molecular Sciences, 2020, 21, 1515. | 1.8 | 36 |
| 722 | Epalrestat improves motor symptoms by reducing oxidative stress and inflammation in the reserpine induced mouse model of Parkinsonâ€™s disease. Animal Models and Experimental Medicine, 2020, 3, 9-21. | 1.3 | 20 |
| 723 | Cell and Tissue Instructive Materials for Central Nervous System Repair. Advanced Functional Materials, 2020, 30, 1909083. | 7.8 | 20 |
| 724 | CHCHD2 harboring Parkinsonâ€™s disease-linked T61I mutation precipitates inside mitochondria and induces precipitation of wild-type CHCHD2. Human Molecular Genetics, 2020, 29, 1096-1106. | 1.4 | 20 |
| 725 | Treatment of Nonmotor Symptoms Associated with Parkinson Disease. Neurologic Clinics, 2020, 38, 269-292. | 0.8 | 21 |
| 726 | MicroRNAâ€150 serves as a diagnostic biomarker and is involved in the inflammatory pathogenesis of Parkinson's disease. Molecular Genetics & Genomic Medicine, 2020, 8, e1189. | 0.6 | 29 |

| # | Article | IF | Citations |
|---|---|---|---|
| 727 | Recent advances in dopaminergic strategies for the treatment of Parkinsonâ€™s disease. Acta Pharmacologica Sinica, 2020, 41, 471-482. | 2.8 | 45 |
| 728 | Perspectives in fluid biomarkers in neurodegeneration from the 2019 biomarkers in neurodegenerative diseases courseâ€"a joint PhD student course at University College London and University of Gothenburg. Alzheimer's Research and Therapy, 2020, 12, 20. | 3.0 | 32 |
| 729 | A trio has turned into a quartet: DJ-1 interacts with the IP3R-Grp75-VDAC complex to control ER-mitochondria interaction. Cell Calcium, 2020, 87, 102186. | 1.1 | 32 |
| 730 | Disturbed expression of autophagy genes in blood of Parkinsonâ€™s disease patients. Gene, 2020, 738, 144454. | 1.0 | 10 |
| 731 | Chronic Infiltration of T Lymphocytes into the Brain in a Non-human Primate Model of Parkinsonâ€™s Disease. Neuroscience, 2020, 431, 73-85. | 1.1 | 21 |
| 732 | Cerebrospinal fluid proteomics implicates the granin family in Parkinsonâ€™s disease. Scientific Reports, 2020, 10, 2479. | 1.6 | 51 |
| 733 | Nonmercaptalbumin as an oxidative stress marker in Parkinsonâ€™s and PARK2 disease. Annals of Clinical and Translational Neurology, 2020, 7, 307-317. | 1.7 | 22 |
| 734 | Mechanisms of alpha-synuclein toxicity: An update and outlook. Progress in Brain Research, 2020, 252, 91-129. | 0.9 | 49 |
| 735 | Neuroprotective effects of novel nitrones: In vitro and in silico studies. European Journal of Pharmacology, 2020, 871, 172926. | 1.7 | 9 |
| 736 | Alpha-Synuclein Physiology and Pathology: A Perspective on Cellular Structures and Organelles. Frontiers in Neuroscience, 2019, 13, 1399. | 1.4 | 104 |
| 737 | An insight into Parkinsonâ€™s disease: researches and its complexities. , 2020, , 59-80. | | 0 |
| 738 | Applications of the stem cell secretome in regenerative medicine. , 2020, , 79-114. | | 1 |
| 739 | Prognostic factors of Rapid symptoms progression in patients with newly diagnosed parkinsonâ€™s disease. Artificial Intelligence in Medicine, 2020, 103, 101807. | 3.8 | 21 |
| 740 | Autophagy in Astrocytes and its Implications in Neurodegeneration. Journal of Molecular Biology, 2020, 432, 2605-2621. | 2.0 | 46 |
| 741 | Validation of freely-available pitch detection algorithms across various noise levels in assessing speech captured by smartphone in Parkinsonâ€™s disease. Biomedical Signal Processing and Control, 2020, 58, 101831. | 3.5 | 22 |
| 742 | Synaptic Changes in Parkinson Disease Assessed with in vivo Imaging. Annals of Neurology, 2020, 87, 329-338. | 2.8 | 112 |
| 743 | Clinical and Neuropathological Features Associated With Loss of RAB39B. Movement Disorders, 2020, 35, 687-693. | 2.2 | 14 |
| 744 | Caenorhabditis elegans as a model system for human diseases. Current Opinion in Biotechnology, 2020, 63, 118-125. | 3.3 | 63 |

| # | Article | IF | Citations |
|---|---|---|---|
| 745 | Parkinson patients without tremor show changed patterns of mechanical muscle oscillations during a specific bilateral motor task compared to controls. Scientific Reports, 2020, 10, 1168. | 1.6 | 9 |
| 746 | The Novel Dual GLP-1/GIP Receptor Agonist DA-CH5 Is Superior to Single GLP-1 Receptor Agonists in the MPTP Model of Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2020, 10, 523-542. | 1.5 | 43 |
| 747 | Genetics of Parkinson's disease: An introspection of its journey towards precision medicine. Neurobiology of Disease, 2020, 137, 104782. | 2.1 | 241 |
| 748 | Serum gamma-glutamyltransferase activity and Parkinsonâ€™s disease risk in men and women. Scientific Reports, 2020, 10, 1258. | 1.6 | 8 |
| 749 | Sexâ€dependent association of urate on the patterns of striatal dopamine depletion in Parkinsonâ€™s disease. European Journal of Neurology, 2020, 27, 773-778. | 1.7 | 9 |
| 750 | Axonal Endoplasmic Reticulum Dynamics and Its Roles in Neurodegeneration. Frontiers in Neuroscience, 2020, 14, 48. | 1.4 | 79 |
| 751 | The Quebec Parkinson Network: A Researcher-Patient Matching Platform and Multimodal Biorepository. Journal of Parkinson's Disease, 2020, 10, 301-313. | 1.5 | 35 |
| 752 | An update on human astrocytes and their role in development and disease. Glia, 2020, 68, 685-704. | 2.5 | 46 |
| 753 | Probiotic Bacillus subtilis Protects against Î±-Synuclein Aggregation in C.Âelegans. Cell Reports, 2020, 30, 367-380.e7. | 2.9 | 114 |
| 754 | An Electrochemical Immunosensor Based on a Self-Assembled Monolayer Modified Electrode for Label-Free Detection of Î±-Synuclein. Sensors, 2020, 20, 617. | 2.1 | 26 |
| 755 | Nanoemulsions for targeting the neurodegenerative diseases: Alzheimer's, Parkinson's and Prion's. Life Sciences, 2020, 245, 117394. | 2.0 | 51 |
| 756 | Possible synergies between isatin, an endogenous MAO inhibitor, and antiparkinsonian agents on the dopamine release from striatum of freely moving rats.. Neuropharmacology, 2020, 171, 108083. | 2.0 | 4 |
| 757 | Mitochondrial turnover and homeostasis in ageing and neurodegeneration. FEBS Letters, 2020, 594, 2370-2379. | 1.3 | 35 |
| 758 | Neuroprotective Effect of Bergamot Juice in 6-OHDA-Induced SH-SY5Y Cell Death, an In Vitro Model of Parkinsonâ€™s Disease. Pharmaceutics, 2020, 12, 326. | 2.0 | 27 |
| 759 | Molecular Hybridization as a Tool in the Design of Multi-target Directed Drug Candidates for Neurodegenerative Diseases. Current Neuropharmacology, 2020, 18, 348-407. | 1.4 | 65 |
| 760 | Orofacial Strength and Voice Quality as Outcome of Levodopa Challenge Test in Parkinson Disease. Laryngoscope, 2020, 130, E896-E903. | 1.1 | 6 |
| 761 | Missing heritability in Parkinsonâ€™s disease: the emerging role of non-coding genetic variation. Journal of Neural Transmission, 2020, 127, 729-748. | 1.4 | 27 |
| 762 | Higher risk of Parkinson disease in patients with primary SjÃ¶grenâ€™s syndrome. Clinical Rheumatology, 2020, 39, 2999-3007. | 1.0 | 7 |

| # | Article | IF | Citations |
|---|---|---|---|
| 763 | Selective neuronal vulnerability in Parkinson's disease. Progress in Brain Research, 2020, 252, 61-89. | 0.9 | 43 |
| 764 | Self-assembled polydopamine nanoparticles improve treatment in Parkinson's disease model mice and suppress dopamine-induced dyskinesia. Acta Biomaterialia, 2020, 109, 220-228. | 4.1 | 46 |
| 765 | Amyloid Formation of Î±-Synuclein Based on the Solubility- and Supersaturation-Dependent Mechanism. Langmuir, 2020, 36, 4671-4681. | 1.6 | 18 |
| 766 | Freezing and piercing of in vitro asymmetric plasma membrane by Î±-synuclein. Communications Biology, 2020, 3, 148. | 2.0 | 9 |
| 767 | Age at Onset of Parkinsonâ€™s Disease Among Ashkenazi Jewish Patients: Contribution of Environmental Factors, LRRK2 p.G2019S and GBA p.N370S Mutations. Journal of Parkinson's Disease, 2020, 10, 1123-1132. | 1.5 | 21 |
| 768 | Deficits in Motor Performance, Neurotransmitters and Synaptic Plasticity in Elderly and Experimental Parkinsonian Mice Lacking GPR37. Frontiers in Aging Neuroscience, 2020, 12, 84. | 1.7 | 14 |
| 769 | Parkinson's Disease Diagnosis Using Neostriatum Radiomic Features Based on T2-Weighted Magnetic Resonance Imaging. Frontiers in Neurology, 2020, 11, 248. | 1.1 | 26 |
| 770 | Structural white matter alterations as compensatory mechanisms in Parkinson's disease: A systematic review of diffusion tensor imaging studies. Journal of Neuroscience Research, 2020, 98, 1398-1416. | 1.3 | 24 |
| 771 | Small heat shock proteins in neurodegenerative diseases. Cell Stress and Chaperones, 2020, 25, 679-699. | 1.2 | 57 |
| 772 | Evidence Supports PA Prescription for Parkinsonâ€™s Disease: Motor Symptoms and Non-Motor Features: A Scoping Review. International Journal of Environmental Research and Public Health, 2020, 17, 2894. | 1.2 | 11 |
| 773 | Intranasal Delivery of Nanoformulations: A Potential Way of Treatment for Neurological Disorders. Molecules, 2020, 25, 1929. | 1.7 | 94 |
| 774 | Effect of hemodynamic characteristic changes of the carotid artery on 6-OHDA-induced Parkinsonâ€™s disease model rats treated by Gut-acupuncture. Journal of King Saud University - Science, 2020, 32, 2675-2681. | 1.6 | 0 |
| 775 | Genetic identification of cell types underlying brain complex traits yields insights into the etiology of Parkinsonâ€™s disease. Nature Genetics, 2020, 52, 482-493. | 9.4 | 216 |
| 776 | Boosting Antioxidant Self-defenses by Grafting Astrocytes Rejuvenates the Aged Microenvironment and Mitigates Nigrostriatal Toxicity in Parkinsonian Brain via an Nrf2-Driven Wnt/Î²-Catenin Prosurvival Axis. Frontiers in Aging Neuroscience, 2020, 12, 24. | 1.7 | 23 |
| 777 | Sudden death in Parkinson's disease: Cerebellum in court. Journal of the Neurological Sciences, 2020, 414, 116854. | 0.3 | 0 |
| 778 | LRRK2 inhibitors induce reversible changes in nonhuman primate lungs without measurable pulmonary deficits. Science Translational Medicine, 2020, 12, . | 5.8 | 85 |
| 779 | Parkinson disease Primer - a true team effort. Nature Reviews Disease Primers, 2020, 6, 31. | 18.1 | 7 |
| 780 | Unilateral intranigral administration of Î²-sitosterol Î²-D-glucoside triggers pathological Î±-synuclein spreading and bilateral nigrostriatal dopaminergic neurodegeneration in the rat. Acta Neuropathologica Communications, 2020, 8, 56. | 2.4 | 12 |

| # | Article | IF | Citations |
|---|---|---|---|
| 781 | Modeling Parkinsonâ€™s Disease Using Induced Pluripotent Stem Cells. Stem Cells International, 2020, 2020, 1-15. | 1.2 | 18 |
| 782 | CAV-2-Mediated GFP and LRRK2G2019S Expression in the Macaca fascicularis Brain. Frontiers in Molecular Neuroscience, 2020, 13, 49. | 1.4 | 2 |
| 783 | The Promise and Challenges of Developing miRNA-Based Therapeutics for Parkinsonâ€™s Disease. Cells, 2020, 9, 841. | 1.8 | 51 |
| 784 | Role of Connexins 30, 36, and 43 in Brain Tumors, Neurodegenerative Diseases, and Neuroprotection. Cells, 2020, 9, 846. | 1.8 | 24 |
| 785 | Historical Perspective: Models of Parkinsonâ€™s Disease. International Journal of Molecular Sciences, 2020, 21, 2464. | 1.8 | 174 |
| 786 | Additional Physical Interventions to Conventional Physical Therapy in Parkinsonâ€™s Disease: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Journal of Clinical Medicine, 2020, 9, 1038. | 1.0 | 19 |
| 787 | <scp>Realâ€World</scp> Nonmotor Changes in Patients with Parkinson's Disease and Motor Fluctuations: <scp>Jâ€FIRST</scp>. Movement Disorders Clinical Practice, 2020, 7, 431-439. | 0.8 | 9 |
| 788 | Recent advances in extracting phenolic compounds from food and their use in disease prevention and as cosmetics. Critical Reviews in Food Science and Nutrition, 2021, 61, 1130-1151. | 5.4 | 61 |
| 789 | An update on cellular and molecular determinants of Parkinson's disease with emphasis on the role of the retromer complex. Journal of Neuroscience Research, 2021, 99, 163-179. | 1.3 | 6 |
| 790 | Using multi-organ culture systems to study Parkinsonâ€™s disease. Molecular Psychiatry, 2021, 26, 725-735. | 4.1 | 16 |
| 791 | THE THALAMUS AND Parkinson's Disease: The Uncertainty of It All. Journal of Magnetic Resonance Imaging, 2021, 53, 319-319. | 1.9 | 0 |
| 792 | Dopamine promotes the neurodegenerative potential of Î²â€synuclein. Journal of Neurochemistry, 2021, 156, 674-691. | 2.1 | 19 |
| 793 | <scp>CD4</scp>+ <scp>Tâ€cell</scp> Transcription Factors in Idiopathic <scp>REM</scp> Sleep Behavior Disorder and Parkinson's Disease. Movement Disorders, 2021, 36, 225-229. | 2.2 | 25 |
| 795 | Rivastigmine in Parkinson's Disease Dementia with Orthostatic Hypotension. Annals of Neurology, 2021, 89, 91-98. | 2.8 | 23 |
| 796 | Neuroprotective effect of rhaponticin against Parkinson disease: Insights from in vitro BVâ€2 model and in vivo MPTPâ€induced mice model. Journal of Biochemical and Molecular Toxicology, 2021, 35, e22631. | 1.4 | 4 |
| 797 | Preliminary Findings on Proline-Rich Protein 14 as a Diagnostic Biomarker for Parkinsonâ€™s Disease. NeuroMolecular Medicine, 2021, 23, 285-291. | 1.8 | 5 |
| 798 | Utility of Imaging of Nigrosomeâ€1 on 3T MRI and Its Comparison with 18Fâ€DOPA PET in the Diagnosis of Idiopathic Parkinson Disease and Atypical Parkinsonism. Movement Disorders Clinical Practice, 2021, 8, 224-230. | 0.8 | 12 |
| 799 | Study of EEG microstates in Parkinsonâ€™s disease: a potential biomarker?. Cognitive Neurodynamics, 2021, 15, 463-471. | 2.3 | 23 |

| # | Article | IF | Citations |
|---|---|---|---|
| 800 | Neuroimaging Detectable Differences between Parkinson's Disease Motor Subtypes: A Systematic Review. Movement Disorders Clinical Practice, 2021, 8, 175-192. | 0.8 | 25 |
| 801 | Letter to the editor: sudden death in ParkinsonÂ´s disease: treating hypertension in the elderly is essential. Expert Opinion on Pharmacotherapy, 2021, 22, 1633-1634. | 0.9 | 0 |
| 802 | Antisense Drugs Make Sense for Neurological Diseases. Annual Review of Pharmacology and Toxicology, 2021, 61, 831-852. | 4.2 | 54 |
| 803 | Deficiency of NEAT1 prevented MPP+-induced inflammatory response, oxidative stress and apoptosis in dopaminergic SK-N-SH neuroblastoma cells via miR-1277-5p/ARHGAP26 axis. Brain Research, 2021, 1750, 147156. | 1.1 | 33 |
| 804 | Impaired autophagy in microglia aggravates dopaminergic neurodegeneration by regulating NLRP3 inflammasome activation in experimental models of Parkinsonâ€™s disease. Brain, Behavior, and Immunity, 2021, 91, 324-338. | 2.0 | 93 |
| 805 | No relationship between SRY variants and risk of Parkinson's disease in Chinese population. Neurobiology of Aging, 2021, 100, 119.e3-119.e6. | 1.5 | 5 |
| 806 | Comparison of susceptibility-weighted imaging and susceptibility map-weighted imaging for the diagnosis of Parkinsonism with nigral hyperintensity. European Journal of Radiology, 2021, 134, 109398. | 1.2 | 6 |
| 807 | Genetics variants and expression of the SCARB2 gene in the pathogenesis of Parkinson's disease in Russia. Neuroscience Letters, 2021, 741, 135509. | 1.0 | 5 |
| 808 | LINC00943 knockdown attenuates MPP<sup>+</sup>-induced neuronal damage via miR-15b-5p/RAB3IP axis in SK-N-SH cells. Neurological Research, 2021, 43, 181-190. | 0.6 | 14 |
| 809 | Probabilistic Mapping of Deep Brain Stimulation: Insights from 15â€‰Years of Therapy. Annals of Neurology, 2021, 89, 426-443. | 2.8 | 68 |
| 810 | Promotive effects of tetrahydroxystilbene glucoside on the differentiation of neural stem cells from the mesencephalon into dopaminergic neurons. Neuroscience Letters, 2021, 742, 135520. | 1.0 | 11 |
| 811 | Reduced Levels of Intestinal Neuropeptides and Neurotrophins in Neurotoxin-Induced Parkinson Disease Mouse Models. Journal of Neuropathology and Experimental Neurology, 2021, 80, 15-20. | 0.9 | 7 |
| 812 | Do Idiopathic Parkinsonâ€™s Disease and Schizophrenia Lie on the Same Genetic Spectrum?. Biological Psychiatry, 2021, 89, 207-208. | 0.7 | 0 |
| 813 | Chitosan coated synergistically engineered nanoemulsion of Ropinirole and nigella oil in the management of Parkinson's disease: Formulation perspective and In vitro and In vivo assessment. International Journal of Biological Macromolecules, 2021, 167, 605-619. | 3.6 | 15 |
| 814 | Revisiting gene delivery to the brain: silencing and editing. Biomaterials Science, 2021, 9, 1065-1087. | 2.6 | 14 |
| 815 | JM-20 protects against 6-hydroxydopamine-induced neurotoxicity in models of Parkinsonâ€™s disease: Mitochondrial protection and antioxidant properties. NeuroToxicology, 2021, 82, 89-98. | 1.4 | 11 |
| 816 | Using artificial intelligence to identify antiâ€hypertensives as possible disease modifying agents in Parkinson's disease. Pharmacoepidemiology and Drug Safety, 2021, 30, 201-209. | 0.9 | 11 |
| 817 | Neuroprotective and neurotoxic effects of endocannabinoid-like compounds, N-arachidonoyl dopamine and N-docosahexaenoyl dopamine in differentiated cultures of induced pluripotent stem cells derived from patients with Parkinsonâ€™s disease. NeuroToxicology, 2021, 82, 108-118. | 1.4 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 818 | Classification of the stages of Parkinsonâ€™s disease using novel higher-order statistical features of EEG signals. Neural Computing and Applications, 2021, 33, 7615-7627. | 3.2 | 10 |
| 819 | Identification of BAG2 and Cathepsin D as Plasma Biomarkers for Parkinsonâ€™s Disease. Clinical and Translational Science, 2021, 14, 606-616. | 1.5 | 16 |
| 820 | Diagnosis of Parkinsonâ€™s disease using deep CNN with transfer learning and data augmentation. Multimedia Tools and Applications, 2021, 80, 10113-10139. | 2.6 | 39 |
| 821 | Chronic MPTP in Mice Damage-specific Neuronal Phenotypes within Dorsal Laminae of the Spinal Cord. Neurotoxicity Research, 2021, 39, 156-169. | 1.3 | 7 |
| 822 | Irreversible incorporation of L-dopa into the C-terminus of Î±-tubulin inhibits binding of molecular motor KIF5B to microtubules and alters mitochondrial traffic along the axon. Neurobiology of Disease, 2021, 147, 105164. | 2.1 | 9 |
| 823 | Molecular landscape of long noncoding RNAs in brain disorders. Molecular Psychiatry, 2021, 26, 1060-1074. | 4.1 | 33 |
| 824 | Traditional Chinese medicine compounds regulate autophagy for treating neurodegenerative disease: A mechanism review. Biomedicine and Pharmacotherapy, 2021, 133, 110968. | 2.5 | 51 |
| 825 | Leonurine, a potential drug for the treatment of cardiovascular system and central nervous system diseases. Brain and Behavior, 2021, 11, e01995. | 1.0 | 25 |
| 826 | Fidelity of the PINK1 knockout rat to oxidative stress and other characteristics of Parkinson disease. Free Radical Biology and Medicine, 2021, 163, 88-101. | 1.3 | 9 |
| 827 | Fluorescent probes for bioimaging of potential biomarkers in Parkinson's disease. Chemical Society Reviews, 2021, 50, 1219-1250. | 18.7 | 90 |
| 828 | Neural induction: Historical views and application to pluripotent stem cells. Development Growth and Differentiation, 2021, 63, 26-37. | 0.6 | 12 |
| 829 | Inflammation and Parkinson's disease pathogenesis: Mechanisms and therapeutic insight. Progress in Molecular Biology and Translational Science, 2021, 177, 175-202. | 0.9 | 21 |
| 830 | Wearable and Biodegradable Sensors for Clinical and Environmental Applications. ACS Applied Electronic Materials, 2021, 3, 68-100. | 2.0 | 46 |
| 831 | Detecting and targeting neurodegenerative disorders using electrospun nanofibrous matrices: current status and applications. Journal of Drug Targeting, 2021, 29, 476-490. | 2.1 | 6 |
| 832 | Gender-Related Vulnerability of Dopaminergic Neural Networks in Parkinson's Disease. Brain Connectivity, 2021, 11, 3-11. | 0.8 | 4 |
| 833 | The burden of rare damaging variants in hereditary atypical parkinsonism genes is increased in patients with Parkinsonâ€™s disease. Neurobiology of Aging, 2021, 100, 118.e5-118.e13. | 1.5 | 2 |
| 834 | Association of rare heterozygous PLA2G6 variants with the risk of Parkinson's disease. Neurobiology of Aging, 2021, 101, 297.e5-297.e8. | 1.5 | 6 |
| 835 | Zuranolone as an oral adjunct to treatment of Parkinsonian tremor: A phase 2, open-label study. Journal of the Neurological Sciences, 2021, 421, 117277. | 0.3 | 16 |

| # | Article | IF | Citations |
|---|---|---|---|
| 836 | Probiotics for Parkinson's disease: Current evidence and future directions. JGH Open, 2021, 5, 414-419. | 0.7 | 41 |
| 837 | Overexpression of thioredoxin reductase 1 can reduce DNA damage, mitochondrial autophagy and endoplasmic reticulum stress in Parkinson's disease. Experimental Brain Research, 2021, 239, 475-490. | 0.7 | 11 |
| 838 | A convolutional oculomotor representation to model parkinsonian fixational patterns from magnified videos. Pattern Analysis and Applications, 2021, 24, 445-457. | 3.1 | 5 |
| 839 | Activity determination of human monoamine oxidase B (Mao B) by selective capturing and amperometric hydrogen peroxide detection. Sensors and Actuators B: Chemical, 2021, 328, 129020. | 4.0 | 4 |
| 840 | Tai chi and Parkinson's disease: a bevy of benefits. Disability and Rehabilitation, 2021, 43, 595-596. | 0.9 | 1 |
| 841 | Reply to: Sudden Death In ParkinsonÂ´s Disease: Treating Hypertension In The Elderly. Expert Opinion on Pharmacotherapy, 2021, 22, 937-938. | 0.9 | 1 |
| 842 | Applications of focused ultrasound in the brain: from thermoablation to drug delivery. Nature Reviews Neurology, 2021, 17, 7-22. | 4.9 | 211 |
| 843 | Clinical and laboratory measures of balance and comparison of balance performances according to postural instability and gait disorders in individuals with Parkinsonâ€™s disease. Somatosensory & Motor Research, 2021, 38, 34-40. | 0.4 | 5 |
| 844 | Multi-Variate vocal data analysis for Detection of Parkinson disease using Deep Learning. Neural Computing and Applications, 2021, 33, 4849-4864. | 3.2 | 28 |
| 845 | Intelligent IoT Framework for Indoor Healthcare Monitoring of Parkinsonâ€™s Disease Patient. IEEE Journal on Selected Areas in Communications, 2021, 39, 593-602. | 9.7 | 33 |
| 846 | Andrographolide suppresses NLRP3 inflammasome activation in microglia through induction of parkin-mediated mitophagy in in-vitro and in-vivo models of Parkinson disease. Brain, Behavior, and Immunity, 2021, 91, 142-158. | 2.0 | 108 |
| 847 | Communityâ€based genetic study of Parkinson's disease in Estonia. Acta Neurologica Scandinavica, 2021, 143, 89-95. | 1.0 | 3 |
| 848 | Pyrroloquinoline quinone promotes mitochondrial biogenesis in rotenone-induced Parkinsonâ€™s disease model via AMPK activation. Acta Pharmacologica Sinica, 2021, 42, 665-678. | 2.8 | 35 |
| 849 | Health monitoring system. , 2021, , 461-480. | | 4 |
| 850 | Exploring Movement Impairments in Patients With Parkinson's Disease Using the Microsoft Kinect Sensor: A Feasibility Study. Frontiers in Neurology, 2020, 11, 610614. | 1.1 | 5 |
| 851 | A Parkinsonâ€™s Disease-relevant Mitochondrial and Neuronal Morphology High-throughput Screening Assay in LUHMES Cells. Bio-protocol, 2021, 11, e3881. | 0.2 | 7 |
| 852 | Possible role of glial cell line-derived neurotrophic factor for predicting cognitive impairment in Parkinsonâ€™s disease: a case-control study. Neural Regeneration Research, 2021, 16, 885. | 1.6 | 8 |
| 853 | ADORA2A rs5760423 and CYP1A2 rs762551 Polymorphisms as Risk Factors for Parkinsonâ€™s Disease. Journal of Clinical Medicine, 2021, 10, 381. | 1.0 | 23 |

| # | Article | IF | Citations |
|---|---|---|---|
| 854 | Generation and Maintenance of Homogeneous Human Midbrain Organoids. Bio-protocol, 2021, 11, e4049. | 0.2 | 4 |
| 855 | <i>PINK1</i> gene mutation by pair truncated sgRNA/Cas9-D10A in cynomolgus monkeys. Zoological Research, 2021, 42, 469-477. | 0.9 | 12 |
| 856 | Self-Assembled Au Nanoparticle Arrays for Precise Metabolic Assay of Cerebrospinal Fluid. ACS Applied Materials & Interfaces, 2021, 13, 4886-4893. | 4.0 | 33 |
| 857 | Prevention of Parkinson's disease-related sudden death. Clinics, 2021, 76, e3266. | 0.6 | 2 |
| 858 | Long non-coding RNA nuclear enriched abundant transcript 1 (NEAT1) sponges microRNA-124-3p to up-regulate phosphodiesterase 4B (PDE4B) to accelerate the progression of Parkinsonâ€™s disease. Bioengineered, 2021, 12, 708-719. | 1.4 | 29 |
| 859 | Etiology and pathogenesis of Parkinson disease. , 2021, , 121-163.e16. | | 2 |
| 860 | Gauging the role and impact of drug interactions and repurposing in neurodegenerative disorders. Current Research in Pharmacology and Drug Discovery, 2021, 2, 100022. | 1.7 | 5 |
| 861 | Electrophysiological Phenotype Characterization of Human iPSCâ€Derived Neuronal Cell Lines by Means of Highâ€Density Microelectrode Arrays. Advanced Biology, 2021, 5, e2000223. | 1.4 | 30 |
| 862 | Oxidative stress in paraquat-induced damage to nervous tissues. , 2021, , 69-78. | | 3 |
| 864 | Data Augmentation Using GAN for Parkinsonâ€™s Disease Prediction. Lecture Notes in Electrical Engineering, 2021, , 589-597. | 0.3 | 1 |
| 865 | Determining the Degree of Dopaminergic Denervation Based on the Loss of Nigral Hyperintensity on SMWI in Parkinsonism. American Journal of Neuroradiology, 2021, 42, 681-687. | 1.2 | 6 |
| 866 | Ã–zellik seÃ§imi ve Derin Ã–ÄŸrenmeye DayalÄ± Parkinson HastalÄ±ÄŸÄ± Tespiti. European Journal of Science and Technology, 0, , . | 0.5 | 0 |
| 867 | The Detection of Parkinson's Disease From Speech Using Voice Source Information. IEEE/ACM Transactions on Audio Speech and Language Processing, 2021, 29, 1925-1936. | 4.0 | 39 |
| 868 | Circadian and Sleep Dysfunctions in Neurodegenerative Disordersâ€”An Update. Frontiers in Neuroscience, 2020, 14, 627330. | 1.4 | 33 |
| 869 | Analysis of DNM2, EPN2 and EXOC4 relative gene expression levels in peripheral blood from Parkinsonâ€™s disease patients. Molekuliarnaia Genetika, Mikrobiologiia I Virusologiia, 2021, 39, 25. | 0.1 | 0 |
| 871 | Targeting PTB as a One-Step Procedure for In Situ Astrocyte-to-Dopamine Neuron Reprogramming in Parkinsonâ€™s Disease. Neuroscience Bulletin, 2021, 37, 430-432. | 1.5 | 7 |
| 872 | Synergistic Effects of Milk-Derived Exosomes and Galactose on Î±-Synuclein Pathology in Parkinsonâ€™s Disease and Type 2 Diabetes Mellitus. International Journal of Molecular Sciences, 2021, 22, 1059. | 1.8 | 22 |
| 873 | Breathing new life into neurotoxic-based monkey models of Parkinson's disease to study the complex biological interplay between serotonin and dopamine. Progress in Brain Research, 2021, 261, 265-285. | 0.9 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 874 | Subcortical grey matter changes associated with motor symptoms evaluated by the Unified Parkinsonâ€™s disease Rating Scale (part III): A longitudinal study in Parkinsonâ€™s disease. NeuroImage: Clinical, 2021, 31, 102745. | 1.4 | 7 |
| 875 | Priming mesenchymal stem cells with uric acid enhances neuroprotective properties in parkinsonian models. Journal of Tissue Engineering, 2021, 12, 204173142110048. | 2.3 | 12 |
| 876 | Genetic Risk Factors and Lysosomal Function in Parkinson Disease. , 0, , . | | 0 |
| 878 | TRPM2 channel in oxidative stress-induced mitochondrial dysfunction and apoptotic cell death. Advances in Protein Chemistry and Structural Biology, 2021, 125, 51-72. | 1.0 | 11 |
| 879 | Induced pluripotent stem cell derived from postmortem tissue in neurodegenerative disease research. , 2021, , 221-249. | | 1 |
| 880 | Hypothalamic Î±-synuclein and its relation to autonomic symptoms and neuroendocrine abnormalities in Parkinson disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2021, 182, 223-233. | 1.0 | 2 |
| 881 | The Evolving Landscape of Exosomes in Neurodegenerative Diseases: Exosomes Characteristics and a Promising Role in Early Diagnosis. International Journal of Molecular Sciences, 2021, 22, 440. | 1.8 | 84 |
| 882 | Inhibition of Orexin/Hypocretin Neurons Ameliorates Elevated Physical Activity and Energy Expenditure in the A53T Mouse Model of Parkinsonâ€™s Disease. International Journal of Molecular Sciences, 2021, 22, 795. | 1.8 | 12 |
| 883 | Cross-talks among GBA mutations, glucocerebrosidase, and Î±-synuclein in GBA-associated Parkinsonâ€™s disease and their targeted therapeutic approaches: a comprehensive review. Translational Neurodegeneration, 2021, 10, 4. | 3.6 | 48 |
| 884 | Changes in Epidemiological Trends and Rehabilitation Usage in Neurological Diseases in Korea: Parkinson's Disease. Brain & Neurorehabilitation, 2021, 14, . | 0.4 | 2 |
| 885 | Transcranial Ultrasound Stimulation Suppresses Neuroinflammation in a Chronic Mouse Model of Parkinson's Disease. IEEE Transactions on Biomedical Engineering, 2021, 68, 3375-3387. | 2.5 | 26 |
| 886 | Signaleeg. Neuroinformatics, 2021, 19, 567-583. | 1.5 | 3 |
| 887 | An Algorithmic Approach for Quantitative Evaluation of Parkinsonâ€™s Disease Symptoms and Medical Treatment Utilizing Wearables and Multi-Criteria Symptoms Assessment. IEEE Access, 2021, 9, 24133-24144. | 2.6 | 3 |
| 888 | Repurposing GLP-1 Receptor Agonists for Parkinsonâ€™s Disease: Current Evidence and Future Opportunities. Pharmaceutical Medicine, 2021, 35, 11-19. | 1.0 | 5 |
| 889 | Role of Microgliosis and NLRP3 Inflammasome in Parkinsonâ€™s Disease Pathogenesis and Therapy. Cellular and Molecular Neurobiology, 2022, 42, 1283-1300. | 1.7 | 31 |
| 890 | Serotonin/dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesia: An update. Progress in Brain Research, 2021, 261, 287-302. | 0.9 | 10 |
| 891 | Interaction between Parkin and Î±-Synuclein in PARK2-Mediated Parkinsonâ€™s Disease. Cells, 2021, 10, 283. | 1.8 | 31 |
| 892 | Caenorhabditis elegans Model Studies Show MPP<sup>+</sup> Is a Simple Member of a Large Group of Related Potent Dopaminergic Toxins. Chemical Research in Toxicology, 2021, 34, 1275-1285. | 1.7 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 893 | Viral infections and their relationship to neurological disorders. Archives of Virology, 2021, 166, 733-753. | 0.9 | 60 |
| 894 | Monitoring the neurotransmitter release of human midbrain organoids using a redox cycling microsensor as a novel tool for personalized Parkinson's disease modelling and drug screening. Analyst, The, 2021, 146, 2358-2367. | 1.7 | 22 |
| 895 | Analytical and Biochemical Perspectives of Protein O-GlcNAcylation. Chemical Reviews, 2021, 121, 1513-1581. | 23.0 | 95 |
| 897 | Animal models of Parkinson's review. AIP Conference Proceedings, 2021, , . | 0.3 | 1 |
| 898 | P2X4 receptor participates in autophagy regulation in Parkinson's disease. Neural Regeneration Research, 2021, 16, 2505. | 1.6 | 15 |
| 899 | Ca2+ homeostasis in brain microvascular endothelial cells. International Review of Cell and Molecular Biology, 2021, 362, 55-110. | 1.6 | 12 |
| 900 | Detecting Effect of Levodopa in Parkinsonâ€™s Disease Patients Using Sustained Phonemes. IEEE Journal of Translational Engineering in Health and Medicine, 2021, 9, 1-9. | 2.2 | 16 |
| 901 | Astrogliosis and sexually dimorphic neurodegeneration and microgliosis in the olfactory bulb in Parkinsonâ€™s disease. Npj Parkinson's Disease, 2021, 7, 11. | 2.5 | 23 |
| 902 | A network-based machine-learning framework to identify both functional modules and disease genes. Human Genetics, 2021, 140, 897-913. | 1.8 | 9 |
| 905 | The Role of Mental Imagery in Parkinsonâ€™s Disease Rehabilitation. Brain Sciences, 2021, 11, 185. | 1.1 | 20 |
| 906 | El Ãºltimo concierto (2012): la fisioterapia en enfermedad de Parkinson para desacelerar la caÃda de una estrella de la mÃºsica clÃ¡sica. Revista De Medicina Y Cine, 2021, 17, 5-15. | 0.1 | 1 |
| 907 | Copper Dependent Modulation of Î±-Synuclein Phosphorylation in Differentiated SHSY5Y Neuroblastoma Cells. International Journal of Molecular Sciences, 2021, 22, 2038. | 1.8 | 9 |
| 908 | Mitophagy, a Form of Selective Autophagy, Plays an Essential Role in Mitochondrial Dynamics of Parkinsonâ€™s Disease. Cellular and Molecular Neurobiology, 2022, 42, 1321-1339. | 1.7 | 26 |
| 910 | Intrinsic Disruption of the M1 Cortical Network in a Mouse Model of Parkinson's Disease. Movement Disorders, 2021, 36, 1565-1577. | 2.2 | 15 |
| 911 | Findings in Chinese Patients With Parkinson's Disease: A Content Analysis From the SML Study. Frontiers in Psychiatry, 2021, 12, 615743. | 1.3 | 5 |
| 912 | Peripheral blood lymphocyte phenotypes in Alzheimer and Parkinsonâ€™s diseases. NeurologÃa (English) Tj ETQq1 1 0.784314 rgBT | 0.2 | 5 |
| 913 | Amauroderma rugosum Protects PC12 Cells against 6-OHDA-Induced Neurotoxicity through Antioxidant and Antiapoptotic Effects. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-15. | 1.9 | 7 |
| 914 | Systematic Review: Quantitative Susceptibility Mapping (QSM) of Brain Iron Profile in Neurodegenerative Diseases. Frontiers in Neuroscience, 2021, 15, 618435. | 1.4 | 83 |

| # | Article | IF | Citations |
|---|---|---|---|
| 915 | The Association Between the Gut Microbiota and Parkinson's Disease, a Meta-Analysis. Frontiers in Aging Neuroscience, 2021, 13, 636545. | 1.7 | 111 |
| 916 | Neurodevelopmental defects and neurodegenerative phenotypes in human brain organoids carrying Parkinsonâ€™s disease-linked DNAJC6 mutations. Science Advances, 2021, 7, . | 4.7 | 52 |
| 917 | Case Report: Bupropion Reduces the [123I]FP-CIT Binding to Striatal Dopamine Transporter. Frontiers in Psychiatry, 2021, 12, 631357. | 1.3 | 2 |
| 918 | A simple-to-use web-based calculator for survival prediction in Parkinsonâ€™s disease. Aging, 2021, 13, 5238-5249. | 1.4 | 8 |
| 919 | Increased Plasma Heme Oxygenase-1 Levels in Patients With Early-Stage Parkinsonâ€™s Disease. Frontiers in Aging Neuroscience, 2021, 13, 621508. | 1.7 | 13 |
| 920 | Parkinsonâ€™s Disease: Is there a Role for Dietary and Herbal Supplements?. CNS and Neurological Disorders - Drug Targets, 2021, 20, 343-365. | 0.8 | 10 |
| 921 | Bidirectional Correlations Between Dopaminergic Function and Motivation in Parkinsonâ€™s Disease. Journal of Geriatric Psychiatry and Neurology, 2021, , 089198872199680. | 1.2 | 3 |
| 922 | The Role of Î±-Synuclein in Methamphetamine-Induced Neurotoxicity. Neurotoxicity Research, 2021, 39, 1007-1021. | 1.3 | 11 |
| 923 | Psychomotor processing and functional decline in Parkinson's disease predicted by the Purdue Pegboard test. International Journal of Geriatric Psychiatry, 2021, 36, 909-916. | 1.3 | 6 |
| 924 | Long Non-coding RNAs in Parkinsonâ€™s Disease. Neurochemical Research, 2021, 46, 1031-1042. | 1.6 | 22 |
| 925 | Voltage-Gated Ca2+ Channels in Dopaminergic Substantia Nigra Neurons: Therapeutic Targets for Neuroprotection in Parkinson's Disease?. Frontiers in Synaptic Neuroscience, 2021, 13, 636103. | 1.3 | 22 |
| 926 | microRNA signatures in prodromal REM sleep behavior disorder and early Parkinson's disease as noninvasive biomarkers. Sleep Medicine, 2021, 78, 160-168. | 0.8 | 6 |
| 928 | Lysozyme Fibrils Alter the Mechanism of Insulin Amyloid Aggregation. International Journal of Molecular Sciences, 2021, 22, 1775. | 1.8 | 7 |
| 929 | Regional Cerebral Cortical Atrophy is Related to Urinary Tract Symptoms in Parkinson's Disease. Journal of Neuroimaging, 2021, 31, 363-371. | 1.0 | 4 |
| 930 | Non-motor complications in late stage Parkinsonâ€™s disease: recognition, management and unmet needs. Expert Review of Neurotherapeutics, 2021, 21, 335-352. | 1.4 | 20 |
| 931 | Alpha-Synuclein in the Regulation of Brain Endothelial and Perivascular Cells: Gaps and Future Perspectives. Frontiers in Immunology, 2021, 12, 611761. | 2.2 | 22 |
| 932 | Inhibition of repulsive guidance molecule-a protects dopaminergic neurons in a mouse model of Parkinsonâ€™s disease. Cell Death and Disease, 2021, 12, 181. | 2.7 | 17 |
| 933 | Regularity of kinematic data between single and dual-task treadmill walking in people with Parkinsonâ€™s disease. Journal of NeuroEngineering and Rehabilitation, 2021, 18, 20. | 2.4 | 6 |

| # | Article | IF | Citations |
|---|---|---|---|
| 934 | Kinase Signaling in Dendritic Development and Disease. Frontiers in Cellular Neuroscience, 2021, 15, 624648. | 1.8 | 18 |
| 935 | Quantum Dots Application in Neurodegenerative Diseases. Thrita, 2021, 9, . | 0.4 | 7 |
| 936 | Energy, Entropy and Quantum Tunneling of Protons and Electrons in Brain Mitochondria: Relation to Mitochondrial Impairment in Aging-Related Human Brain Diseases and Therapeutic Measures. Biomedicines, 2021, 9, 225. | 1.4 | 9 |
| 937 | Multi-Electrode Array Analysis Identifies Complex Dopamine Responses and Glucose Sensing Properties of Substantia Nigra Neurons in Mouse Brain Slices. Frontiers in Synaptic Neuroscience, 2021, 13, 635050. | 1.3 | 13 |
| 938 | A Novel SNCA A30G Mutation Causes Familial ParkinsonÊ¼s Disease. Movement Disorders, 2021, 36, 1624-1633. | 2.2 | 54 |
| 939 | Î±-synuclein impairs autophagosome maturation through abnormal actin stabilization. PLoS Genetics, 2021, 17, e1009359. | 1.5 | 49 |
| 940 | Alpha-Synuclein: Mechanisms of Release and Pathology Progression in Synucleinopathies. Cells, 2021, 10, 375. | 1.8 | 54 |
| 941 | Venoms as an adjunctive therapy for Parkinsonâ€™s disease: where are we now and where are we going?. Future Science OA, 2021, 7, FSO642. | 0.9 | 4 |
| 942 | High dose expression of heme oxigenase-1 induces retinal degeneration through ER stress-related DDIT3. Molecular Neurodegeneration, 2021, 16, 16. | 4.4 | 14 |
| 943 | Re. â€œTo bee or not to bee? The bee extract propolis as a bioactive compound in the burden of lifestyle diseasesâ€• Nutrition, 2021, 93, 111241. | 1.1 | 0 |
| 945 | Modelling Parkinsonâ€™s Disease: iPSCs towards Better Understanding of Human Pathology. Brain Sciences, 2021, 11, 373. | 1.1 | 19 |
| 946 | Analysis of the Neuroproteome Associated With Cell Therapy After Intranigral Grafting in a Mouse Model of Parkinson Disease. Frontiers in Neuroscience, 2021, 15, 621121. | 1.4 | 1 |
| 947 | Opposing functions of Î²-arrestin 1 and 2 in Parkinsonâ€™s disease via microglia inflammation and Nprl3. Cell Death and Differentiation, 2021, 28, 1822-1836. | 5.0 | 30 |
| 948 | Î²-lactolin, a Monoamine Oxidase B Inhibitory Lactopeptide, Suppresses Reactive Oxygen Species Production in Lipopolysaccharide-Stimulated Astrocytes. Applied Sciences (Switzerland), 2021, 11, 3034. | 1.3 | 1 |
| 949 | The relationship between attention and static balance disturbance in patients with Parkinsonâ€™s disease. Neurological Sciences, 2021, 42, 5107-5115. | 0.9 | 1 |
| 950 | Intragastric Administration of Casein Leads to Nigrostriatal Disease Progressed Accompanied with Persistent Nigrostriatalâ€"Intestinal Inflammation Activited and Intestinal Microbiotaâ€"Metabolic Disorders Induced in MPTP Mouse Model of Parkinsonâ€™s Disease. Neurochemical Research, 2021, 46, 1514-1539. | 1.6 | 9 |
| 951 | Reduced erythrocytic CHCHD2 mRNA is associated with brain pathology of Parkinsonâ€™s disease. Acta Neuropathologica Communications, 2021, 9, 37. | 2.4 | 8 |
| 953 | Exosomes derived from miR-188-3p-modified adipose-derived mesenchymal stem cells protect Parkinsonâ€™s disease. Molecular Therapy - Nucleic Acids, 2021, 23, 1334-1344. | 2.3 | 79 |

| # | Article | IF | Citations |
|---|---|---|---|
| 954 | Sign-specific stimulation â€˜hotâ€™ and â€˜coldâ€™ spots in Parkinsonâ€™s disease validated with machine learning. Brain Communications, 2021, 3, fcab027. | 1.5 | 20 |
| 955 | Can chronopharmacology improve the therapeutic management of neurological diseases?. Fundamental and Clinical Pharmacology, 2021, 35, 564-581. | 1.0 | 6 |
| 956 | Parkinson's Disease and Sudden Unexpected Death. Journal of the American Medical Directors Association, 2021, 22, 723-724. | 1.2 | 0 |
| 957 | CD33 rs3865444 as a risk factor for Parkinsonâ€™s disease. Neuroscience Letters, 2021, 748, 135709. | 1.0 | 7 |
| 958 | Docosahexaenoic and Arachidonic Acids as Neuroprotective Nutrients throughout the Life Cycle. Nutrients, 2021, 13, 986. | 1.7 | 63 |
| 959 | The Importance of Drosophila melanogaster Research to UnCover Cellular Pathways Underlying Parkinsonâ€™s Disease. Cells, 2021, 10, 579. | 1.8 | 17 |
| 960 | Therapeutic Potential of AAV1-Rheb(S16H) Transduction against Neurodegenerative Diseases. International Journal of Molecular Sciences, 2021, 22, 3064. | 1.8 | 1 |
| 961 | Parkinsonâ€™s Disease - A Review on Advances and Treatment Strategies. Materials Science Forum, 0, 1025, 230-235. | 0.3 | 0 |
| 962 | A More Homogeneous Phenotype in Parkinson's Disease Related to R1441G Mutation in the LRRK2 Gene. Frontiers in Neurology, 2021, 12, 635396. | 1.1 | 10 |
| 964 | Antidepressant-like effect of guanosine involves activation of AMPA receptor and BDNF/TrkB signaling. Purinergic Signalling, 2021, 17, 285-301. | 1.1 | 14 |
| 965 | Current State-of-the-Art and Unresolved Problems in Using Human Induced Pluripotent Stem Cell-Derived Dopamine Neurons for Parkinsonâ€™s Disease Drug Development. International Journal of Molecular Sciences, 2021, 22, 3381. | 1.8 | 11 |
| 966 | Enfermedad de Parkinson: actualizaciÃ³n de estudios preclÃnicos con el uso de cÃ©lulas troncales pluripotentes inducidas. NeurologÃa, 2021, , . | 0.3 | 1 |
| 967 | TNF-Î± and Î±-synuclein fibrils differently regulate human astrocyte immune reactivity and impair mitochondrial respiration. Cell Reports, 2021, 34, 108895. | 2.9 | 35 |
| 968 | Pain in Parkinson's disease: Mechanism-based treatment strategies. Current Opinion in Supportive and Palliative Care, 2021, 15, 108-115. | 0.5 | 11 |
| 969 | Longitudinal Changes in Neuromelanin MRI Signal in Parkinson's Disease: A Progression Marker. Movement Disorders, 2021, 36, 1592-1602. | 2.2 | 52 |
| 970 | Attentional dysfunction and the punding spectrum in Parkinson's disease. Parkinsonism and Related Disorders, 2021, 84, 23-28. | 1.1 | 7 |
| 971 | Applicability of optical coherence tomography angiography (OCTA) imaging in Parkinsonâ€™s disease. Scientific Reports, 2021, 11, 5520. | 1.6 | 8 |
| 972 | Assessment of Amyloid Forming Tendency of Peptide Sequences from Amyloid Beta and Tau Proteins Using Force-Field, Semi-Empirical, and Density Functional Theory Calculations. International Journal of Molecular Sciences, 2021, 22, 3244. | 1.8 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 973 | Secreted Extracellular Vesicle Molecular Cargo as a Novel Liquid Biopsy Diagnostics of Central Nervous System Diseases. International Journal of Molecular Sciences, 2021, 22, 3267. | 1.8 | 13 |
| 975 | Rapid eye movement sleep behavior disorder and rapid eye movement sleep without atonia are more frequent in advanced versus early Parkinsonâ€™s disease. Sleep, 2021, 44, . | 0.6 | 16 |
| 976 | Neurospheres: a potential in vitro model for the study of central nervous system disorders. Molecular Biology Reports, 2021, 48, 3649-3663. | 1.0 | 14 |
| 977 | Neurothreads: Development of supportive carriers for mature dopaminergic neuron differentiation and implantation. Biomaterials, 2021, 270, 120707. | 5.7 | 12 |
| 978 | A New Rise of Non-Human Primate Models of Synucleinopathies. Biomedicines, 2021, 9, 272. | 1.4 | 8 |
| 979 | Circuit Mechanisms of L-DOPA-Induced Dyskinesia (LID). Frontiers in Neuroscience, 2021, 15, 614412. | 1.4 | 8 |
| 980 | Translational research on Myology and Mobility Medicine: 2021 semi-virtual PDM3 from Thermae of Euganean Hills, May 26 - 29, 2021. European Journal of Translational Myology, 2021, 31, . | 0.8 | 12 |
| 981 | Appraisal of antiâ€Parkinson activity of rhinacanthinâ€C in haloperidolâ€induced parkinsonism in mice: A mechanistic approach. Journal of Food Biochemistry, 2021, 45, e13677. | 1.2 | 7 |
| 982 | Prolonged dopamine D3 receptor stimulation promotes dopamine transporter ubiquitination and degradation through a PKC-dependent mechanism. Pharmacological Research, 2021, 165, 105434. | 3.1 | 13 |
| 984 | Association Between Microscopic Colitis and Parkinson's Disease in a Swedish Population. Movement Disorders, 2021, 36, 1919-1926. | 2.2 | 9 |
| 985 | Current perspectives on galvanic vestibular stimulation in the treatment of Parkinsonâ€™s disease. Expert Review of Neurotherapeutics, 2021, 21, 405-418. | 1.4 | 15 |
| 986 | Icaritin Provides Neuroprotection in Parkinsonâ€™s Disease by Attenuating Neuroinflammation, Oxidative Stress, and Energy Deficiency. Antioxidants, 2021, 10, 529. | 2.2 | 27 |
| 987 | Morphological analysis of subcortical structures for assessment of cognitive dysfunction in Parkinsonâ€™s disease using multi-atlas based segmentation. Cognitive Neurodynamics, 2021, 15, 835-845. | 2.3 | 4 |
| 988 | Trojan Horse Delivery of 4,4â€²â€Dimethoxychalcone for Parkinsonian Neuroprotection. Advanced Science, 2021, 8, 2004555. | 5.6 | 30 |
| 989 | Neurorobotic Models of Neurological Disorders: A Mini Review. Frontiers in Neurorobotics, 2021, 15, 634045. | 1.6 | 7 |
| 990 | Effects of Î±-Synuclein-Associated Post-Translational Modifications in Parkinsonâ€™s Disease. ACS Chemical Neuroscience, 2021, 12, 1061-1071. | 1.7 | 35 |
| 991 | Nanoemulsion Improves the Neuroprotective Effects of Curcumin in an Experimental Model of Parkinsonâ€™s Disease. Neurotoxicity Research, 2021, 39, 787-799. | 1.3 | 27 |
| 992 | Dâ€butylphthalide inhibits rotenoneâ€induced oxidative stress in microglia via regulation of the Keap1/Nrf2/HOâ€1 signaling pathway. Experimental and Therapeutic Medicine, 2021, 21, 597. | 0.8 | 9 |

| # | Article | IF | Citations |
|---|---|---|---|
| 993 | Effective Connectivity During Rest and Music Listening: An EEG Study on Parkinsonâ€™s Disease. Frontiers in Aging Neuroscience, 2021, 13, 657221. | 1.7 | 6 |
| 994 | The Neuroprotective Effects of GPR4 Inhibition through the Attenuation of Caspase Mediated Apoptotic Cell Death in an MPTP Induced Mouse Model of Parkinsonâ€™s Disease. International Journal of Molecular Sciences, 2021, 22, 4674. | 1.8 | 14 |
| 996 | Excessive daytime sleepiness in Parkinson's disease: A systematic review and meta-analysis. Parkinsonism and Related Disorders, 2021, 85, 133-140. | 1.1 | 32 |
| 997 | Comprehensive serum metabolic and proteomic characterization on cognitive dysfunction in Parkinsonâ€™s disease. Annals of Translational Medicine, 2021, 9, 559-559. | 0.7 | 5 |
| 998 | Novel therapeutic approaches for Parkinsonâ€™s disease by targeting brain cholesterol homeostasis. Journal of Pharmacy and Pharmacology, 2021, 73, 862-873. | 1.2 | 7 |
| 999 | Nucleic Acidâ€“Based Therapeutics in Orphan Neurological Disorders: Recent Developments. Frontiers in Molecular Biosciences, 2021, 8, 643681. | 1.6 | 10 |
| 1000 | RNA-Targeting Splicing Modifiers: Drug Development and Screening Assays. Molecules, 2021, 26, 2263. | 1.7 | 21 |
| 1001 | Synthesis and Biological Evaluation of [18F]FECNT-d4 as a Novel PET Agent for Dopamine Transporter Imaging. Molecular Imaging and Biology, 2021, 23, 733-744. | 1.3 | 7 |
| 1004 | Resveratrol in Rodent Models of Parkinsonâ€™s Disease: A Systematic Review of Experimental Studies. Frontiers in Pharmacology, 2021, 12, 644219. | 1.6 | 35 |
| 1005 | Murine Models of Lysosomal Storage Diseases Exhibit Differences in Brain Protein Aggregation and Neuroinflammation. Biomedicines, 2021, 9, 446. | 1.4 | 12 |
| 1007 | A computerized method to assess Parkinsonâ€™s disease severity from gait variability based on gender. Biomedical Signal Processing and Control, 2021, 66, 102497. | 3.5 | 6 |
| 1008 | Fyn Kinase-Mediated PKCÎ´ Y311 Phosphorylation Induces Dopaminergic Degeneration in Cell Culture and Animal Models: Implications for the Identification of a New Pharmacological Target for Parkinsonâ€™s Disease. Frontiers in Pharmacology, 2021, 12, 631375. | 1.6 | 4 |
| 1009 | Progression of Nonmotor Symptoms in Parkinsonâ€™s Disease by Sex and Motor Laterality. Parkinson's Disease, 2021, 2021, 1-12. | 0.6 | 5 |
| 1010 | Treatment Options for Motor and Non-Motor Symptoms of Parkinsonâ€™s Disease. Biomolecules, 2021, 11, 612. | 1.8 | 80 |
| 1011 | Baroreflex dysfunction in Parkinsonâ€™s disease: integration of central and peripheral mechanisms. Journal of Neurophysiology, 2021, 125, 1425-1439. | 0.9 | 12 |
| 1012 | Genetic and Transcriptomic Biomarkers in Neurodegenerative Diseases: Current Situation and the Road Ahead. Cells, 2021, 10, 1030. | 1.8 | 11 |
| 1013 | Do naturally occurring antioxidants protect against neurodegeneration of the dopaminergic system? A systematic revision in animal models of Parkinson's disease. Current Neuropharmacology, 2021, 19, . | 1.4 | 2 |
| 1014 | Importance of Nanoparticles for the Delivery of Antiparkinsonian Drugs. Pharmaceutics, 2021, 13, 508. | 2.0 | 17 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1015 | Unsupervised Cell Segmentation and Labelling in Neural Tissue Images. Applied Sciences (Switzerland), 2021, 11, 3733. | 1.3 | 1 |
| 1016 | A New Tool to Study Parkinsonism in the Context of Aging: MPTP Intoxication in a Natural Model of Multimorbidity. International Journal of Molecular Sciences, 2021, 22, 4341. | 1.8 | 2 |
| 1017 | Computer-assisted Parkinson's disease diagnosis using fuzzy optimum- path forest and Restricted Boltzmann Machines. Computers in Biology and Medicine, 2021, 131, 104260. | 3.9 | 32 |
| 1018 | MICOS and the mitochondrial inner membrane morphology â€“ when things get out of shape. FEBS Letters, 2021, 595, 1159-1183. | 1.3 | 43 |
| 1019 | Administration of quercetin improves mitochondria quality control and protects the neurons in 6-OHDA-lesioned Parkinson's disease models. Aging, 2021, 13, 11738-11751. | 1.4 | 46 |
| 1020 | Plasminogen Activators in Neurovascular and Neurodegenerative Disorders. International Journal of Molecular Sciences, 2021, 22, 4380. | 1.8 | 11 |
| 1021 | Exploring the Use of Intracranial and Extracranial (Remote) Photobiomodulation Devices in Parkinsonâ€™s Disease: A Comparison of Direct and Indirect Systemic Stimulations. Journal of Alzheimer's Disease, 2021, 83, 1399-1413. | 1.2 | 18 |
| 1022 | First-Time Disclosure of CVN424, a Potent and Selective GPR6 Inverse Agonist for the Treatment of Parkinsonâ€™s Disease: Discovery, Pharmacological Validation, and Identification of a Clinical Candidate. Journal of Medicinal Chemistry, 2021, 64, 9875-9890. | 2.9 | 12 |
| 1023 | Single-cell brain atlas of Parkinson's disease mouse model. Journal of Genetics and Genomics, 2021, 48, 277-288. | 1.7 | 20 |
| 1024 | A nano-composite based regenerative neuro biosensor sensitive to Parkinsonism-associated protein DJ-1/Park7 in cerebrospinal fluid and saliva. Bioelectrochemistry, 2021, 138, 107734. | 2.4 | 13 |
| 1025 | Neuroprotective effects of pomegranate (Punica granatum L.) juice and seed extract in paraquat-induced mouse model of Parkinsonâ€™s disease. BMC Complementary Medicine and Therapies, 2021, 21, 130. | 1.2 | 11 |
| 1026 | Cardiolipin, Mitochondria, and Neurological Disease. Trends in Endocrinology and Metabolism, 2021, 32, 224-237. | 3.1 | 113 |
| 1027 | Biomaterials for Drugs Noseâ€“Brain Transport: A New Therapeutic Approach for Neurological Diseases. Materials, 2021, 14, 1802. | 1.3 | 16 |
| 1028 | Oral Dysbiosis and Inflammation in Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2021, 11, 619-631. | 1.5 | 35 |
| 1029 | Polymorphisms of Dopamine Receptor Genes and Parkinsonâ€™s Disease: Clinical Relevance and Future Perspectives. International Journal of Molecular Sciences, 2021, 22, 3781. | 1.8 | 17 |
| 1030 | Pharmacological inhibition of nSMase2 reduces brain exosome release and Î±-synuclein pathology in a Parkinsonâ€™s disease model. Molecular Brain, 2021, 14, 70. | 1.3 | 15 |
| 1031 | Prodromal neuroinvasion of pathological Î±-synuclein in brainstem reticular nuclei and white matter lesions in a model of Î±-synucleinopathy. Brain Communications, 2021, 3, fcab104. | 1.5 | 7 |
| 1032 | Back to the future: lessons from past viral infections and the link with Parkinsonâ€™s disease. Neuronal Signaling, 2021, 5, NS20200051. | 1.7 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1033 | The Reninâ€“Angiotensin System Modulates Dopaminergic Neurotransmission: A New Player on the Scene. Frontiers in Synaptic Neuroscience, 2021, 13, 638519. | 1.3 | 18 |
| 1034 | Brain lipidomics as a rising field in neurodegenerative contexts: Perspectives with Machine Learning approaches. Frontiers in Neuroendocrinology, 2021, 61, 100899. | 2.5 | 33 |
| 1035 | Investigation of itch in Parkinson disease. Itch (Philadelphia, Pa ), 2021, 6, e49-e49. | 1.0 | 0 |
| 1036 | When the Balance Tips: Dysregulation of Mitochondrial Dynamics as a Culprit in Disease. International Journal of Molecular Sciences, 2021, 22, 4617. | 1.8 | 11 |
| 1037 | Towards physiologically relevant human pluripotent stem cell (hPSC) models of Parkinsonâ€™s disease. Stem Cell Research and Therapy, 2021, 12, 253. | 2.4 | 9 |
| 1038 | Tooth Loss and Blood Pressure in Parkinsonâ€™s Disease Patients: An Exploratory Study on NHANES Data. International Journal of Environmental Research and Public Health, 2021, 18, 5032. | 1.2 | 11 |
| 1040 | Deep learningâ€based scheme to diagnose Parkinson's disease. Expert Systems, 2022, 39, e12739. | 2.9 | 18 |
| 1041 | The promise of crowdfunding to finance R&D of novel diagnostics and therapeutics for incurable diseases. Drug Discovery Today, 2021, 26, 2205-2208. | 3.2 | 1 |
| 1042 | Loss of p21-activated kinase Mbt/PAK4 causes Parkinson-like phenotypes inDrosophila. DMM Disease Models and Mechanisms, 2021, 14, . | 1.2 | 9 |
| 1043 | Gene therapy restores dopamine transporter expression and ameliorates pathology in iPSC and mouse models of infantile parkinsonism. Science Translational Medicine, 2021, 13, . | 5.8 | 25 |
| 1044 | Nanomedicine against Alzheimerâ€™s and Parkinsonâ€™s Disease. Current Pharmaceutical Design, 2021, 27, 1507-1545. | 0.9 | 7 |
| 1045 | Momordica Charantia Polysaccharides Attenuates MPP+-Induced Injury in Parkinsonâ€™s Disease Mice and Cell Models by Regulating TLR4/MyD88/NF-ÎºB Pathway. International Journal of Polymer Science, 2021, 2021, 1-15. | 1.2 | 3 |
| 1046 | Transâ€Ethnic Fineâ€Mapping of the Major Histocompatibility Complex Region Linked to Parkinson's Disease. Movement Disorders, 2021, 36, 1805-1814. | 2.2 | 14 |
| 1047 | Rhythm and groove as cognitive mechanisms of dance intervention in Parkinsonâ€™s disease. PLoS ONE, 2021, 16, e0249933. | 1.1 | 8 |
| 1048 | Accelerating diagnosis of Parkinsonâ€™s disease through risk prediction. BMC Neurology, 2021, 21, 201. | 0.8 | 15 |
| 1049 | Sorting Out Sorting Nexins Functions in the Nervous System in Health and Disease. Molecular Neurobiology, 2021, 58, 4070-4106. | 1.9 | 15 |
| 1050 | Effect of reading passage length on quantitative acoustic speech assessment in Czech-speaking individuals with Parkinson's disease treated with subthalamic nucleus deep brain stimulation. Journal of the Acoustical Society of America, 2021, 149, 3366-3374. | 0.5 | 1 |
| 1051 | Golf as a Physical Activity to Potentially Reduce the Risk of Falls in Older Adults with Parkinsonâ€™s Disease. Sports, 2021, 9, 72. | 0.7 | 8 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1052 | Naturally Occurring Parkinsonâ€™s Disease Raises the Need for Nonhuman Primates in Neurodegenerative Diseases Research. Neuroscience Bulletin, 2021, 37, 1267-1269. | 1.5 | 1 |
| 1053 | Evidence and perspectives of cell senescence in neurodegenerative diseases. Biomedicine and Pharmacotherapy, 2021, 137, 111327. | 2.5 | 52 |
| 1054 | Metabolic Study of Stable Isotope Labeled Indolinone Derivative in Hepatocyte Cell by UPLC/Q TOF MS. Journal of the American Society for Mass Spectrometry, 2021, 32, 1538-1544. | 1.2 | 4 |
| 1055 | The bile acid TUDCA and neurodegenerative disorders: An overview. Life Sciences, 2021, 272, 119252. | 2.0 | 57 |
| 1056 | Tapping the Potential of Multimodal Non-invasive Brain Stimulation to Elucidate the Pathophysiology of Movement Disorders. Frontiers in Human Neuroscience, 2021, 15, 661396. | 1.0 | 2 |
| 1057 | Study of the collagen type VI alpha 3 (COL6A3) gene in Parkinsonâ€™s disease. BMC Neurology, 2021, 21, 187. | 0.8 | 6 |
| 1058 | Discovery of a Necroptosis Inhibitor Improving Dopaminergic Neuronal Loss after MPTP Exposure in Mice. International Journal of Molecular Sciences, 2021, 22, 5289. | 1.8 | 8 |
| 1059 | Effectiveness of Cognitive Rehabilitation in Parkinsonâ€™s Disease: A Systematic Review and Meta-Analysis. Journal of Personalized Medicine, 2021, 11, 429. | 1.1 | 13 |
| 1060 | The Role of the Effects of Autophagy on NLRP3 Inflammasome in Inflammatory Nervous System Diseases. Frontiers in Cell and Developmental Biology, 2021, 9, 657478. | 1.8 | 28 |
| 1061 | The Cryo-EM Effect: Structural Biology of Neurodegenerative Disease Aggregates. Journal of Neuropathology and Experimental Neurology, 2021, 80, 514-529. | 0.9 | 11 |
| 1062 | Oxidative stress and regulated cell death in Parkinsonâ€™s disease. Ageing Research Reviews, 2021, 67, 101263. | 5.0 | 162 |
| 1063 | Dopaminergic and Serotonergic Degeneration and Cortical [ 18 F ]Fluorodeoxyglucose Positron Emission Tomography in De Novo Parkinson's Disease. Movement Disorders, 2021, 36, 2293-2302. | 2.2 | 7 |
| 1064 | Carvacrol as a Potential Neuroprotective Agent for Neurological Diseases: A Systematic Review Article. CNS and Neurological Disorders - Drug Targets, 2021, 20, 942-953. | 0.8 | 15 |
| 1065 | Probiotic Supplementation Facilitates Recovery of 6-OHDA-Induced Motor Deficit via Improving Mitochondrial Function and Energy Metabolism. Frontiers in Aging Neuroscience, 2021, 13, 668775. | 1.7 | 28 |
| 1066 | Edaravone Plays Protective Effects on LPS-Induced Microglia by Switching M1/M2 Phenotypes and Regulating NLRP3 Inflammasome Activation. Frontiers in Pharmacology, 2021, 12, 691773. | 1.6 | 13 |
| 1067 | Non-Motor Symptoms of Parkinsonâ€™s Disease: The Neurobiology of Early Psychiatric and Cognitive Dysfunction. Neuroscientist, 2023, 29, 97-116. | 2.6 | 23 |
| 1069 | Fluid transport in the brain. Physiological Reviews, 2022, 102, 1025-1151. | 13.1 | 192 |
| 1070 | Harnessing the immune system for the treatment of Parkinsonâ€™s disease. Brain Research, 2021, 1758, 147308. | 1.1 | 10 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1071 | System biology and bioinformatics pipeline to identify comorbidities risk association: Neurodegenerative disorder case study. PLoS ONE, 2021, 16, e0250660. | 1.1 | 4 |
| 1072 | C<sub>36</sub> and C<sub>35</sub>E (E=N and B) Fullerenes as Potential Nanovehicles for Neuroprotective Drugs: A Comparative DFT Study. ChemistrySelect, 2021, 6, 4844-4858. | 0.7 | 5 |
| 1073 | <scp><sup>123</sup>Iâ€Metaiodobenzylguanidine</scp> Myocardial Scintigraphy in Discriminating Degenerative Parkinsonisms. Movement Disorders Clinical Practice, 2021, 8, 717-724. | 0.8 | 3 |
| 1074 | A novel treatment strategy to prevent Parkinsonâ€™s disease: focus on iron regulatory protein 1 (IRP1). International Journal of Neuroscience, 2023, 133, 67-76. | 0.8 | 9 |
| 1075 | Mitochondrial D-Loop Region Methylation and Copy Number in Peripheral Blood DNA of Parkinsonâ€™s Disease Patients. Genes, 2021, 12, 720. | 1.0 | 14 |
| 1076 | Energy-Efficient Integrated Circuit Solutions Toward Miniaturized Closed-Loop Neural Interface Systems. Frontiers in Neuroscience, 2021, 15, 667447. | 1.4 | 9 |
| 1077 | Kaempferol alleviates LD-mitochondrial damage by promoting autophagy: Implications in Parkinson's disease. Redox Biology, 2021, 41, 101911. | 3.9 | 43 |
| 1078 | The Long-Term Impact of Levodopa/Carbidopa Intestinal Gel on â€˜Offâ€™-time in Patients with Advanced Parkinsonâ€™s Disease: A Systematic Review. Advances in Therapy, 2021, 38, 2854-2890. | 1.3 | 41 |
| 1079 | A selective NLRP3 inflammasome inhibitor attenuates behavioral deficits and neuroinflammation in a mouse model of Parkinson's disease. Journal of Neuroimmunology, 2021, 354, 577543. | 1.1 | 27 |
| 1080 | Alpha-Synuclein and Mitochondrial Dysfunction in Parkinsonâ€™s Disease: The Emerging Role of VDAC. Biomolecules, 2021, 11, 718. | 1.8 | 29 |
| 1081 | Challenges in the diagnosis of Parkinson's disease. Lancet Neurology, The, 2021, 20, 385-397. | 4.9 | 468 |
| 1082 | Bioinformatics analysis and identification of genes and molecular pathways involved in Parkinsonâ€™s disease in patients with mutations in the glucocerebrosidase gene. NeuroReport, 2021, 32, 918-924. | 0.6 | 1 |
| 1083 | The Cross-Links of Endoplasmic Reticulum Stress, Autophagy, and Neurodegeneration in Parkinsonâ€™s Disease. Frontiers in Aging Neuroscience, 2021, 13, 691881. | 1.7 | 45 |
| 1084 | miR-335 Targets LRRK2 and Mitigates Inflammation in Parkinsonâ€™s Disease. Frontiers in Cell and Developmental Biology, 2021, 9, 661461. | 1.8 | 18 |
| 1085 | Lipid droplets in the nervous system. Journal of Cell Biology, 2021, 220, . | 2.3 | 82 |
| 1086 | Functional variant rs17525453 within RAB35 gene promoter is possibly associated with increased risk of Parkinson's disease in Taiwanese population.. Neurobiology of Aging, 2021, 107, 189-196. | 1.5 | 0 |
| 1087 | Drosophila tubulin polymerization promoting protein mutants reveal pathological correlates relevant to human Parkinsonâ€™s disease. Scientific Reports, 2021, 11, 13614. | 1.6 | 7 |
| 1088 | Prevention of MEK-ERK-1/2 hyper-activation underlines the neuroprotective effect of Glycyrrhiza glabra L. (Yashtimadhu) against rotenone-induced cellular and molecular aberrations. Journal of Ethnopharmacology, 2021, 274, 114025. | 2.0 | 13 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1090 | Acupuncture for Parkinsonâ€™s Disease: Efficacy Evaluation and Mechanisms in the Dopaminergic Neural Circuit. Neural Plasticity, 2021, 2021, 1-23. | 1.0 | 20 |
| 1091 | Regulatory miRNAâ€“mRNA Networks in Parkinsonâ€™s Disease. Cells, 2021, 10, 1410. | 1.8 | 12 |
| 1092 | Î±-Synuclein pathology in Parkinson disease activates homeostatic NRF2 anti-oxidant response. Acta Neuropathologica Communications, 2021, 9, 105. | 2.4 | 17 |
| 1093 | Integrating the Roles of Midbrain Dopamine Circuits in Behavior and Neuropsychiatric Disease. Biomedicines, 2021, 9, 647. | 1.4 | 23 |
| 1094 | Characteristics of Objective Sleep and Its Related Risk Factors Among Parkinson's Disease Patients With and Without Restless Legs Syndrome. Frontiers in Neurology, 2021, 12, 644385. | 1.1 | 4 |
| 1095 | Association of Dynamic Changes in Metabolic Syndrome Status with the Risk of Parkinsonâ€™s Disease: A Nationwide Cohort Study. Journal of Parkinson's Disease, 2021, 11, 1-9. | 1.5 | 3 |
| 1096 | Peripheral and Central Glutamate Dyshomeostasis in Neurodegenerative Disorders. Current Neuropharmacology, 2021, 19, 1069-1089. | 1.4 | 13 |
| 1097 | Chemical and Biological Molecules Involved in Differentiation, Maturation, and Survival of Dopaminergic Neurons in Health and Parkinsonâ€™s Disease: Physiological Aspects and Clinical Implications. Biomedicines, 2021, 9, 754. | 1.4 | 10 |
| 1098 | Glutathione-decorated fluorescent carbon quantum dots for sensitive and selective detection of levodopa. Analytica Chimica Acta, 2021, 1165, 338513. | 2.6 | 37 |
| 1099 | Pragmatic abilities in early Parkinsonâ€™s disease. Brain and Cognition, 2021, 150, 105706. | 0.8 | 8 |
| 1100 | Neuroprotective gain of Apelin/APJ system. Neuropeptides, 2021, 87, 102131. | 0.9 | 20 |
| 1101 | Progress on the application of positron emission tomography imaging of cannabinoid type 1 receptor in neuropsychiatric diseases. Zhejiang Da Xue Xue Bao Yi Xue Ban = Journal of Zhejiang University Medical Sciences, 2021, 50, 1-8. | 0.1 | 0 |
| 1102 | RNA pull-down confocal nanoscanning (RP-CONA) detects quercetin as pri-miR-7/HuR interaction inhibitor that decreases Î±-synuclein levels. Nucleic Acids Research, 2021, 49, 6456-6473. | 6.5 | 7 |
| 1103 | Inflammation, epigenetics, and metabolism converge to cell senescence and ageing: the regulation and intervention. Signal Transduction and Targeted Therapy, 2021, 6, 245. | 7.1 | 119 |
| 1104 | The Role of Intermittent Fasting in Parkinson's Disease. Frontiers in Neurology, 2021, 12, 682184. | 1.1 | 9 |
| 1105 | Involvement of Peroxiredoxin-3, Thioredoxin-2, and Protein Deglycase-1 in Cypermethrin-Induced Parkinsonism. Molecular Neurobiology, 2021, 58, 4745-4757. | 1.9 | 9 |
| 1106 | Mouse Embryonic Stem Cells Expressing GDNF Show Enhanced Dopaminergic Differentiation and Promote Behavioral Recovery After Grafting in Parkinsonian Rats. Frontiers in Cell and Developmental Biology, 2021, 9, 661656. | 1.8 | 5 |
| 1107 | Mechanisms of Metal-Induced Mitochondrial Dysfunction in Neurological Disorders. Toxics, 2021, 9, 142. | 1.6 | 23 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1108 | Pramipexole attenuates neuronal injury in Parkinson's disease by targeting miR-96 to activate BNIP3-mediated mitophagy. Neurochemistry International, 2021, 146, 104972. | 1.9 | 14 |
| 1109 | Gastroparesis in Parkinson Disease: Pathophysiology, and Clinical Management. Brain Sciences, 2021, 11, 831. | 1.1 | 23 |
| 1110 | Domain-Independent Inhibition of CBP/p300 Attenuates Î±-Synuclein Aggregation. ACS Chemical Neuroscience, 2021, 12, 2273-2279. | 1.7 | 7 |
| 1111 | Towards Parkinsonâ€™s Disease Prognosis Using Self-Supervised Learning and Anomaly Detection. , 2021, , . | | 3 |
| 1112 | Co-editing PINK1 and DJ-1 Genes Via Adeno-Associated Virus-Delivered CRISPR/Cas9 System in Adult Monkey Brain Elicits Classical Parkinsonian Phenotype. Neuroscience Bulletin, 2021, 37, 1271-1288. | 1.5 | 25 |
| 1113 | Behavioral Phenotyping in a Murine Model of GBA1-Associated Parkinson Disease. International Journal of Molecular Sciences, 2021, 22, 6826. | 1.8 | 3 |
| 1114 | The C-Terminal Domain of LRRK2 with the G2019S Substitution Increases Mutant A53T Î±-Synuclein Toxicity in Dopaminergic Neurons In Vivo. International Journal of Molecular Sciences, 2021, 22, 6760. | 1.8 | 7 |
| 1115 | Bilirubin: A Promising Therapy for Parkinsonâ€™s Disease. International Journal of Molecular Sciences, 2021, 22, 6223. | 1.8 | 7 |
| 1116 | Structural Features and Toxicity of Î±-Synuclein Oligomers Grown in the Presence of DOPAC. International Journal of Molecular Sciences, 2021, 22, 6008. | 1.8 | 8 |
| 1117 | Sirtuins as pharmacological targets in neurodegenerative and neuropsychiatric disorders. British Journal of Pharmacology, 2022, 179, 1496-1511. | 2.7 | 18 |
| 1118 | Structural and functional neuroimaging changes associated with cognitive impairment and dementia in Parkinson's disease. Psychiatry Research - Neuroimaging, 2021, 312, 111273. | 0.9 | 11 |
| 1119 | Nocebo effects on motor performance: A systematic literature review. Scandinavian Journal of Psychology, 2021, 62, 665-674. | 0.8 | 5 |
| 1120 | Wearable sensors in the diagnosis and study of Parkinsonâ€™s disease symptoms: a systematic review. Journal of Medical Engineering and Technology, 2021, 45, 532-545. | 0.8 | 13 |
| 1121 | Mitochondrial genetic variation in human bioenergetics, adaptation, and adult disease. American Journal of Human Biology, 2021, , e23629. | 0.8 | 1 |
| 1122 | Trend of recognizing depression symptoms and antidepressants use in newly diagnosed Parkinson's disease: Populationâ€based study. Brain and Behavior, 2021, 11, e2228. | 1.0 | 8 |
| 1123 | Oxidative modification impairs SERCA activity in Drosophila and human cell models of Parkinson's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2021, 1867, 166152. | 1.8 | 9 |
| 1124 | Neuroprotective Effect of Astersaponin I against Parkinson's Disease through Autophagy Induction. Biomolecules and Therapeutics, 2021, 29, 615-629. | 1.1 | 5 |
| 1125 | Neuroprotective Effects of Trehalose and Sodium Butyrate on Preformed Fibrillar Form of Î±-Synuclein-Induced Rat Model of Parkinsonâ€™s Disease. ACS Chemical Neuroscience, 2021, 12, 2643-2660. | 1.7 | 20 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1126 | PARK Genes Link Mitochondrial Dysfunction and Alpha-Synuclein Pathology in Sporadic Parkinsonâ€™s Disease. Frontiers in Cell and Developmental Biology, 2021, 9, 612476. | 1.8 | 32 |
| 1127 | The unfolding palette of COVID-19 multisystemic syndrome and its neurological manifestations. Brain, Behavior, & Immunity - Health, 2021, 14, 100251. | 1.3 | 22 |
| 1128 | Prediction of motor Unified Parkinson's Disease Rating Scale scores in patients with Parkinsonâ€™s disease using surface electromyography. Clinical Neurophysiology, 2021, 132, 1708-1713. | 0.7 | 14 |
| 1129 | Altered Sensory Representations in Parkinsonian Cortical and Basal Ganglia Networks. Neuroscience, 2021, 466, 10-25. | 1.1 | 6 |
| 1130 | Parkinsonâ€™s disease patient-specific neuronal networks carrying the LRRK2 G2019S mutation unveil early functional alterations that predate neurodegeneration. Npj Parkinson's Disease, 2021, 7, 55. | 2.5 | 11 |
| 1131 | Fibrillar Î±-synuclein induces neurotoxic astrocyte activation via RIP kinase signaling and NF-ÎºB. Cell Death and Disease, 2021, 12, 756. | 2.7 | 37 |
| 1132 | Mechanistic roles for altered O-GlcNAcylation in neurodegenerative disorders. Biochemical Journal, 2021, 478, 2733-2758. | 1.7 | 28 |
| 1134 | Glucagon-Like Peptide-1 Receptor Agonist Ameliorates 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) Neurotoxicity Through Enhancing Mitophagy Flux and Reducing Î±-Synuclein and Oxidative Stress. Frontiers in Molecular Neuroscience, 2021, 14, 697440. | 1.4 | 22 |
| 1135 | Insights into the Mechanism of the Therapeutic Potential of Herbal Monoamine Oxidase Inhibitors in Neurological Diseases. Current Drug Targets, 2022, 23, 286-310. | 1.0 | 6 |
| 1136 | Relationship between 123I-FP-CIT-SPECT and motor severity in drug-naive patients with Parkinson's disease. Journal of the Neurological Sciences, 2021, 426, 117476. | 0.3 | 1 |
| 1137 | Cross-platform transcriptional profiling identifies common and distinct molecular pathologies in Lewy body diseases. Acta Neuropathologica, 2021, 142, 449-474. | 3.9 | 27 |
| 1138 | The Parkinson disease connectome â€” insights from new imaging studies. Nature Reviews Neurology, 2021, 17, 527-528. | 4.9 | 5 |
| 1139 | Parkinson disease-associated cognitive impairment. Nature Reviews Disease Primers, 2021, 7, 47. | 18.1 | 391 |
| 1140 | Telemonitoring via Questionnaires Reduces Outpatient Healthcare Consumption in Parkinson's Disease. Movement Disorders Clinical Practice, 2021, 8, 1075-1082. | 0.8 | 4 |
| 1141 | Altered Spontaneous Neural Activity and Functional Connectivity in Parkinsonâ€™s Disease With Subthalamic Microlesion. Frontiers in Neuroscience, 2021, 15, 699010. | 1.4 | 9 |
| 1142 | A Systematic Review of Parkinsonâ€™s Disease Pharmacogenomics: Is There Time for Translation into the Clinics?. International Journal of Molecular Sciences, 2021, 22, 7213. | 1.8 | 5 |
| 1144 | Several miRNAs derived from serum extracellular vesicles are potential biomarkers for early diagnosis and progression of Parkinsonâ€™s disease. Translational Neurodegeneration, 2021, 10, 25. | 3.6 | 37 |
| 1145 | miRâ€29câ€3p regulates TET2 expression and inhibits autophagy process in Parkinson's disease models. Genes To Cells, 2021, 26, 684-697. | 0.5 | 10 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1146 | Fast and robust supervised machine learning approach for classification and prediction of Parkinsonâ€™s disease onset. Computer Methods in Biomechanics and Biomedical Engineering: Imaging and Visualization, 2021, 9, 690-706. | 1.3 | 3 |
| 1147 | Implantation of human olfactory ecto-mesenchymal stem cells restores locomotion in a rat model of Parkinson's disease. Journal of Chemical Neuroanatomy, 2021, 114, 101961. | 1.0 | 8 |
| 1148 | Action Observation and Motor Imagery Improve <scp>Dual Task</scp> in Parkinson's Disease: A Clinical/<scp>fMRI</scp> Study. Movement Disorders, 2021, 36, 2569-2582. | 2.2 | 34 |
| 1149 | The Emerging Role of Long Non-Coding RNAs and MicroRNAs in Neurodegenerative Diseases: A Perspective of Machine Learning. Biomolecules, 2021, 11, 1132. | 1.8 | 25 |
| 1150 | Curcumin, Resveratrol and Cannabidiol as Natural Key Prototypes in Drug Design for Neuroprotective Agents. Current Neuropharmacology, 2022, 20, 1297-1328. | 1.4 | 2 |
| 1151 | Technological readiness and implementation of genomicâ€driven precision medicine for complex diseases. Journal of Internal Medicine, 2021, 290, 602-620. | 2.7 | 18 |
| 1152 | Identification of Parkinsonâ€™s Disease-Causing Genes via Omics Data. Frontiers in Genetics, 2021, 12, 712164. | 1.1 | 7 |
| 1153 | Modulation of Neuroinflammation by the Gut Microbiota in Prion and Prion-Like Diseases. Pathogens, 2021, 10, 887. | 1.2 | 7 |
| 1154 | DJ-1 inhibits microglial activation and protects dopaminergic neurons in vitro and in vivo through interacting with microglial p65. Cell Death and Disease, 2021, 12, 715. | 2.7 | 19 |
| 1155 | Monoamine Oxidase Inhibition by Major Tanshinones from Salvia miltiorrhiza and Selective Muscarinic Acetylcholine M4 Receptor Antagonism by Tanshinone I. Biomolecules, 2021, 11, 1001. | 1.8 | 4 |
| 1156 | Short-term deceleration capacity of heart rate: a sensitive marker of cardiac autonomic dysfunction in idiopathic Parkinsonâ€™s disease. Clinical Autonomic Research, 2021, 31, 729-736. | 1.4 | 2 |
| 1157 | Recalling the pathology of Parkinson's disease; lacking exact figure of prevalence and genetic evidence in Asia with an alarming outcome: A time to stepâ€up. Clinical Genetics, 2021, 100, 659-677. | 1.0 | 8 |
| 1158 | Effects of task-oriented training combined with aerobic training on serum BDNF, GDNF, IGF-1, VEGF, TNF-Î±, and IL-1Î² levels in people with Parkinson's disease: A randomized controlled study. Experimental Gerontology, 2021, 150, 111384. | 1.2 | 12 |
| 1159 | Molecular Tuning of the Nanoâ€“Bio Interface: Alpha-Synucleinâ€™s Surface Targeting with Doped Carbon Nanostructures. ACS Applied Bio Materials, 2021, 4, 6073-6083. | 2.3 | 3 |
| 1160 | Novelty of Sphingolipids in the Central Nervous System Physiology and Disease: Focusing on the Sphingolipid Hypothesis of Neuroinflammation and Neurodegeneration. International Journal of Molecular Sciences, 2021, 22, 7353. | 1.8 | 18 |
| 1161 | Mutual Interactions between Brain States and Alzheimerâ€™s Disease Pathology: A Focus on Gamma and Slow Oscillations. Biology, 2021, 10, 707. | 1.3 | 16 |
| 1162 | Melatonin Attenuates Neuroinflammation by Down-Regulating NLRP3 Inflammasome via a SIRT1-Dependent Pathway in MPTP-Induced Models of Parkinsonâ€™s Disease. Journal of Inflammation Research, 2021, Volume 14, 3063-3075. | 1.6 | 32 |
| 1163 | Objective Measurement of Walking Activity Using Wearable Technologies in People with Parkinson Disease: A Systematic Review Protocol. Biomedicine Hub, 2021, 6, 64-68. | 0.4 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1164 | Nanotechnologyâ€Based Strategies for Early Diagnosis of Central Nervous System Disorders. Advanced NanoBiomed Research, 2021, 1, 2100008. | 1.7 | 16 |
| 1165 | Grand Challenges in Molecular Medicine for Disease Prevention and Treatment Through Cyclical Innovation. Frontiers in Molecular Medicine, 2021, 1, . | 0.6 | 2 |
| 1166 | Cell-Type-Specific High Throughput Toxicity Testing in Human Midbrain Organoids. Frontiers in Molecular Neuroscience, 2021, 14, 715054. | 1.4 | 19 |
| 1167 | Developing the ATX(N) classification for use across the Alzheimer disease continuum. Nature Reviews Neurology, 2021, 17, 580-589. | 4.9 | 144 |
| 1168 | International Multicenter Analysis of Brain Structure Across Clinical Stages of Parkinson's Disease. Movement Disorders, 2021, 36, 2583-2594. | 2.2 | 54 |
| 1169 | Mortality of People with Parkinson's Disease in a Large <scp>UK</scp>â€Based Cohort Study: Time Trends and Relationship to Disease Duration. Movement Disorders, 2021, 36, 2811-2820. | 2.2 | 8 |
| 1170 | GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects. Frontiers in Endocrinology, 2021, 12, 721135. | 1.5 | 103 |
| 1171 | The Role of Cell-Free RNA in Clinical Diagnosis and Evaluation of Cell-Free RNA Extraction Methods. IFMBE Proceedings, 2022, , 637-656. | 0.2 | 0 |
| 1172 | The post-diagnosis sleep quality of patients with Parkinson's disease. British Journal of Neuroscience Nursing, 2021, 17, 148-154. | 0.1 | 0 |
| 1173 | Non-Genetic Risk Factors for Parkinsonâ€™s Disease: An Overview of 46 Systematic Reviews. Journal of Parkinson's Disease, 2021, 11, 919-935. | 1.5 | 16 |
| 1174 | The Impact of SNCA Variations and Its Product Alpha-Synuclein on Non-Motor Features of Parkinsonâ€™s Disease. Life, 2021, 11, 804. | 1.1 | 10 |
| 1175 | From Bioelectronics to Nanobioelectronics: The Biomedical Electronics Translational Research Center [Highlights]. IEEE Nanotechnology Magazine, 2021, 15, 3-6. | 0.9 | 0 |
| 1176 | In silico comparative analysis of LRRK2 interactomes from brain, kidney and lung. Brain Research, 2021, 1765, 147503. | 1.1 | 6 |
| 1177 | Potential roles of gut microbiota and microbial metabolites in Parkinsonâ€™s disease. Ageing Research Reviews, 2021, 69, 101347. | 5.0 | 40 |
| 1178 | Case series: Newâ€onset freezing of gait in combined use of deep brain stimulation and Levodopa. Clinical Case Reports (discontinued), 2021, 9, e04695. | 0.2 | 0 |
| 1179 | Detection of hypomimia in patients with Parkinsonâ€™s disease via smile videos. Annals of Translational Medicine, 2021, 9, 1307-1307. | 0.7 | 7 |
| 1181 | Posttranslational modifications & lithiumâ€™s therapeutic effectâ€”Potential biomarkers for clinical responses in psychiatric & neurodegenerative disorders. Neuroscience and Biobehavioral Reviews, 2021, 127, 424-445. | 2.9 | 7 |
| 1182 | Different Alterations of Agonist and Antagonist Binding to 5-HT1A Receptor in a Rat Model of Parkinsonâ€™s Disease and Levodopa-Induced Dyskinesia: A MicroPET Study. Journal of Parkinson's Disease, 2021, 11, 1257-1269. | 1.5 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1183 | Microbiota-Gut-Brain Communication in the SARS-CoV-2 Infection. Cells, 2021, 10, 1993. | 1.8 | 17 |
| 1184 | Diffusion MRI Captures White Matter Microstructure Alterations in PRKN Disease. Journal of Parkinson's Disease, 2021, 11, 1221-1235. | 1.5 | 1 |
| 1185 | The Human Hippocampus in Parkinsonâ€™s Disease: An Integrative Stereological and Proteomic Study. Journal of Parkinson's Disease, 2021, 11, 1345-1365. | 1.5 | 27 |
| 1186 | Enrichment of rare variants in E3 ubiquitin ligase genes in Early onset Parkinson's disease. Neurobiology of Aging, 2022, 109, 273-278. | 1.5 | 6 |
| 1187 | Deep Learning-Based Approach for Parkinsonâ€™s Disease Detection Using Region of Interest. Lecture Notes in Networks and Systems, 2022, , 1-13. | 0.5 | 6 |
| 1188 | 5-Lipoxygenase as an emerging target against age-related brain disorders. Ageing Research Reviews, 2021, 69, 101359. | 5.0 | 11 |
| 1189 | Assessment of Acoustic Features and Machine Learning for Parkinsonâ€™s Detection. Journal of Healthcare Engineering, 2021, 2021, 1-13. | 1.1 | 20 |
| 1190 | L-3,4-Dihydroxyphenylalanine Recovers Circadian Rhythm Disturbances in the Rat Models of Parkinson's Disease by Regulating the D1R-ERK1/2-mTOR Pathway. Frontiers in Aging Neuroscience, 2021, 13, 719885. | 1.7 | 6 |
| 1192 | Role of Rho-Associated Protein Kinase Inhibition As Therapeutic Strategy for Parkinsonâ€™s Disease: Dopaminergic Survival and Enhanced Mitophagy. Cureus, 2021, 13, e16973. | 0.2 | 3 |
| 1193 | Psychometric investigation of the affiliate stigma scale in Mexican Parkinsonâ€™s disease caregivers: Development of a short form. NeuroRehabilitation, 2021, , 1-11. | 0.5 | 3 |
| 1194 | Quercetin hinders microglial activation to alleviate neurotoxicity via the interplay between NLRP3 inflammasome and mitophagy. Redox Biology, 2021, 44, 102010. | 3.9 | 179 |
| 1196 | UHPLC-MS-based metabolomics and chemoinformatics study reveals the neuroprotective effect and chemical characteristic in Parkinsonâ€™s disease mice after oral administration of Wen-Shen-Yang-Gan decoction. Aging, 2021, 13, 19510-19528. | 1.4 | 3 |
| 1197 | Impact of Glucocorticoid on a Cellular Model of Parkinsonâ€™s Disease: Oxidative Stress and Mitochondrial Function. Brain Sciences, 2021, 11, 1106. | 1.1 | 6 |
| 1198 | Extracellular Vesicles, Stem Cells and the Role of miRNAs in Neurodegeneration. Current Neuropharmacology, 2022, 20, 1450-1478. | 1.4 | 5 |
| 1199 | Clinical and Genetic Analysis of Costa Rican Patients With Parkinson's Disease. Frontiers in Neurology, 2021, 12, 656342. | 1.1 | 4 |
| 1200 | The Ageing Brain: Molecular and Cellular Basis of Neurodegeneration. Frontiers in Cell and Developmental Biology, 2021, 9, 683459. | 1.8 | 94 |
| 1201 | Discrimination of idiopathic Parkinsonâ€™s disease and vascular parkinsonism based on gait time series and the levodopa effect. Journal of Biomechanics, 2021, 125, 110214. | 0.9 | 7 |
| 1202 | Neuroprotective Effects of Delta-9-Tetrahydrocannabinol against FeSO4- and H2O2-Induced Cell Damage on Dopaminergic Neurons in Primary Mesencephalic Cell Culture. Planta Medica International Open, 2021, 8, e88-e95. | 0.3 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1203 | Parkinsonâ€™s Disease: A Nanotheranostic Approach Targeting Alpha-Synuclein Aggregation. Frontiers in Cell and Developmental Biology, 2021, 9, 707441. | 1.8 | 10 |
| 1204 | Evaluating the role of ARSA in Chinese patients with Parkinson's disease. Neurobiology of Aging, 2022, 109, 269-272. | 1.5 | 5 |
| 1205 | Generation of hiPSC-Derived Functional Dopaminergic Neurons in Alginate-Based 3D Culture. Frontiers in Cell and Developmental Biology, 2021, 9, 708389. | 1.8 | 13 |
| 1206 | Safety and Tolerability of Active Immunotherapy Targeting Î±-Synuclein with PD03A in Patients with Early Parkinsonâ€™s Disease: A Randomized, Placebo-Controlled, Phase 1 Study. Journal of Parkinson's Disease, 2021, 11, 1079-1089. | 1.5 | 29 |
| 1207 | A subcortical network for implicit visuo-spatial attention: Implications for Parkinson's Disease. Cortex, 2021, 141, 421-435. | 1.1 | 4 |
| 1209 | The Prion-Like Spreading of Alpha-Synuclein in Parkinsonâ€™s Disease: Update on Models and Hypotheses. International Journal of Molecular Sciences, 2021, 22, 8338. | 1.8 | 47 |
| 1210 | Genome-wide screen identifies curli amyloid fibril as a bacterial component promoting host neurodegeneration. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, . | 3.3 | 32 |
| 1211 | Low molecular weight polysialic acid prevents lipopolysaccharideâ€induced inflammatory dopaminergic neurodegeneration in humanized <scp>SIGLEC11</scp> transgenic mice. Glia, 2021, 69, 2845-2862. | 2.5 | 12 |
| 1212 | Microglial inclusions and neurofilament light chain release follow neuronal Î±-synuclein lesions in long-term brain slice cultures. Molecular Neurodegeneration, 2021, 16, 54. | 4.4 | 20 |
| 1213 | A Multiâ€Step Model of Parkinson's Disease Pathogenesis. Movement Disorders, 2021, 36, 2530-2538. | 2.2 | 13 |
| 1216 | The Trajectory of Motor Deterioration to Death in Parkinson's Disease. Frontiers in Neurology, 2021, 12, 670567. | 1.1 | 4 |
| 1217 | Neuroinflammation in neurological disorders: pharmacotherapeutic targets from bench to bedside. Metabolic Brain Disease, 2021, 36, 1591-1626. | 1.4 | 65 |
| 1218 | Mikroglial Toll-benzeri ReseptÃ¶rlerin Alzheimer ve Parkinson HastalÄ±klarÄ±ndaki RolÃ¼. Akdeniz Medical Journal, 0, , 448-456. | 0.0 | 0 |
| 1219 | Noninvasive vagus nerve stimulation in Parkinsonâ€™s disease: current status and future prospects. Expert Review of Medical Devices, 2021, 18, 971-984. | 1.4 | 15 |
| 1220 | Caffeine, a natural methylxanthine nutraceutical, exerts dopaminergic neuroprotection. Neurochemistry International, 2021, 148, 105066. | 1.9 | 8 |
| 1221 | Ca2+ handling at the mitochondria-ER contact sites in neurodegeneration. Cell Calcium, 2021, 98, 102453. | 1.1 | 49 |
| 1222 | Analysis of Impulse Control Disorders (ICDs) and Factors Associated with Their Development in a Parkinsonâ€™s Disease Population. Healthcare (Switzerland), 2021, 9, 1263. | 1.0 | 1 |
| 1223 | Dysregulation of mitochondrial and proteolysosomal genes in Parkinsonâ€™s disease myeloid cells. Nature Aging, 2021, 1, 850-863. | 5.3 | 16 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1224 | LMK235, a small molecule inhibitor of HDAC4/5, protects dopaminergic neurons against neurotoxin- and Î±-synuclein-induced degeneration in cellular models of Parkinson's disease. Molecular and Cellular Neurosciences, 2021, 115, 103642. | 1.0 | 14 |
| 1225 | Neuroprotective Effects of Neuropeptide Y against Neurodegenerative Disease. Current Neuropharmacology, 2022, 20, 1717-1725. | 1.4 | 14 |
| 1226 | Perinatal exposure to a glyphosate-based herbicide causes dysregulation of dynorphins and an increase of neural precursor cells in the brain of adult male rats. Toxicology, 2021, 461, 152922. | 2.0 | 12 |
| 1227 | Living with the enemy: from protein-misfolding pathologies we know, to those we want to know. Ageing Research Reviews, 2021, 70, 101391. | 5.0 | 16 |
| 1228 | Electroactive Smart Materials for Neural Tissue Regeneration. ACS Applied Bio Materials, 2021, 4, 6604-6618. | 2.3 | 7 |
| 1230 | Automated speech analysis in early untreated Parkinson's disease: Relation to gender and dopaminergic transporter imaging. European Journal of Neurology, 2022, 29, 81-90. | 1.7 | 33 |
| 1231 | A convolutional-recurrent neural network approach to resting-state EEG classification in Parkinsonâ€™s disease. Journal of Neuroscience Methods, 2021, 361, 109282. | 1.3 | 42 |
| 1232 | Hypomimia May Influence the Facial Emotion Recognition Ability in Patients with Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2022, 12, 185-197. | 1.5 | 7 |
| 1233 | Elucidating the Neuroprotective Role of PPARs in Parkinsonâ€™s Disease: A Neoteric and Prospective Target. International Journal of Molecular Sciences, 2021, 22, 10161. | 1.8 | 14 |
| 1234 | Therapeutic Potential of Natural Products in Treating Neurodegenerative Disorders and Their Future Prospects and Challenges. Molecules, 2021, 26, 5327. | 1.7 | 53 |
| 1235 | Age-related amyloidosis outside the brain: A state-of-the-art review. Ageing Research Reviews, 2021, 70, 101388. | 5.0 | 14 |
| 1236 | Methamphetamine and heightened risk for early-onset stroke and Parkinson's disease: A review. Experimental Neurology, 2021, 343, 113793. | 2.0 | 13 |
| 1237 | The blood biomarkers puzzle â€“ A review of protein biomarkers in neurodegenerative diseases. Journal of Neuroscience Methods, 2021, 361, 109281. | 1.3 | 14 |
| 1238 | Exploring the Role of Orexinergic Neurons in Parkinsonâ€™s Disease. Neurotoxicity Research, 2021, 39, 2141-2153. | 1.3 | 8 |
| 1239 | Antiparkinsonian activity of new N-methyl-D-aspartate receptor ligands in the arecoline hyperkinesis test. Meditsinskiy Sovet, 2021, , 406-412. | 0.1 | 2 |
| 1240 | Treadmill exercise alleviates neuronal damage by suppressing NLRP3 inflammasome and microglial activation in the MPTP mouse model of Parkinsonâ€™s disease. Brain Research Bulletin, 2021, 174, 349-358. | 1.4 | 11 |
| 1241 | Investigation of Therapeutic Response Markers for Acupuncture in Parkinsonâ€™s Disease: An Exploratory Pilot Study. Diagnostics, 2021, 11, 1697. | 1.3 | 3 |
| 1242 | Suggesting 7,8-dihydroxyflavone as a promising nutraceutical against CNS disorders. Neurochemistry International, 2021, 148, 105068. | 1.9 | 13 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1243 | NSAID use is not associated with Parkinsonâ€™s disease incidence: A Norwegian Prescription Database study. PLoS ONE, 2021, 16, e0256602. | 1.1 | 7 |
| 1244 | Genotype-Phenotype Correlations in Monogenic Parkinson Disease: A Review on Clinical and Molecular Findings. Frontiers in Neurology, 2021, 12, 648588. | 1.1 | 23 |
| 1245 | Continuous Subcutaneous Apomorphine Infusion in Advanced Parkinsonâ€™s Disease: A Systematic Review. Cureus, 2021, 13, e17949. | 0.2 | 2 |
| 1246 | Voltammetric Determination of Levodopa Using Mesoporous Carbonâ€"Modified Screen-Printed Carbon Sensors. Sensors, 2021, 21, 6301. | 2.1 | 8 |
| 1247 | Vagus nerve ultrasonography in Parkinson's disease: A systematic review and meta-analysis. Autonomic Neuroscience: Basic and Clinical, 2021, 234, 102835. | 1.4 | 12 |
| 1248 | Cholinergic Receptor Modulation as a Target for Preventing Dementia in Parkinsonâ€™s Disease. Frontiers in Neuroscience, 2021, 15, 665820. | 1.4 | 14 |
| 1249 | The antioxidant Rutin counteracts the pathological impact of Î±-synuclein on the enteric nervous system in vitro. Biological Chemistry, 2022, 403, 103-122. | 1.2 | 5 |
| 1250 | Convolutional neural network optimizes the application of diffusion kurtosis imaging in Parkinsonâ€™s disease. Brain Informatics, 2021, 8, 18. | 1.8 | 1 |
| 1251 | Integration of functional genomics data to uncover cell type-specific pathways affected in Parkinson's disease. Biochemical Society Transactions, 2021, 49, 2091-2100. | 1.6 | 1 |
| 1252 | Abnormal Intracortical Functions in Parkinsonâ€™s Disease with Rapid Eye Movement Sleep Behaviour Disorder. Canadian Journal of Neurological Sciences, 2022, 49, 672-677. | 0.3 | 5 |
| 1253 | Combining Automated Organoid Workflows with Artificial Intelligenceâ€Based Analyses: Opportunities to Build a New Generation of Interdisciplinary Highâ€Throughput Screens for Parkinson's Disease and Beyond. Movement Disorders, 2021, 36, 2745-2762. | 2.2 | 10 |
| 1254 | Restoring lost nigrostriatal fibers in Parkinsonâ€™s disease based on clinically-inspired design criteria. Brain Research Bulletin, 2021, 175, 168-185. | 1.4 | 14 |
| 1255 | Alpha-synuclein pathology, microgliosis, and parvalbumin neuron loss in the amygdala associated with enhanced fear in the Thy1-aSyn model of Parkinson's disease. Neurobiology of Disease, 2021, 158, 105478. | 2.1 | 15 |
| 1256 | Search for safer and potent natural inhibitors of Parkinson's disease. Neurochemistry International, 2021, 149, 105135. | 1.9 | 15 |
| 1257 | Association of Serum Uric Acid Levels in Meigeâ€™s Syndrome. Frontiers in Neuroscience, 2021, 15, 755056. | 1.4 | 3 |
| 1258 | Insulin-like growth factor II prevents oxidative and neuronal damage in cellular and mice models of Parkinson's disease. Redox Biology, 2021, 46, 102095. | 3.9 | 16 |
| 1259 | Diterpene glycosides from Holothuria scabra exert the Î±-synuclein degradation and neuroprotection against Î±-synuclein-Mediated neurodegeneration in C. elegans model. Journal of Ethnopharmacology, 2021, 279, 114347. | 2.0 | 10 |
| 1260 | Delivery of pOXR1 through an injectable liposomal nanoparticle enhances spinal cord injury regeneration by alleviating oxidative stress. Bioactive Materials, 2021, 6, 3177-3191. | 8.6 | 25 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1261 | An updated reappraisal of synapsins: structure, function and role in neurological and psychiatric disorders. Neuroscience and Biobehavioral Reviews, 2021, 130, 33-60. | 2.9 | 22 |
| 1262 | Nanotechnology-based drug delivery for central nervous system disorders. Biomedicine and Pharmacotherapy, 2021, 143, 112117. | 2.5 | 60 |
| 1263 | Dynamic changes of activated AHR in microglia and astrocytes in the substantia nigra-striatum system in an MPTP-induced Parkinsonâ€™s disease mouse model. Brain Research Bulletin, 2021, 176, 174-183. | 1.4 | 13 |
| 1264 | Constitutive silencing of LRRK2 kinase activity leads to early glucocerebrosidase deregulation and late impairment of autophagy in vivo. Neurobiology of Disease, 2021, 159, 105487. | 2.1 | 16 |
| 1265 | Modeling spatiotemporal patterns of gait anomaly with a CNN-LSTM deep neural network. Expert Systems With Applications, 2021, 185, 115582. | 4.4 | 11 |
| 1266 | Genkwanin suppresses MPP+-induced cytotoxicity by inhibiting TLR4/MyD88/NLRP3 inflammasome pathway in a cellular model of Parkinsonâ€™s disease. NeuroToxicology, 2021, 87, 62-69. | 1.4 | 13 |
| 1267 | Systematic analysis of the molecular mechanisms mediated by coffee in Parkinsonâ€™s disease based on network pharmacology approach. Journal of Functional Foods, 2021, 87, 104764. | 1.6 | 7 |
| 1268 | A systematic comparison of neurotoxicity of bisphenol A and its derivatives in zebrafish. Science of the Total Environment, 2022, 805, 150210. | 3.9 | 55 |
| 1269 | Growth differentiation factor 5: a neurotrophic factor with neuroprotective potential in Parkinsonâ€™s disease. Neural Regeneration Research, 2022, 17, 38. | 1.6 | 5 |
| 1270 | Neurodegenerative Motor Conditions. , 2022, , 106-114. | | 0 |
| 1271 | Altered autophagy on the path to Parkinson's disease. , 2022, , 271-286. | | 0 |
| 1273 | Andrographolide, a Diterpene from Andrographis paniculata, and its Influence on the Progression of Neurodegenerative Disorders. , 2021, , 79-112. | | 1 |
| 1274 | A Novel Nitrogen-Doped Dual-Emission Carbon Dots as an Effective Fluorescent Probe for Ratiometric Detection Dopamine. Nano, 2021, 16, 2150030. | 0.5 | 3 |
| 1275 | Impaired mitochondrial energy metabolism. , 2021, , 93-118. | | 2 |
| 1276 | Biological implications and limitations of a cynomolgus monkey with naturally occurring Parkinsonâ€™s disease. Zoological Research, 2021, 42, 138-140. | 0.9 | 9 |
| 1278 | Sudden death in a rat model of Parkinsonâ€™s disease. Clinics, 2021, 76, e2974. | 0.6 | 0 |
| 1279 | Diagnostic and theranostic intranasal nanointerventions for brain diseases. , 2021, , 287-303. | | 1 |
| 1280 | Neurological Disorders: Biochemistry of Drug Resistance and Future Challenges. , 2021, , 255-277. | | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1281 | Induced Expression of kir6.2 in A1 Astrocytes Propagates Inflammatory Neurodegeneration via Drp1-dependent Mitochondrial Fission. Frontiers in Pharmacology, 2020, 11, 618992. | 1.6 | 11 |
| 1282 | Peripheral Leukocytosis Predicts Cognitive Decline but Not Behavioral Disturbances: A Nationwide Study of Alzheimerâ€™s and Parkinsonâ€™s Disease Patients. Dementia and Geriatric Cognitive Disorders, 2021, 50, 143-152. | 0.7 | 6 |
| 1283 | The circadian system in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2021, 179, 301-313. | 1.0 | 3 |
| 1284 | Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide dual receptor agonist DA-CH5 is superior to exendin-4 in protecting neurons in the 6-hydroxydopamine rat Parkinson model. Neural Regeneration Research, 2021, 16, 1660. | 1.6 | 22 |
| 1285 | Gastrointestinal Dysfunction in Parkinsonâ€™s Disease. Journal of Clinical Medicine, 2021, 10, 493. | 1.0 | 37 |
| 1286 | Plasma-borne indicators of inflammasome activity in Parkinsonâ€™s disease patients. Npj Parkinson's Disease, 2021, 7, 2. | 2.5 | 34 |
| 1287 | The magnetic-nanoparticle-assisted sensitive detection of nitrated Î±-syn in blood based on a sensitizing electrochemical layer. Nanoscale, 2021, 13, 8107-8117. | 2.8 | 9 |
| 1288 | Exploring the contribution of the mitochondrial disulfide relay system to Parkinsonâ€™s disease: the PINK1/CHCHD4 interplay. Neural Regeneration Research, 2021, 16, 2222. | 1.6 | 5 |
| 1289 | Genome editing of hPSCs: Recent progress in hPSC-based disease modeling for understanding disease mechanisms. Progress in Molecular Biology and Translational Science, 2021, 181, 271-287. | 0.9 | 1 |
| 1290 | Copper oxide integrated perylene diimide self-assembled graphitic pencil for robust non-enzymatic dopamine detection. RSC Advances, 2021, 11, 25084-25095. | 1.7 | 19 |
| 1291 | The Association between Early-Life Gut Microbiota and Long-Term Health and Diseases. Journal of Clinical Medicine, 2021, 10, 459. | 1.0 | 118 |
| 1292 | MicroRNAs in sudden death in parkinson's disease: Could the news be packaged?. Annals of Indian Academy of Neurology, 2021, 24, 268. | 0.2 | 0 |
| 1293 | Assessment of the Telomere Length and Its Effect on the Symptomatology of Parkinsonâ€™s Disease. Antioxidants, 2021, 10, 137. | 2.2 | 9 |
| 1294 | Parkinson's disease: Genetic-driven therapeutic approaches. , 2021, , 135-159. | | 0 |
| 1295 | From the nose to the brain, nanomedicine drug delivery. , 2021, , 153-180. | | 2 |
| 1296 | Progress in generating iPSC-derived dopaminergic neurons as accurate models of neurodegenerative disease. , 2021, , 181-203. | | 0 |
| 1297 | Opicapone: A Review in Parkinsonâ€™s Disease. CNS Drugs, 2021, 35, 121-131. | 2.7 | 17 |
| 1298 | Potential effects of mesenchymal stem cell derived extracellular vesicles and exosomal miRNAs in neurological disorders. Neural Regeneration Research, 2021, 16, 2359. | 1.6 | 40 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1299 | Animal Models of Metabolic Disorders in the Study of Neurodegenerative Diseases: An Overview. Frontiers in Neuroscience, 2020, 14, 604150. | 1.4 | 31 |
| 1300 | A Data-Driven Biophysical Computational Model of Parkinsonâ€™s Disease Based on Marmoset Monkeys. IEEE Access, 2021, 9, 122548-122567. | 2.6 | 8 |
| 1301 | Lithium and Therapeutic Targeting of GSK-3. Cells, 2021, 10, 255. | 1.8 | 49 |
| 1302 | Observation of an Î±-synuclein liquid droplet state and its maturation into Lewy body-like assemblies. Journal of Molecular Cell Biology, 2021, 13, 282-294. | 1.5 | 65 |
| 1303 | DNA damage and repair in Parkinson's disease: Recent advances and new opportunities. Journal of Neuroscience Research, 2021, 99, 180-189. | 1.3 | 37 |
| 1304 | ER-Mitochondria Calcium Transfer, Organelle Contacts and Neurodegenerative Diseases. Advances in Experimental Medicine and Biology, 2020, 1131, 719-746. | 0.8 | 29 |
| 1305 | Modulation of CNS Functions by Deep Brain Stimulation: Insights Provided byÂMolecular Imaging. , 2021, , 1177-1244. | | 3 |
| 1306 | Knockout Mouse Models Provide Insight into the Biological Functions of CRL1 Components. Advances in Experimental Medicine and Biology, 2020, 1217, 147-171. | 0.8 | 5 |
| 1307 | Correlation between the availability of dopamine transporter and olfactory function in healthy subjects. European Radiology, 2018, 28, 1756-1760. | 2.3 | 14 |
| 1308 | Chemometric modeling of PET imaging agents for diagnosis of Parkinsonâ€™s disease: a QSAR approach. Structural Chemistry, 2020, 31, 1969-1981. | 1.0 | 2 |
| 1309 | The Role of Mitochondria in Neurodegenerative Diseases: the Lesson from Alzheimerâ€™s Disease and Parkinsonâ€™s Disease. Molecular Neurobiology, 2020, 57, 2959-2980. | 1.9 | 180 |
| 1310 | Discovery and development of ASK1 inhibitors. Progress in Medicinal Chemistry, 2020, 59, 101-179. | 4.1 | 17 |
| 1311 | Regulation and function of V-ATPases in physiology and disease. Biochimica Et Biophysica Acta - Biomembranes, 2020, 1862, 183341. | 1.4 | 80 |
| 1312 | Facile nose-to-brain delivery of rotigotine-loaded polymer micelles thermosensitive hydrogels: In vitro characterization and in vivo behavior study. International Journal of Pharmaceutics, 2020, 577, 119046. | 2.6 | 42 |
| 1313 | Beyond the Neuropsychiatric Horizon: Assessing the Risk of Sudden Unexpected Death in Parkinson Disease. Journal of the American Medical Directors Association, 2017, 18, 988. | 1.2 | 4 |
| 1314 | Allosteric inhibition of LRRK2, where are we now. Biochemical Society Transactions, 2020, 48, 2185-2194. | 1.6 | 10 |
| 1315 | The emerging role of Î±-synuclein truncation in aggregation and disease. Journal of Biological Chemistry, 2020, 295, 10224-10244. | 1.6 | 99 |
| 1316 | Mitophagy pathways in health and disease. Journal of Cell Biology, 2020, 219, . | 2.3 | 121 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1317 | Personalized dynamic transport of magnetic nanorobots inside the brain vasculature. Nanotechnology, 2020, 31, 495706. | 1.3 | 17 |
| 1318 | Light therapy: a new option for neurodegenerative diseases. Chinese Medical Journal, 2021, 134, 634-645. | 0.9 | 15 |
| 1319 | Contribution of aging oral microbiota in getting neurodegenerative diseases. Reviews in Medical Microbiology, 2021, 32, 90-94. | 0.4 | 5 |
| 1335 | Closed-Loop Neuromodulation for Parkinsonâ€™s Disease: Current State and Future Directions. IEEE Transactions on Molecular, Biological, and Multi-Scale Communications, 2021, 7, 209-223. | 1.4 | 7 |
| 1336 | Bradykinesia Recognition in Parkinsonâ€™s Disease via Single RGB Video. ACM Transactions on Knowledge Discovery From Data, 2020, 14, 1-19. | 2.5 | 4 |
| 1337 | Minireview on the Relations between Gut Microflora and Parkinsonâ€™s Disease: Further Biochemical (Oxidative Stress), Inflammatory, and Neurological Particularities. Oxidative Medicine and Cellular Longevity, 2020, 2020, 1-15. | 1.9 | 18 |
| 1338 | Alpha-Synuclein to the Rescue: Immune Cell Recruitment by Alpha-Synuclein during Gastrointestinal Infection. Journal of Innate Immunity, 2017, 9, 437-440. | 1.8 | 43 |
| 1339 | Crosstalk and Interplay between the Ubiquitin-Proteasome System and Autophagy. Molecules and Cells, 2017, 40, 441-449. | 1.0 | 201 |
| 1340 | Serum Uric Acid, Serum Uric Acid to Serum Creatinine Ratio and Serum Bilirubin in Patients With Parkinsonâ€™s Disease: A Case-Control Study. Journal of Clinical Medicine Research, 2020, 12, 172-179. | 0.6 | 11 |
| 1341 | The therapeutic potential of mitochondrial transplantation for the treatment of neurodegenerative disorders. Reviews in the Neurosciences, 2021, 32, 203-217. | 1.4 | 18 |
| 1342 | Tai Chi versus routine exercise in patients with early- or mild-stage Parkinson's disease: a retrospective cohort analysis. Brazilian Journal of Medical and Biological Research, 2020, 53, e9171. | 0.7 | 15 |
| 1343 | Mitochondrial and autophagic alterations in skin fibroblasts from Parkinson disease patients with Parkin mutations. Aging, 2019, 11, 3750-3767. | 1.4 | 25 |
| 1344 | Genetic networks in Parkinsonâ€™s and Alzheimerâ€™s disease. Aging, 2020, 12, 5221-5243. | 1.4 | 25 |
| 1345 | p27Kip1 regulates alpha-synuclein expression. Oncotarget, 2018, 9, 16368-16379. | 0.8 | 6 |
| 1346 | Role of p27Kip1 as a transcriptional regulator. Oncotarget, 2018, 9, 26259-26278. | 0.8 | 32 |
| 1347 | The Potential Role of Dysfunctions in Neuron-Microglia Communication in the Pathogenesis of Brain Disorders. Current Neuropharmacology, 2020, 18, 408-430. | 1.4 | 49 |
| 1348 | Modeling Parkinsonâ€™s Disease in Zebrafish. CNS and Neurological Disorders - Drug Targets, 2020, 19, 386-399. | 0.8 | 16 |
| 1349 | Protection from the Pathogenesis of Neurodegenerative Disorders, including Alzheimerâ€™s Disease, Amyotrophic Lateral Sclerosis, Huntingtonâ€™s Disease, and Parkinsonâ€™s Diseases, through the Mitigation of Reactive Oxygen Species. Journal of Neuroscience and Neurological Disorders, 2019, 3, 148-161. | 0.1 | 10 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1350 | Parkinson HastalÄ±ÄŸÄ±nÄ±n Derecesi ile YÃ¼rÃ¼yÃ¼ÅŸ DeÄŸiÅŸkenliÄŸi ArasÄ±ndaki Ä°liÅŸkinin BulanÄ±k TekrarlÄ±lÄ±k GrafiÄŸine AraÅŸtÄ±rÄ±lmasÄ±. European Journal of Science and Technology, 0, , 410-419. | 0.5 | 1 |
| 1351 | Culprit or Bystander: Defective Mitophagy in Alzheimerâ€™s Disease. Frontiers in Cell and Developmental Biology, 2019, 7, 391. | 1.8 | 11 |
| 1352 | Cellular Senescence in Neurodegenerative Diseases. Frontiers in Cellular Neuroscience, 2020, 14, 16. | 1.8 | 164 |
| 1353 | Clinical Features of Parkinsonâ€™s Disease: The Evolution of Critical Symptoms. Biology, 2020, 9, 103. | 1.3 | 57 |
| 1354 | Quantifying Spontaneous Ca<sup>2+</sup> Fluxes and their Downstream Effects in Primary Mouse Midbrain Neurons. Journal of Visualized Experiments, 2020, , . | 0.2 | 5 |
| 1355 | Î±-synuclein promotes progression of Parkinson's disease by upregulating autophagy signaling pathway to activate NLRP3 inflammasome. Experimental and Therapeutic Medicine, 2020, 19, 931-938. | 0.8 | 28 |
| 1356 | Beclin 1 Complex and Neurodegenerative Disorders. Advances in Medical Diagnosis, Treatment, and Care, 2020, , 236-260. | 0.1 | 2 |
| 1357 | Antibody-based immunotherapies for Parkinsonian syndromes. Neural Regeneration Research, 2019, 14, 1903. | 1.6 | 3 |
| 1358 | The role of exercise in brain DNA damage. Neural Regeneration Research, 2020, 15, 1981. | 1.6 | 11 |
| 1359 | Possible Link between Porphyromonas gingivalis and Amyloidosis in the Pathogenesis of Alzheimerâ€™s and Parkinsonâ€™s Disease.. , 0, , 1-12. | | 1 |
| 1360 | Novel Botulinum Toxin Injection Protocols for Parkinson Tremor and Essential Tremor â€“ the Yale Technique and Sensor-Based Kinematics Procedure for Safe and Effective Treatment. Tremor and Other Hyperkinetic Movements, 2020, 10, 61. | 1.1 | 11 |
| 1361 | Sphingolipids in neuroinflammation: a potential target for diagnosis and therapy. BMB Reports, 2020, 53, 28-34. | 1.1 | 41 |
| 1362 | Functional Neurological Symptom Disorder in a Patient with Parkinsonâ€™s Disease and Psychotic Features: A Case Report. Journal of Kermanshah University of Medical Sciences, 2020, 24, . | 0.1 | 1 |
| 1363 | Sudden unexpected death in Parkinson's disease (SUDPAR): a review of publications since the decade of the brain. Clinics, 2017, 72, 649-651. | 0.6 | 41 |
| 1364 | The mitochondrial calcium uniporter: a new therapeutic target for Parkinson's disease-related cardiac dysfunctions?. Clinics, 2020, 75, e1299. | 0.6 | 8 |
| 1365 | A fully automated high-throughput workflow for 3D-based chemical screening in human midbrain organoids. ELife, 2020, 9, . | 2.8 | 117 |
| 1366 | A gut bacterial amyloid promotes Î±-synuclein aggregation and motor impairment in mice. ELife, 2020, 9, . | 2.8 | 251 |
| 1367 | N-acetylcysteine protects against motor, optomotor and morphological deficits induced by 6-OHDA in zebrafish larvae. PeerJ, 2018, 6, e4957. | 0.9 | 23 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1368 | Exploiting spectral and cepstral handwriting features on diagnosing Parkinsonâ€™s disease. IEEE Access, 2021, , 1-1. | 2.6 | 7 |
| 1369 | VGF as a biomarker and therapeutic target in neurodegenerative and psychiatric diseases. Brain Communications, 2021, 3, fcab261. | 1.5 | 35 |
| 1370 | 6-hydroxydopamine and ovariectomy has no effect on heart rate variability parameters of females. Clinics, 2021, 76, e3175. | 0.6 | 0 |
| 1371 | Target-binding behavior of IDPs via pre-structured motifs. Progress in Molecular Biology and Translational Science, 2021, 183, 187-247. | 0.9 | 4 |
| 1372 | Functional Connectomics and Disease Progression in Drugâ€NaÃ¯ve Parkinson's Disease Patients. Movement Disorders, 2021, 36, 1603-1616. | 2.2 | 27 |
| 1373 | Predicting Parkinsonâ€™s Disease and Its Pathology via Simple Clinical Variables. Journal of Parkinson's Disease, 2022, 12, 341-351. | 1.5 | 8 |
| 1374 | Brain regions susceptible to alpha-synuclein spreading. Molecular Psychiatry, 2022, 27, 758-770. | 4.1 | 24 |
| 1375 | Facetâ€Dependent Biodegradable Mn<sub>3</sub>O<sub>4</sub> Nanoparticles for Ameliorating Parkinson's Disease. Advanced Healthcare Materials, 2021, 10, e2101316. | 3.9 | 23 |
| 1376 | Myelinâ€associated oligodendrocyte basic protein rs616147 polymorphism as a risk factor for Parkinson's disease. Acta Neurologica Scandinavica, 2022, 145, 223-228. | 1.0 | 10 |
| 1377 | The Possible Role of Bifidobacterium longum BB536 and Lactobacillus rhamnosus HN001 on Locomotor Activity and Oxidative Stress in a Rotenone-Induced Zebrafish Model of Parkinsonâ€™s Disease. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-11. | 1.9 | 12 |
| 1378 | Temporal and spatial evolution of various functional neurons during demyelination induced by cuprizone. Journal of Neurophysiology, 2021, 126, 1756-1771. | 0.9 | 2 |
| 1379 | A High-Throughput Chemical Screen in DJ-1Î² Mutant Flies Identifies Zaprinast as a Potential Parkinson's Disease Treatment. Neurotherapeutics, 2021, 18, 2565-2578. | 2.1 | 6 |
| 1380 | NÃ¶rodejeneratif HastalÄ±klarda Umut Verici Bir TerapÃ¶tik Hedef: Sestrin-2. SaÄŸlÄ±k Akademisi Kastamonu, 0, , . | 0.0 | 0 |
| 1382 | Interaction between coxsackievirus B3 infection and Î±-synuclein in models of Parkinsonâ€™s disease. PLoS Pathogens, 2021, 17, e1010018. | 2.1 | 8 |
| 1383 | Direct targeting of wild-type glucocerebrosidase by antipsychotic quetiapine improves pathogenic phenotypes in Parkinsonâ€™s disease models. JCI Insight, 2021, 6, . | 2.3 | 6 |
| 1384 | NME1 Protects Against Neurotoxin-, Î±-Synuclein- and LRRK2-Induced Neurite Degeneration in Cell Models of Parkinsonâ€™s Disease. Molecular Neurobiology, 2022, 59, 61-76. | 1.9 | 6 |
| 1385 | Oxidative Stress and Cellular Dysfunction in Neurodegenerative. Neuromethods, 2022, , 121-154. | 0.2 | 0 |
| 1386 | Fine-mapping of Parkinsonâ€™s disease susceptibility loci identifies putative causal variants. Human Molecular Genetics, 2022, 31, 888-900. | 1.4 | 21 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1387 | Cationic Carbosilane Dendrimers Prevent Abnormal Î±-Synuclein Accumulation in Parkinsonâ€™s Disease Patient-Specific Dopamine Neurons. Biomacromolecules, 2021, 22, 4582-4591. | 2.6 | 12 |
| 1388 | Selfâ€Catalytic Small Interfering RNA Nanocarriers for Synergistic Treatment of Neurodegenerative Diseases. Advanced Materials, 2022, 34, e2105711. | 11.1 | 30 |
| 1389 | Preventing amyotrophic lateral sclerosis: insights from pre-symptomatic neurodegenerative diseases. Brain, 2022, 145, 27-44. | 3.7 | 38 |
| 1390 | Interventional Strategies for Parkinson Disease: Can Neural Precursor Cells Forge a Path Ahead?. ACS Chemical Neuroscience, 2021, 12, 3785-3794. | 1.7 | 4 |
| 1391 | Polygenic Risk Scores Contribute to Personalized Medicine of Parkinsonâ€™s Disease. Journal of Personalized Medicine, 2021, 11, 1030. | 1.1 | 12 |
| 1392 | Pathogenic LRRK2 control of primary cilia and Hedgehog signaling in neurons and astrocytes of mouse brain. ELife, 2021, 10, . | 2.8 | 47 |
| 1393 | The effect and safety of levodopa alone versus levodopa sparing therapy for early Parkinsonâ€™s disease: a systematic review and meta-analysis. Journal of Neurology, 2022, 269, 1834-1850. | 1.8 | 2 |
| 1394 | Revisiting brain stimulation in Parkinsonâ€™s disease. Science, 2021, 374, 153-154. | 6.0 | 2 |
| 1395 | Lack of Parkinsonian Pathology and Neurodegeneration in Mice After Long-Term Injections of a Proteasome Inhibitor in Olfactory Bulb and Amygdala. Frontiers in Aging Neuroscience, 2021, 13, 698979. | 1.7 | 2 |
| 1397 | Tremor and Rigidity in Patients with Parkinsonâ€™s Disease: Emphasis on Epidemiology, Pathophysiology and Contributing Factors. CNS and Neurological Disorders - Drug Targets, 2022, 21, 596-609. | 0.8 | 6 |
| 1398 | Apolipoprotein E Genotype Contributes to Motor Progression in Parkinson's Disease. Movement Disorders, 2022, 37, 196-200. | 2.2 | 20 |
| 1399 | A six-metabolite panel as potential blood-based biomarkers for Parkinsonâ€™s disease. Npj Parkinson's Disease, 2021, 7, 94. | 2.5 | 19 |
| 1400 | Comprehensive Analysis of LIN28A in Chinese Patients With Early Onset Parkinsonâ€™s Disease. Frontiers in Genetics, 2021, 12, 740096. | 1.1 | 2 |
| 1401 | Targeting Microglial Î±-Synuclein/TLRs/NF-kappaB/NLRP3 Inflammasome Axis in Parkinsonâ€™s Disease. Frontiers in Immunology, 2021, 12, 719807. | 2.2 | 71 |
| 1402 | Diagnostic AI Modeling and Pseudo Time Series Profiling of AD and PD Based on Individualized Serum Proteome Data. Frontiers in Bioinformatics, 2021, 1, . | 1.0 | 2 |
| 1403 | Biomaterial Strategies for Restorative Therapies in Parkinsonâ€™s Disease. ACS Chemical Neuroscience, 2021, 12, 4224-4235. | 1.7 | 7 |
| 1404 | Targeting PDZ domains as potential treatment for viral infections, neurodegeneration and cancer. Biology Direct, 2021, 16, 15. | 1.9 | 12 |
| 1405 | Gastric Helicobacter suis Infection Partially Protects against Neurotoxicity in A 6-OHDA Parkinsonâ€™s Disease Mouse Model. International Journal of Molecular Sciences, 2021, 22, 11328. | 1.8 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1406 | Enhanced Plasmonic Biosensor Utilizing Paired Antibody and Label-Free Fe3O4 Nanoparticles for Highly Sensitive and Selective Detection of Parkinsonâ€™s Î±-Synuclein in Serum. Biosensors, 2021, 11, 402. | 2.3 | 12 |
| 1407 | Astrocyte dysfunction in Parkinson's disease: from the perspectives of transmitted Î±-synuclein and genetic modulation. Translational Neurodegeneration, 2021, 10, 39. | 3.6 | 31 |
| 1408 | How much time is needed in clinical practice to reach a diagnosis of clinically established Parkinson's disease?. Parkinsonism and Related Disorders, 2021, 92, 53-58. | 1.1 | 6 |
| 1409 | Linking COVID-19 and Parkinson's disease: Targeting the role of Vitamin-D. Biochemical and Biophysical Research Communications, 2021, 583, 14-21. | 1.0 | 10 |
| 1413 | Application of Normalized Compression Distance and Lempel-Ziv Jaccard Distance in Micro-electrode Signal Stream Classification for the Surgical Treatment of Parkinsonâ€™s Disease. Studies in Logic, Grammar and Rhetoric, 2018, 56, 45-57. | 0.2 | 0 |
| 1414 | Functional Data and Long Short-Term Memory Networks for Diagnosis of Parkinsonâ€™s Disease. Lecture Notes in Computer Science, 2019, , 655-663. | 1.0 | 0 |
| 1415 | Understanding Neurodegeneration and Neuroprotection Through Genetic Screens in Drosophila. , 2019, , 55-88. | | 2 |
| 1416 | Nanobiotechnology in Parkinsonâ€™s Disease. , 2019, , 177-208. | | 0 |
| 1417 | In-silico Targets in Neurodegenerative Disorders. , 2019, , 403-419. | | 0 |
| 1418 | Diagnosis of Parkinsonâ€™s Disease in Genetic Cohort Patients via Stage-Wise Hierarchical Deep Polynomial Ensemble Learning. Lecture Notes in Computer Science, 2019, , 142-150. | 1.0 | 1 |
| 1419 | Parkin Protein: The Missing Link Between Cardiovascular and Parkinsonâ€™s Disease. , 2019, , 489-501. | | 0 |
| 1420 | Neuropsychology. , 2019, , 1-3. | | 0 |
| 1425 | Neurodegenerative Diseases and Changes in Artistic Expression. , 2020, , 27-39. | | 1 |
| 1428 | Parkinsonâ€™s Disease and Hypotensive Syndromes. , 2020, , 157-166. | | 0 |
| 1433 | Nutrition dilemma: gastrostomy in a patient with Parkinson's disease. Collaboration of a palliative care specialist and a neurologist. Neurologie Pro Praxi, 2020, 21, 97-99. | 0.0 | 1 |
| 1436 | L-DOPA-Induced Dyskinesia in a Genetic Drosophila Model of Parkinson's Disease. Experimental Neurobiology, 2020, 29, 273-284. | 0.7 | 8 |
| 1437 | for Disease-Modifying Agents in Parkinsonâ€™s. Neuromethods, 2021, , 161-175. | 0.2 | 0 |
| 1438 | for in Parkinsonâ€™s. Neuromethods, 2021, , 367-377. | 0.2 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1440 | Chronic Exposure to Paraquat Induces Alpha-Synuclein Pathogenic Modifications in Drosophila. International Journal of Molecular Sciences, 2021, 22, 11613. | 1.8 | 10 |
| 1441 | An Interactive Review on the Role of Tocotrienols in the Neurodegenerative Disorders. Frontiers in Nutrition, 2021, 8, 754086. | 1.6 | 4 |
| 1442 | Exercising D. melanogaster Modulates the Mitochondrial Proteome and Physiology. The Effect on Lifespan Depends upon Age and Sex. International Journal of Molecular Sciences, 2021, 22, 11606. | 1.8 | 0 |
| 1443 | Astrocytic <scp>VEGFA</scp>: An essential mediator in bloodâ€“brainâ€barrier disruption in Parkinson's disease. Glia, 2022, 70, 337-353. | 2.5 | 44 |
| 1444 | Altered substrate metabolism in neurodegenerative disease: new insights from metabolic imaging. Journal of Neuroinflammation, 2021, 18, 248. | 3.1 | 20 |
| 1445 | Non-Immersive Virtual Reality to Improve Balance and Reduce Risk of Falls in People Diagnosed with Parkinsonâ€™s Disease: A Systematic Review. Brain Sciences, 2021, 11, 1435. | 1.1 | 14 |
| 1446 | Blood Neurofilament Light Chain in Parkinsonâ€™s Disease: Comparability between Parkinsonâ€™s Progression Markers Initiative (PPMI) and Asian Cohorts. Journal of Clinical Medicine, 2021, 10, 5085. | 1.0 | 7 |
| 1447 | Metabolomics in degenerative brain diseases. Brain Research, 2021, 1773, 147704. | 1.1 | 9 |
| 1448 | Environmental neurotoxicants and inflammasome activation in Parkinsonâ€™s disease â€“ A focus on the gut-brain axis. International Journal of Biochemistry and Cell Biology, 2022, 142, 106113. | 1.2 | 7 |
| 1449 | Neuroinflammation in Parkinson's disease: a meta-analysis of PET imaging studies. Journal of Neurology, 2022, 269, 2304-2314. | 1.8 | 18 |
| 1451 | Efficacy of 11C-2Î²-carbomethoxy-3Î²-(4-fluorophenyl) tropane positron emission tomography combined with 18F-fluorodeoxyglucose positron emission tomography in the diagnosis of early Parkinson disease. Medicine (United States), 2020, 99, e23395. | 0.4 | 0 |
| 1452 | Association between serum bilirubin concentration and Parkinson's disease: a meta-analysis. Chinese Medical Journal, 2021, 134, 655-661. | 0.9 | 4 |
| 1453 | Solving The Maze of Diagnosing Parkinsonâ€™s Disease based on Portable EEG Sensing to be Adaptable to Go In-The-Wild. , 2020, , . | | 1 |
| 1454 | Niacin and Butyrate: Nutraceuticals Targeting Dysbiosis and Intestinal Permeability in Parkinsonâ€™s Disease. Nutrients, 2021, 13, 28. | 1.7 | 23 |
| 1455 | Treatment of Parkinsonâ€™s Disease by MAO-B Inhibitors, New Therapies and Future Challenges - A Mini-Review. Combinatorial Chemistry and High Throughput Screening, 2020, 23, 847-861. | 0.6 | 7 |
| 1456 | Ultrasensitive electrochemical biosensors for dopamine and cholesterol: recent advances, challenges and strategies. Chemical Communications, 2021, 57, 13084-13113. | 2.2 | 27 |
| 1457 | Muscle thickness and functional performance of patients with Parkinsonâ€™s disease. Revista Brasileira De Cineantropometria E Desempenho Humano, 0, 22, . | 0.5 | 0 |
| 1458 | Serotonin in Parkinson's disease. Handbook of Behavioral Neuroscience, 2020, 31, 969-979. | 0.7 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1459 | BIOFEEDBACK IN TREATMENT OF COGNITIVE AND PSYCHO-EMOTIONAL DISORDERS IN PATIENTS WITH EARLY STAGES OF PARKINSONâ€™S DISEASE. Bulletin of Problems Biology and Medicine, 2020, 3, 89. | 0.0 | 0 |
| 1460 | <i>Vitis vinifera</i>: An Alternative for the Prevention of Neurodegenerative Diseases. Journal of Oleo Science, 2020, 69, 1147-1161. | 0.6 | 6 |
| 1461 | Gene Therapy Applications. , 2020, , 165-185. | | 0 |
| 1462 | A new neuroprotective strategy for the drug therapy of Parkinson's disease. , 2020, , 529-545. | | 0 |
| 1463 | Environmental and genetic risk factors for Parkinson's disease. , 2020, , 57-71. | | 0 |
| 1464 | Classification of Parkinson's Disease by Analyzing Multiple Vocal Features Sets. , 2020, , . | | 8 |
| 1468 | A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data. Frontiers in Neurology, 2021, 12, 705407. | 1.1 | 36 |
| 1469 | Ceramide accumulation induces mitophagy and impairs Î²-oxidation in PINK1 deficiency. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, . | 3.3 | 34 |
| 1470 | Diffusion Measure Changes of Substantia Nigra Subregions and the Ventral Tegmental Area in Newly Diagnosed Parkinsonâ€™s Disease. Experimental Neurobiology, 2021, 30, 365-373. | 0.7 | 2 |
| 1471 | Orientation of Î±-Synuclein at Negatively Charged Lipid Vesicles: Linear Dichroism Reveals Time-Dependent Changes in Helix Binding Mode. Journal of the American Chemical Society, 2021, 143, 18899-18906. | 6.6 | 8 |
| 1472 | An Update on the Critical Role of Î±-Synuclein in Parkinsonâ€™s Disease and Other Synucleinopathies: from Tissue to Cellular and Molecular Levels. Molecular Neurobiology, 2022, 59, 620-642. | 1.9 | 21 |
| 1473 | Proteome-Wide Profiling of Cellular Targets Modified by Dopamine Metabolites Using a Bio-Orthogonally Functionalized Catecholamine. ACS Chemical Biology, 2021, 16, 2581-2594. | 1.6 | 12 |
| 1474 | Materials Chemistry of Neural Interface Technologies and Recent Advances in Three-Dimensional Systems. Chemical Reviews, 2022, 122, 5277-5316. | 23.0 | 31 |
| 1475 | Convolutional neural network ensemble for Parkinson's disease detection from voice recordings. Computers in Biology and Medicine, 2022, 141, 105021. | 3.9 | 47 |
| 1476 | Short- and Long-Term Effect of Parkinsonâ€™s Disease Multimodal Complex Treatment. Brain Sciences, 2021, 11, 1460. | 1.1 | 6 |
| 1477 | Disruption of mitochondrial complex I induces progressive parkinsonism. Nature, 2021, 599, 650-656. | 13.7 | 247 |
| 1478 | Single-cell Transcriptional Changes in Neurodegenerative Diseases. Neuroscience, 2021, 479, 192-205. | 1.1 | 11 |
| 1479 | Nature-inspired dynamic gene-loaded nanoassemblies for the treatment of brain diseases. Advanced Drug Delivery Reviews, 2022, 180, 114029. | 6.6 | 9 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1480 | Data on dose-dependent cytotoxicity of rotenone and neuroprotection conferred by Yashtimadhu (Glycyrrhiza glabra L.) in an in vitro Parkinson's disease model. Data in Brief, 2021, 39, 107535. | 0.5 | 2 |
| 1481 | Macroautophagy and Mitophagy in Neurodegenerative Disorders: Focus on Therapeutic Interventions. Biomedicines, 2021, 9, 1625. | 1.4 | 10 |
| 1482 | Nanomaterials as novel agents for amelioration of Parkinsonâ€™s disease. Nano Today, 2021, 41, 101328. | 6.2 | 18 |
| 1483 | Association of visual impairment with risk for future Parkinson's disease. EClinicalMedicine, 2021, 42, 101189. | 3.2 | 6 |
| 1488 | Mechanisms of synaptic vesicle recycling provide a platform to explore mechanisms of neurodegeneration. Neuroforum, 2020, 26, 219-226. | 0.2 | 1 |
| 1489 | COMPARISON OF STATIC POSTURAL BALANCE IN PATIENTS WITH SWEDDS AND PARKINSONâ€™S DISEASE. Journal of Mechanics in Medicine and Biology, 2020, 20, 2040013. | 0.3 | 7 |
| 1496 | Impaired Hand Dexterity Function in a Non-human Primate Model with Chronic Parkinsonâ€™s Disease. Experimental Neurobiology, 2020, 29, 376-388. | 0.7 | 2 |
| 1497 | The Association of Dexmedetomidine with Firing Properties in Pallidal Neurons. Canadian Journal of Neurological Sciences, 2021, 48, 525-533. | 0.3 | 3 |
| 1498 | LPS induces dopamine depletion and iron accumulation in substantia nigra in rat models of Parkinson's disease. International Journal of Clinical and Experimental Pathology, 2018, 11, 4942-4949. | 0.5 | 1 |
| 1499 | Altered neural oscillations during complex sequential movements in patients with Parkinsonâ€™s disease. NeuroImage: Clinical, 2021, 32, 102892. | 1.4 | 4 |
| 1501 | Role of melatonin in TLR4-mediated inflammatory pathway in the MTPT-induced mouse model. NeuroToxicology, 2022, 88, 168-177. | 1.4 | 12 |
| 1502 | Asparagine endopeptidase deletion ameliorates cognitive impairments by inhibiting proinflammatory microglial activation in MPTP mouse model of Parkinson disease. Brain Research Bulletin, 2022, 178, 120-130. | 1.4 | 4 |
| 1503 | Cognitive and visual processing performance in Parkinson's disease patients with vs without visual hallucinations: A meta-analysis. Cortex, 2022, 146, 161-172. | 1.1 | 12 |
| 1504 | Biosensor approaches on the diagnosis of neurodegenerative diseases: Sensing the past to the future. Journal of Pharmaceutical and Biomedical Analysis, 2022, 209, 114479. | 1.4 | 13 |
| 1505 | The phonetic footprint of Parkinsonâ€™s disease. Computer Speech and Language, 2022, 72, 101321. | 2.9 | 3 |
| 1506 | Relative Levels of DNM2, EPN2, and EXOC4 Gene Expression in Peripheral Blood of Parkinsonâ€™s Disease Patients. Molecular Genetics, Microbiology and Virology, 2021, 36, 139-143. | 0.0 | 0 |
| 1507 | Circadian rhythms in neurodegenerative disorders. Nature Reviews Neurology, 2022, 18, 7-24. | 4.9 | 94 |
| 1508 | Distinct patterns of speech disorder in early-onset and late-onset de-novo Parkinsonâ€™s disease. Npj Parkinson's Disease, 2021, 7, 98. | 2.5 | 19 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1509 | Cardiac and Autonomic Dysfunctions Assessed Through Recurrence Quantitative Analysis of Electrocardiogram Signals and an Application to the 6-Hydroxydopamine Parkinsonâ€™s Disease Animal Model. Frontiers in Physiology, 2021, 12, 725218. | 1.3 | 2 |
| 1510 | Apathy as a Within-Person Mediator of Depressive Symptoms and Cognition in Parkinson's Disease: Longitudinal Mediation Analyses. American Journal of Geriatric Psychiatry, 2022, 30, 664-674. | 0.6 | 6 |
| 1511 | Respiratory disorders of Parkinsonâ€™s disease. Journal of Neurophysiology, 2022, 127, 1-15. | 0.9 | 11 |
| 1512 | Levodopa-Loaded 3D-Printed Poly (Lactic) Acid/Chitosan Neural Tissue Scaffold as a Promising Drug Delivery System for the Treatment of Parkinsonâ€™s Disease. Applied Sciences (Switzerland), 2021, 11, 10727. | 1.3 | 17 |
| 1513 | Bright Light Therapy for Parkinson Disease: A Literature Review and Meta-Analysis of Randomized Controlled Trials. Biology, 2021, 10, 1205. | 1.3 | 7 |
| 1514 | Diffusion Tensor Imaging Along the Perivascular Space Index in Different Stages of Parkinsonâ€™s Disease. Frontiers in Aging Neuroscience, 2021, 13, 773951. | 1.7 | 44 |
| 1515 | Autophagy in Î±-Synucleinopathiesâ€”An Overstrained System. Cells, 2021, 10, 3143. | 1.8 | 12 |
| 1516 | Protective effects of 6â€gingerol on 6â€hydroxydopamineâ€induced apoptosis in PC12 cells through modulation of SAPK/JNK and survivin activation. Journal of Biochemical and Molecular Toxicology, 2022, 36, e22956. | 1.4 | 11 |
| 1519 | Lessons from metabolic perturbations in lysosomal storage disorders for neurodegeneration. Current Opinion in Systems Biology, 2022, 29, 100408. | 1.3 | 6 |
| 1520 | Lipid-Based Nanocarriers via Nose-to-Brain Pathway for Central Nervous System Disorders. Neurochemical Research, 2022, 47, 552-573. | 1.6 | 19 |
| 1521 | Deconstructing the molecular genetics behind the PINK1/Parkin axis in Parkinsonâ€™s disease using Drosophila melanogaster as a model organism. Egyptian Journal of Medical Human Genetics, 2021, 22, . | 0.5 | 3 |
| 1522 | G-Quadruplexes in Neurobiology and Virology: Functional Roles and Potential Therapeutic Approaches. Jacs Au, 2021, 1, 2146-2161. | 3.6 | 24 |
| 1523 | Rational Design of Thermosensitive Hydrogel to Deliver Nanocrystals with Intranasal Administration for Brain Targeting in Parkinsonâ€™s Disease. Research, 2021, 2021, 9812523. | 2.8 | 12 |
| 1524 | Three decades of Cdk5. Journal of Biomedical Science, 2021, 28, 79. | 2.6 | 52 |
| 1525 | Footprints of a microbial toxin from the gut microbiome to mesencephalic mitochondria. Gut, 2023, 72, 73-89. | 6.1 | 22 |
| 1526 | Reâ€Analysis of the <scp>STEADYâ€PD II</scp> Trialâ€”Evidence for Slowing the Progression of Parkinson's Disease. Movement Disorders, 2022, 37, 334-342. | 2.2 | 20 |
| 1527 | Parkinsonâ€™s Disease Is Associated With Dysregulation of Circulatory Levels of lncRNAs. Frontiers in Immunology, 2021, 12, 763323. | 2.2 | 9 |
| 1528 | Non-coding RNAs and their bioengineering applications for neurological diseases. Bioengineered, 2021, 12, 11675-11698. | 1.4 | 14 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1529 | Abnormal accumulation of lipid droplets in neurons induces the conversion of alpha-Synuclein to proteolytic resistant forms in a Drosophila model of Parkinsonâ€™s disease. PLoS Genetics, 2021, 17, e1009921. | 1.5 | 16 |
| 1530 | Ultrasound imaging of vagus nerves in patients with Parkinson's disease. Bulletin of Russian State Medical University, 2021, , . | 0.3 | 0 |
| 1531 | The role of cardiovascular autonomic failure in the differential diagnosis of Î±-synucleinopathies. Neurological Sciences, 2022, 43, 187-198. | 0.9 | 5 |
| 1532 | Intranasal Exposure to Low-Dose Rotenone Induced Alpha-Synuclein Accumulation and Parkinsonâ€™s Like Symptoms Without Loss of Dopaminergic Neurons. Neurotoxicity Research, 2021, , 1. | 1.3 | 10 |
| 1533 | Cognitive and Behavior Deficits in Parkinsonâ€™s Disease with Alteration of FDG-PET Irrespective of Age. Geriatrics (Switzerland), 2021, 6, 110. | 0.6 | 1 |
| 1534 | Î±â€Synuclein antisense transcript SNCAâ€AS1 regulates synapsesâ€and agingâ€related genes suggesting its implication in Parkinson's disease. Aging Cell, 2021, 20, e13504. | 3.0 | 20 |
| 1535 | Protein Misfolding and Aggregation: The Relatedness between Parkinsonâ€™s Disease and Hepatic Endoplasmic Reticulum Storage Disorders. International Journal of Molecular Sciences, 2021, 22, 12467. | 1.8 | 7 |
| 1536 | Gamified Dual-Task Training for Individuals with Parkinson Disease: An Exploratory Study on Feasibility, Safety, and Efficacy. International Journal of Environmental Research and Public Health, 2021, 18, 12384. | 1.2 | 5 |
| 1537 | Antioxidative role of Traditional Chinese Medicine in Parkinson's disease. Journal of Ethnopharmacology, 2022, 285, 114821. | 2.0 | 16 |
| 1538 | Two Birds One Stone: The Neuroprotective Effect of Antidiabetic Agents on Parkinson Diseaseâ€”Focus on Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors. Antioxidants, 2021, 10, 1935. | 2.2 | 15 |
| 1539 | Multi-omic insights into Parkinson's Disease: From genetic associations to functional mechanisms. Neurobiology of Disease, 2022, 163, 105580. | 2.1 | 20 |
| 1540 | Neuropsychology. , 2021, , 3463-3465. | | 0 |
| 1542 | A Predictive Visual Analytics System for Studying Neurodegenerative Disease Based on DTI Fiber Tracts. IEEE Transactions on Visualization and Computer Graphics, 2023, 29, 2020-2035. | 2.9 | 2 |
| 1543 | Immune response during idiopathic Parkinson's disease: From humans to animal models. International Review of Movement Disorders, 2021, 2, 261-301. | 0.1 | 1 |
| 1544 | Î±-Synuclein Aggregation and Propagation in the Pathomechanisms of Parkinsonâ€™s Disease. Juntendo Medical Journal, 2021, 67, 530-536. | 0.1 | 0 |
| 1545 | Proteostasis impairment and ER stress as a possible target to treat Parkinson's disease. International Review of Movement Disorders, 2021, 2, 245-260. | 0.1 | 0 |
| 1546 | Mechanisms of VPS35-mediated neurodegeneration in Parkinson's disease. International Review of Movement Disorders, 2021, 2, 221-244. | 0.1 | 7 |
| 1547 | A Comprehensive Review on the Role of the Gut Microbiome in Human Neurological Disorders. Clinical Microbiology Reviews, 2022, 35, e0033820. | 5.7 | 138 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1548 | Mechanistic Insights Expatiating the Redox-Active-Metal-Mediated Neuronal Degeneration in Parkinsonâ€™s Disease. International Journal of Molecular Sciences, 2022, 23, 678. | 1.8 | 12 |
| 1549 | The Views and Needs of People With Parkinson Disease Regarding Wearable Devices for Disease Monitoring: Mixed Methods Exploration. JMIR Formative Research, 2022, 6, e27418. | 0.7 | 12 |
| 1550 | Aminochrome Induces Neuroinflammation and Dopaminergic Neuronal Loss: A New Preclinical Model to Find Anti-inflammatory and Neuroprotective Drugs for Parkinsonâ€™s Disease. Cellular and Molecular Neurobiology, 2023, 43, 265-281. | 1.7 | 3 |
| 1551 | One-Carbon Metabolism: Pulling the Strings behind Aging and Neurodegeneration. Cells, 2022, 11, 214. | 1.8 | 32 |
| 1552 | Emerging Roles for Aberrant Astrocytic Calcium Signals in Parkinsonâ€™s Disease. Frontiers in Physiology, 2021, 12, 812212. | 1.3 | 7 |
| 1553 | White Matter Connectivity between Structures of the Basal Ganglia using 3T and 7T. Neuroscience, 2022, 483, 32-39. | 1.1 | 0 |
| 1554 | A bidirectional Hopf bifurcation analysis of Parkinsonâ€™s oscillation in a simplified basal ganglia model. Journal of Theoretical Biology, 2022, 536, 110979. | 0.8 | 4 |
| 1555 | Reactive oxygen species scavenging by hemin-based nanosheets reduces Parkinsonâ€™s disease symptoms in an animal model. Chemical Engineering Journal, 2022, 432, 134356. | 6.6 | 16 |
| 1556 | Effect of Metabolic Syndrome on Parkinsonâ€™s Disease: A Systematic Review. Clinics, 2021, 76, e3379. | 0.6 | 3 |
| 1558 | Human-Induced Pluripotent Stem Cellâ€“Based Models for Studying Sex-Specific Differences in Neurodegenerative Diseases. Advances in Experimental Medicine and Biology, 2021, , 57-88. | 0.8 | 4 |
| 1559 | Selenium Neuroprotection in Neurodegenerative Disorders. , 2021, , 1-35. | | 2 |
| 1560 | Engineered models for studying blood-brain-barrier-associated brain physiology and pathology. Organoid, 0, 1, e10. | 0.0 | 2 |
| 1561 | A Disease in Search for a Biomarker: MicroRNAs in Parkinsonâ€™s Disease. Timisoara Medical Journal, 2021, 2021, 1. | 0.1 | 0 |
| 1562 | Fortgeschrittener Morbus Parkinson: Therapieentscheidung auf einheitlicher Bewertungsbasis. , 0, , . | | 0 |
| 1563 | Development of a Liquid Chromatographic Method for Apomorphine Hydrochloride Quantitation in the Active Pharmaceutical Ingredients and in the Dosage Forms. Eurasian Journal of Biological and Chemical Sciences, 0, , . | 0.0 | 0 |
| 1564 | Sex-specific relationship between serum uric acid levels and the prevalence of large vessel occlusion in acute ischemic stroke. Clinical and Experimental Hypertension, 2022, 44, 154-158. | 0.5 | 0 |
| 1565 | Understanding the Burdens Associated with Huntingtonâ€™s Disease in Manifest Patients and Care Partnersâ€“Comparing to Parkinsonâ€™s Disease and the General Population. Brain Sciences, 2022, 12, 161. | 1.1 | 8 |
| 1566 | Artificial Intelligent Olfactory System for the Diagnosis of Parkinsonâ€™s Disease. ACS Omega, 2022, 7, 4001-4010. | 1.6 | 11 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1567 | A Sensor-Based Perspective in Early-Stage Parkinsonâ€™s Disease: Current State and the Need for Machine Learning Processes. Sensors, 2022, 22, 409. | 2.1 | 12 |
| 1568 | Tau Knockout and Î±-Synuclein A53T Synergy Modulated Parvalbumin-Positive Neurons Degeneration Staging in Substantia Nigra Pars Reticulata of Parkinsonâ€™s Disease-Liked Model. Frontiers in Aging Neuroscience, 2021, 13, 784665. | 1.7 | 1 |
| 1569 | Functional connectivity in Parkinsonâ€™s disease candidates for deep brain stimulation. Npj Parkinson's Disease, 2022, 8, 4. | 2.5 | 9 |
| 1570 | Polymorphisms of the dopamine metabolic and signaling pathways are associated with susceptibility to motor levodopa-induced complications (MLIC) in Parkinsonâ€™s disease: a systematic review and meta-analysis. Neurological Sciences, 2022, 43, 3649-3670. | 0.9 | 7 |
| 1571 | Levodopa-induced dyskinesia: a historical review of Parkinsonâ€™s disease, dopamine, and modern advancements in research and treatment. Journal of Neurology, 2022, 269, 2892-2909. | 1.8 | 10 |
| 1572 | Recent progress of macrophage vesicle-based drug delivery systems. Drug Delivery and Translational Research, 2022, 12, 2287-2302. | 3.0 | 11 |
| 1573 | Parkinsonâ€™s Disease Subtyping Using Clinical Features and Biomarkers: Literature Review and Preliminary Study of Subtype Clustering. Diagnostics, 2022, 12, 112. | 1.3 | 12 |
| 1574 | The Effect of Speech Fragmentation and Audio Encodings on Automatic Parkinsonâ€™s Disease Recognition. Journal of Biomedical Science and Engineering, 2022, 15, 6-25. | 0.2 | 1 |
| 1575 | Detection of Freezing of Gait Using Convolutional Neural Networks and Data From Lower Limb Motion Sensors. IEEE Transactions on Biomedical Engineering, 2022, 69, 2256-2267. | 2.5 | 16 |
| 1576 | Roles of Transcription Factors in the Development and Reprogramming of the Dopaminergic Neurons. International Journal of Molecular Sciences, 2022, 23, 845. | 1.8 | 16 |
| 1578 | Caregiver Burden and Quality of Life in Late Stage Parkinsonâ€™s Disease. Brain Sciences, 2022, 12, 111. | 1.1 | 13 |
| 1579 | Systemic deficiency of GM1 ganglioside in Parkinsonâ€™s disease tissues and its relation to the disease etiology. Glycoconjugate Journal, 2022, 39, 75. | 1.4 | 12 |
| 1580 | Ticagrelor for prevention of stroke and cognitive impairment in patients with vascular high-risk factors: A meta-analysis of randomized controlled trials. International Journal of Cardiology, 2022, 353, 96-102. | 0.8 | 5 |
| 1581 | The Role of Single Nucleotide Polymorphisms of Monoamine Oxidase B, Dopamine D2 Receptor, and DOPA Decarboxylase Receptors Among Patients Treated for Parkinsonâ€™s Disease. Journal of Molecular Neuroscience, 2022, , 1. | 1.1 | 2 |
| 1583 | The Signaling and Pharmacology of the Dopamine D1 Receptor. Frontiers in Cellular Neuroscience, 2021, 15, 806618. | 1.8 | 14 |
| 1584 | A Transcriptome Analysis of mRNAs and Long Non-Coding RNAs in Patients with Parkinsonâ€™s Disease. International Journal of Molecular Sciences, 2022, 23, 1535. | 1.8 | 13 |
| 1586 | Effects of cognitive rehabilitation in Parkinson disease: a meta-analysis. Neurological Sciences, 2022, 43, 2323-2337. | 0.9 | 3 |
| 1587 | Neurogenetic traits outline vulnerability to cortical disruption in Parkinsonâ€™s disease. NeuroImage: Clinical, 2022, 33, 102941. | 1.4 | 4 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1588 | Optimization of Thymidine Kinase-Based Safety Switch for Neural Cell Therapy. Cells, 2022, 11, 502. | 1.8 | 4 |
| 1589 | Neuroprotective Effects of Resveratrol in In vivo and In vitro Experimental Models of Parkinsonâ€™s Disease: a Systematic Review. Neurotoxicity Research, 2022, 40, 319-345. | 1.3 | 26 |
| 1590 | Neurodegeneration and neuroinflammation are linked, but independent of alphaâ€synuclein inclusions, in a seeding/spreading mouse model of Parkinson's disease. Glia, 2022, 70, 935-960. | 2.5 | 30 |
| 1591 | The interactions between adipose tissue secretions and Parkinson's disease: The role of leptin. European Journal of Neuroscience, 2022, 55, 873-891. | 1.2 | 3 |
| 1592 | A Multiscale, Systems-Level, Neuropharmacological Model of Cortico-Basal Ganglia System for Arm Reaching Under Normal, Parkinsonian, and Levodopa Medication Conditions. Frontiers in Computational Neuroscience, 2021, 15, 756881. | 1.2 | 3 |
| 1593 | Parkinson's disease protein PARK7 prevents metabolite and protein damage caused by a glycolytic metabolite. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, . | 3.3 | 29 |
| 1595 | Novel Series of Dual NRF2 Inducers and Selective MAO-B Inhibitors for the Treatment of Parkinsonâ€™s Disease. Antioxidants, 2022, 11, 247. | 2.2 | 4 |
| 1596 | Redesigning therapies for pantothenate kinaseâ€“associated neurodegeneration. Journal of Biological Chemistry, 2022, 298, 101577. | 1.6 | 12 |
| 1597 | Switching Roles: Beneficial Effects of Adipose Tissue-Derived Mesenchymal Stem Cells on Microglia and Their Implication in Neurodegenerative Diseases. Biomolecules, 2022, 12, 219. | 1.8 | 5 |
| 1598 | Effects of dance therapy on non-motor symptoms in patients with Parkinsonâ€™s disease: a systematic review and meta-analysis. Aging Clinical and Experimental Research, 2022, 34, 1201-1208. | 1.4 | 19 |
| 1599 | Indirect comparison of apomorphine sublingual film and levodopa inhalation powder for Parkinson's disease â€˜OFFâ€™ episodes. Journal of Comparative Effectiveness Research, 2022, 11, 285-295. | 0.6 | 3 |
| 1600 | Targeting Î±-Synuclein in Parkinson's Disease by Induced Pluripotent Stem Cell Models. Frontiers in Neurology, 2021, 12, 786835. | 1.1 | 3 |
| 1601 | Correcting Differential Gene Expression Analysis for Cytoâ€”Architectural Alterations in Substantia Nigra of Parkinsonâ€™s Disease Patients Reveals Known and Potential Novel Diseaseâ€”Associated Genes and Pathways. Cells, 2022, 11, 198. | 1.8 | 0 |
| 1602 | Recent Developments in Positron Emission Tomography Tracers for Proteinopathies Imaging in Dementia. Frontiers in Aging Neuroscience, 2021, 13, 751897. | 1.7 | 12 |
| 1603 | Current Status of Telemedicine for Parkinsonâ€™s Disease in Japan: A Single-Center Cross-Sectional Questionnaire Survey. Journal of Movement Disorders, 2022, 15, 58-61. | 0.7 | 9 |
| 1604 | Metabolic Alterations in a Drosophila Model of Parkinsonâ€™s Disease Based on DJ-1 Deficiency. Cells, 2022, 11, 331. | 1.8 | 12 |
| 1605 | Effects of Baduanjin Exercise on Rehabilitation of Patients With Mild to Moderate Parkinsonâ€™s Disease. Frontiers in Neuroscience, 2021, 15, 827180. | 1.4 | 4 |
| 1606 | Quantification Analysis of Sleep Based on Smartwatch Sensors for Parkinsonâ€™s Disease. Biosensors, 2022, 12, 74. | 2.3 | 15 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1607 | Parkinsonâ€™s Disease in Light of the COVID-19 Pandemic. Brain Sciences, 2022, 12, 143. | 1.1 | 7 |
| 1608 | The Impact of Parkinsonâ€™s Disease on General and Specific Motor Aptitudes: A Study of Older Brazilian Adults. Perceptual and Motor Skills, 2022, 129, 253-268. | 0.6 | 0 |
| 1609 | Neurodegeneration in the centrally-projecting Edingerâ€“Westphal nucleus contributes to the non-motor symptoms of Parkinsonâ€™s disease in the rat. Journal of Neuroinflammation, 2022, 19, 31. | 3.1 | 13 |
| 1610 | Neuropsychiatric Treatments for Parkinson's Disease: Nonpharmacological Approaches. Seminars in Neurology, 2022, 42, 158-167. | 0.5 | 2 |
| 1611 | Can the lack of fibrillar form of alpha-synuclein in Lewy bodies be explained by its catalytic activity?. Mathematical Biosciences, 2022, 344, 108754. | 0.9 | 2 |
| 1612 | Deep <scp>Learningâ€Based</scp> Neuromelanin <scp>MRI</scp> Changes of Isolated <scp>REM</scp> Sleep Behavior Disorder. Movement Disorders, 2022, 37, 1064-1069. | 2.2 | 13 |
| 1613 | 6-Benzyloxyphthalides as selective and reversible monoamine oxidase B inhibitors with antioxidant and anti-neuroinflammatory activities for Parkinsonâ€™s disease treatment. Bioorganic Chemistry, 2022, 120, 105623. | 2.0 | 6 |
| 1614 | Urolithin A promotes mitophagy and suppresses NLRP3 inflammasome activation in lipopolysaccharide-induced BV2 microglial cells and MPTP-induced Parkinson's disease model. Neuropharmacology, 2022, 207, 108963. | 2.0 | 53 |
| 1615 | Robust structural color beads by self-adhesion amorphous colloidal particles for detection of cerebrospinal fluid biomarkers. Chemical Engineering Journal, 2022, 434, 134657. | 6.6 | 5 |
| 1616 | Vortioxetine ameliorates motor and cognitive impairments in the rotenone-induced Parkinson's disease via targeting TLR-2 mediated neuroinflammation. Neuropharmacology, 2022, 208, 108977. | 2.0 | 15 |
| 1617 | Stigma in Parkinson's disease: Placing it outside the body. Clinics, 2022, 77, 100008. | 0.6 | 2 |
| 1618 | Comorbidities in patients with Parkinson's disease. Buletinul AÅžM: ÅžtiinÅ£e Medicale, 2022, 71, 30-34. | 0.0 | 0 |
| 1619 | Sudden unexpected death in Parkinson's disease: Insights from clinical practice. Clinics, 2022, 77, 100001. | 0.6 | 5 |
| 1620 | iPSC-based disease modeling and drug discovery in cardinal neurodegenerative disorders. Cell Stem Cell, 2022, 29, 189-208. | 5.2 | 71 |
| 1621 | Brain single-nucleus transcriptomics highlights that polystyrene nanoplastics potentially induce Parkinsonâ€™s disease-like neurodegeneration by causing energy metabolism disorders in mice. Journal of Hazardous Materials, 2022, 430, 128459. | 6.5 | 48 |
| 1625 | Genetic lesions of the noradrenergic system trigger induction of oxidative stress and inflammation in the ventral midbrain. Neurochemistry International, 2022, 155, 105302. | 1.9 | 3 |
| 1626 | Programmed Death-1 Deficiency Aggravates Motor Dysfunction in MPTP Model of Parkinson's Disease by Inducing Microglial Activation and Neuroinflammation in Mice. Molecular Neurobiology, 2022, 59, 2642-2655. | 1.9 | 3 |
| 1627 | Parkinson's disease: From genetics to molecular dysfunction and targeted therapeutic approaches. Genes and Diseases, 2023, 10, 786-798. | 1.5 | 4 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1628 | Self-Stigma in Parkinson's Disease: A 3-Year Prospective Cohort Study. Frontiers in Aging Neuroscience, 2022, 14, 790897. | 1.7 | 5 |
| 1629 | Parkinson disease: Protective role and function of neuropeptides. Peptides, 2022, 151, 170713. | 1.2 | 6 |
| 1631 | Dl-3-n-Butylphthalide Rescues Dopaminergic Neurons in Parkinsonâ€™s Disease Models by Inhibiting the NLRP3 Inflammasome and Ameliorating Mitochondrial Impairment. Frontiers in Immunology, 2021, 12, 794770. | 2.2 | 44 |
| 1632 | Mitochondrial Phenotypes in Parkinsonâ€™s Diseasesâ€”A Focus on Human iPSC-Derived Dopaminergic Neurons. Cells, 2021, 10, 3436. | 1.8 | 7 |
| 1633 | Autophagy-Lysosomal Pathway as Potential Therapeutic Target in Parkinsonâ€™s Disease. Cells, 2021, 10, 3547. | 1.8 | 28 |
| 1634 | Mitochondrial dysfunction in protein conformational disorders. Journal of Genetics, 2018, 97, 703-713. | 0.4 | 1 |
| 1635 | Artificial intelligence in Parkinsonâ€™s diseaseâ€”symptoms identification and monitoring. , 2022, , 35-52. | | 1 |
| 1636 | The pathophysiology of sexual dysfunction in Parkinson's disease: An overview. International Review of Neurobiology, 2022, 162, 21-34. | 0.9 | 3 |
| 1637 | Analysis methods for the gut microbiome in neuropsychiatric and neurodegenerative disorders. Computational and Structural Biotechnology Journal, 2022, 20, 1097-1110. | 1.9 | 5 |
| 1638 | Fabrication of NiFeB flexible electrode via electroless deposition towards selective and sensitive detection of dopamine. Journal of Materials Chemistry B, 2022, 10, 3681-3686. | 2.9 | 3 |
| 1641 | Samba, deep water, and poles: a framework for exercise prescription in Parkinson's disease. Sport Sciences for Health, 2022, 18, 1119-1127. | 0.4 | 7 |
| 1642 | Function and therapeutic value of astrocytes in neurological diseases. Nature Reviews Drug Discovery, 2022, 21, 339-358. | 21.5 | 160 |
| 1643 | Goal management training and psychoeducation / mindfulness for treatment of executive dysfunction in Parkinsonâ€™s disease: A feasibility pilot trial. PLoS ONE, 2022, 17, e0263108. | 1.1 | 6 |
| 1644 | Proton Magnetic Resonance Spectroscopy for Diagnosis of Non-Motor Symptoms in Parkinson's Disease. Frontiers in Neurology, 2022, 13, 594711. | 1.1 | 5 |
| 1645 | Olfactory dysfunction is associated with motor function only in tremor-dominant Parkinsonâ€™s disease. Neurological Sciences, 2022, 43, 4193-4201. | 0.9 | 8 |
| 1647 | Cytokines, miRNAs, and Antioxidants as Combined Non-invasive Biomarkers for Parkinsonâ€™s Disease. Journal of Molecular Neuroscience, 2022, 72, 1133-1140. | 1.1 | 8 |
| 1648 | A holistic approach to evaluating Parkinsonâ€™s disease, using the Delphi method: a linear evaluation index. Arquivos De Neuro-Psiquiatria, 2022, 80, 145-152. | 0.3 | 0 |
| 1649 | Antioxidant Therapy in Oxidative Stress-Induced Neurodegenerative Diseases: Role of Nanoparticle-Based Drug Delivery Systems in Clinical Translation. Antioxidants, 2022, 11, 408. | 2.2 | 49 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1650 | Association Between Dystonia-Related Genetic Loci and Parkinson's Disease in Eastern China. Frontiers in Neurology, 2021, 12, 711050. | 1.1 | 2 |
| 1651 | Homocysteine and Dementia in Parkinson Disease. , 0, , . | | 0 |
| 1652 | Prodrug Therapies for Infectious and Neurodegenerative Diseases. Pharmaceutics, 2022, 14, 518. | 2.0 | 3 |
| 1653 | Differentiating Parkinsonâ€™s Disease from Essential Tremor Using Transcranial Sonography: A Systematic Review and Meta-Analysis. Journal of Parkinson's Disease, 2022, 12, 1115-1123. | 1.5 | 7 |
| 1654 | Peripheral Immune Cell Numbers and C-Reactive Protein in Parkinsonâ€™s Disease: Results from a Population-Based Study. Journal of Parkinson's Disease, 2022, 12, 667-678. | 1.5 | 8 |
| 1655 | Echinacoside Protects Dopaminergic Neurons Through Regulating IL-6/JAK2/STAT3 Pathway in Parkinsonâ€™s Disease Model. Frontiers in Pharmacology, 2022, 13, 848813. | 1.6 | 9 |
| 1656 | Lysosomal ceramides regulate cathepsin B-mediated processing of saposin C and glucocerebrosidase activity. Human Molecular Genetics, 2022, 31, 2424-2437. | 1.4 | 11 |
| 1657 | Prodromal Parkinson's disease: hype or hope for disease-modification trials?. Translational Neurodegeneration, 2022, 11, 11. | 3.6 | 21 |
| 1658 | Modeling Parkinson's disease in LRRK2 mice: focus on synaptic dysfunction and the autophagy-lysosomal pathway. Biochemical Society Transactions, 2022, 50, 621-632. | 1.6 | 10 |
| 1659 | The Unfolded Protein Responses in Health, Aging, and Neurodegeneration: Recent Advances and Future Considerations. Frontiers in Molecular Neuroscience, 2022, 15, 831116. | 1.4 | 28 |
| 1660 | The Complex Mechanisms by Which Neurons Die Following DNA Damage in Neurodegenerative Diseases. International Journal of Molecular Sciences, 2022, 23, 2484. | 1.8 | 21 |
| 1661 | Contribution of Autophagy-Lysosomal Pathway in the Exosomal Secretion of Alpha-Synuclein and Its Impact in the Progression of Parkinsonâ€™s Disease. Frontiers in Molecular Neuroscience, 2022, 15, 805087. | 1.4 | 13 |
| 1662 | Significant modulations of linc001128 and linc0938 with miR-24-3p and miR-30c-5p in Parkinson disease. Scientific Reports, 2022, 12, 2569. | 1.6 | 12 |
| 1663 | Australian Parkinsonâ€™s Genetics Study (APGS): pilot (n=1532). BMJ Open, 2022, 12, e052032. | 0.8 | 1 |
| 1664 | Effects of Exercise on Parkinsonâ€™s Disease: A Meta-Analysis of Brain Imaging Studies. Frontiers in Human Neuroscience, 2022, 16, 796712. | 1.0 | 3 |
| 1665 | Altered Dynamic Functional Connectivity in de novo Parkinsonâ€™s Disease Patients With Depression. Frontiers in Aging Neuroscience, 2021, 13, 789785. | 1.7 | 11 |
| 1666 | Acupuncture in the Treatment of Parkinsonâ€™s Disease with Sleep Disorders and Dose Response. BioMed Research International, 2022, 2022, 1-7. | 0.9 | 8 |
| 1667 | Î±-Synuclein-containing erythrocytic extracellular vesicles: essential contributors to hyperactivation of monocytes in Parkinsonâ€™s disease. Journal of Neuroinflammation, 2022, 19, 53. | 3.1 | 17 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1668 | Leveraging a Surrogate Outcome to Improve Inference on a Partially Missing Target Outcome. Biometrics, 2023, 79, 1472-1484. | 0.8 | 1 |
| 1669 | A Secretory Vesicle Failure in Parkinson's Disease Occurs in Human Platelets. Annals of Neurology, 2022, 91, 697-703. | 2.8 | 2 |
| 1670 | Redox signaling at the crossroads of human health andÂdisease. MedComm, 2022, 3, e127. | 3.1 | 44 |
| 1671 | Altered Neural Network Connectivity Predicts Depression in de novo Parkinsonâ€™s Disease. Frontiers in Neuroscience, 2022, 16, 828651. | 1.4 | 6 |
| 1672 | Integrating deep learning and unbiased automated high-content screening to identify complex disease signatures in human fibroblasts. Nature Communications, 2022, 13, 1590. | 5.8 | 29 |
| 1673 | Hsp90 in Human Diseases: Molecular Mechanisms to Therapeutic Approaches. Cells, 2022, 11, 976. | 1.8 | 13 |
| 1674 | Change in the incidence of Parkinsonâ€™s disease in a large UK primary care database. Npj Parkinson's Disease, 2022, 8, 23. | 2.5 | 12 |
| 1675 | Diffusion Tensor Imaging Reveals Deep Brain Structure Changes in Early Parkinsonâ€™s Disease Patients with Various Sleep Disorders. Brain Sciences, 2022, 12, 463. | 1.1 | 1 |
| 1676 | Multivariate genomic and transcriptomic determinants of imaging-derived personalized therapeutic needs in Parkinsonâ€™s disease. Scientific Reports, 2022, 12, 5483. | 1.6 | 3 |
| 1677 | Strengthening Communication and Collaboration in the Fragmented German Healthcare System: A Mixed-Method Evaluation of an Interdisciplinary Network for Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2022, 12, 1307-1317. | 1.5 | 4 |
| 1678 | Nutraceuticals as Modulators of Autophagy: Relevance in Parkinsonâ€™s Disease. International Journal of Molecular Sciences, 2022, 23, 3625. | 1.8 | 8 |
| 1679 | Evaluation of Brain SPECT with 99mTc-TRODAT-1 in the Differential Diagnosis of Parkinsonism. Parkinson's Disease, 2022, 2022, 1-10. | 0.6 | 1 |
| 1680 | Midsagittal corpus callosal thickness and cognitive impairment in Parkinson's disease. European Journal of Neuroscience, 2022, 55, 1859-1872. | 1.2 | 5 |
| 1681 | Methylated Cytochrome P450 and the Solute Carrier Family of Genes Correlate With Perturbations in Bile Acid Metabolism in Parkinsonâ€™s Disease. Frontiers in Neuroscience, 2022, 16, 804261. | 1.4 | 4 |
| 1682 | Direct Medical Costs of Parkinsonâ€™s Disease in Southern China: A Cross-Sectional Study Based on Health Insurance Claims Data in Guangzhou City. International Journal of Environmental Research and Public Health, 2022, 19, 3238. | 1.2 | 1 |
| 1683 | Subtle anomaly detection: Application to brain MRI analysis of de novo Parkinsonian patients. Artificial Intelligence in Medicine, 2022, 125, 102251. | 3.8 | 4 |
| 1684 | Cardiovascular/Stroke Risk Stratification in Parkinsonâ€™s Disease Patients Using Atherosclerosis Pathway and Artificial Intelligence Paradigm: A Systematic Review. Metabolites, 2022, 12, 312. | 1.3 | 21 |
| 1685 | Immune Response Modifications in the Genetic Forms of Parkinsonâ€™s Disease: What Do We Know?. International Journal of Molecular Sciences, 2022, 23, 3476. | 1.8 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1686 | The Role of Voltage-Gated Calcium Channels in Basal Ganglia Neurodegenerative Disorders. Current Neuropharmacology, 2023, 21, 183-201. | 1.4 | 6 |
| 1687 | Protective Effect of Amber Extract on Human Dopaminergic Cells against 6-Hydroxydopamine-Induced Neurotoxicity. Molecules, 2022, 27, 1817. | 1.7 | 4 |
| 1688 | Small molecule C381 targets the lysosome to reduce inflammation and ameliorate disease in models of neurodegeneration. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2121609119. | 3.3 | 14 |
| 1689 | Oral Mucosa Derived Î±â^'Synuclein as a Potential Diagnostic Biomarker for Parkinsonâ€²s Disease. Frontiers in Aging Neuroscience, 2022, 14, 867528. | 1.7 | 5 |
| 1690 | Azepine-Indole Alkaloids From Psychotria nemorosa Modulate 5-HT2A Receptors and Prevent in vivo Protein Toxicity in Transgenic Caenorhabditis elegans. Frontiers in Neuroscience, 2022, 16, 826289. | 1.4 | 2 |
| 1691 | An assessment of the rescue action of resveratrol in parkin loss of function-induced oxidative stress in Drosophila melanogaster. Scientific Reports, 2022, 12, 3922. | 1.6 | 15 |
| 1692 | Long-term hyperglycemia aggravates Î±-synuclein aggregation and dopaminergic neuronal loss in aÂParkinsonâ€™s disease mouse model. Translational Neurodegeneration, 2022, 11, 14. | 3.6 | 16 |
| 1693 | Hyperhidrosis in Parkinson's disease: a 3â€year prospective cohort study. Journal of the European Academy of Dermatology and Venereology, 2022, , . | 1.3 | 2 |
| 1694 | Mammalian target of rapamycin (mTOR) signaling pathway and traumatic brain injury: A novel insight into targeted therapy. Cell Biochemistry and Function, 2022, 40, 232-247. | 1.4 | 19 |
| 1695 | Insights Into the Role of Heat Shock Protein 27 in the Development of Neurodegeneration. Frontiers in Molecular Neuroscience, 2022, 15, 868089. | 1.4 | 2 |
| 1696 | Solving neurodegeneration: common mechanisms and strategies for new treatments. Molecular Neurodegeneration, 2022, 17, 23. | 4.4 | 83 |
| 1697 | The Cost Effectiveness of Levodopa-Carbidopa Intestinal Gel in the Treatment of Advanced Parkinsonâ€™s Disease in England. Pharmacoeconomics, 2022, 40, 559-574. | 1.7 | 5 |
| 1698 | Cerebrovascular responses to somatomotor stimulation in Parkinsonâ€™s disease: A multivariate analysis. Journal of Cerebral Blood Flow and Metabolism, 2022, 42, 1547-1558. | 2.4 | 4 |
| 1699 | Effects of behavioural swallowing therapy in patients with Parkinsonâ€™s disease: A systematic review. International Journal of Speech-Language Pathology, 2023, 25, 269-280. | 0.6 | 5 |
| 1700 | A local volumetric covariance descriptor for markerless Parkinsonian gait pattern quantification. Multimedia Tools and Applications, 2022, 81, 30733-30748. | 2.6 | 1 |
| 1701 | Toward Automated Articulation Rate Analysis via Connected Speech in Dysarthrias. Journal of Speech, Language, and Hearing Research, 2022, 65, 1386-1401. | 0.7 | 3 |
| 1702 | Aromatase inhibitors and the incidence of Parkinson disease: A populationâ€based cohort study. Cancer, 2022, 128, 2339-2347. | 2.0 | 2 |
| 1703 | An Overview of the Evidence and Mechanism of Drugâ€“Herb Interactions Between Propolis and Pharmaceutical Drugs. Frontiers in Pharmacology, 2022, 13, 876183. | 1.6 | 15 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1704 | Parkin as a Molecular Bridge Linking Alzheimerâ€™s and Parkinsonâ€™s Diseases?. Biomolecules, 2022, 12, 559. | 1.8 | 3 |
| 1705 | Mitochondria-lysosome contact site dynamics and misregulation in neurodegenerative diseases. Trends in Neurosciences, 2022, 45, 312-322. | 4.2 | 40 |
| 1706 | Cryptotanshinone ameliorates MPP+-induced oxidative stress and apoptosis of SH-SY5Y neuroblastoma cells: the role of STAT3 in Parkinsonâ€™s disease. Metabolic Brain Disease, 2022, , 1. | 1.4 | 3 |
| 1707 | Chapter 5 â€“ â€œParkinson's disease â€“ A role of non-enzymatic posttranslational modifications in disease onset and progression?â€. Molecular Aspects of Medicine, 2022, 86, 101096. | 2.7 | 8 |
| 1708 | A Potential Mechanism for Targeting Aggregates With Proteasomes and Disaggregases in Liquid Droplets. Frontiers in Aging Neuroscience, 2022, 14, 854380. | 1.7 | 6 |
| 1709 | Does SARS-CoV-2 affect neurodegenerative disorders? TLR2, a potential receptor for SARS-CoV-2 in the CNS. Experimental and Molecular Medicine, 2022, 54, 447-454. | 3.2 | 19 |
| 1710 | Sphingolipid control of cognitive functions in health and disease. Progress in Lipid Research, 2022, 86, 101162. | 5.3 | 21 |
| 1711 | Daidzein alleviates neuronal damage and oxidative stress via GSK3Î²/Nrf2 pathway in mice. Journal of Functional Foods, 2022, 92, 105060. | 1.6 | 7 |
| 1712 | Nuclear imaging in Parkinson's disease: The past, the present, and the future. Journal of the Neurological Sciences, 2022, 436, 120220. | 0.3 | 5 |
| 1713 | Altered Functional Connectivity of Ventral Striatum Subregions in De-novo Parkinsonâ€™s Disease with Depression. Neuroscience, 2022, 491, 13-22. | 1.1 | 4 |
| 1714 | Evaluation of the relationship between SORL1 gene polymorphism and Parkinson's disease in the Chinese population. Neuroscience Letters, 2022, 778, 136602. | 1.0 | 3 |
| 1715 | Peripheral administration of the Class-IIa HDAC inhibitor MC1568 partially protects against nigrostriatal neurodegeneration in the striatal 6-OHDA rat model of Parkinsonâ€™s disease. Brain, Behavior, and Immunity, 2022, 102, 151-160. | 2.0 | 12 |
| 1716 | Parkinsonâ€™s disease diagnosis using neural networks: Survey and comprehensive evaluation. Information Processing and Management, 2022, 59, 102909. | 5.4 | 17 |
| 1717 | Invited review: Unearthing the mechanisms of age-related neurodegenerative disease using Caenorhabditis elegans. Comparative Biochemistry and Physiology Part A, Molecular & Integrative Physiology, 2022, 267, 111166. | 0.8 | 2 |
| 1718 | Dopamine depletion can be predicted by the aperiodic component of subthalamic local field potentials. Neurobiology of Disease, 2022, 168, 105692. | 2.1 | 16 |
| 1719 | Neuronal SH2B1 attenuates apoptosis in an MPTP mouse model of Parkinson's disease via promoting PLIN4 degradation. Redox Biology, 2022, 52, 102308. | 3.9 | 4 |
| 1720 | Recent advancements in Micro-engineered devices for surface and deep brain animal studies: A review. Sensing and Bio-Sensing Research, 2022, 36, 100483. | 2.2 | 2 |
| 1721 | Brain-gut-microbiota axis in Parkinsonâ€™s disease: A historical review and future perspective. Brain Research Bulletin, 2022, 183, 84-93. | 1.4 | 17 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1722 | Mitochondrial dysfunction and energy changes of black-substance neurons in experimental parkinson's disease in rats and mothors. Modern Medical Technologies, 2021, , 22-30. | 0.1 | 0 |
| 1723 | Enhancing Clinical Information Display to Improve Patient Encounters: Human-Centered Design and Evaluation of the Parkinson Disease-BRIDGE Platform. JMIR Human Factors, 2022, 9, e33967. | 1.0 | 2 |
| 1724 | An inertial sensor-based algorithm for turning detection during gait. , 2021, 2021, 6372-6375. | | 2 |
| 1725 | Advances in the Deep Brain Stimulation for Parkinsonâ€™s Disease. , 2021, , . | | 2 |
| 1726 | Evaluation of Orthostatic Reactions in Real-World Environments Using Wearable Sensors. , 2021, 2021, 6987-6990. | | 4 |
| 1727 | Mitophagy in neurological disorders. Journal of Neuroinflammation, 2021, 18, 297. | 3.1 | 34 |
| 1728 | Efficacy and safety of light therapy for Parkinson disease. Chinese Medical Journal, 2021, Publish Ahead of Print, . | 0.9 | 1 |
| 1729 | Efficacy and Safety of Light Therapy as a Home Treatment for Motor and Non-Motor Symptoms of Parkinson Disease: A Meta-Analysis. Medical Science Monitor, 2022, 28, e935074. | 0.5 | 4 |
| 1730 | P.0439 Antiparkinsonian activity of new glutamate N-methyl-D-aspartate receptor ligands - imidazole-4, 5-dicarboxylic acid derivatives in the arecoline hyperkinesis test. European Neuropsychopharmacology, 2021, 53, S319-S320. | 0.3 | 0 |
| 1731 | Triagem virtual de inibidores da MAO-B, um alvo molecular na doenÃ§a de Parkinson. Revista Neurociencias, 0, 29, 1-26. | 0.0 | 0 |
| 1732 | Insulin-like Growth Factor II Prevents MPP+ and Glucocorticoid Mitochondrial-Oxidative and Neuronal Damage in Dopaminergic Neurons. Antioxidants, 2022, 11, 41. | 2.2 | 3 |
| 1733 | The Parkinsonâ€™s Disease Progression Neuroimaging Initiative. Behavioural Neurology, 2021, 2021, 1-8. | 1.1 | 3 |
| 1734 | Cerebral dopamine neurotrophic factor protects and repairs dopamine neurons by novel mechanism. Molecular Psychiatry, 2022, 27, 1310-1321. | 4.1 | 34 |
| 1735 | Mitochondria-Microbiota Interaction in Neurodegeneration. Frontiers in Aging Neuroscience, 2021, 13, 776936. | 1.7 | 7 |
| 1736 | Role of Mitochondrial Protein Import in Age-Related Neurodegenerative and Cardiovascular Diseases. Cells, 2021, 10, 3528. | 1.8 | 8 |
| 1738 | The effect of polygenic risk on white matter microstructural degeneration in Parkinson's disease: A longitudinal Diffusion Tensor Imaging study. European Journal of Neurology, 2022, 29, 1000-1010. | 1.7 | 3 |
| 1739 | Exploring Drug Metabolism by the Gut Microbiota: Modes of Metabolism and Experimental Approaches. Drug Metabolism and Disposition, 2022, 50, 224-234. | 1.7 | 14 |
| 1740 | Global Trends in the Incidence, Prevalence, and Years Lived With Disability of Parkinson's Disease in 204 Countries/Territories From 1990 to 2019. Frontiers in Public Health, 2021, 9, 776847. | 1.3 | 199 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1741 | Pharmabiotic Based on Lactobacillus fermentum Strain U-21 Modulates the Toxic Effect of 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine as Parkinsonism Inducer in Mice. Human Physiology, 2021, 47, 891-900. | 0.1 | 1 |
| 1743 | Validation of cepstral peak prominence in assessing early voice changes of Parkinson's disease: Effect of speaking task and ambient noise. Journal of the Acoustical Society of America, 2021, 150, 4522-4533. | 0.5 | 12 |
| 1744 | Perillyl Alcohol Attenuates NLRP3 Inflammasome Activation and Rescues Dopaminergic Neurons in Experimental In Vitro and In Vivo Models of Parkinsonâ€™s Disease. ACS Chemical Neuroscience, 2022, 13, 53-68. | 1.7 | 15 |
| 1745 | Simultaneous administration of coffee and rasagiline/l-dopa protects against paraquat-induced neurochemical and motor behavior impairments in vivo. Bulletin of the National Research Centre, 2021, 45, . | 0.7 | 3 |
| 1747 | LRRK2 signaling in neurodegeneration: two decades of progress. Essays in Biochemistry, 2021, 65, 859-872. | 2.1 | 7 |
| 1748 | A Systematic Study and Potential Limitations of Proton-ELISA Platform for Î±-Synuclein Antigen Detection. Chemosensors, 2022, 10, 5. | 1.8 | 2 |
| 1749 | Design and Implementation of an Instrumented walking cane for Detection of Freezing of Gait. , 2021, , . | | 0 |
| 1750 | Inhibition of anandamide hydrolysis does not rescue respiratory abnormalities observed in an animal model of Parkinson's disease. Experimental Physiology, 2022, 107, 161-174. | 0.9 | 0 |
| 1751 | Deep learning reveals personalized spatial spectral abnormalities of high delta and low alpha bands in EEG of patients with early Parkinsonâ€™s disease. Journal of Neural Engineering, 2021, 18, 066036. | 1.8 | 14 |
| 1752 | Metabolic Profile in Plasma AND CSF of LEVODOPA-induced Dyskinesia in Parkinsonâ€™s Disease: Focus on Neuroinflammation. Molecular Neurobiology, 2022, 59, 1140-1150. | 1.9 | 9 |
| 1753 | Assessment of a Robotic Walker in Older Adults With Parkinson's Disease in Daily Living Activities. Frontiers in Neurorobotics, 2021, 15, 742281. | 1.6 | 2 |
| 1756 | Chitosan oligosaccharides exert neuroprotective effectsviamodulating the PI3K/Akt/Bcl-2 pathway in a Parkinsonian model. Food and Function, 2022, 13, 5838-5853. | 2.1 | 11 |
| 1757 | A Comprehensive Study of Explainable Artificial Intelligence in Healthcare. Studies in Computational Intelligence, 2022, , 475-502. | 0.7 | 39 |
| 1758 | Association between cigarette smoking and Parkinsonâ€™s disease: a neuroimaging study. Therapeutic Advances in Neurological Disorders, 2022, 15, 175628642210925. | 1.5 | 15 |
| 1759 | Pramipexole Inhibits Neuronal Apoptosis in Rats with Parkinsonâ€™s Disease. Journal of Healthcare Engineering, 2022, 2022, 1-5. | 1.1 | 2 |
| 1760 | A Randomized Firstâ€inâ€Human Study With UBâ€312, a UBIThÂ® Î±â€Synuclein Peptide Vaccine. Movement Disorders, 2022, 37, 1416-1424. | 2.2 | 16 |
| 1762 | Minimally Detectable Change of Speech Intelligibility in Speakers With Multiple Sclerosis and Parkinson's Disease. Journal of Speech, Language, and Hearing Research, 2022, 65, 1858-1866. | 0.7 | 8 |
| 1763 | Genetic Variability of the Vitamin D Receptor Affects Susceptibility to Parkinsonâ€™s Disease and Dopaminergic Treatment Adverse Events. Frontiers in Aging Neuroscience, 2022, 14, 853277. | 1.7 | 4 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1764 | Parkinsonâ€™s Disease Detection from Resting-State EEG Signals Using Common Spatial Pattern, Entropy, and Machine Learning Techniques. Diagnostics, 2022, 12, 1033. | 1.3 | 22 |
| 1765 | Anti-Inflammatory and Neuroprotective Mechanisms of GTS-21, an Î±7 Nicotinic Acetylcholine Receptor Agonist, in Neuroinflammation and Parkinsonâ€™s Disease Mouse Models. International Journal of Molecular Sciences, 2022, 23, 4420. | 1.8 | 8 |
| 1766 | Stereotaxic-assisted gene therapy in Alzheimerâ€™s and Parkinsonâ€™s diseases: therapeutic potentials and clinical frontiers. Expert Review of Neurotherapeutics, 2022, 22, 319-335. | 1.4 | 1 |
| 1767 | Gut Microbiota as a Hidden Player in the Pathogenesis of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2022, 86, 1501-1526. | 1.2 | 9 |
| 1768 | Functional Brain Dysconnectivity in Parkinson's Disease: A 5â€Year Longitudinal Study. Movement Disorders, 2022, 37, 1444-1453. | 2.2 | 11 |
| 1770 | Anti-Parkinsonian Therapy: Strategies for Crossing the Bloodâ€“Brain Barrier and Nano-Biological Effects of Nanomaterials. Nano-Micro Letters, 2022, 14, 105. | 14.4 | 18 |
| 1771 | Self-reported periodontitis and C-reactive protein in Parkinsonâ€™s disease: a cross-sectional study of two American cohorts. Npj Parkinson's Disease, 2022, 8, 40. | 2.5 | 11 |
| 1772 | Dexmedetomidine Can Enhance PINK1/Parkin-Mediated Mitophagy in MPTP-Induced PD Mice Model by Activating AMPK. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-17. | 1.9 | 4 |
| 1838 | Early metabolic impairment as a contributor to neurodegenerative disease: Mechanisms and potential pharmacological intervention. Obesity, 2022, 30, 982-993. | 1.5 | 11 |
| 1839 | Nanoparticle Properties Influence Transendothelial Migration of Monocytes. Langmuir, 2022, 38, 5603-5616. | 1.6 | 5 |
| 1840 | Glycation modulates glutamatergic signaling and exacerbates Parkinsonâ€™s disease-like phenotypes. Npj Parkinson's Disease, 2022, 8, 51. | 2.5 | 15 |
| 1841 | Contribution of proteases to the hallmarks of aging and to ageâ€related neurodegeneration. Aging Cell, 2022, 21, e13603. | 3.0 | 19 |
| 1842 | Human neural stem cell-derived extracellular vesicles protect against Parkinsonâ€™s disease pathologies. Journal of Nanobiotechnology, 2022, 20, 198. | 4.2 | 29 |
| 1843 | Defects of Nutrient Signaling and Autophagy in Neurodegeneration. Frontiers in Cell and Developmental Biology, 2022, 10, 836196. | 1.8 | 8 |
| 1844 | Identification of the Raman Salivary Fingerprint of Parkinsonâ€™s Disease Through the Spectroscopicâ€“ Computational Combinatory Approach. Frontiers in Neuroscience, 2021, 15, 704963. | 1.4 | 12 |
| 1845 | Development of medical polymers for applications in neurological disorders. , 2022, , 369-402. | | 0 |
| 1846 | Involvement of cholesterol and Î²-amyloid in the initiation and progression of Alzheimerâ€™s disease. , 2022, , 715-745. | | 0 |
| 1847 | Association between Trichlorophenols and Neurodegenerative Diseases: A Cross-Sectional Study from Nhanes 2003-2010. SSRN Electronic Journal, 0, , . | 0.4 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1848 | Bio-Inspired Algorithms. Advances in Medical Technologies and Clinical Practice Book Series, 2022, , 1-22. | 0.3 | 0 |
| 1849 | Role of SARS-CoV-2 in Modifying Neurodegenerative Processes in Parkinsonâ€™s Disease: A Narrative Review. Brain Sciences, 2022, 12, 536. | 1.1 | 6 |
| 1850 | MiR-9-5p Inhibits the MMP+-Induced Neuron Apoptosis through Regulating SCRIB/Î²-Catenin Signaling in Parkinsonâ€™s Disease. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-13. | 1.9 | 4 |
| 1851 | Extracellular Alpha-Synuclein: Mechanisms for Glial Cell Internalization and Activation. Biomolecules, 2022, 12, 655. | 1.8 | 16 |
| 1852 | Effects of Low-Intensity Vestibular Noise Stimulation on Postural Instability in Patients with Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2022, 12, 1611-1618. | 1.5 | 3 |
| 1853 | 3D Printed Mini-Floating-Polypill for Parkinsonâ€™s Disease: Combination of Levodopa, Benserazide, and Pramipexole in Various Dosing for Personalized Therapy. Pharmaceutics, 2022, 14, 931. | 2.0 | 18 |
| 1854 | Barriers and Motivations to Provide Dental Care to Adult Patients with Movement Disorders. International Journal of Environmental Research and Public Health, 2022, 19, 5256. | 1.2 | 2 |
| 1855 | Efficacy of Traditional Herbal Medicine Treatment Based on Pattern Identification for Idiopathic Parkinsonâ€™s Disease: A Protocol for Systematic Review and Meta-Analysis. Evidence-based Complementary and Alternative Medicine, 2022, 2022, 1-5. | 0.5 | 2 |
| 1856 | Evaluation of chewing ability in cerebrovascular accident and Parkinsonâ€™s disease. Clinical Archives of Communication Disorders, 2022, 7, 7-14. | 0.3 | 0 |
| 1857 | Pathwayâ€Specific Remodeling of Thalamostriatal Synapses in a Mouse Model of Parkinson's Disease. Movement Disorders, 2022, 37, 1164-1174. | 2.2 | 7 |
| 1858 | Noradrenergic deficits contribute to apathy in Parkinsonâ€™s disease through the precision of expected outcomes. PLoS Computational Biology, 2022, 18, e1010079. | 1.5 | 19 |
| 1859 | Parkinsonâ€™s Disease: Overview of Transcription Factor Regulation, Genetics, and Cellular and Animal Models. Frontiers in Neuroscience, 2022, 16, . | 1.4 | 7 |
| 1860 | Vocal changes in a zebra finch model of Parkinsonâ€™s disease characterized by alpha-synuclein overexpression in the song-dedicated anterior forebrain pathway. PLoS ONE, 2022, 17, e0265604. | 1.1 | 7 |
| 1861 | Gait Abnormalities in Parkinsonâ€™s Disease Are Associated with Extracellular Free-Water Characteristics in the Substantia Nigra. Journal of Parkinson's Disease, 2022, 12, 1575-1590. | 1.5 | 4 |
| 1862 | Alpha-Synuclein Targeting Therapeutics for Parkinson's Disease and Related Synucleinopathies. Frontiers in Neurology, 2022, 13, . | 1.1 | 16 |
| 1863 | Targeting the Type 5 Metabotropic Glutamate Receptor: A Potential Therapeutic Strategy for Neurodegenerative Diseases?. Frontiers in Pharmacology, 2022, 13, . | 1.6 | 9 |
| 1864 | Cognitive Impact of Deep Brain Stimulation in Parkinsonâ€™s Disease Patients: A Systematic Review. Frontiers in Human Neuroscience, 2022, 16, . | 1.0 | 6 |
| 1865 | Environmental neurotoxic pesticide exposure induces gut inflammation and enteric neuronal degeneration by impairing enteric glial mitochondrial function in pesticide models of Parkinsonâ€™s disease: Potential relevance to gut-brain axis inflammation in Parkinsonâ€™s disease pathogenesis. International Journal of Biochemistry and Cell Biology, 2022, 147, 106225. | 1.2 | 11 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1866 | An Early Disturbance in Serotonergic Neurotransmission Contributes to the Onset of Parkinsonian Phenotypes in Drosophila melanogaster. Cells, 2022, 11, 1544. | 1.8 | 3 |
| 1867 | Targeting mitochondrial bioenergetics as a promising therapeutic strategy in metabolic and neurodegenerative diseases. Biomedical Journal, 2022, 45, 733-748. | 1.4 | 16 |
| 1868 | The Role of miR-20 in Health and Disease of the Central Nervous System. Cells, 2022, 11, 1525. | 1.8 | 4 |
| 1869 | Deep brain stimulation in the subthalamic nucleus for Parkinsonâ€™s disease can restore dynamics of striatal networks. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2120808119. | 3.3 | 15 |
| 1870 | The Chinese Parkinson's Disease Registry (<scp>CPDR</scp>): Study Design and Baseline Patient Characteristics. Movement Disorders, 2022, 37, 1335-1345. | 2.2 | 13 |
| 1871 | How Does Deep Brain Stimulation Change the Course of Parkinson's Disease?. Movement Disorders, 2022, 37, 1581-1592. | 2.2 | 29 |
| 1872 | Network Pharmacology and Absolute Bacterial Quantification-Combined Approach to Explore the Mechanism of Tianqi Pingchan Granule Against 6-OHDA-Induced Parkinsonâ€™s Disease in Rats. Frontiers in Nutrition, 2022, 9, . | 1.6 | 2 |
| 1873 | Neurogenesis in aging and age-related neurodegenerative diseases. Ageing Research Reviews, 2022, 78, 101636. | 5.0 | 41 |
| 1874 | Mobile and wearable sensors for data-driven health monitoring system: State-of-the-art and future prospect. Expert Systems With Applications, 2022, 202, 117362. | 4.4 | 28 |
| 1875 | The Effects of Musical Therapy on Parkinsonâ€™s Patients. Journal of Aging and Long-Term Care, 2021, , 11-17. | 0.1 | 0 |
| 1876 | Exercise in Parkinsonâ€™s disease. , 2022, , 403-412. | | 1 |
| 1877 | Effects of Nabilone on Sleep Outcomes in Patients with Parkinson's Disease: A Postâ€hoc Analysis of <scp>NMSâ€Nab</scp> Study. Movement Disorders Clinical Practice, 2022, 9, 751-758. | 0.8 | 10 |
| 1878 | Understanding the contributions of VPS35 and the retromer in neurodegenerative disease. Neurobiology of Disease, 2022, 170, 105768. | 2.1 | 14 |
| 1879 | Symptomatic Care in Multiple System Atrophy: State of the Art. Cerebellum, 2023, 22, 433-446. | 1.4 | 7 |
| 1880 | Rosmarinic Acid Inhibits Mitochondrial Damage by Alleviating Unfolded Protein Response. Frontiers in Pharmacology, 2022, 13, . | 1.6 | 8 |
| 1881 | Plasma miR-153 and miR-223 Levels as Potential Biomarkers in Parkinsonâ€™s Disease. Frontiers in Neuroscience, 2022, 16, . | 1.4 | 7 |
| 1882 | Convergent Molecular Pathways in Type 2 Diabetes Mellitus and Parkinsonâ€™s Disease: Insights into Mechanisms and Pathological Consequences. Molecular Neurobiology, 2022, , . | 1.9 | 4 |
| 1883 | Therapeutic application of GLP-1 and GIP receptor agonists in Parkinsonâ€™s disease. Expert Opinion on Therapeutic Targets, 2022, 26, 445-460. | 1.5 | 15 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1884 | Idiopathic Parkinsonâ€™s disease and chronic pain in the era of deep brain stimulation: a systematic review and meta-analysis. Journal of Neurosurgery, 2022, 137, 1821-1830. | 0.9 | 7 |
| 1885 | Therapeutic potential of leucine-rich repeat kinase 2 inhibitors for Parkinson's disease treatment. , 2022, , 623-655. | | 0 |
| 1888 | An EEG-based approach for Parkinsonâ€™s disease diagnosis using capsule network. , 2022, , . | | 3 |
| 1889 | Protein interaction networks in neurodegenerative diseases: From physiological function to aggregation. Journal of Biological Chemistry, 2022, 298, 102062. | 1.6 | 30 |
| 1890 | High-throughput analysis of hematopoietic stem cell engraftment after intravenous and intracerebroventricular dosing. Molecular Therapy, 2022, 30, 3209-3225. | 3.7 | 4 |
| 1891 | TGF-Î² as a Key Modulator of Astrocyte Reactivity: Disease Relevance and Therapeutic Implications. Biomedicines, 2022, 10, 1206. | 1.4 | 25 |
| 1892 | The Effects of Different Anesthesia Methods on the Treatment of Parkinsonâ€™s Disease by Bilateral Deep Brain Stimulation of the Subthalamic Nucleus. Frontiers in Neuroscience, 2022, 16, . | 1.4 | 2 |
| 1894 | The macular inner plexiform layer thickness as an early diagnostic indicator for Parkinsonâ€™s disease. Npj Parkinson's Disease, 2022, 8, . | 2.5 | 5 |
| 1895 | Association of Catechol-O-Methyltransferase Gene rs4680 Polymorphism and Levodopa Induced Dyskinesia in Parkinsonâ€™s Disease: A Meta-Analysis and Systematic Review. Journal of Geriatric Psychiatry and Neurology, 2023, 36, 98-106. | 1.2 | 3 |
| 1896 | Treatment paradigms in Parkinson's Disease and Covid-19. International Review of Neurobiology, 2022, , . | 0.9 | 1 |
| 1897 | Research Hotspots and Trends of Exercise on Parkinson's Disease: A Global Bibliometric Analysis From 2012 to 2021. Frontiers in Human Neuroscience, 2022, 16, . | 1.0 | 1 |
| 1898 | Role of glutamate receptor complex in the organism. Ligands of NMDA receptors in neurodegenerative processes â€“ a modern state of the problem. Reviews on Clinical Pharmacology and Drug Therapy, 2022, 20, 17-28. | 0.2 | 1 |
| 1899 | Phytocannabinoids and Cannabis-Based Products as Alternative Pharmacotherapy in Neurodegenerative Diseases: From Hypothesis to Clinical Practice. Frontiers in Cellular Neuroscience, 0, 16, . | 1.8 | 12 |
| 1900 | Pathological Role of Natural Killer Cells in Parkinson's Disease: A Systematic Review. Frontiers in Aging Neuroscience, 0, 14, . | 1.7 | 2 |
| 1903 | ANTÄ°PARKÄ°NSON Ä°LAÃ‡LARINA VERÄ°LEN BÄ°REYSEL YANITTA FARMAKOGENETÄ°ÄžÄ°N ROLÃœ. Ankara Universitesi Eczacilik Fakultesi Dergisi, 0, , 523-536. | 0.2 | 0 |
| 1905 | Polygenic Resilience Modulates the Penetrance of Parkinson Disease Genetic Risk Factors. Annals of Neurology, 2022, 92, 270-278. | 2.8 | 10 |
| 1906 | Deep Clinical Phenotyping of Parkinsonâ€™s Disease: Towards a New Era of Research and Clinical Care. Phenomics, 2022, 2, 349-361. | 0.9 | 3 |
| 1907 | Influence of Molecular Structures on Fluorescence of Flavonoids and Their Detection in Mammalian Cells. Biomedicines, 2022, 10, 1265. | 1.4 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1908 | Melatonin as an Anti-Aging Therapy for Age-Related Cardiovascular and Neurodegenerative Diseases. Frontiers in Aging Neuroscience, 0, 14, . | 1.7 | 20 |
| 1909 | Effect of Physical Activity on Depression in Patients with Parkinsonâ€™s Disease: A Systematic Review and Meta-Analysis. International Journal of Environmental Research and Public Health, 2022, 19, 6849. | 1.2 | 8 |
| 1910 | Effects of Qihuang Needling on Motor Function for Patients With Parkinson's Disease: Study Protocol for a Multicenter, Randomized Controlled Trial. Frontiers in Neurology, 2022, 13, . | 1.1 | 2 |
| 1911 | Revisiting Preclinical Observations of Several Histamine H3 Receptor Antagonists/Inverse Agonists in Cognitive Impairment, Anxiety, Depression, and Sleepâ€“Wake Cycle Disorder. Frontiers in Pharmacology, 0, 13, . | 1.6 | 9 |
| 1912 | Modeling Parkinson's diseaseâ€related symptoms in alphaâ€synuclein overexpressing mice. Brain and Behavior, 2022, 12, . | 1.0 | 8 |
| 1913 | Chronic di(2-ethylhexyl) phthalate exposure leads to dopaminergic neuron degeneration through mitochondrial dysfunction in C. elegans. Environmental Pollution, 2022, 307, 119574. | 3.7 | 6 |
| 1914 | Exogenous Otx2 protects midbrain dopaminergic neurons from MPP+ by interacting with ATP5a1 and promoting ATP synthesis. NeuroToxicology, 2022, 91, 211-217. | 1.4 | 1 |
| 1915 | A Pitx3-deficient developmental mouse model for fine motor, olfactory, and gastrointestinal symptoms of Parkinson's disease. Neurobiology of Disease, 2022, 170, 105777. | 2.1 | 3 |
| 1916 | Combining Filtering and Cross-Correlation Efficiently for Streaming Time Series. ACM Transactions on Knowledge Discovery From Data, 2022, 16, 1-24. | 2.5 | 13 |
| 1918 | Histoire naturelle de la maladie deÂParkinson idiopathique. , 2022, , 239-251. | | 0 |
| 1919 | Does length of time since diagnosis in Parkinsonâ€™s disease influence heart rate variability? A cross-sectional study. Arquivos De Neuro-Psiquiatria, 0, , . | 0.3 | 0 |
| 1920 | A Machine Learning approach for Early Detection of Parkinsonâ€™s Disease Using acoustic traces. , 2022, , . | | 8 |
| 1921 | Impact of Parkinsonâ€™s Disease on Functional Mobility at Different Stages. Frontiers in Aging Neuroscience, 0, 14, . | 1.7 | 5 |
| 1922 | Deep Learning Paradigm for Cardiovascular Disease/Stroke Risk Stratification in Parkinsonâ€™s Disease Affected by COVID-19: A Narrative Review. Diagnostics, 2022, 12, 1543. | 1.3 | 7 |
| 1923 | Attenuated brain white matter functional network interactions in Parkinson's disease. Human Brain Mapping, 2022, 43, 4567-4579. | 1.9 | 4 |
| 1924 | Mass spectrometry methods for analysis of extracellular matrix components in neurological diseases. Mass Spectrometry Reviews, 2023, 42, 1848-1875. | 2.8 | 4 |
| 1925 | GLP-1 Receptor Agonists in Neurodegeneration: Neurovascular Unit in the Spotlight. Cells, 2022, 11, 2023. | 1.8 | 11 |
| 1926 | Intranasal Nanoemulsions A Potential Strategy for Targeting The Neurodegenerative Disorder: Parkinson's.. CNS and Neurological Disorders - Drug Targets, 2022, 21, . | 0.8 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1927 | Platelets and the Role of P2X Receptors in Nociception, Pain, Neuronal Toxicity and Thromboinflammation. International Journal of Molecular Sciences, 2022, 23, 6585. | 1.8 | 7 |
| 1928 | In vivo detection of hydrogen sulfide in the brain of live mouse: application in neuroinflammation models. European Journal of Nuclear Medicine and Molecular Imaging, 0, , . | 3.3 | 5 |
| 1929 | Î±-Synuclein molecular behavior and nigral proteomic profiling distinguish subtypes of Lewy body disorders. Acta Neuropathologica, 2022, 144, 167-185. | 3.9 | 12 |
| 1930 | Effects of Resistance Training on Motor- and Non-Motor Symptoms in Patients with Parkinsonâ€™s Disease: A Systematic Review and Meta-Analysis. Journal of Parkinson's Disease, 2022, 12, 1783-1806. | 1.5 | 9 |
| 1931 | Morphometric imaging and quantitative susceptibility mapping as complementary tools in the diagnosis of parkinsonisms. European Journal of Neurology, 2022, 29, 2944-2955. | 1.7 | 4 |
| 1932 | Downregulation of CDK5 signaling in the dorsal striatum alters striatal microcircuits implicating the association of pathologies with circadian behavior in mice. Molecular Brain, 2022, 15, . | 1.3 | 9 |
| 1933 | The Pathological Mechanism Between the Intestine and Brain in the Early Stage of Parkinson's Disease. Frontiers in Aging Neuroscience, 0, 14, . | 1.7 | 3 |
| 1934 | Objective Measurement of Walking Activity Using Wearable Technologies in People with Parkinson Disease: A Systematic Review. Sensors, 2022, 22, 4551. | 2.1 | 4 |
| 1935 | Feasibility, Safety, and Effectiveness of Telerehabilitation in Mild-to-Moderate Parkinson's Disease. Frontiers in Neurology, 0, 13, . | 1.1 | 10 |
| 1936 | Inter-organellar Communication in Parkinson's and Alzheimer's Disease: Looking Beyond Endoplasmic Reticulum-Mitochondria Contact Sites. Frontiers in Neuroscience, 0, 16, . | 1.4 | 10 |
| 1937 | Acupuncture Regulates Symptoms of Parkinsonâ€™s Disease via Brain Neural Activity and Functional Connectivity in Mice. Frontiers in Aging Neuroscience, 0, 14, . | 1.7 | 6 |
| 1938 | PCDH8 protects MPP+-induced neuronal injury in SH-SY5Y cells by inhibiting MAPK pathway. Molecular and Cellular Toxicology, 0, , . | 0.8 | 0 |
| 1939 | Closing the loop for patients with Parkinson disease: where are we?. Nature Reviews Neurology, 2022, 18, 497-507. | 4.9 | 19 |
| 1940 | C. elegans as an Animal Model to Study the Intersection of DNA Repair, Aging and Neurodegeneration. Frontiers in Aging, 0, 3, . | 1.2 | 9 |
| 1941 | Vitamin D Status and Parkinsonâ€™s Disease. Brain Sciences, 2022, 12, 790. | 1.1 | 18 |
| 1942 | Efficacy and safety of apomorphine pump infusion in Filipino patients insufficiently controlled on oral anti-Parkinson medications: an open-label, pilot study. International Journal of Neuroscience, 2024, 134, 131-136. | 0.8 | 0 |
| 1943 | N-cystaminylbiguanide MC001 prevents neuron cell death and alleviates motor deficits in the MPTP-model of Parkinsonâ€™s disease. Neuroscience Letters, 2022, 784, 136751. | 1.0 | 1 |
| 1944 | Spatially-directed magnetic molecularly imprinted polymers with good anti-interference for simultaneous enrichment and detection of dual disease-related bio-indicators. Nanoscale, 2022, 14, 11343-11352. | 2.8 | 4 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1945 | Spotlight on non-motor symptoms and Covid-19. International Review of Neurobiology, 2022, , . | 0.9 | 0 |
| 1946 | Neural correlates of working memory and compensation at different stages of cognitive impairment in Parkinsonâ€™s disease. NeuroImage: Clinical, 2022, 35, 103100. | 1.4 | 6 |
| 1948 | Oral Dysbiosis and Neurodegenerative Diseases: Correlations and Potential Causations. Microorganisms, 2022, 10, 1326. | 1.6 | 6 |
| 1949 | Study protocol for using a smartphone application to investigate speech biomarkers of Parkinsonâ€™s disease and other synucleinopathies: SMARTSPEECH. BMJ Open, 2022, 12, e059871. | 0.8 | 10 |
| 1950 | The immunology of Parkinsonâ€™s disease. Seminars in Immunopathology, 2022, 44, 659-672. | 2.8 | 30 |
| 1951 | Microglia Phenotypes in Aging and Neurodegenerative Diseases. Cells, 2022, 11, 2091. | 1.8 | 76 |
| 1953 | Long noncoding RNA SNHG14 knockdown exerts a neuroprotective role in MPP+-induced Parkinsonâ€™s disease cell model through mediating miR-135b-5p/KPNA4 axis. Metabolic Brain Disease, 2022, 37, 2363-2373. | 1.4 | 5 |
| 1954 | Newly Approved and InvestigationalÂDrugsÂfor Motor Symptom Control in Parkinson's Disease. Drugs, 2022, 82, 1027-1053. | 4.9 | 8 |
| 1955 | The Burden of Progressive Supranuclear Palsy on Patients, Caregivers, and Healthcare Systems by PSP Phenotype: A Cross-Sectional Study. Frontiers in Neurology, 0, 13, . | 1.1 | 2 |
| 1956 | Protective Effects of Polysaccharides in Neurodegenerative Diseases. Frontiers in Aging Neuroscience, 0, 14, . | 1.7 | 9 |
| 1957 | Mitochondrial function and cellular energy maintenance during aging in a Drosophila melanogaster model of Parkinson disease. Mitochondrion, 2022, 65, 166-175. | 1.6 | 4 |
| 1959 | Patient Experience in Early-Stage Parkinsonâ€™s Disease: Using a Mixed Methods Analysis to Identify Which Concepts Are Cardinal for Clinical Trial Outcome Assessment. Neurology and Therapy, 2022, 11, 1319-1340. | 1.4 | 7 |
| 1960 | Polydopamine-Based Nanocomposite as a Biomimetic Antioxidant with a Variety of Enzymatic Activities for Parkinsonâ€™s Disease. ACS Applied Materials & Interfaces, 2022, 14, 32901-32913. | 4.0 | 17 |
| 1962 | Neuronal and glial characterization in the rostrocaudal axis of the human anterior olfactory nucleus: Involvement in Parkinsonâ€™s disease. Frontiers in Neuroanatomy, 0, 16, . | 0.9 | 2 |
| 1963 | Semaglutide Protects against 6-OHDA Toxicity by Enhancing Autophagy and Inhibiting Oxidative Stress. Parkinson's Disease, 2022, 2022, 1-10. | 0.6 | 1 |
| 1965 | Targeting the â€œhallmarks of agingâ€•to slow aging and treat age-related disease: fact or fiction?. Molecular Psychiatry, 2023, 28, 242-255. | 4.1 | 27 |
| 1966 | Pilot Study for Correlation of Heart Rate Variability and Dopamine Transporter Brain Imaging in Patients with Parkinsonian Syndrome. Sensors, 2022, 22, 5055. | 2.1 | 1 |
| 1967 | Progress and Setbacks in Translating a Decade of Ferroptosis Research into Clinical Practice. Cells, 2022, 11, 2134. | 1.8 | 4 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1968 | CHCHD2 maintains mitochondrial contact site and cristae organizing system stability and protects against mitochondrial dysfunction in an experimental model of Parkinson's disease. Chinese Medical Journal, 2022, 135, 1588-1596. | 0.9 | 5 |
| 1969 | Bidirectional Relationship Between Sleep Disturbances and Parkinson's Disease. Frontiers in Neurology, 0, 13, . | 1.1 | 8 |
| 1970 | Predictors of health-related quality of life in Parkinsonâ€™s disease: the impact of overlap between health-related quality of life and clinical measures. Quality of Life Research, 2022, 31, 3241-3252. | 1.5 | 2 |
| 1971 | Huangqin Decoction Exerts Beneficial Effects on Rotenone-Induced Rat Model of Parkinson's Disease by Improving Mitochondrial Dysfunction and Alleviating Metabolic Abnormality of Mitochondria. Frontiers in Aging Neuroscience, 0, 14, . | 1.7 | 4 |
| 1973 | Opicapone as an add-on to levodopa for reducing end-of-dose motor fluctuations in Parkinsonâ€™s disease: a systematic review and meta-analysis. Journal of Comparative Effectiveness Research, 2022, 11, 889-904. | 0.6 | 3 |
| 1974 | Lysosomal functions and dysfunctions: Molecular and cellular mechanisms underlying Gaucher disease and its association with Parkinson disease. Advanced Drug Delivery Reviews, 2022, 187, 114402. | 6.6 | 20 |
| 1975 | Role of platelet in Parkinsonâ€™s disease: Insights into pathophysiology & theranostic solutions. Ageing Research Reviews, 2022, 80, 101681. | 5.0 | 7 |
| 1976 | Amyloid aggregates exert cell toxicity causing irreversible damages in the endoplasmic reticulum. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2022, 1868, 166485. | 1.8 | 23 |
| 1977 | A novel aged mouse model of recurrent intracerebral hemorrhage in the bilateral striatum. Neural Regeneration Research, 2023, 18, 344. | 1.6 | 0 |
| 1978 | Deciphering Intertwined Molecular Pathways Underlying Metabolic Syndrome Leading to Parkinsonâ€™s Disease. ACS Chemical Neuroscience, 2022, 13, 2240-2251. | 1.7 | 2 |
| 1979 | On linear parameter varying control of timeâ€delayed positive systems. International Journal of Robust and Nonlinear Control, 2022, 32, 8614-8627. | 2.1 | 2 |
| 1980 | Insights into the roles of bacterial infection and antibiotics in Parkinsonâ€™s disease. Frontiers in Cellular and Infection Microbiology, 0, 12, . | 1.8 | 2 |
| 1981 | Ultrasmall Coordination Polymers for Alleviating ROS-Mediated Inflammatory and Realizing Neuroprotection against Parkinsonâ€™s Disease. Research, 2022, 2022, . | 2.8 | 9 |
| 1982 | The role of histone modifications: from neurodevelopment to neurodiseases. Signal Transduction and Targeted Therapy, 2022, 7, . | 7.1 | 63 |
| 1983 | Update to the Treatment of Parkinsonâ€™s Disease Based on the Gut-Brain Axis Mechanism. Frontiers in Neuroscience, 0, 16, . | 1.4 | 11 |
| 1984 | Actions of Metformin in the Brain: A New Perspective of Metformin Treatments in Related Neurological Disorders. International Journal of Molecular Sciences, 2022, 23, 8281. | 1.8 | 12 |
| 1985 | <scp>Î±â€Synuclein V15A</scp> Variant in Familial Parkinson's Disease Exhibits a Weaker Lipidâ€Binding Property. Movement Disorders, 2022, 37, 2075-2085. | 2.2 | 11 |
| 1986 | Hypoxia and Alpha-Synuclein: Inextricable Link Underlying the Pathologic Progression of Parkinson's Disease. Frontiers in Aging Neuroscience, 0, 14, . | 1.7 | 10 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1987 | Parkinsonâ€™s disease multimodal complex treatment improves gait performance: an exploratory wearable digital device-supported study. Journal of Neurology, 2022, 269, 6067-6085. | 1.8 | 3 |
| 1988 | Multifactor Progression of Parkinson's Disease: Role of Diet and Exposure to Microbiome-Borne Curli. SSRN Electronic Journal, 0, , . | 0.4 | 0 |
| 1989 | How I treat Parkinson's disease. Arquivos De Neuro-Psiquiatria, 2022, 80, 94-104. | 0.3 | 2 |
| 1990 | Sleep-controlling neurons are sensitive and vulnerable to multiple forms of Î±-synuclein: implications for the early appearance of sleeping disorders in Î±-synucleinopathies. Cellular and Molecular Life Sciences, 2022, 79, . | 2.4 | 5 |
| 1991 | Re-routing Metabolism by the Mitochondrial Pyruvate Carrier Inhibitor MSDC-0160 Attenuates Neurodegeneration in a Rat Model of Parkinsonâ€™s Disease. Molecular Neurobiology, 2022, 59, 6170-6182. | 1.9 | 6 |
| 1992 | Risk of Parkinsonâ€™s disease in multiple sclerosis and neuromyelitis optica spectrum disorder: a nationwide cohort study in South Korea. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 1209-1215. | 0.9 | 8 |
| 1993 | Synaptic Disruption by Soluble Oligomers in Patients with Alzheimerâ€™s and Parkinsonâ€™s Disease. Biomedicines, 2022, 10, 1743. | 1.4 | 6 |
| 1994 | Is telomerase a hidden player? Therapeutic potential of natural telomerase activators against age-related diseases. Phytochemistry Reviews, 0, , . | 3.1 | 1 |
| 1995 | CSF-derived extracellular vesicles from patients with Parkinsonâ€™s disease induce symptoms and pathology. Brain, 2023, 146, 209-224. | 3.7 | 23 |
| 1996 | Parkinsonâ€™s Disease Etiology: Insights and Associations with Phosphate Toxicity. International Journal of Molecular Sciences, 2022, 23, 8060. | 1.8 | 2 |
| 1997 | Automated quantification of dopaminergic immunostained neurons in substantia nigra using freely available software. Medical and Biological Engineering and Computing, 0, , . | 1.6 | 0 |
| 1998 | Moxifloxacin Disrupts and Attenuates AÎ²42 Fibril and Oligomer Formation: Plausibly Repositioning an Antibiotic as Therapeutic against Alzheimerâ€™s Disease. ACS Chemical Neuroscience, 2022, 13, 2529-2539. | 1.7 | 5 |
| 1999 | Transcriptome Profiling Reveals Differential Expression of Circadian Behavior Genes in Peripheral Blood of Monozygotic Twins Discordant for Parkinsonâ€™s Disease. Cells, 2022, 11, 2599. | 1.8 | 1 |
| 2000 | Imperative Role of Machine Learning Algorithm for Detection of Parkinsonâ€™s Disease: Review, Challenges and Recommendations. Diagnostics, 2022, 12, 2003. | 1.3 | 31 |
| 2001 | Glucocerebrosidase mutations and Parkinson disease. Journal of Neural Transmission, 2022, 129, 1105-1117. | 1.4 | 19 |
| 2003 | Organâ€Onâ€Aâ€Chip Models of the Bloodâ€“Brain Barrier: Recent Advances and Future Prospects. Small, 2022, 18, . | 5.2 | 14 |
| 2004 | Role of Protein Damage Inflicted by Dopamine Metabolites in Parkinsonâ€™s Disease: Evidence, Tools, and Outlook. Chemical Research in Toxicology, 2022, 35, 1789-1804. | 1.7 | 9 |
| 2005 | Motivational disturbances in rodent models of neuropsychiatric disorders. Frontiers in Behavioral Neuroscience, 0, 16, . | 1.0 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 2006 | Physiological and Pathological Functions of Neuronal Hemoglobin: A Key Underappreciated Protein in Parkinsonâ€™s Disease. International Journal of Molecular Sciences, 2022, 23, 9088. | 1.8 | 5 |
| 2007 | Association of Genetic Variant Linked to Hemochromatosis With Brain Magnetic Resonance Imaging Measures of Iron and Movement Disorders. JAMA Neurology, 2022, 79, 919. | 4.5 | 8 |
| 2009 | Multiple system atrophy. Nature Reviews Disease Primers, 2022, 8, . | 18.1 | 59 |
| 2010 | The association between urinary pentosidine levels and cognition in drug-naÃ¯ve patients with Parkinsonâ€™s disease. Neurological Sciences, 2022, 43, 6323-6328. | 0.9 | 1 |
| 2011 | Identification of ADP/ATP Translocase 1 as a Novel Glycoprotein and Its Association with Parkinsonâ€™s Disease. Neurochemical Research, 2022, 47, 3355-3368. | 1.6 | 1 |
| 2014 | Family History for Neurodegeneration in Multiple System Atrophy: Does it Indicate Susceptibility?. Movement Disorders, 2022, 37, 2310-2312. | 2.2 | 2 |
| 2015 | Detection and assessment of Parkinson's disease based on gait analysis: A survey. Frontiers in Aging Neuroscience, 0, 14, . | 1.7 | 14 |
| 2016 | fNIRS-based brain state transition features to signify functional degeneration after Parkinsonâ€™s disease. Journal of Neural Engineering, 2022, 19, 046038. | 1.8 | 3 |
| 2017 | Effects of Brain Factorâ€˜7Â® against motor deficit and oxidative stress in a mouse model of MPTPâ€˜induced Parkinson's disease. Experimental and Therapeutic Medicine, 2022, 24, . | 0.8 | 1 |
| 2018 | Exposure to static magnetic field facilitates selective attention and neuroplasticity in rats. Brain Research Bulletin, 2022, 189, 111-120. | 1.4 | 1 |
| 2019 | Î±-Synuclein Interaction with Lipid Bilayer Discs. Langmuir, 2022, 38, 10216-10224. | 1.6 | 2 |
| 2020 | Lipid Nanoparticles: Promising Treatment Approach for Parkinsonâ€™s Disease. International Journal of Molecular Sciences, 2022, 23, 9361. | 1.8 | 23 |
| 2021 | Transcriptome deregulation of peripheral monocytes and whole blood in GBA-related Parkinsonâ€™s disease. Molecular Neurodegeneration, 2022, 17, . | 4.4 | 17 |
| 2022 | Characterization of Nasco grape pomace-loaded nutriosomes and their neuroprotective effects in the MPTP mouse model of Parkinsonâ€™s disease. Frontiers in Pharmacology, 0, 13, . | 1.6 | 8 |
| 2023 | Oxidative stress and synaptic dysfunction in rodent models of Parkinson's disease. Neurobiology of Disease, 2022, 173, 105851. | 2.1 | 17 |
| 2024 | DiHuangYin decoction protects dopaminergic neurons in a Parkinson's disease model by alleviating peripheral inflammation. Phytomedicine, 2022, 105, 154357. | 2.3 | 2 |
| 2025 | Combined cell-based therapy strategies for the treatment of Parkinsonâ€™s disease: focus on mesenchymal stromal cells. Neural Regeneration Research, 2023, 18, 478. | 1.6 | 9 |
| 2026 | A decision support system for automated diagnosis of Parkinsonâ€™s disease from EEG using FAWT and entropy features. Biomedical Signal Processing and Control, 2023, 79, 104116. | 3.5 | 15 |

| # | Article | IF | Citations |
|---|---|---|---|
| 2028 | The heterogeneity of microglial activation and its epigenetic and non-coding RNA regulations in the immunopathogenesis of neurodegenerative diseases. Cellular and Molecular Life Sciences, 2022, 79, . | 2.4 | 12 |
| 2029 | Chlorogenic Acid: a Polyphenol from Coffee Rendered Neuroprotection Against Rotenone-Induced Parkinsonâ€™s Disease by GLP-1 Secretion. Molecular Neurobiology, 2022, 59, 6834-6856. | 1.9 | 13 |
| 2030 | Imaging the Limbic System in Parkinsonâ€™s Diseaseâ€”A Review of Limbic Pathology and Clinical Symptoms. Brain Sciences, 2022, 12, 1248. | 1.1 | 13 |
| 2031 | GPBAR1 preserves neurite and synapse of dopaminergic neurons via RAD21-OPCML signaling: Role in preventing Parkinson's disease in mouse model and human patients. Pharmacological Research, 2022, 184, 106459. | 3.1 | 4 |
| 2032 | Indoor VOCs exposure induced Parkinson-like behaviors through autophagy dysfunction and NLRP3 inflammasome-mediated neuroinflammation. Journal of Hazardous Materials, 2022, 440, 129818. | 6.5 | 3 |
| 2033 | CP-AGCN: Pytorch-based attention informed graph convolutional network for identifying infants at risk of cerebral palsy. Software Impacts, 2022, 14, 100419. | 0.8 | 2 |
| 2034 | Impact of aging on the central nervous system: Approaches for antiaging. , 2023, , 403-412. | | 0 |
| 2035 | Emerging roles of GPR109A in regulation of neuroinflammation in neurological diseases and pain. Neural Regeneration Research, 2023, 18, 763. | 1.6 | 12 |
| 2036 | Parkinsonâ€™s disease effective biomarkers based on Hjorth features improved by machine learning. Expert Systems With Applications, 2023, 212, 118772. | 4.4 | 13 |
| 2037 | Progressive autonomic failure. , 2022, , 297-337. | | 0 |
| 2038 | Bloodâ€“brain barrier (BBB)-on-a-chip: a promising breakthrough in brain disease research. Lab on A Chip, 2022, 22, 3579-3602. | 3.1 | 20 |
| 2039 | COVID-19: The cynosure of rise of Parkinson's disease. International Review of Neurobiology, 2022, , 251-262. | 0.9 | 0 |
| 2040 | Sex and gender differences in dementia. International Review of Neurobiology, 2022, , 179-233. | 0.9 | 3 |
| 2042 | Interplay of alpha-synuclein pathology and gut microbiome in Parkinsonâ€™s disease. , 2022, , 159-178. | | 1 |
| 2043 | Multimodal exercise program contributes to balance and motor functions in men and women with Parkinson's disease differently: an intervention study. Motriz Revista De Educacao Fisica, 0, 28, . | 0.3 | 1 |
| 2044 | Polypharmacology in Clinical Applications: Neurological Polypharmacology. , 2022, , 231-269. | | 0 |
| 2045 | An antibody scanning method for the detection of Î±-synuclein oligomers in the serum of Parkinson's disease patients. Chemical Science, 2022, 13, 13815-13828. | 3.7 | 4 |
| 2046 | The implication of cardio-oncology on Parkinson's disease: answers begin to emerge. Clinics, 2022, 77, 100085. | 0.6 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 2047 | Mitochondrial Dysregulation and the Influence in Neurodegenerative Diseases. Advances in Experimental Medicine and Biology, 2022, , 109-118. | 0.8 | 1 |
| 2048 | A Riemannian Deep Learning Representation to Describe Gait Parkinsonian Locomotor Patterns. , 2022, , . | | 0 |
| 2049 | A Spatio-Temporal Hypomimic Deep Descriptor to Discriminate Parkinsonian Patients. , 2022, , . | | 2 |
| 2050 | Wrist Movement Variability Assessment in Individuals with Parkinsonâ€™s Disease. Healthcare (Switzerland), 2022, 10, 1656. | 1.0 | 2 |
| 2051 | A Novel C-Type Lectin Receptor-Targeted Î±-Synuclein-Based Parkinson Vaccine Induces Potent Immune Responses and Therapeutic Efficacy in Mice. Vaccines, 2022, 10, 1432. | 2.1 | 2 |
| 2052 | DJ-1 is an essential downstream mediator in PINK1/parkin-dependent mitophagy. Brain, 2022, 145, 4368-4384. | 3.7 | 24 |
| 2053 | Structural magnetic resonance imaging findings and histopathological correlations in motor neuron diseasesâ€”A systematic review and meta-analysis. Frontiers in Neurology, 0, 13, . | 1.1 | 8 |
| 2054 | Research Progress on the Role of RNA m6A Modification in Glial Cells in the Regulation of Neurological Diseases. Biomolecules, 2022, 12, 1158. | 1.8 | 10 |
| 2055 | Mid51/Fis1 mitochondrial oligomerization complex drives lysosomal untethering and network dynamics. Journal of Cell Biology, 2022, 221, . | 2.3 | 13 |
| 2056 | CRISPR and iPSCs: Recent Developments and Future Perspectives in Neurodegenerative Disease Modelling, Research, and Therapeutics. Neurotoxicity Research, 2022, 40, 1597-1623. | 1.3 | 10 |
| 2058 | Deep Brain Stimulation Impact on Voice and Speech Quality in Parkinson's Disease: A Systematic Review. Otolaryngology - Head and Neck Surgery, 2023, 168, 307-318. | 1.1 | 7 |
| 2059 | Respiratory deficits in a female rat model of Parkinson's disease. Experimental Physiology, 0, , . | 0.9 | 0 |
| 2060 | Aberrant gray matter volume and functional connectivity in Parkinsonâ€™s disease with minor hallucination. Frontiers in Aging Neuroscience, 0, 14, . | 1.7 | 5 |
| 2061 | An overview of long noncoding RNAs: Biology, functions, therapeutics, analysis methods, and bioinformatics tools. Cell Biochemistry and Function, 2022, 40, 800-825. | 1.4 | 3 |
| 2062 | Polymorphism of Drug Transporters, Rather Than Metabolizing Enzymes, Conditions the Pharmacokinetics of Rasagiline. Pharmaceutics, 2022, 14, 2001. | 2.0 | 5 |
| 2063 | Validation of the <scp>OPTIMIPARK</scp> Questionnaire: A tool to optimize treatment in Parkinson's disease.. Movement Disorders Clinical Practice, 0, , . | 0.8 | 0 |
| 2064 | Mitochondrial morphology and synaptic structure altered in the retina of parkin-deficient mice. Neuroscience Letters, 2022, 790, 136888. | 1.0 | 2 |
| 2065 | Quercetin Protects against MPP+/MPTP-Induced Dopaminergic Neuron Death in Parkinsonâ€™s Disease by Inhibiting Ferroptosis. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-17. | 1.9 | 31 |

| # | Article | IF | Citations |
|---|---|---|---|
| 2067 | L-Ornithine L-Aspartate Restores Mitochondrial Function and Modulates Intracellular Calcium Homeostasis in Parkinsonâ€™s Disease Models. Cells, 2022, 11, 2909. | 1.8 | 6 |
| 2068 | Inflammatory gut as a pathologic and therapeutic target in Parkinsonâ€™s disease. Cell Death Discovery, 2022, 8, . | 2.0 | 5 |
| 2070 | Network Pharmacology and Molecular Docking Analyses Unveil the Mechanisms of Yiguanjian Decoction against Parkinsonâ€™s Disease from Inner/Outer Brain Perspective. BioMed Research International, 2022, 2022, 1-25. | 0.9 | 3 |
| 2071 | Regulation of microglial physiology by the microbiota. Gut Microbes, 2022, 14, . | 4.3 | 14 |
| 2072 | High-content phenotyping of Parkinson's disease patient stem cell-derived midbrain dopaminergic neurons using machine learning classification. Stem Cell Reports, 2022, 17, 2349-2364. | 2.3 | 8 |
| 2073 | Pyroptosis in development, inflammation and disease. Frontiers in Immunology, 0, 13, . | 2.2 | 20 |
| 2074 | Advances in the Therapeutic Use of Non-Ergot Dopamine Agonists in the Treatment of Motor and Non-Motor Symptoms of Parkinsonâ€™s Disease. Current Neuropharmacology, 2023, 21, 1224-1240. | 1.4 | 4 |
| 2075 | Non-motor symptoms burden in motor-fluctuating patients with Parkinsonâ€™s disease may be alleviated by safinamide: the VALE-SAFI study. Journal of Neural Transmission, 2022, 129, 1331-1338. | 1.4 | 4 |
| 2076 | Sequestration of Inflammation in Parkinsonâ€™s Disease via Stem Cell Therapy. International Journal of Molecular Sciences, 2022, 23, 10138. | 1.8 | 3 |
| 2077 | Role of Glial Cell-Derived Oxidative Stress in Blood-Brain Barrier Damage after Acute Ischemic Stroke. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-14. | 1.9 | 11 |
| 2078 | Monoamine-oxidase Type B Inhibitors and Cognitive Functions in Parkinsonâ€™s Disease: Beyond the Primary Mechanism of Action. Current Neuropharmacology, 2023, 21, 1214-1223. | 1.4 | 3 |
| 2079 | Study of the Effects of Nicotine and Caffeine for the Treatment of Parkinsonâ€™s Disease. Applied Biochemistry and Biotechnology, 2023, 195, 639-654. | 1.4 | 3 |
| 2080 | Uric Acid in Parkinsonâ€²s Disease: What Is the Connection?. Movement Disorders, 2022, 37, 2173-2183. | 2.2 | 18 |
| 2081 | Prosaposin Reduces Î±-Synuclein in Cells and Saposin C Dislodges it from Glucosylceramide-enriched Lipid Membranes. Journal of Molecular Neuroscience, 2022, 72, 2313-2325. | 1.1 | 4 |
| 2082 | Lysosomal Pathogenesis of Parkinson's Disease: Insights From LRRK2 and GBA1 Rodent Models. Neurotherapeutics, 2023, 20, 127-139. | 2.1 | 5 |
| 2083 | Citronellol Prevents 6-OHDA-Induced Oxidative Stress, Mitochondrial Dysfunction, and Apoptosis in Parkinson Disease Model of SH-SY5Y Cells via Modulating ROS-NO, MAPK/ERK, and PI3K/Akt Signaling Pathways. Neurotoxicity Research, 2022, 40, 2221-2237. | 1.3 | 6 |
| 2084 | Brain-Targeted Biomimetic Nanodecoys with Neuroprotective Effects for Precise Therapy of Parkinsonâ€™s Disease. ACS Central Science, 2022, 8, 1336-1349. | 5.3 | 18 |
| 2085 | Using Deep Learning for Task and Tremor Type Classification in People with Parkinsonâ€™s Disease. Sensors, 2022, 22, 7322. | 2.1 | 4 |

| # | Article | IF | Citations |
|---|---|---|---|
| 2086 | In silico prediction of parkinsonian motor deficits-related neurotoxicants based on the adverse outcome pathway concept. Archives of Toxicology, 2022, 96, 3305-3314. | 1.9 | 4 |
| 2087 | Neurodegenerative diseases and blood pressure variability: A comprehensive review from HOPE Asia. Journal of Clinical Hypertension, 2022, 24, 1204-1217. | 1.0 | 2 |
| 2088 | Parkinsonism in Genetic Neurodevelopmental Disorders: A Systematic Review. Movement Disorders Clinical Practice, 2023, 10, 17-31. | 0.8 | 3 |
| 2089 | Associations of anthropometric cardiometabolic risk factors and leg fat accumulation in children and adolescents from Poland. American Journal of Human Biology, 0, , . | 0.8 | 0 |
| 2091 | Perspective on Cav-1 for its Potential as Newer Therapeutics for Parkinsonâ€™s Disease. CNS and Neurological Disorders - Drug Targets, 2023, 22, 1429-1438. | 0.8 | 3 |
| 2092 | Mitochondrialâ€Targeting Vitamin B<sub>3</sub> Ameliorates the Phenotypes of Parkinson's Disease In Vitro and In Vivo by Restoring Mitochondrial Function. Advanced Therapeutics, 2022, 5, . | 1.6 | 2 |
| 2093 | Research trends and frontiers in exercise for movement disorders: A bibliometric analysis of global research from 2010 to 2021. Frontiers in Aging Neuroscience, 0, 14, . | 1.7 | 1 |
| 2094 | Recent advances in dopamine D<sub>2</sub> receptor ligands in the treatment of neuropsychiatric disorders. Medicinal Research Reviews, 2023, 43, 55-211. | 5.0 | 8 |
| 2095 | Activities of Daily Living are Improved by Inpatient Multimodal Complex Treatment for <scp>PD</scp> â€“ a realâ€world cohort study. Movement Disorders Clinical Practice, 0, , . | 0.8 | 0 |
| 2096 | Astrocytes regulate neuronal network activity by mediating synapse remodeling. Neuroscience Research, 2023, 187, 3-13. | 1.0 | 3 |
| 2097 | AMPK-dependent autophagy activation and alpha-Synuclein clearance: a putative mechanism behind alpha-mangostinâ€™s neuroprotection in a rotenone-induced mouse model of Parkinsonâ€™s disease. Metabolic Brain Disease, 0, , . | 1.4 | 9 |
| 2098 | APOE in the bullseye of neurodegenerative diseases: impact of the APOE genotype in Alzheimerâ€™s disease pathology and brain diseases. Molecular Neurodegeneration, 2022, 17, . | 4.4 | 62 |
| 2099 | Priming mesenchymal stem cells with Î±-synuclein enhances neuroprotective properties through induction of autophagy in Parkinsonian models. Stem Cell Research and Therapy, 2022, 13, . | 2.4 | 7 |
| 2100 | ANTIOXIDANT ROLE OF DJ-1 PROTEIN IN THE PATHOGENESIS OF PARKINSON'S DISEASE. Eurasian Journal of Applied Biotechnology, 2022, , 3-13. | 0.0 | 0 |
| 2101 | Computational design of rasagiline derivatives: Searching for enhanced antioxidant capability. International Journal of Quantum Chemistry, 2023, 123, . | 1.0 | 1 |
| 2102 | The Therapeutic Potential of Salidroside for ParkinsonÊ¼s Disease. Planta Medica, 2023, 89, 353-363. | 0.7 | 0 |
| 2103 | Association of Total Bilirubin with Motor Signs in Early Parkinsonâ€™s Disease in LRRK2 Variant Carriers. Journal of Molecular Neuroscience, 0, , . | 1.1 | 0 |
| 2104 | Biodiversity and Bioprospecting of Fungal Endophytes from the Antarctic Plant Colobanthus quitensis. Journal of Fungi (Basel, Switzerland), 2022, 8, 979. | 1.5 | 8 |

| # | Article | IF | Citations |
|---|---|---|---|
| 2105 | Alpha-synuclein Immunization Strategies for Synucleinopathies in Clinical Studies: A Biological Perspective. Neurotherapeutics, 2022, 19, 1489-1502. | 2.1 | 12 |
| 2107 | Social, affective, and non-motoric bodily cues to the Sense of Agency: A systematic review of the experience of control. Neuroscience and Biobehavioral Reviews, 2022, 142, 104900. | 2.9 | 5 |
| 2108 | Genetics in parkinsonâ€™s disease: From better disease understanding to machine learning based precision medicine. Frontiers in Molecular Medicine, 0, 2, . | 0.6 | 0 |
| 2109 | Multiscale imaging informs translational mouse modeling of neurological disease. Neuron, 2022, 110, 3688-3710. | 3.8 | 3 |
| 2110 | Vacuolar ATPase (V-ATPase) Proton Pump and Its Significance in Human Health. Biochemistry, 0, , . | 0.8 | 0 |
| 2111 | Therapeutic Approaches to Non-Motor Symptoms of Parkinson's Disease: A Current Update on Preclinical Evidence. Current Neuropharmacology, 2023, 21, 560-577. | 1.4 | 2 |
| 2112 | Graphene oxide reinforced silk fibroin nanocomposite as an electroactive interface for the estimation of dopamine. RSC Advances, 2022, 12, 29319-29328. | 1.7 | 0 |
| 2113 | Effects of COVID-19 on Outpatient Visitation of Japanese Parkinsonâ€™s Disease and Parkinsonism Patients Receiving Rehabilitation. Advances in Parkinson S Disease, 2022, 11, 11-22. | 0.2 | 0 |
| 2114 | Autonomic and cardiorespiratory responses to the active tilt test in individuals with Parkinson disease: cross-sectional study. Arquivos De Neuro-Psiquiatria, 2022, 80, 689-698. | 0.3 | 1 |
| 2115 | Early Detection of Parkinsonâ€™s Disease Using Convolutional Neural Network. , 2022, , . | | 2 |
| 2118 | Impact of the Renin-Angiotensin System on the Pathogeny and Pharmacotherapeutics of Neurodegenerative Diseases. Biomolecules, 2022, 12, 1429. | 1.8 | 4 |
| 2119 | Combining NGN2 programming and dopaminergic patterning for a rapid and efficient generation of hiPSC-derived midbrain neurons. Scientific Reports, 2022, 12, . | 1.6 | 6 |
| 2120 | Mitochondrial biogenesis, telomere length and cellular senescence in Parkinsonâ€™s disease and Lewy body dementia. Scientific Reports, 2022, 12, . | 1.6 | 13 |
| 2121 | Association between gout and the development of Parkinsonâ€™s disease: a systematic review and meta-analysis. BMC Neurology, 2022, 22, . | 0.8 | 1 |
| 2123 | Zebrafish as a model organism for neurodegenerative disease. Frontiers in Molecular Neuroscience, 0, 15, . | 1.4 | 18 |
| 2125 | Neuroprotective Effects of Sodium Butyrate and Monomethyl Fumarate Treatment through GPR109A Modulation and Intestinal Barrier Restoration on PD Mice. Nutrients, 2022, 14, 4163. | 1.7 | 9 |
| 2126 | The Role of Diet and Dietary Patterns in Parkinsonâ€™s Disease. Nutrients, 2022, 14, 4472. | 1.7 | 18 |
| 2127 | Diffusion Tensor Imaging Analysis Along the Perivascular Space Index in Primary Parkinsonâ€™s Disease Patients With and Without Freezing of Gait. Neuroscience, 2022, 506, 51-57. | 1.1 | 6 |

| # | Article | IF | Citations |
|---|---|---|---|
| 2128 | Couples facing the â€œhoneymoon periodâ€•of Parkinson's disease: A qualitative study of dyadic functioning. British Journal of Health Psychology, 0, , . | 1.9 | 0 |
| 2129 | Therapeutic function of a novel rat induced pluripotent stem cell line in a 6â€˜OHDAâ€˜induced rat model of Parkinson's disease. International Journal of Molecular Medicine, 2022, 50, . | 1.8 | 0 |
| 2130 | Human Induced Pluripotent Stem Cell Phenotyping and Preclinical Modeling of Familial Parkinsonâ€™s Disease. Genes, 2022, 13, 1937. | 1.0 | 4 |
| 2131 | Altered prefrontal neurochemistry in the DJ-1 knockout mouse model of Parkinsonâ€™s disease: complementary semi-quantitative analyses with in vivo magnetic resonance spectroscopy and MALDI-MSI. Analytical and Bioanalytical Chemistry, 2022, 414, 7977-7987. | 1.9 | 4 |
| 2132 | Role of SUMOylation in Neurodegenerative Diseases. Cells, 2022, 11, 3395. | 1.8 | 11 |
| 2133 | Assessing the Neurotoxicity of a Sub-Optimal Dose of Rotenone in Zebrafish (Danio rerio) and the Possible Neuroactive Potential of Valproic Acid, Combination of Levodopa and Carbidopa, and Lactic Acid Bacteria Strains. Antioxidants, 2022, 11, 2040. | 2.2 | 4 |
| 2134 | Exploring the Connection Between the Gut Microbiome and Parkinsonâ€™s Disease Symptom Progression and Pathology: Implications for Supplementary Treatment Options. Journal of Parkinson's Disease, 2022, 12, 2339-2352. | 1.5 | 1 |
| 2135 | Functional profile in Parkinsonâ€™s disease and predictors of gait speed. European Journal of Physiotherapy, 0, , 1-7. | 0.7 | 0 |
| 2136 | Dysregulation of Circulatory Levels of lncRNAs in Parkinsonâ€™s Disease. Molecular Neurobiology, 2023, 60, 317-328. | 1.9 | 8 |
| 2137 | State-of-the-art review of the clinical research on menopause and hormone replacement therapy association with Parkinsonâ€™s disease: What meta-analysis studies cannot tell us. Frontiers in Aging Neuroscience, 0, 14, . | 1.7 | 2 |
| 2138 | The DNA Methylation in Neurological Diseases. Cells, 2022, 11, 3439. | 1.8 | 20 |
| 2140 | Proline Metabolism in Neurological and Psychiatric Disorders. Molecules and Cells, 2022, 45, 781-788. | 1.0 | 3 |
| 2141 | A review of the preclinical and clinical studies on the role of the gut microbiome in aging and neurodegenerative diseases and its modulation. Frontiers in Cellular Neuroscience, 0, 16, . | 1.8 | 8 |
| 2142 | The ADORA1 mutation linked to early-onset Parkinsonâ€™s disease alters adenosine A1-A2A receptor heteromer formation and function. Biomedicine and Pharmacotherapy, 2022, 156, 113896. | 2.5 | 8 |
| 2143 | Effects of Mutations and Post-Translational Modifications on Î±-Synuclein In Vitro Aggregation. Journal of Molecular Biology, 2022, 434, 167859. | 2.0 | 17 |
| 2144 | Reelin protects against pathological Î±-synuclein accumulation and dopaminergic neurodegeneration after environmental enrichment in Parkinson's disease. Neurobiology of Disease, 2022, 175, 105898. | 2.1 | 3 |
| 2145 | Non-invasive brain stimulation for treating psychiatric symptoms in Parkinsonâ€™s disease: A systematic review and meta-analysis. Journal of Clinical Neuroscience, 2022, 106, 83-90. | 0.8 | 2 |
| 2146 | Neural progenitor cells derived from fibroblasts induced by small molecule compounds under hypoxia for treatment of Parkinsonâ€™s disease in rats. Neural Regeneration Research, 2023, 18, 1090. | 1.6 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 2147 | Plant bioactives as promising therapeutic agents in Parkinsonâ€™s disease targeting oxidative stress during aging. , 2023, , 329-357. | | 0 |
| 2148 | Guidelines for Therapeutic Management of Parkinsonâ€™s Disease in China. , 2022, , 3079-3098. | | 0 |
| 2149 | Calcium Channels and Selective Neuronal Vulnerability in Parkinsonâ€™s Disease. , 2022, , 575-598. | | 2 |
| 2150 | PET imaging in animal models of Parkinsonâ€™s disease. Behavioural Brain Research, 2023, 438, 114174. | 1.2 | 3 |
| 2151 | A Machine Leaning based Parkinsonâ€™s Detection using Acoustic Features. , 2022, , . | | 0 |
| 2152 | Biosignal Monitoring System for Patients with Neurodegenerative Diseases: A WSN in a Suit. , 2022, , . | | 0 |
| 2153 | Marine Natural Products from the Russian Pacific as Sources of Drugs for Neurodegenerative Diseases. Marine Drugs, 2022, 20, 708. | 2.2 | 8 |
| 2154 | Effectiveness and safety of herbal medicine Ukgansan for clinical symptoms in Parkinson's disease: A pilot, randomized, assessor-blinded clinical trial. Frontiers in Neurology, 0, 13, . | 1.1 | 1 |
| 2155 | Inhibiting von Hippelâ€'Lindau protein-mediated Dishevelled ubiquitination protects against experimental parkinsonism. Acta Pharmacologica Sinica, 2023, 44, 940-953. | 2.8 | 2 |
| 2156 | Mitochondrial haplogroups and cognitive progression in Parkinsonâ€™s disease. Brain, 2023, 146, 42-49. | 3.7 | 3 |
| 2157 | Rotenone induced olfactory deficit in Parkinson's Disease Rat model: The protective role of adenosine A2A receptors Antagonist. Journal of Chemical Neuroanatomy, 2022, , 102188. | 1.0 | 1 |
| 2158 | Chronic Treatment with the Probiotics Lacticaseibacillus rhamnosus GG and Bifidobacterium lactis BB12 Attenuates Motor Impairment, Striatal Microglial Activation, and Dopaminergic Loss in Rats with 6-Hydroxydopamine-induced Hemiparkinsonism. Neuroscience, 2022, 507, 79-98. | 1.1 | 3 |
| 2159 | Chronic Microcystin-LR-Induced Î±-Synuclein Promotes Neuroinflammation Through Activation of the NLRP3 Inflammasome in Microglia. Molecular Neurobiology, 2023, 60, 884-900. | 1.9 | 6 |
| 2160 | Melanin and Neuromelanin: Linking Skin Pigmentation and Parkinson's Disease. Movement Disorders, 2023, 38, 185-195. | 2.2 | 5 |
| 2161 | Structure-Based Discovery of Small-Molecule Inhibitors of the Autocatalytic Proliferation of Î±-Synuclein Aggregates. Molecular Pharmaceutics, 2023, 20, 183-193. | 2.3 | 13 |
| 2162 | Protein and Gene Delivery Systems for Neurodegenerative Disorders: Where Do We Stand Today?. Pharmaceutics, 2022, 14, 2425. | 2.0 | 8 |
| 2163 | Classification of Parkinsonâ€™s disease motor phenotype: a machine learning approach. Journal of Neural Transmission, 2022, 129, 1447-1461. | 1.4 | 0 |
| 2164 | Parkinsonâ€™s Disease Wearable Gait Analysis: Kinematic and Dynamic Markers for Diagnosis. Sensors, 2022, 22, 8773. | 2.1 | 6 |

| # | Article | IF | Citations |
|---|---|---|---|
| 2165 | Bioinformatics analysis of gene expression profile and functional analysis in periodontitis and Parkinsonâ€™s disease. Frontiers in Aging Neuroscience, 0, 14, . | 1.7 | 2 |
| 2166 | DOPAnization of tyrosine in Î±-synuclein by tyrosine hydroxylase leads to the formation of oligomers. Nature Communications, 2022, 13, . | 5.8 | 6 |
| 2167 | Generation of a human induced pluripotent stem cell line (UNAMi001-A) from a Mexican patient with sporadic Parkinsonâ€™s disease. Stem Cell Research, 2022, , 102972. | 0.3 | 0 |
| 2168 | A prebiotic diet modulates microglial states and motor deficits in Î±-synuclein overexpressing mice. ELife, 0, 11, . | 2.8 | 18 |
| 2169 | Prediction of Movement Ratings and Deep Brain Stimulation Parameters in Idiopathic Parkinsonâ€™s Disease. Neuromodulation, 2022, , . | 0.4 | 2 |
| 2170 | Nonreceptor Tyrosine Kinase c-Abl-Mediated PHB2 Phosphorylation Aggravates Mitophagy Disorder in Parkinsonâ€™s Disease Model. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-20. | 1.9 | 5 |
| 2171 | Analysis of handgrip strength, pulling force using the upper limbs, and ground reaction forces in the task of boarding a bus between healthy elderly individuals and those with Parkinsonâ€™s disease. Physiotherapy Theory and Practice, 0, , 1-10. | 0.6 | 1 |
| 2172 | Subtyping of early-onset Parkinsonâ€™s disease using cluster analysis: A large cohort study. Frontiers in Aging Neuroscience, 0, 14, . | 1.7 | 4 |
| 2173 | Differential interactions of Î±-synuclein conformers affect refolding and activity of proteins. Journal of Biochemistry, 0, , . | 0.9 | 3 |
| 2174 | Molecular heterogeneity in the substantia nigra: A roadmap for understanding PD motor pathophysiology. Neurobiology of Disease, 2022, 175, 105925. | 2.1 | 8 |
| 2175 | Redox Modulation of Mitochondrial Proteins in the Neurotoxicant Models of Parkinson's Disease. Antioxidants and Redox Signaling, 2023, 38, 824-852. | 2.5 | 4 |
| 2176 | Biomechanical evaluation of an exoskeleton for rehabilitation of individuals with Parkinson's disease. Irbm, 2022, , . | 3.7 | 2 |
| 2178 | Recent Advances in Electrophysiological Recording Platforms for Brain and Heart Organoids. Advanced NanoBiomed Research, 2022, 2, . | 1.7 | 9 |
| 2179 | Mass Spectrometryâ€“Based Proteomics Analysis of Human Substantia Nigra From Parkinson's Disease Patients Identifies Multiple Pathways Potentially Involved in the Disease. Molecular and Cellular Proteomics, 2023, 22, 100452. | 2.5 | 15 |
| 2180 | 6-Hydroxydopamine (6-OHDA) rodent model of Parkinsonâ€™s disease: Investigating neural control of cardiorespiratory function. , 2023, , 493-506. | | 0 |
| 2181 | Modeling of Parkinsonâ€™s disease in Drosophila based on DJ-1 deficiency. , 2023, , 467-480. | | 3 |
| 2182 | â€œSwiss Army Knifeâ€•black phosphorus-based nanodelivery platform for synergistic antiparkinsonian therapy via remodeling the brain microenvironment. Journal of Controlled Release, 2023, 353, 752-766. | 4.8 | 10 |
| 2183 | Neuroprotective effect of secukinumab against rotenone induced Parkinson's disease in rat model: Involvement of IL-17, HMGB-1/TLR4 axis and BDNF/TrKB cascade. International Immunopharmacology, 2023, 114, 109571. | 1.7 | 8 |

| # | Article | IF | Citations |
|---|---|---|---|
| 2184 | Rhynchophylline-encapsulating core-shell nanoparticles to overcome blood-brain-barrier and inhibit drug efflux for efficient anti-Parkinson therapy. Applied Materials Today, 2023, 30, 101715. | 2.3 | 3 |
| 2185 | Exercise training has a protective effect in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice model with improved neural and intestinal pathology and modified intestinal flora. Behavioural Brain Research, 2023, 439, 114240. | 1.2 | 2 |
| 2186 | VGG11 Parkinsonâ€™s Disease Detection Based onÂVoice Attributes. Communications in Computer and Information Science, 2022, , 58-70. | 0.4 | 0 |
| 2187 | Aging and Neurodegenerative Diseases: Why do Nerve Cells Die?. , 2022, , 27-103. | | 0 |
| 2188 | Detection of freezing of gait episodes in patients with parkinson's disease using electroencephalography and motion sensors: A protocol and its feasibility results. Neurological Sciences and Neurophysiology, 2022, 39, 200. | 0.1 | 0 |
| 2189 | Management of Fluctuating Parkinsonâ€™s Disease: From Science to Clinical Wisdom. European Medical Journal (Chelmsford, England), 0, , 34-39. | 3.0 | 0 |
| 2190 | Transformers for 1D signals in Parkinsonâ€™s disease detection from gait. , 2022, , . | | 6 |
| 2191 | Parkinson's Disease Classification with Self-supervised Learning and Attention Mechanism. , 2022, , . | | 1 |
| 2192 | Research on Innovative Design of Auxiliary RehabilitationTraining Suits for Parkinson's Disease Based on AHP/SET/TRIZ Integration. , 2022, , . | | 0 |
| 2194 | Thiocyanate Reduces Motor Impairment in the hMPO-A53T PD Mouse Model While Reducing MPO-Oxidation of Alpha Synuclein in Enlarged LYVE1/AQP4 Positive Periventricular Glymphatic Vessels. Antioxidants, 2022, 11, 2342. | 2.2 | 1 |
| 2195 | Approaching the Gut and Nasal Microbiota in Parkinsonâ€™s Disease in the Era of the Seed Amplification Assays. Brain Sciences, 2022, 12, 1579. | 1.1 | 3 |
| 2196 | Transformer-based severity detection of Parkinson's symptoms from gait. , 2022, , . | | 0 |
| 2197 | New Insights into the Gut Microbiota in Neurodegenerative Diseases from the Perspective of Redox Homeostasis. Antioxidants, 2022, 11, 2287. | 2.2 | 8 |
| 2198 | The effects of bioactive components from the rhizome of gastrodia elata blume (Tianma) on the characteristics of Parkinsonâ€™s disease. Frontiers in Pharmacology, 0, 13, . | 1.6 | 11 |
| 2199 | The Effects of Dietary Interventions on Brain Aging and Neurological Diseases. Nutrients, 2022, 14, 5086. | 1.7 | 9 |
| 2200 | Levodopa-Induced Dyskinesia in Parkinsonâ€™s Disease: Pathogenesis and Emerging Treatment Strategies. Cells, 2022, 11, 3736. | 1.8 | 24 |
| 2201 | Unveiling sex-based differences in Parkinson's disease: a comprehensive meta-analysis of transcriptomic studies. Biology of Sex Differences, 2022, 13, . | 1.8 | 20 |
| 2202 | Occupational therapy for people with Parkinsonâ€™s disease in Israel: A SWOT analysis. Scandinavian Journal of Occupational Therapy, 2023, 30, 673-683. | 1.1 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 2203 | Protein aggregation and calcium dysregulation are hallmarks of familial Parkinsonâ€™s disease in midbrain dopaminergic neurons. Npj Parkinson's Disease, 2022, 8, . | 2.5 | 14 |
| 2204 | Association between Parkinsonâ€™s Disease Medication and the Risk of Lower Urinary Tract Infection (LUTI): A Retrospective Cohort Study. Journal of Clinical Medicine, 2022, 11, 7077. | 1.0 | 0 |
| 2205 | A Focus on Astrocyte Contribution to Parkinsonâ€™s Disease Etiology. Biomolecules, 2022, 12, 1745. | 1.8 | 3 |
| 2206 | ParkinSense: A Novel Approach to Remote Idiopathic Parkinsonâ€™s Disease Diagnosis, Severity Profiling, and Telemonitoring via Ensemble Learning and Multimodal Data Fusion on Webcam-Derived Digital Biomarkers. , 2022, , . | | 0 |
| 2207 | Iron Brain Menace: The Involvement of Ferroptosis in Parkinson Disease. Cells, 2022, 11, 3829. | 1.8 | 15 |
| 2209 | Detection of Parkinsoâ€™s disease using Convolutional Neural Networks and Data Augmentation with SPECT images. , 2022, , . | | 2 |
| 2210 | The effects of microbiota abundance on symptom severity in Parkinsonâ€™s disease: A systematic review. Frontiers in Aging Neuroscience, 0, 14, . | 1.7 | 2 |
| 2211 | A novel Î±-ketoamide reactivity-based two-photon fluorogenic probe for visualizing peroxynitrite in Parkinson's disease models. Journal of Innovative Optical Health Sciences, 0, , . | 0.5 | 1 |
| 2213 | Ganoderic Acid A targeting leucineâ€rich repeat kinase 2 involved in Parkinson's diseaseâ€“A computational study. Aging Medicine (Milton (N S W)), 2023, 6, 272-280. | 0.9 | 2 |
| 2214 | Transcriptomic analyses reveal neuronal specificity of Leigh syndrome associated genes. Journal of Inherited Metabolic Disease, 2023, 46, 243-260. | 1.7 | 3 |
| 2215 | Gastrointestinal biopsy of normal mucosa or nonspecific inflammation and risk of neurodegenerative disease: Nationwide matched cohort study. European Journal of Neurology, 0, , . | 1.7 | 1 |
| 2216 | Relevance of biochemical deep phenotyping for a personalised approach to Parkinsonâ€™s disease. Neuroscience, 2022, , . | 1.1 | 3 |
| 2217 | Functions and dysfunctions of oligodendrocytes in neurodegenerative diseases. Frontiers in Cellular Neuroscience, 0, 16, . | 1.8 | 5 |
| 2218 | Long-Term Averaged Spectrum Descriptors of Dysarthria in Patients With Parkinson's Disease Treated With Subthalamic Nucleus Deep Brain Stimulation. Journal of Speech, Language, and Hearing Research, 2022, 65, 4690-4699. | 0.7 | 2 |
| 2219 | Nomogram to Predict the Probability of Functional Dependence in Early Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2023, 13, 49-55. | 1.5 | 2 |
| 2220 | Microbiome and Metabolome Insights into the Role of the Gastrointestinalâ€“Brain Axis in Parkinsonâ€™s and Alzheimerâ€™s Disease: Unveiling Potential Therapeutic Targets. Metabolites, 2022, 12, 1222. | 1.3 | 6 |
| 2222 | Gut-initiated neuroprotection in Parkinsonâ€™s disease: When microbes turn the tables in the battle against neuroinflammation. Brain, Behavior, and Immunity, 2023, 108, 350-352. | 2.0 | 1 |
| 2224 | Mechanistic models of Î±-synuclein homeostasis for Parkinson's disease: A blueprint for therapeutic intervention. Frontiers in Applied Mathematics and Statistics, 0, 8, . | 0.7 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 2225 | Therapeutic potential of melatonin and its derivatives in aging and neurodegenerative diseases. Biogerontology, 2023, 24, 183-206. | 2.0 | 5 |
| 2227 | Step-Counting Accuracy of a Commercial Smartwatch in Mild-to-Moderate PD Patients and Effect of Spatiotemporal Gait Parameters, Laterality of Symptoms, Pharmacological State, and Clinical Variables. Sensors, 2023, 23, 214. | 2.1 | 2 |
| 2228 | Machine Learning Framework for Prediction of Parkinsonâ€™s Disease in Cloud Environment. Lecture Notes in Electrical Engineering, 2023, , 15-26. | 0.3 | 1 |
| 2229 | Antiparkinsonian Agents in Investigational Polymeric Micro- and Nano-Systems. Pharmaceutics, 2023, 15, 13. | 2.0 | 2 |
| 2230 | Cerebellar alterations in Parkinsonâ€™s disease with postural instability and gait disorders. Journal of Neurology, 2023, 270, 1735-1744. | 1.8 | 5 |
| 2231 | Association between serum lipid levels over time and risk of Parkinsonâ€™s disease. Scientific Reports, 2022, 12, . | 1.6 | 5 |
| 2233 | Vitamin D in Neurological Diseases. International Journal of Molecular Sciences, 2023, 24, 87. | 1.8 | 13 |
| 2234 | Effects of Apamin on MPP+-Induced Calcium Overload and Neurotoxicity by Targeting CaMKII/ERK/p65/STAT3 Signaling Pathways in Dopaminergic Neuronal Cells. International Journal of Molecular Sciences, 2022, 23, 15255. | 1.8 | 4 |
| 2235 | Targeting G Protein-Coupled Receptors in the Treatment of Parkinsonâ€™s Disease. Journal of Molecular Biology, 2023, 435, 167927. | 2.0 | 2 |
| 2237 | The genetic background of Parkinsonâ€™s disease and novel therapeutic targets. Expert Opinion on Therapeutic Targets, 0, , 1-10. | 1.5 | 2 |
| 2238 | Alcohol and Parkinsonâ€™s Disease: A Systematic Review and Meta-Analysis. Journal of Parkinson's Disease, 2022, 12, 2369-2381. | 1.5 | 5 |
| 2239 | Caffeine improves mitochondrial function in PINK1B9-null mutant Drosophila melanogaster. Journal of Bioenergetics and Biomembranes, 2023, 55, 1-13. | 1.0 | 2 |
| 2240 | Dopamine, Immunity, and Disease. Pharmacological Reviews, 2023, 75, 62-158. | 7.1 | 43 |
| 2241 | Determination of the motor status of patients with advanced Parkinsonâ€™s disease under levodopaâ€“carbidopa intestinal gel using a machine learning model. Acta Neurologica Belgica, 2023, 123, 565-570. | 0.5 | 2 |
| 2242 | Multi-Disease Validation of the RUDAS for Cognitive Screening in Alzheimerâ€™s Disease, Parkinsonâ€™s Disease, and Multiple Sclerosis. Journal of Alzheimer's Disease, 2022, , 1-13. | 1.2 | 3 |
| 2243 | Bone Tissue and the Nervous System: What Do They Have in Common?. Cells, 2023, 12, 51. | 1.8 | 5 |
| 2244 | Statins block mammalian target of rapamycin pathway: a possible novel therapeutic strategy for inflammatory, malignant and neurodegenerative diseases. Inflammopharmacology, 2023, 31, 57-75. | 1.9 | 10 |
| 2245 | Psychophysical Evaluation of Visual vs. Computerâ€Aided Detection of Brain Lesions on Magnetic Resonance Images. Journal of Magnetic Resonance Imaging, 2023, 58, 642-649. | 1.9 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 2246 | Brain modulation by the gut microbiota: From disease to therapy. Journal of Advanced Research, 2023, 53, 153-173. | 4.4 | 16 |
| 2247 | Hypoxic stress accelerates the propagation of pathological alphaâ€synuclein and degeneration of dopaminergic neurons. CNS Neuroscience and Therapeutics, 0, , . | 1.9 | 1 |
| 2248 | Dyskinesia and Parkinsonâ€™s disease: animal model, drug targets, and agents in preclinical testing. Expert Opinion on Therapeutic Targets, 2022, 26, 837-851. | 1.5 | 5 |
| 2249 | Biomimetically Engineered Amyloid-Shelled Gold Nanocomplexes for Discovering Î±-Synuclein Oligomer-Degrading Drugs. ACS Applied Materials & Interfaces, 2023, 15, 2538-2551. | 4.0 | 2 |
| 2250 | Characterization of Hemodynamic Alteration in Parkinson's Disease and Effect on Resting-State Connectivity. Neuroscience, 2023, 524, 233-241. | 1.1 | 2 |
| 2251 | The Effect of Blood Lipids, Type 2 Diabetes, and Body Mass Index on Parkinsonâ€™s Disease: A Korean Mendelian Randomization Study. Journal of Movement Disorders, 2023, 16, 79-85. | 0.7 | 5 |
| 2252 | Chaperone-Dependent Mechanisms as a Pharmacological Target for Neuroprotection. International Journal of Molecular Sciences, 2023, 24, 823. | 1.8 | 6 |
| 2253 | The Role of Fecal Microbiota Transplantation in the Treatment of Neurodegenerative Diseases: A Review. International Journal of Molecular Sciences, 2023, 24, 1001. | 1.8 | 19 |
| 2254 | Sophora alopecuroides Alleviates Neuroinflammation and Oxidative Damage of Parkinsonâ€™s Disease In Vitro and In Vivo. The American Journal of Chinese Medicine, 2023, 51, 309-328. | 1.5 | 2 |
| 2255 | Gait Patterns Coded asÂRiemannian Mean Covariances toÂSupport Parkinsonâ€™s Disease Diagnosis. Lecture Notes in Computer Science, 2022, , 3-14. | 1.0 | 1 |
| 2256 | Therapeutic Potential of Natural Compounds in Neurodegenerative Diseases: Insights from Clinical Trials. Pharmaceutics, 2023, 15, 212. | 2.0 | 8 |
| 2257 | Validation of the cross-cultural dementia screening test in Alzheimerâ€™s disease and Parkinsonâ€™s disease. Frontiers in Psychology, 0, 13, . | 1.1 | 1 |
| 2258 | Circadian rhythms in the bloodâ€“brain barrier: impact on neurological disorders and stress responses. Molecular Brain, 2023, 16, . | 1.3 | 17 |
| 2259 | Nonâ€ergot dopamine agonist therapy for Parkinson's disease in Japan: A claims database analysis. Neurology and Clinical Neuroscience, 0, , . | 0.2 | 0 |
| 2260 | The Consequences of GBA Deficiency in the Autophagyâ€“Lysosome System in Parkinsonâ€™s Disease Associated with GBA. Cells, 2023, 12, 191. | 1.8 | 9 |
| 2261 | Association between Beta Oscillations from Subthalamic Nucleus and Quantitative Susceptibility Mapping in Deep Gray Matter Structures in Parkinsonâ€™s Disease. Brain Sciences, 2023, 13, 81. | 1.1 | 0 |
| 2262 | HSP70-binding motifs function as protein quality control degrons. Cellular and Molecular Life Sciences, 2023, 80, . | 2.4 | 6 |
| 2263 | Mendelian Randomization Analysis Reveals No Causal Relationship Between Plasma Î±-Synuclein and Parkinsonâ€™s Disease. Molecular Neurobiology, 0, , . | 1.9 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 2264 | The effects of synbiotic supplementation on oxidative stress markers, mental status, and quality of life in patients with Parkinsonâ€™s disease: A double-blind, placebo-controlled, randomized controlled trial. Journal of Functional Foods, 2023, 100, 105397. | 1.6 | 2 |
| 2265 | Knockdown of SEMA7A alleviates MPP<sup>+</sup>â€induced apoptosis and inflammation in BV2 microglia via PPARâ€Î³ activation and MAPK inactivation. Immunity, Inflammation and Disease, 2023, 11, . | 1.3 | 1 |
| 2266 | The Potential of ANK1 to Predict Parkinsonâ€™s Disease. Genes, 2023, 14, 226. | 1.0 | 0 |
| 2267 | Risk of Parkinson disease associated with pesticide exposure and protection by probiotics. Materials Today: Proceedings, 2022, 69, A1-A11. | 0.9 | 3 |
| 2268 | Delivery of Biomimetic Liposomes via Meningeal Lymphatic Vessels Route for Targeted Therapy of Parkinsonâ€™s Disease. Research, 2023, 6, . | 2.8 | 3 |
| 2269 | Applications of microphysiological systems to disease models in the biopharmaceutical industry: Opportunities and challenges. ALTEX: Alternatives To Animal Experimentation, 0, , . | 0.9 | 2 |
| 2270 | Effects of a probiotic suspension Symproveâ„¢ on a rat early-stage Parkinsonâ€™s disease model. Frontiers in Aging Neuroscience, 0, 14, . | 1.7 | 4 |
| 2271 | Morphologic brain network predicts levodopa responsiveness in Parkinson disease. Frontiers in Aging Neuroscience, 0, 14, . | 1.7 | 0 |
| 2272 | 4-Aminopyridine Protects Nigral Dopaminergic Neurons in the MPTP Mouse Model of Parkinsonâ€™s Disease. Neurochemical Research, 2023, 48, 1707-1715. | 1.6 | 1 |
| 2273 | The evaluation of the nutritional status in Parkinsonâ€™s disease: geriatric nutritional risk index comparison with mini nutritional assessment questionnaire. Nutritional Neuroscience, 0, , 1-8. | 1.5 | 1 |
| 2274 | Gold Nanoclusters Enhance the Efficacy of the Polymer-Based Chaperone in Restoring and Maintaining the Native Conformation of Human Islet Amyloid Polypeptide. ACS Applied Materials & Interfaces, 2023, 15, 3409-3419. | 4.0 | 1 |
| 2276 | Myrcene Salvages Rotenone-Induced Loss of Dopaminergic Neurons by Inhibiting Oxidative Stress, Inflammation, Apoptosis, and Autophagy. Molecules, 2023, 28, 685. | 1.7 | 8 |
| 2277 | The burden of Parkinsonâ€™s disease in the Middle East and North Africa region, 1990â€“2019: results from the global burden of disease study 2019. BMC Public Health, 2023, 23, . | 1.2 | 7 |
| 2278 | Sex Differences in the Level of Homocysteine in Alzheimerâ€™s Disease and Parkinsonâ€™s Disease Patients: A Meta-Analysis. Brain Sciences, 2023, 13, 153. | 1.1 | 1 |
| 2279 | Human mini-brains for reconstituting central nervous system disorders. Lab on A Chip, 2023, 23, 964-981. | 3.1 | 3 |
| 2280 | In vivoÂoverexpression of synaptogyrinâ€3 promotes striatal synapticÂdopamineÂuptakeÂin LRRK2<sup>R1441G</sup>Âmutant mouse model of Parkinson's disease. Brain and Behavior, 2023, 13, . | 1.0 | 2 |
| 2282 | Association of AQP4 single nucleotide polymorphisms (rs335929 and rs2075575) with Parkinsonâ€™s disease: A case-control study. Neuroscience Letters, 2023, 797, 137062. | 1.0 | 4 |
| 2283 | Cross-sectional proteomic expression in Parkinson's disease-related proteins in drug-naÃ¯ve patients vs healthy controls with longitudinal clinical follow-up. Neurobiology of Disease, 2023, 177, 105997. | 2.1 | 7 |

| # | Article | IF | Citations |
|---|---|---|---|
| 2284 | Sleep behaviors and Parkinson's disease: A bidirectional Mendelian randomization analysis. Behavioural Brain Research, 2023, 441, 114281. | 1.2 | 3 |
| 2285 | Upregulation of RIPK1 implicates in HEK 293T cell death upon transient transfection of A53T-Î±-synuclein. International Journal of Biological Macromolecules, 2023, 230, 123216. | 3.6 | 1 |
| 2286 | Depressive symptoms and axial motor disorders in individuals with Parkinson's disease: a cross-sectional study. Arquivos De Neuro-Psiquiatria, 2022, 80, 1126-1133. | 0.3 | 0 |
| 2287 | Role and Dysregulation of miRNA in Patients with Parkinsonâ€™s Disease. International Journal of Molecular Sciences, 2023, 24, 712. | 1.8 | 8 |
| 2289 | Immune Modulatory Effects of Ketogenic Diet in Different Disease Conditions. Immuno, 2023, 3, 1-15. | 0.6 | 8 |
| 2290 | Modulation of Muscarinic Signalling in the Central Nervous System by Steroid Hormones and Neurosteroids. International Journal of Molecular Sciences, 2023, 24, 507. | 1.8 | 2 |
| 2291 | Cannabidivarin alleviates Î±â€synuclein aggregation via <scp>DAF</scp>â€16 in Caenorhabditis elegans. FASEB Journal, 2023, 37, . | 0.2 | 2 |
| 2292 | Protein composition of axonal dopamine release sites in the striatum. ELife, 0, 11, . | 2.8 | 7 |
| 2293 | Transcriptome Analysis Reveals a Two-Gene Signature Links to Motor Progression and Alterations of Immune Cells in Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2023, 13, 25-38. | 1.5 | 2 |
| 2294 | Identification of the molecular mechanism of insulin-like growth factor-1 (IGF-1): a promising therapeutic target for neurodegenerative diseases associated with metabolic syndrome. Cell and Bioscience, 2023, 13, . | 2.1 | 10 |
| 2295 | Additional Role of Midbrain F-18 FP-CIT Uptake on PET in Evaluation of Essential Tremor and Parkinsonism. Current Medical Imaging, 2023, 19, . | 0.4 | 0 |
| 2297 | Î±-Synuclein Induced the Occurrence of RBD via Interaction with OX1R and Modulated Its Degradation. NeuroMolecular Medicine, 2023, 25, 286-300. | 1.8 | 4 |
| 2298 | Three-Dimensional Analysis of Sex- and Gonadal Status- Dependent Microglial Activation in a Mouse Model of Parkinsonâ€™s Disease. Pharmaceuticals, 2023, 16, 152. | 1.7 | 3 |
| 2299 | Competing endogenous RNA (ceRNA) networks in Parkinson's disease: A systematic review. Frontiers in Cellular Neuroscience, 0, 17, . | 1.8 | 4 |
| 2300 | A Microfluidic System for Investigating Anticipatory Medication Effects on Dopamine Homeostasis in Dopaminergic Cells. Analytical Chemistry, 2023, 95, 3153-3159. | 3.2 | 2 |
| 2301 | The pivotal role of JAK/STAT and IRS/PI3K signaling pathways in neurodegenerative diseases: Mechanistic approaches to polyphenols and alkaloids. Phytomedicine, 2023, 112, 154686. | 2.3 | 13 |
| 2302 | Phytotherapeutic alternatives for neurodegenerative dementias: Scientific review, discussion and therapeutic proposal. Phytotherapy Research, 2023, 37, 1176-1211. | 2.8 | 2 |
| 2303 | An fNIRS-Based Dynamic Functional Connectivity Analysis Method to Signify Functional Neurodegeneration of Parkinsonâ€™s Disease. IEEE Transactions on Neural Systems and Rehabilitation Engineering, 2023, 31, 1199-1207. | 2.7 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 2304 | Upregulation of Formaldehyde in Parkinsonâ€™s Disease Found by a Near-Infrared Lysosome-Targeted Fluorescent Probe. Analytical Chemistry, 2023, 95, 2925-2931. | 3.2 | 16 |
| 2306 | Comprehensive analysis of non-synonymous SNPs related to Parkinsonâ€™s disease and molecular dynamics simulation of PRKN mutants. Results in Chemistry, 2023, 5, 100817. | 0.9 | 0 |
| 2307 | Diseases with the highest mortality. , 2023, , 29-69. | | 0 |
| 2308 | Environmental and genetic risk factors for Parkinsonâ€™s disease. Bulletin of Siberian Medicine, 2023, 21, 105-113. | 0.1 | 0 |
| 2309 | Role of Nanomedicine-Based Therapeutics in the Treatment of CNS Disorders. Molecules, 2023, 28, 1283. | 1.7 | 5 |
| 2310 | Formulation of buccal films in Parkinsonâ€™s disease. , 2023, , . | | 0 |
| 2311 | Dynamic Regulation of DNA Methylation and Brain Functions. Biology, 2023, 12, 152. | 1.3 | 9 |
| 2312 | Evolution characteristics of dynamic balance disorder over the course of PD and relationship with dopamine depletion. Frontiers in Aging Neuroscience, 0, 14, . | 1.7 | 0 |
| 2313 | The deficiency of Maged1 attenuates Parkinson's disease progression in mice. Molecular Brain, 2023, 16, . | 1.3 | 2 |
| 2314 | An AI-guided screen identifies probucol as an enhancer of mitophagy through modulation of lipid droplets. PLoS Biology, 2023, 21, e3001977. | 2.6 | 6 |
| 2316 | The Pharmacological Activity of Garlic (Allium sativum) in Parkinsonâ€™s Disease: From Molecular Mechanisms to the Therapeutic Potential. ACS Chemical Neuroscience, 2023, 14, 1033-1044. | 1.7 | 2 |
| 2318 | ÐŸÐÐ›Ð†ÐÐ¢Ð˜Ð’ÐÐ•Ð”ÐžÐŸÐžÐœÐžÐ“Ð•Ð£ Ð’Ð•Ð”Ð•ÐÐÐ† ÐŸÐÐ¦Ð†Ð„ÐÐ¢Ð’ Ð— Ð¥Ð’ÐžÐÐžÐ‘ÐžÐ® ÐŸÐÐšÐ†ÐÐ¢ÐžÐ• Cre | | |
| 2319 | Protective effects of 24-epibrassinolide against the 6-OHDA zebrafish model of Parkinson's disease. Comparative Biochemistry and Physiology Part - C: Toxicology and Pharmacology, 2023, , 109630. | 1.3 | 1 |
| 2320 | NF-Î°B/c-Rel DNA-binding is reduced in substantia nigra and peripheral blood mononuclear cells of Parkinson's disease patients. Neurobiology of Disease, 2023, 180, 106067. | 2.1 | 2 |
| 2322 | Carrier-free quercetin nanomedicine blocks NLRP3 deubiquitination and TXNIP recruitment for Parkinsonâ€™s disease therapy. Chemical Engineering Journal, 2023, 464, 142697. | 6.6 | 1 |
| 2323 | The complex molecular pharmacology of the dopamine D2 receptor: Implications for pramipexole, ropinirole, and rotigotine. , 2023, 245, 108392. | | 4 |
| 2324 | Selecting the Best Animal Model of Parkinsonâ€™s Disease for Your Research Purpose: Insight from in vivo PET Imaging Studies. Current Neuropharmacology, 2023, 21, 1241-1272. | 1.4 | 2 |
| 2325 | Non-invasive auditory and visual stimulation attenuates Î±-Synuclein deposition and improves motor and non-motor symptoms in PD mice. Experimental Neurology, 2023, 364, 114396. | 2.0 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 2326 | Acupuncture inhibits autophagy and repairs synapses by activating the mTOR pathway in Parkinsonâ€™s disease depression model rats. Brain Research, 2023, 1808, 148320. | 1.1 | 6 |
| 2328 | Selenium Neuroprotection in Neurodegenerative Disorders. , 2022, , 2489-2523. | | 1 |
| 2329 | Issues of diagnostics and treatment of vitamin D deficiency in older patients. KliniÄeskoe Pitanie I Metabolizm, 2023, 3, 230-245. | 0.6 | 1 |
| 2330 | Protective effect of <scp>GK2</scp> fused <scp>BLVRA</scp> protein against oxidative stressâ€induced dopaminergic neuronal cell damage. FEBS Journal, 2023, 290, 2923-2938. | 2.2 | 0 |
| 2331 | Proteomic profiling reveals the potential mechanisms and regulatory targets of sirtuin 4 in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonâ€™s mouse model. Frontiers in Neuroscience, 0, 16, . | 1.4 | 3 |
| 2332 | Preventive effects of nano-graphene oxide against Parkinsonâ€™s disease via reactive oxygen species scavenging and anti-inflammation. BMB Reports, 2023, 56, 202-207. | 1.1 | 2 |
| 2333 | Protective Effects of Flavonoid Rutin Against Aminochrome Neurotoxicity. Neurotoxicity Research, 0, , . | 1.3 | 3 |
| 2334 | Optimizing levodopa therapy, when and how? Perspectives on the importance of delivery and the potential for an early combination approach. Expert Review of Neurotherapeutics, 2023, 23, 15-24. | 1.4 | 2 |
| 2335 | Recognition of Parkinson's disease and Parkinson's dementia based on gait analysis and machine learning. , 2023, , . | | 0 |
| 2336 | Common Mechanisms Underlying Î±-Synuclein-Induced Mitochondrial Dysfunction in Parkinsonâ€™s Disease. Journal of Molecular Biology, 2023, 435, 167992. | 2.0 | 13 |
| 2337 | Microstructure of Brain Nuclei in Early Parkinsonâ€™s Disease: Longitudinal Diffusion Kurtosis Imaging. Journal of Parkinson's Disease, 2023, 13, 233-242. | 1.5 | 1 |
| 2338 | ASC specks exacerbate Î±â€˜synuclein pathology via amplifying NLRP3 inflammasome activities. Journal of Neuroinflammation, 2023, 20, . | 3.1 | 2 |
| 2339 | Towards early detection of neurodegenerative diseases: A gut feeling. Frontiers in Cell and Developmental Biology, 0, 11, . | 1.8 | 7 |
| 2340 | A Low-Cost System Using a Big-Data Deep-Learning Framework for Assessing Physical Telerehabilitation: A Proof-of-Concept. Healthcare (Switzerland), 2023, 11, 507. | 1.0 | 0 |
| 2342 | Cerebral Small Vessel Disease Progression Increases Risk of Incident Parkinsonism. Annals of Neurology, 2023, 93, 1130-1141. | 2.8 | 4 |
| 2343 | Functionally Validating Evolutionary Conserved Risk Genes for Parkinsonâ€™s Disease in Drosophila melanogaster. Insects, 2023, 14, 168. | 1.0 | 0 |
| 2344 | Translational molecular imaging and drug development in Parkinsonâ€™s disease. Molecular Neurodegeneration, 2023, 18, . | 4.4 | 11 |
| 2345 | Pyroptosis as a double-edged sword: The pathogenic and therapeutic roles in inflammatory diseases and cancers. Life Sciences, 2023, 318, 121498. | 2.0 | 11 |

| # | Article | IF | Citations |
|---|---|---|---|
| 2346 | Neurodegeneration cell per cell. Neuron, 2023, 111, 767-786. | 3.8 | 8 |
| 2347 | Neuroprotective Effects of Sodium Butyrate by Restoring Gut Microbiota and Inhibiting TLR4 Signaling in Mice with MPTP-Induced Parkinsonâ€™s Disease. Nutrients, 2023, 15, 930. | 1.7 | 12 |
| 2348 | Relevance of 18F-DOPA visual and semi-quantitative PET metrics for the diagnostic of Parkinson disease in clinical practice: a machine learning-based inference study. EJNMMI Research, 2023, 13, . | 1.1 | 4 |
| 2350 | Descriptive Predictive Model for Parkinsonâ€™s Disease Analysis. Lecture Notes in Electrical Engineering, 2023, , 105-118. | 0.3 | 0 |
| 2351 | Screening of Monoamine Oxidase Inhibitors from Seeds of Nigella glandulifera Freyn et Sint. by Ligand Fishing and Their Neuroprotective Activity. Plants, 2023, 12, 882. | 1.6 | 0 |
| 2352 | Disease mechanisms as Subtypes: Mitochondrial and bioenergetic dysfunction. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2023, , 53-66. | 1.0 | 0 |
| 2353 | Hallmarks of neurodegenerative diseases. Cell, 2023, 186, 693-714. | 13.5 | 222 |
| 2354 | Common and distinct roles of amygdala subregional functional connectivity in non-motor symptoms of Parkinsonâ€™s disease. Npj Parkinson's Disease, 2023, 9, . | 2.5 | 5 |
| 2355 | <scp>LRRK2</scp> Inhibition by <scp>BIIB122</scp> in Healthy Participants and Patients with Parkinson's Disease. Movement Disorders, 2023, 38, 386-398. | 2.2 | 18 |
| 2356 | Parkinson's disease research in Morocco: a review. Neurodegenerative Disease Management, 0, , . | 1.2 | 0 |
| 2357 | Signaling pathways in Parkinsonâ€™s disease: molecular mechanisms and therapeutic interventions. Signal Transduction and Targeted Therapy, 2023, 8, . | 7.1 | 37 |
| 2358 | Pros and cons for statins use and risk of Parkinson's disease: An updated perspective. Pharmacology Research and Perspectives, 2023, 11, . | 1.1 | 17 |
| 2359 | Functional and structural alterations as diagnostic imaging markers for depression in de novo Parkinsonâ€™s disease. Frontiers in Neuroscience, 0, 17, . | 1.4 | 2 |
| 2360 | Role of Animal Models in Parkinson's Disease (PD): What role they play in preclinical translational research. CNS and Neurological Disorders - Drug Targets, 2023, 22, . | 0.8 | 0 |
| 2361 | Extracellular protein homeostasis in neurodegenerative diseases. Nature Reviews Neurology, 0, , . | 4.9 | 3 |
| 2362 | Current Treatments and New, Tentative Therapies for Parkinsonâ€™s Disease. Pharmaceutics, 2023, 15, 770. | 2.0 | 4 |
| 2363 | Features of VR Rehabilitation in Patients with Parkinson's Disease. UkraÃ¯nsÊ¹kij Å¾urnal Medicini BÃ¬ologÃ¬Ã¯ Ta Sportu, 2023, 8, 41-49. | 0.0 | 0 |
| 2364 | Efficacy of herbal medicine treatment based on syndrome differentiation for Parkinsonâ€™s disease: A systematic review and meta-analysis of randomized placebo-controlled clinical trials. Frontiers in Pharmacology, 0, 14, . | 1.6 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 2365 | Recent Advances in the Treatment of Genetic Forms of Parkinsonâ€™s Disease: Hype or Hope?. Cells, 2023, 12, 764. | 1.8 | 3 |
| 2366 | Extracellular Vesicles, Cell-Penetrating Peptides and miRNAs as Future Novel Therapeutic Interventions for Parkinsonâ€™s and Alzheimerâ€™s Disease. Biomedicines, 2023, 11, 728. | 1.4 | 6 |
| 2367 | The PPN and motor control: Preclinical studies to deep brain stimulation for Parkinsonâ€™s disease. Frontiers in Neural Circuits, 0, 17, . | 1.4 | 6 |
| 2368 | Fecal microbiota transplantation in Parkinson's diseaseâ€"A randomized repeat-dose, placebo-controlled clinical pilot study. Frontiers in Neurology, 0, 14, . | 1.1 | 16 |
| 2369 | Experimental models of chemically induced Parkinsonâ€™s disease in zebrafish at the embryonic larval stage: a systematic review. Journal of Toxicology and Environmental Health - Part B: Critical Reviews, 2023, 26, 201-237. | 2.9 | 8 |
| 2371 | Development of Small Molecules Targeting Î±-Synuclein Aggregation: A Promising Strategy to Treat Parkinsonâ€™s Disease. Pharmaceutics, 2023, 15, 839. | 2.0 | 10 |
| 2372 | Circadian Rhythmicity in Aging and Parkinsonâ€™s Disease. Healthy Ageing and Longevity, 2023, , 237-255. | 0.2 | 0 |
| 2373 | Caenorhabditis elegans as a Model System to Study Human Neurodegenerative Disorders. Biomolecules, 2023, 13, 478. | 1.8 | 6 |
| 2374 | Changes in Liver Lipidomic Profile in G2019S-LRRK2 Mouse Model of Parkinsonâ€™s Disease. Cells, 2023, 12, 806. | 1.8 | 2 |
| 2375 | Detecting Parkinson disease features with walking activity data. , 2023, , . | | 0 |
| 2376 | Predictors of cognitive impairment in newly diagnosed Parkinsonâ€™s disease with normal cognition at baseline: A 5-year cohort study. Frontiers in Aging Neuroscience, 0, 15, . | 1.7 | 3 |
| 2377 | Parkinsonâ€™s Disease, Parkinsonisms, and Mitochondria: the Role of Nuclear and Mitochondrial DNA. Current Neurology and Neuroscience Reports, 2023, 23, 131-147. | 2.0 | 3 |
| 2378 | Brain-wide transcriptome-based metabolic alterations in Parkinson's disease: human inter-region and human-experimental model correlations. Molecular Omics, 2023, 19, 522-537. | 1.4 | 1 |
| 2379 | Anticipatory Postural Adjustments and Compensatory Postural Responses to Multidirectional Perturbationsâ€"Effects of Medication and Subthalamic Nucleus Deep Brain Stimulation in Parkinsonâ€™s Disease. Brain Sciences, 2023, 13, 454. | 1.1 | 2 |
| 2380 | Fabry Disease and Central Nervous System Involvement: From Big to Small, from Brain to Synapse. International Journal of Molecular Sciences, 2023, 24, 5246. | 1.8 | 2 |
| 2381 | Disturb mitochondrial associated proteostasis: Neurodegeneration and imperfect ageing. Frontiers in Cell and Developmental Biology, 0, 11, . | 1.8 | 4 |
| 2382 | Synaptic Density and Glucose Consumption in Patients with <scp>Lewy Body Diseases</scp>: An [<scp><sup>11</sup>C</scp>]<scp>UCBâ€‰</scp> and [<scp><sup>18</sup>F</scp>]<scp>FDG PET</scp> Study. Movement Disorders, 2023, 38, 796-805. | 2.2 | 6 |
| 2383 | RNA regulation in brain function and disease 2022 (NeuroRNA): A conference report. Frontiers in Molecular Neuroscience, 0, 16, . | 1.4 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 2384 | Potassium Channels in Parkinsonâ€™s Disease: Potential Roles in Its Pathogenesis and Innovative Molecular Targets for Treatment. Pharmacological Reviews, 2023, 75, 758-788. | 7.1 | 12 |
| 2385 | Dopamine transporter and synaptic vesicle sorting defects underlie auxilin-associated Parkinsonâ€™s disease. Cell Reports, 2023, 42, 112231. | 2.9 | 10 |
| 2386 | Role of hippocampal subfields in neurodegenerative disease progression analyzed with a multi-scale attention-based network. NeuroImage: Clinical, 2023, 38, 103370. | 1.4 | 3 |
| 2387 | Development of Novel Fluorinated Polyphenols as Selective Inhibitors of DYRK1A/B Kinase for Treatment of Neuroinflammatory Diseases including Parkinsonâ€™s Disease. Pharmaceuticals, 2023, 16, 443. | 1.7 | 3 |
| 2388 | Oral and intestinal dysbiosis in Parkinson's disease. Revue Neurologique, 2023, 179, 937-946. | 0.6 | 4 |
| 2389 | Abnormal dynamic functional connectivity changes correlated with non-motor symptoms of Parkinsonâ€™s disease. Frontiers in Neuroscience, 0, 17, . | 1.4 | 3 |
| 2390 | Among Gerontogens, Heavy Metals Are a Class of Their Own: A Review of the Evidence for Cellular Senescence. Brain Sciences, 2023, 13, 500. | 1.1 | 3 |
| 2391 | Novel druggable mechanism of Parkinson's disease: Potential therapeutics and underlying pathogenesis based on ferroptosis. Medicinal Research Reviews, 2023, 43, 872-896. | 5.0 | 9 |
| 2393 | The Role of Diet as a Modulator of the Inflammatory Process in the Neurological Diseases. Nutrients, 2023, 15, 1436. | 1.7 | 18 |
| 2394 | Properties of Poly (Lactic-co-Glycolic Acid) and Progress of Poly (Lactic-co-Glycolic Acid)-Based Biodegradable Materials in Biomedical Research. Pharmaceuticals, 2023, 16, 454. | 1.7 | 24 |
| 2395 | Matrix metalloproteinase-9 inhibition prevents aquaporin-4 depolarization-mediated glymphatic dysfunction in Parkinsonâ€™s disease. Journal of Advanced Research, 2024, 56, 125-136. | 4.4 | 8 |
| 2396 | Assessment of Multivariate Information Transmission in Space-Time-Frequency Domain: A Case Study for EEG Signals. IEEE Transactions on Neural Systems and Rehabilitation Engineering, 2023, 31, 1764-1775. | 2.7 | 0 |
| 2397 | Editorial: Data science in neuro- and onco-biology. Frontiers in Applied Mathematics and Statistics, 0, 9, . | 0.7 | 0 |
| 2398 | Synergistic effects of lipopolysaccharide and rotenone on dopamine neuronal damage in rats. CNS Neuroscience and Therapeutics, 2023, 29, 2281-2291. | 1.9 | 2 |
| 2399 | Speech and gait abnormalities in motor subtypes of deâ€novo Parkinson's disease. CNS Neuroscience and Therapeutics, 2023, 29, 2101-2110. | 1.9 | 3 |
| 2400 | Immune Regulatory Functions of Macrophages and Microglia in Central Nervous System Diseases. International Journal of Molecular Sciences, 2023, 24, 5925. | 1.8 | 4 |
| 2401 | Novel Insight into Functions of Transcription Factor EB (TFEB) in Alzheimerâ€™s Disease and Parkinsonâ€™s Disease. , 2023, 14, 652. | | 6 |
| 2402 | Activators of Nrf2 to Counteract Neurodegenerative Diseases. Antioxidants, 2023, 12, 778. | 2.2 | 7 |

| # | Article | IF | Citations |
|---|---|---|---|
| 2403 | Probing motor dynamics at the muscle levelâ€"Acoustic myography in Parkinson's disease. Physiological Reports, 2023, 11, . | 0.7 | 1 |
| 2404 | The Potential Use of Honey as a Neuroprotective Agent for the Management of Neurodegenerative Diseases. Nutrients, 2023, 15, 1558. | 1.7 | 1 |
| 2405 | Dopaminergic System in Promoting Recovery from General Anesthesia. Brain Sciences, 2023, 13, 538. | 1.1 | 1 |
| 2406 | A story of the potential effect of non-steroidal anti-inflammatory drugs (NSAIDs) in Parkinsonâ€™s disease: beneficial or detrimental effects. Inflammopharmacology, 2023, 31, 673-688. | 1.9 | 11 |
| 2407 | Vitamin C, vitamin E, Î²-carotene and risk of Parkinsonâ€™s disease: a systematic review and doseâ€“response meta-analysis of observational studies. Nutritional Neuroscience, 0, , 1-13. | 1.5 | 3 |
| 2408 | Sustainable production of active pharmaceutical ingredients from lignin-based benzoic acid derivatives via â€œdemand orientationâ€• Green Chemistry, 2023, 25, 3791-3815. | 4.6 | 6 |
| 2409 | Polymeric nanosystems for neurological therapeutics. , 2023, , 723-759. | | 0 |
| 2410 | Novel therapeutic approaches to target neurodegeneration. British Journal of Pharmacology, 2023, 180, 1651-1673. | 2.7 | 5 |
| 2411 | Sex hormones differentially contribute to Parkinson disease in males: A multimodal biomarker study. European Journal of Neurology, 2023, 30, 1983-1990. | 1.7 | 5 |
| 2412 | The small GTPase Rit2 modulates LRRK2 kinase activity, is required for lysosomal function and protects against alpha-synuclein neuropathology. Npj Parkinson's Disease, 2023, 9, . | 2.5 | 5 |
| 2413 | Microglia Mediated Neuroinflammation in Parkinsonâ€™s Disease. Cells, 2023, 12, 1012. | 1.8 | 19 |
| 2414 | Fountain of youthâ€"Targeting autophagy in aging. Frontiers in Aging Neuroscience, 0, 15, . | 1.7 | 1 |
| 2415 | The role of microbiota-gut-brain axis in neurodegenerative diseases: biochemical and therapeutic aspects. , 0, , 71-89. | | 0 |
| 2416 | A novel method for the therapeutic drug monitoring of biperiden in plasma by GC-MS using salt-assisted liquidâ€“liquid microextraction. Clinica Chimica Acta, 2023, 543, 117322. | 0.5 | 1 |
| 2417 | Rationale and Development of Tavapadon, a D1/D5-Selective Partial Dopamine Agonist for the Treatment of Parkinsonâ€™s Disease. CNS and Neurological Disorders - Drug Targets, 2024, 23, 476-487. | 0.8 | 3 |
| 2418 | Modulation of cytotoxic amyloid fibrillation and mitochondrial damage of Î±-synuclein by catechols mediated conformational changes. Scientific Reports, 2023, 13, . | 1.6 | 7 |
| 2420 | Blood-brain Barrier and Neurovascular Unit Dysfunction in Parkinson's Disease: From Clinical Insights to Pathogenic Mechanisms and Novel Therapeutic Approaches. CNS and Neurological Disorders - Drug Targets, 2024, 23, 315-330. | 0.8 | 1 |
| 2421 | Dorsolateral Nigral Hyperintensity on 1. <scp>5â€‰T</scp> Versus <scp>3â€‰T</scp> Susceptibilityâ€Weighted Magnetic Resonance Imaging in Neurodegenerative Parkinsonism. Movement Disorders Clinical Practice, 0, , . | 0.8 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 2422 | Migratory Response of Cells in Neurogenic Niches to Neuronal Death: The Onset of Harmonic Repair?. International Journal of Molecular Sciences, 2023, 24, 6587. | 1.8 | 3 |
| 2423 | Tumor necrosis factor Î±-induced protein 3 mediates inflammation and neuronal autophagy in Parkinsonâ€™s disease via the NFÎºB and mTOR pathways. Neuroscience Letters, 2023, 805, 137223. | 1.0 | 1 |
| 2424 | Polyamines in Parkinson's Disease: Balancing Between Neurotoxicity and Neuroprotection. Annual Review of Biochemistry, 2023, 92, 435-464. | 5.0 | 11 |
| 2425 | Quinolines: Privileged Scaffolds for Developing New Antiâ€neurodegenerative Agents. ChemistrySelect, 2023, 8, . | 0.7 | 5 |
| 2426 | Imaging the lower limb network in Parkinsonâ€™s disease. NeuroImage: Clinical, 2023, 38, 103399. | 1.4 | 1 |
| 2427 | The cervical lymph node contributes to peripheral inflammation related to Parkinsonâ€™s disease. Journal of Neuroinflammation, 2023, 20, . | 3.1 | 5 |
| 2428 | Association of coffee consumption and striatal volume in patients with Parkinson's disease and healthy controls. CNS Neuroscience and Therapeutics, 0, , . | 1.9 | 0 |
| 2429 | Revisiting the critical roles of reactive astrocytes in neurodegeneration. Molecular Psychiatry, 2023, 28, 2697-2706. | 4.1 | 10 |
| 2431 | Machine Learning Applications in the Study of Parkinsonâ€™s Disease: A Systematic Review. Current Bioinformatics, 2023, 18, . | 0.7 | 0 |
| 2432 | On-Tissue Chemical Derivatization for Comprehensive Mapping of Brain Carboxyl and Aldehyde Metabolites by MALDIâ€“MS Imaging. Journal of the American Society for Mass Spectrometry, 2023, 34, 836-846. | 1.2 | 6 |
| 2433 | Revisiting Alpha-Synuclein Pathways to Inflammation. International Journal of Molecular Sciences, 2023, 24, 7137. | 1.8 | 6 |
| 2434 | Lewy bodies, iron, inflammation and neuromelanin: pathological aspects underlying Parkinsonâ€™s disease. Journal of Neural Transmission, 2023, 130, 627-646. | 1.4 | 8 |
| 2435 | Neuromuscular assessment of force development, postural, and gait performance under cognitive-motor dual-tasking in healthy older adults and early Parkinson's disease patients: Study protocol for a cross-sectional Mobile Brain/Body Imaging (MoBI) study. Open Research Europe, 0, 3, 58. | 2.0 | 0 |
| 2436 | Association between Respiratory Function and Motor Function in Different Stages of Parkinsonâ€™s Disease. European Neurology, 2023, 86, 242-249. | 0.6 | 0 |
| 2438 | Explainable classification of Parkinsonâ€™s disease using deep learning trained on a large multi-center database of T1-weighted MRI datasets. NeuroImage: Clinical, 2023, 38, 103405. | 1.4 | 5 |
| 2440 | Second Harmonic Generation Signatures of Supramolecular Assemblies Based on Amide Moieties. ChemPhysChem, 0, , . | 1.0 | 0 |
| 2441 | PARK7/DJ-1 in microglia: implications in Parkinsonâ€™s disease and relevance as a therapeutic target. Journal of Neuroinflammation, 2023, 20, . | 3.1 | 5 |
| 2442 | Multiple tethers of organelle contact sites are involved in Î±-synuclein toxicity in yeast. Molecular Biology of the Cell, 0, , . | 0.9 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 2443 | Phosphodiesterase-4 Inhibition in Parkinsonâ€™s Disease: Molecular Insights and Therapeutic Potential. Cellular and Molecular Neurobiology, 2023, 43, 2713-2741. | 1.7 | 3 |
| 2444 | Development and early qualitative evidence of two novel patient-reported outcome instruments to assess daily functioning in people with early-stage Parkinsonâ€™s. Journal of Patient-Reported Outcomes, 2023, 7, . | 0.9 | 5 |
| 2445 | Vector enabled CRISPR gene editing â€“ A revolutionary strategy for targeting the diversity of brain pathologies. Coordination Chemistry Reviews, 2023, 487, 215172. | 9.5 | 0 |
| 2446 | Redox Imbalance in Neurological Disorders in Adults and Children. Antioxidants, 2023, 12, 965. | 2.2 | 3 |
| 2447 | Cntnap4 partial deficiency exacerbates Î±-synuclein pathology through astrocyteâ€“microglia C3-C3aR pathway. Cell Death and Disease, 2023, 14, . | 2.7 | 4 |
| 2469 | An Understanding of Different Mechanisms Leading to Neurodegenerative Diseases. , 2023, , 1-53. | | 0 |
| 2474 | Multi-functional Ligands and Molecular Hybridization: Conceptual Aspects and Application in the Innovative Design of Drug Candidate Prototypes for Neurodegenerative Diseases. Frontiers in Clinical Drug Research CNS and Neurological Disorders, 2023, , 1-157. | 0.1 | 0 |
| 2484 | Regulation of biological processes by intrinsically chiral engineered materials. Nature Reviews Materials, 2023, 8, 403-413. | 23.3 | 12 |
| 2488 | Neurological Applications of Magnetic Resonance-Guided Focused Ultrasound Therapy. , 2023, , 1337-1345. | | 0 |
| 2489 | Uncovering Novel Therapeutic Targets for Parkinsonâ€™s Disease. ACS Chemical Neuroscience, 2023, 14, 1935-1949. | 1.7 | 2 |
| 2491 | Dystonia and Parkinsonâ€™s disease: Do they have a shared biology?. International Review of Neurobiology, 2023, , . | 0.9 | 0 |
| 2512 | Diet, disease severity, and energy expenditure in amyotrophic lateral sclerosis (ALS). , 2023, , 123-140. | | 0 |
| 2516 | Arbutin as a natural soluble glycosylated phenol and usage in neuroinflammation. , 2023, , 525-539. | | 0 |
| 2517 | Role of mediterranean diet in Parkinson's disease. , 2023, , 649-665. | | 0 |
| 2521 | New insights on the potential effect of vinpocetine in Parkinsonâ€™s disease: one of the neglected warden and baffling topics. Metabolic Brain Disease, 2023, 38, 1831-1840. | 1.4 | 4 |
| 2526 | Human Neuronavigation Using Coherent Anti-Sokes Raman Scattering Spectroscopy and Diffuse Reflectance Spectroscopy for Deep Brain Stimulation Surgery. , 2023, , . | | 0 |
| 2538 | Perspective Chapter: The Role of Dopamine Receptors in Neuropsychiatric Diseases. , 0, , . | | 0 |
| 2545 | Cellular senescence and neurodegeneration. Human Genetics, 2023, 142, 1247-1262. | 1.8 | 4 |

| # | Article | IF | Citations |
|---|---|---|---|
| 2599 | Perspective Chapter: The Role of Dopamine Receptors in Neuropsychiatric Diseases. , 0, , . | | 1 |
| 2607 | Neuroprotective effects of flavonoids. , 2023, , 133-200. | | 1 |
| 2610 | Purinergic Signaling in Parkinsonâ€™s Disease. , 2023, , 203-221. | | 0 |
| 2612 | Heavy Metal Mediated Progressive Degeneration and Its Noxious Effects on Brain Microenvironment. Biological Trace Element Research, 2024, 202, 1411-1427. | 1.9 | 4 |
| 2634 | Medicinal Plants Against Neurological Viral Diseases: Ethnopharmacology, Chemistry, Clinical, and Preclinical Studies. Reference Series in Phytochemistry, 2023, , 1-64. | 0.2 | 0 |
| 2635 | An Explainable Approach forÂEarly Parkinson Disease Detection Using Deep Learning. Communications in Computer and Information Science, 2023, , 326-339. | 0.4 | 0 |
| 2652 | Does vitamin D protect or treat Parkinsonâ€™s disease? A narrative review. Naunyn-Schmiedeberg's Archives of Pharmacology, 2024, 397, 33-40. | 1.4 | 3 |
| 2653 | Exploring Federated Learning for Speech-based Parkinsonâ€™s Disease Detection. , 2023, , . | | 1 |
| 2656 | Cognitive impairment and dementia in young onset Parkinsonâ€™s disease. Journal of Neurology, 2023, 270, 5793-5812. | 1.8 | 2 |
| 2671 | Photobiomodulation Therapy for Parkinsonâ€™s Disease. Synthesis Lectures on Biomedical Engineering, 2023, , 191-219. | 0.1 | 0 |
| 2673 | Machine Learning Applications that Might Support Home-Based Screening of Parkinsonâ€™s Disease: A Scoping Review. Lecture Notes in Networks and Systems, 2023, , 431-442. | 0.5 | 0 |
| 2676 | The risk of criminal behavior in the elderly and patients with neurodegenerative disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2023, , 181-196. | 1.0 | 0 |
| 2677 | Copper trafficking system in cells: insights into coordination chemistry and toxicity. Dalton Transactions, 0, , . | 1.6 | 0 |
| 2680 | Health Guardian: Using Multi-modal Data to Understand Individual Health. , 2023, , . | | 0 |
| 2685 | DOPA decarboxylase is an emerging biomarker for Parkinsonian disorders including preclinical Lewy body disease. Nature Aging, 2023, 3, 1201-1209. | 5.3 | 7 |
| 2688 | Current and novel infusion therapies for patients with Parkinson's disease. Journal of Neural Transmission, 0, , . | 1.4 | 2 |
| 2706 | Functionalized Nanocrystals and Theranostic Applications. , 2023, , 331-359. | | 0 |
| 2724 | Ayurveda: Ayurvedic herbs against neurological disorders: are they golden nuggets?. , 2023, , 1-40. | | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 2728 | Synucleinopathies. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2023, , 175-202. | 1.0 | 0 |
| 2739 | Role of Stem Cells as a Protective Agent against Neurological Complications. , 2023, , 69-90. | | 0 |
| 2742 | Neurodegenerative Erkrankungen und VerÃnderungen des kÃ¼nstlerischen Ausdrucks. , 2023, , 29-42. | | 0 |
| 2751 | A CNN Approach to Detect Parkinson's Disease using T1-Weighted, T2-Weighted, and Flair MRI. , 2023, , . | | 0 |
| 2772 | Retinal Changes in Parkinsonâ€™s Disease: A Non-invasive Biomarker for Early Diagnosis. Cellular and Molecular Neurobiology, 2023, 43, 3983-3996. | 1.7 | 2 |
| 2777 | Antioxidants as Adjuncts to Conventional Therapies Against Oxidative Stress. Food Bioactive Ingredients, 2023, , 215-247. | 0.3 | 0 |
| 2788 | White matter changes in Parkinsonâ€™s disease. Npj Parkinson's Disease, 2023, 9, . | 2.5 | 3 |
| 2799 | Inflammation as common link to progressive neurological diseases. Archives of Toxicology, 0, , . | 1.9 | 1 |
| 2824 | Parkinson's Disease Prediction Using Efficient Analysis of Machine Learning Algorithms. , 2023, , . | | 0 |
| 2846 | Cost Effectiveness of Deep Brain Stimulation for Parkinsonâ€™s Disease: A Systematic Review. Applied Health Economics and Health Policy, 2024, 22, 181-192. | 1.0 | 0 |
| 2863 | Monitoring the Effect of Levodopa Using Sustained Phonemes in Parkinsonâ€™s Disease Patients. , 2023, , . | | 0 |
| 2864 | Analysis of the Relationship Between Muscle Tones and Abnormal Postures in a Computational Model. , 2023, , . | | 0 |
| 2875 | Macro and micro-sleep dysfunctions as translational biomarkers for Parkinsonâ€™s disease. International Review of Neurobiology, 2024, , 187-209. | 0.9 | 0 |
| 2876 | Is Lyapunov exponent a reliable metric to detect dynamic stability in Parkinsonâ€™s disease?. , 2023, , . | | 0 |
| 2878 | Analysis of biomarkers in speculative CNS-enriched extracellular vesicles for parkinsonian disorders: a comprehensive systematic review and diagnostic meta-analysis. Journal of Neurology, 0, , . | 1.8 | 0 |
| 2909 | Medicinal Plants Against Neurological Viral Diseases: Ethnopharmacology, Chemistry, and Clinical and Preclinical Studies. Reference Series in Phytochemistry, 2024, , 747-807. | 0.2 | 0 |
| 2914 | A Quantitative Evaluation Method for Parkinson's Disease. Communications in Computer and Information Science, 2024, , 415-421. | 0.4 | 0 |
| 2920 | Dual-task gait training improves cognition and resting-state functional connectivity in Parkinsonâ€™s disease with postural instability and gait disorders. Journal of Neurology, 2024, 271, 2031-2041. | 1.8 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 2928 | Self-supervised Distillation and Multi-scale Network for Parkinsonâ€™s Disease Classification. , 2023, , . | | 0 |
| 2929 | Neuroprotection induced by apigenin. , 2024, , 1241-1262. | | 0 |
| 2930 | Overview of the effects of andrographolide on disorders of the central nervous system. , 2024, , 1197-1220. | | 0 |
| 2938 | Cellular interaction with sericin: a basis for noncommunicable and infectious diseases. , 2024, , 653-688. | | 0 |
| 2939 | Machine learning for Developing neurorehabilitation-aided assistive devices. , 2024, , 121-148. | | 0 |
| 2943 | Patient diaries in movement disorders. , 2024, , 129-148. | | 0 |
| 2944 | Application of ResLSTM in Hypomimia Video Detection for Parkinson's Disease. , 2023, , . | | 0 |
| 2947 | Medical professional's viewpoint and clinical adoption. , 2024, , 27-37. | | 0 |
| 2962 | Unmasking the Movements. Advances in Medical Technologies and Clinical Practice Book Series, 2024, , 70-92. | 0.3 | 0 |
| 2988 | Neurotrophic Factors in Parkinsonâ€™s Disease: Clinical Trials. Pancreatic Islet Biology, 2024, , 109-137. | 0.1 | 0 |
| 2991 | Therapeutic Training and Personal Assistance. , 2023, , 59-71. | | 0 |
| 2992 | The application of biosensors in precision medicine. , 2024, , 133-162. | | 0 |
| 2997 | Proteomics: Unraveling the Cross Talk Between Innate Immunity and Disease Pathophysiology, Diagnostics, and Treatment Options. Advances in Experimental Medicine and Biology, 2024, , 221-242. | 0.8 | 0 |
| 3002 | Neurobehavioral Analysis to Assess Olfactory and Motor Dysfunction in Parkinsonâ€™s Disease. Methods in Molecular Biology, 2024, , 511-528. | 0.4 | 0 |
| 3004 | Ion Channels and Metal Ions in Parkinsonâ€™s Disease: Historical Perspective to the Current Scenario. Methods in Molecular Biology, 2024, , 529-557. | 0.4 | 0 |
| 3013 | Involvement of Autophagic Machinery in Neuropathogenesis: Targeting and Relevant Methods of Detection. Methods in Molecular Biology, 2024, , . | 0.4 | 0 |
| 3038 | Ayurveda-Inspired Reverse Pharmacology in Drug Discovery. , 2024, , 121-134. | | 0 |